CA2403644A1 - Drug metabolizing enzymes - Google Patents
Drug metabolizing enzymes Download PDFInfo
- Publication number
- CA2403644A1 CA2403644A1 CA002403644A CA2403644A CA2403644A1 CA 2403644 A1 CA2403644 A1 CA 2403644A1 CA 002403644 A CA002403644 A CA 002403644A CA 2403644 A CA2403644 A CA 2403644A CA 2403644 A1 CA2403644 A1 CA 2403644A1
- Authority
- CA
- Canada
- Prior art keywords
- polynucleotide
- polypeptide
- seq
- dme
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004190 Enzymes Human genes 0.000 title abstract description 98
- 108090000790 Enzymes Proteins 0.000 title abstract description 98
- 239000003814 drug Substances 0.000 title abstract description 50
- 229940079593 drug Drugs 0.000 title abstract description 45
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 258
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 258
- 239000002157 polynucleotide Substances 0.000 claims abstract description 258
- 238000000034 method Methods 0.000 claims abstract description 155
- 230000014509 gene expression Effects 0.000 claims abstract description 98
- 239000005557 antagonist Substances 0.000 claims abstract description 17
- 239000000556 agonist Substances 0.000 claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 217
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 207
- 229920001184 polypeptide Polymers 0.000 claims description 201
- 210000004027 cell Anatomy 0.000 claims description 143
- 150000001875 compounds Chemical class 0.000 claims description 114
- 239000012634 fragment Substances 0.000 claims description 110
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 100
- 230000000694 effects Effects 0.000 claims description 79
- 150000007523 nucleic acids Chemical class 0.000 claims description 75
- 239000000523 sample Substances 0.000 claims description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
- 230000027455 binding Effects 0.000 claims description 46
- 238000012360 testing method Methods 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 44
- 239000002773 nucleotide Substances 0.000 claims description 44
- 125000003729 nucleotide group Chemical group 0.000 claims description 44
- 238000009396 hybridization Methods 0.000 claims description 42
- 102000039446 nucleic acids Human genes 0.000 claims description 42
- 108020004707 nucleic acids Proteins 0.000 claims description 42
- 230000000295 complement effect Effects 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 24
- 238000012216 screening Methods 0.000 claims description 23
- 230000002163 immunogen Effects 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 17
- 239000012472 biological sample Substances 0.000 claims description 15
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 230000009870 specific binding Effects 0.000 claims description 9
- 230000009261 transgenic effect Effects 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 8
- 230000001988 toxicity Effects 0.000 claims description 8
- 231100000419 toxicity Toxicity 0.000 claims description 8
- 238000012408 PCR amplification Methods 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 230000005875 antibody response Effects 0.000 claims 2
- 210000000628 antibody-producing cell Anatomy 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 24
- 239000013604 expression vector Substances 0.000 abstract description 18
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 106
- 229940088598 enzyme Drugs 0.000 description 96
- 102000004169 proteins and genes Human genes 0.000 description 60
- 235000018102 proteins Nutrition 0.000 description 54
- 239000000758 substrate Substances 0.000 description 52
- 239000013598 vector Substances 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 46
- 235000001014 amino acid Nutrition 0.000 description 40
- 108091028043 Nucleic acid sequence Proteins 0.000 description 37
- 150000001413 amino acids Chemical class 0.000 description 36
- 229940024606 amino acid Drugs 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 34
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 31
- 208000035475 disorder Diseases 0.000 description 29
- -1 N-acyltransferase Proteins 0.000 description 28
- 239000002299 complementary DNA Substances 0.000 description 28
- 239000013615 primer Substances 0.000 description 28
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 26
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 25
- 108091034117 Oligonucleotide Proteins 0.000 description 23
- 101150053185 P450 gene Proteins 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 23
- 125000000539 amino acid group Chemical group 0.000 description 22
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 21
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 21
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- 230000001105 regulatory effect Effects 0.000 description 20
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 19
- 102000018832 Cytochromes Human genes 0.000 description 18
- 108010052832 Cytochromes Proteins 0.000 description 18
- 108010070675 Glutathione transferase Proteins 0.000 description 18
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 18
- 238000002869 basic local alignment search tool Methods 0.000 description 17
- 230000000875 corresponding effect Effects 0.000 description 17
- 238000006467 substitution reaction Methods 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 16
- 230000007812 deficiency Effects 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 15
- 230000003197 catalytic effect Effects 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 108010044467 Isoenzymes Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 230000000692 anti-sense effect Effects 0.000 description 14
- 238000004422 calculation algorithm Methods 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 238000013518 transcription Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 13
- 241000894007 species Species 0.000 description 13
- 238000013519 translation Methods 0.000 description 13
- 230000014616 translation Effects 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 12
- 108010057167 dimethylaniline monooxygenase (N-oxide forming) Proteins 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 239000002676 xenobiotic agent Substances 0.000 description 12
- 108010012715 Superoxide dismutase Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000700584 Simplexvirus Species 0.000 description 10
- 108090001033 Sulfotransferases Proteins 0.000 description 10
- 102000004896 Sulfotransferases Human genes 0.000 description 10
- 102000019197 Superoxide Dismutase Human genes 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 238000001415 gene therapy Methods 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 10
- 241001430294 unidentified retrovirus Species 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 101150085511 PEDS1 gene Proteins 0.000 description 9
- 102100037592 Plasmanylethanolamine desaturase Human genes 0.000 description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 9
- 230000001363 autoimmune Effects 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229960003180 glutathione Drugs 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000004060 metabolic process Effects 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 229920003199 poly(diethylsiloxane) Polymers 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 9
- 229950005741 rolipram Drugs 0.000 description 9
- 241000710929 Alphavirus Species 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- 102000004308 Carboxylic Ester Hydrolases Human genes 0.000 description 8
- 108090000863 Carboxylic Ester Hydrolases Proteins 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 101710202061 N-acetyltransferase Proteins 0.000 description 8
- 102000015636 Oligopeptides Human genes 0.000 description 8
- 108010038807 Oligopeptides Proteins 0.000 description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 description 8
- 210000001508 eye Anatomy 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- 108090000994 Catalytic RNA Proteins 0.000 description 7
- 102000053642 Catalytic RNA Human genes 0.000 description 7
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 7
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 102100025541 S-acyl fatty acid synthase thioesterase, medium chain Human genes 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 150000001720 carbohydrates Chemical group 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 238000001784 detoxification Methods 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 108020001096 dihydrofolate reductase Proteins 0.000 description 7
- 230000036267 drug metabolism Effects 0.000 description 7
- 230000002124 endocrine Effects 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 208000030159 metabolic disease Diseases 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 108091092562 ribozyme Proteins 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 108010032326 thioesterase II Proteins 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 102100038108 Arylamine N-acetyltransferase 1 Human genes 0.000 description 6
- 208000012239 Developmental disease Diseases 0.000 description 6
- 208000017701 Endocrine disease Diseases 0.000 description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 description 6
- 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 101710192343 NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 6
- 102100036777 NADPH:adrenodoxin oxidoreductase, mitochondrial Human genes 0.000 description 6
- 101710104207 Probable NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 102000005488 Thioesterase Human genes 0.000 description 6
- 229930003316 Vitamin D Natural products 0.000 description 6
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 6
- 238000006640 acetylation reaction Methods 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 231100000357 carcinogen Toxicity 0.000 description 6
- 239000003183 carcinogenic agent Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 102000004419 dihydrofolate reductase Human genes 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 208000030533 eye disease Diseases 0.000 description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000002987 primer (paints) Substances 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 108020002982 thioesterase Proteins 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 6
- 241001529453 unidentified herpesvirus Species 0.000 description 6
- 235000019166 vitamin D Nutrition 0.000 description 6
- 239000011710 vitamin D Substances 0.000 description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 description 6
- 229940046008 vitamin d Drugs 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 102000000584 Calmodulin Human genes 0.000 description 5
- 108010041952 Calmodulin Proteins 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 101000884385 Homo sapiens Arylamine N-acetyltransferase 1 Proteins 0.000 description 5
- 101000609949 Homo sapiens Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta Proteins 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 102100039174 Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta Human genes 0.000 description 5
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 5
- 108010004977 Vasopressins Proteins 0.000 description 5
- 102000002852 Vasopressins Human genes 0.000 description 5
- 230000021736 acetylation Effects 0.000 description 5
- 102000005421 acetyltransferase Human genes 0.000 description 5
- 108020002494 acetyltransferase Proteins 0.000 description 5
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 5
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 5
- 230000036952 cancer formation Effects 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 231100000504 carcinogenesis Toxicity 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 5
- 210000000172 cytosol Anatomy 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000003228 microsomal effect Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 229960003726 vasopressin Drugs 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 102100033149 Cytochrome b5 reductase 4 Human genes 0.000 description 4
- 108030005700 Cytochrome-b5 reductases Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102000005486 Epoxide hydrolase Human genes 0.000 description 4
- 108020002908 Epoxide hydrolase Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 102000030902 Galactosyltransferase Human genes 0.000 description 4
- 108060003306 Galactosyltransferase Proteins 0.000 description 4
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 4
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 101001034811 Homo sapiens Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 4
- 101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 108010045510 NADPH-Ferrihemoprotein Reductase Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 108090000754 Phosphoric Triester Hydrolases Proteins 0.000 description 4
- 102000004203 Phosphoric Triester Hydrolases Human genes 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 241000714474 Rous sarcoma virus Species 0.000 description 4
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 150000004982 aromatic amines Chemical class 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- 208000001088 cerebrotendinous xanthomatosis Diseases 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 108010048607 glycerophosphodiester phosphodiesterase Proteins 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 208000036796 hyperbilirubinemia Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 210000001589 microsome Anatomy 0.000 description 4
- 230000036457 multidrug resistance Effects 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 150000002924 oxiranes Chemical class 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000007442 rickets Diseases 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 description 4
- 229950005371 zaprinast Drugs 0.000 description 4
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 3
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 3
- 208000026872 Addison Disease Diseases 0.000 description 3
- 208000003200 Adenoma Diseases 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 102100027950 Bile acid-CoA:amino acid N-acyltransferase Human genes 0.000 description 3
- 108030000726 Bile acid-CoA:amino acid N-acyltransferases Proteins 0.000 description 3
- 235000021318 Calcifediol Nutrition 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108010051152 Carboxylesterase Proteins 0.000 description 3
- 102000013392 Carboxylesterase Human genes 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 102100031655 Cytochrome b5 Human genes 0.000 description 3
- 108010007167 Cytochromes b5 Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 3
- 108010074122 Ferredoxins Proteins 0.000 description 3
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 description 3
- 101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 description 3
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 102000004157 Hydrolases Human genes 0.000 description 3
- 108090000604 Hydrolases Proteins 0.000 description 3
- 206010020850 Hyperthyroidism Diseases 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010068073 Kynurenine-oxoglutarate transaminase Proteins 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 3
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000710961 Semliki Forest virus Species 0.000 description 3
- 102100036916 Sodium-coupled neutral amino acid transporter 1 Human genes 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 102100036407 Thioredoxin Human genes 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 241000723873 Tobacco mosaic virus Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 101710148271 UDP-glucose:glycoprotein glucosyltransferase 1 Proteins 0.000 description 3
- 102100029151 UDP-glucuronosyltransferase 1A10 Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 102100026523 Vitamin D 25-hydroxylase Human genes 0.000 description 3
- 108030007274 Vitamin D 25-hydroxylases Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000005091 airway smooth muscle Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 3
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 231100000317 environmental toxin Toxicity 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 3
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 230000002363 herbicidal effect Effects 0.000 description 3
- 239000004009 herbicide Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000006195 histone acetylation Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000000688 human artificial chromosome Anatomy 0.000 description 3
- 102000001718 human gonad-specific transporter Human genes 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000005805 hydroxylation reaction Methods 0.000 description 3
- 208000003532 hypothyroidism Diseases 0.000 description 3
- 230000002989 hypothyroidism Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 229960003350 isoniazid Drugs 0.000 description 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 239000003471 mutagenic agent Substances 0.000 description 3
- 231100000707 mutagenic chemical Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 231100000299 mutagenicity Toxicity 0.000 description 3
- 230000007886 mutagenicity Effects 0.000 description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 108060008226 thioredoxin Proteins 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000005891 transamination reaction Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 201000011296 tyrosinemia Diseases 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 2
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 229930182840 (S)-nicotine Natural products 0.000 description 2
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- GACDQMDRPRGCTN-KQYNXXCUSA-N 3'-phospho-5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](OP(O)(O)=O)[C@H]1O GACDQMDRPRGCTN-KQYNXXCUSA-N 0.000 description 2
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 102100036664 Adenosine deaminase Human genes 0.000 description 2
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 2
- 102000005602 Aldo-Keto Reductases Human genes 0.000 description 2
- 108010084469 Aldo-Keto Reductases Proteins 0.000 description 2
- 208000007887 Alphavirus Infections Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108060000550 Aryl sulfotransferase Proteins 0.000 description 2
- 102000008097 Aryl sulfotransferase Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100021973 Carbonyl reductase [NADPH] 1 Human genes 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 2
- 206010018325 Congenital glaucomas Diseases 0.000 description 2
- 208000001819 Crigler-Najjar Syndrome Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 2
- 102100032788 Dimethylaniline monooxygenase [N-oxide-forming] 1 Human genes 0.000 description 2
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 2
- 206010013883 Dwarfism Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 241001635598 Enicostema Species 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108030006091 Flavin-containing monooxygenases Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 208000009139 Gilbert Disease Diseases 0.000 description 2
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 108010004901 Haloalkane dehalogenase Proteins 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 102000018802 High Mobility Group Proteins Human genes 0.000 description 2
- 108010052512 High Mobility Group Proteins Proteins 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 2
- 101000640793 Homo sapiens UDP-galactose translocator Proteins 0.000 description 2
- 101000672037 Homo sapiens UDP-glucose:glycoprotein glucosyltransferase 2 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 201000002980 Hyperparathyroidism Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000013038 Hypocalcemia Diseases 0.000 description 2
- 206010058359 Hypogonadism Diseases 0.000 description 2
- 208000029663 Hypophosphatemia Diseases 0.000 description 2
- 206010021067 Hypopituitarism Diseases 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 2
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 208000010557 Lipid storage disease Diseases 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 2
- 208000012583 Menkes disease Diseases 0.000 description 2
- 108010061951 Methemoglobin Proteins 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 102100023897 NADPH-cytochrome P450 reductase Human genes 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 2
- 208000008457 Neurologic Manifestations Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000039036 PDE4 family Human genes 0.000 description 2
- 108091065684 PDE4 family Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 description 2
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 2
- 102000005782 Squalene Monooxygenase Human genes 0.000 description 2
- 108020003891 Squalene monooxygenase Proteins 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 102100029862 Sulfotransferase 1E1 Human genes 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 206010044242 Toxic nodular goitre Diseases 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 206010068233 Trimethylaminuria Diseases 0.000 description 2
- HDYANYHVCAPMJV-LXQIFKJMSA-N UDP-alpha-D-glucuronic acid Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O HDYANYHVCAPMJV-LXQIFKJMSA-N 0.000 description 2
- 102100033782 UDP-galactose translocator Human genes 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 2
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229940100228 acetyl coenzyme a Drugs 0.000 description 2
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000008236 biological pathway Effects 0.000 description 2
- 210000000625 blastula Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000006652 catabolic pathway Effects 0.000 description 2
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 208000007864 coumarin resistance Diseases 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010064 diabetes insipidus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- 238000007323 disproportionation reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002616 endonucleolytic effect Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 108010017360 estrone sulfotransferase Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000002190 fatty acyls Chemical group 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108010022687 fumarylacetoacetase Proteins 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000023611 glucuronidation Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 201000000079 gynecomastia Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 150000002443 hydroxylamines Chemical class 0.000 description 2
- 230000000705 hypocalcaemia Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 201000008284 inappropriate ADH syndrome Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229940058690 lanosterol Drugs 0.000 description 2
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 208000014416 lysosomal lipid storage disease Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 208000005135 methemoglobinemia Diseases 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000009251 neurologic dysfunction Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 208000007064 occipital horn syndrome Diseases 0.000 description 2
- 150000002903 organophosphorus compounds Chemical class 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960001476 pentoxifylline Drugs 0.000 description 2
- 230000000858 peroxisomal effect Effects 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229950004354 phosphorylcholine Drugs 0.000 description 2
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- MDYOLVRUBBJPFM-UHFFFAOYSA-N tropolone Chemical compound OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229940094720 viagra Drugs 0.000 description 2
- 229960000744 vinpocetine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000002034 xenobiotic effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- CCPPLLJZDQAOHD-GJGKEFFFSA-N (+)-vernolic acid Chemical compound CCCCC[C@H]1O[C@H]1C\C=C/CCCCCCCC(O)=O CCPPLLJZDQAOHD-GJGKEFFFSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- LTMJJNPVAMLQGV-PWNYCUMCSA-N (-)-(2R,3R)-2,3-dihydroxybutanamide Chemical compound C[C@@H](O)[C@@H](O)C(N)=O LTMJJNPVAMLQGV-PWNYCUMCSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- YBADLXQNJCMBKR-UHFFFAOYSA-M (4-nitrophenyl)acetate Chemical compound [O-]C(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-M 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 description 1
- OKZYCXHTTZZYSK-ZCFIWIBFSA-N (R)-5-phosphomevalonic acid Chemical compound OC(=O)C[C@@](O)(C)CCOP(O)(O)=O OKZYCXHTTZZYSK-ZCFIWIBFSA-N 0.000 description 1
- YGPSJZOEDVAXAB-UHFFFAOYSA-N (R)-Kynurenine Natural products OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 1
- CQSLTKIXAJTQGA-DHZHZOJOSA-N (e)-12,13-dihydroxyoctadec-9-enoic acid Chemical compound CCCCCC(O)C(O)C\C=C\CCCCCCCC(O)=O CQSLTKIXAJTQGA-DHZHZOJOSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- 150000000180 1,2-diols Chemical class 0.000 description 1
- 101710138112 1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate dehydrogenase Proteins 0.000 description 1
- VVJYUAYZJAKGRQ-UHFFFAOYSA-N 1-[4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C(O)C1 VVJYUAYZJAKGRQ-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 description 1
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 description 1
- 108090000937 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenases Proteins 0.000 description 1
- 108010031881 2,3-dihydroxy-2,3-dihydro-p-cumate dehydrogenase Proteins 0.000 description 1
- QYIMSPSDBYKPPY-BANQPHDMSA-N 2,3-epoxysqualene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC1OC1(C)C QYIMSPSDBYKPPY-BANQPHDMSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 1
- 108030003488 2-deoxy-D-gluconate 3-dehydrogenases Proteins 0.000 description 1
- FGSBNBBHOZHUBO-UHFFFAOYSA-N 2-oxoadipic acid Chemical compound OC(=O)CCCC(=O)C(O)=O FGSBNBBHOZHUBO-UHFFFAOYSA-N 0.000 description 1
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 1
- FCKJYANJHNLEEP-OIMXRAFZSA-N 24,25-Dihydroxyvitamin D Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@H](O)CCC1=C FCKJYANJHNLEEP-OIMXRAFZSA-N 0.000 description 1
- 108010067837 3,4-dihydroxyphenylacetate 2,3-dioxygenase Proteins 0.000 description 1
- 102000009878 3-Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- 102100039358 3-hydroxyacyl-CoA dehydrogenase type-2 Human genes 0.000 description 1
- 108090000124 3-hydroxybutyrate dehydrogenases Proteins 0.000 description 1
- 102000034279 3-hydroxybutyrate dehydrogenases Human genes 0.000 description 1
- YHKWFDPEASWKFQ-UHFFFAOYSA-N 3-nitrobenzene-1,2-diol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1O YHKWFDPEASWKFQ-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 108010051365 4-chlorophenylacetate 3,4-dioxygenase Proteins 0.000 description 1
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 102100028626 4-hydroxyphenylpyruvate dioxygenase Human genes 0.000 description 1
- 108030005241 4-hydroxyphenylpyruvate oxidases Proteins 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 108010038076 5-carboxymethyl-2-hydroxymuconate Delta-isomerase Proteins 0.000 description 1
- 108030004445 5-carboxymethyl-2-hydroxymuconic-semialdehyde dehydrogenases Proteins 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 108010087628 5-oxopent-3-ene-1,2,5-tricarboxylate decarboxylase Proteins 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 108010014831 7-alpha-hydroxysteroid dehydrogenase Proteins 0.000 description 1
- XEBKSQSGNGRGDW-YFHOEESVSA-N 9,10-DiHOME Chemical compound CCCCC\C=C/CC(O)C(O)CCCCCCCC(O)=O XEBKSQSGNGRGDW-YFHOEESVSA-N 0.000 description 1
- 108010044267 Abnormal Hemoglobins Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QTXZASLUYMRUAN-QLQASOTGSA-N Acetyl coenzyme A (Acetyl-CoA) Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1.O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QTXZASLUYMRUAN-QLQASOTGSA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 208000020576 Adrenal disease Diseases 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 208000009888 Adrenocortical Adenoma Diseases 0.000 description 1
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 108010058882 Alcohol sulfotransferase Proteins 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 208000005223 Alkalosis Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108010006591 Apoenzymes Proteins 0.000 description 1
- 102100029361 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 1
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100036465 Autoimmune regulator Human genes 0.000 description 1
- 101000758783 Bacillus subtilis (strain 168) Probable 4-hydroxyphenylacetate 3-monooxygenase Proteins 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical class OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
- 108010081290 Bile-salt sulfotransferase Proteins 0.000 description 1
- 208000015163 Biliary Tract disease Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108010088278 Branched-chain-amino-acid transaminase Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100025399 Breast cancer type 2 susceptibility protein Human genes 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010073997 Bromide peroxidase Proteins 0.000 description 1
- 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000173351 Camvirus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000492 Carbonyl Reductase (NADPH) Proteins 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010007747 Cataract congenital Diseases 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 239000005496 Chlorsulfuron Substances 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 102100032404 Cholinesterase Human genes 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010957 Copper deficiency Diseases 0.000 description 1
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 description 1
- 108010002154 Cortisone Reductase Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010011321 Craniorachischisis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 108010028689 Cytochrome-B(5) Reductase Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- JDMUPRLRUUMCTL-VIFPVBQESA-N D-pantetheine 4'-phosphate Chemical compound OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS JDMUPRLRUUMCTL-VIFPVBQESA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 description 1
- 102100037846 Dehydrogenase/reductase SDR family member 4 Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012565 Developmental glaucoma Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 description 1
- 101100351286 Dictyostelium discoideum pdeE gene Proteins 0.000 description 1
- 208000005872 Diffuse Esophageal Spasm Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000027877 Disorders of Sex Development Diseases 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101000899168 Drosophila melanogaster Beta-1,3-galactosyltransferase brn Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 208000011345 Duchenne and Becker muscular dystrophy Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014567 Empty Sella Syndrome Diseases 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 206010058838 Enterocolitis infectious Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010015251 Erythroblastosis foetalis Diseases 0.000 description 1
- 101710100588 Erythroid transcription factor Proteins 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 208000007217 Esophageal Stenosis Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010073922 Estradiol Dehydrogenases Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108020005637 FAD dependent oxidoreductase Proteins 0.000 description 1
- 102000007384 FAD-dependent oxidoreductase Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 206010049290 Feminisation acquired Diseases 0.000 description 1
- 208000034793 Feminization Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 208000007300 Fibrolamellar hepatocellular carcinoma Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010072104 Fructose intolerance Diseases 0.000 description 1
- 208000010263 Fructose-1,6-Diphosphatase Deficiency Diseases 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 102100029115 Fumarylacetoacetase Human genes 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000001287 Galactorrhea Diseases 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 102100033840 General transcription factor IIF subunit 1 Human genes 0.000 description 1
- 101000866605 Geobacillus sp. (strain PA-9) 4-hydroxyphenylacetate 3-monooxygenase oxygenase component Proteins 0.000 description 1
- GVVPGTZRZFNKDS-YFHOEESVSA-N Geranyl diphosphate Natural products CC(C)=CCC\C(C)=C/COP(O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-YFHOEESVSA-N 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- SAEBUDRWKUXLOM-ACZMJKKPSA-N Glu-Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O SAEBUDRWKUXLOM-ACZMJKKPSA-N 0.000 description 1
- QXDXIXFSFHUYAX-MNXVOIDGSA-N Glu-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O QXDXIXFSFHUYAX-MNXVOIDGSA-N 0.000 description 1
- CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000004538 Gordon syndrome Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010061201 Helminthic infection Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 108010068377 Hemoglobin M Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019713 Hepatic vein thrombosis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 206010019878 Hereditary fructose intolerance Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- WZOGEMJIZBNFBK-CIUDSAMLSA-N His-Asp-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O WZOGEMJIZBNFBK-CIUDSAMLSA-N 0.000 description 1
- SDTPKSOWFXBACN-GUBZILKMSA-N His-Glu-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O SDTPKSOWFXBACN-GUBZILKMSA-N 0.000 description 1
- YADRBUZBKHHDAO-XPUUQOCRSA-N His-Gly-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C)C(O)=O YADRBUZBKHHDAO-XPUUQOCRSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 description 1
- 101000981987 Homo sapiens N-alpha-acetyltransferase 20 Proteins 0.000 description 1
- 101000629622 Homo sapiens Serine-pyruvate aminotransferase Proteins 0.000 description 1
- 101000640836 Homo sapiens Sodium-coupled neutral amino acid transporter 4 Proteins 0.000 description 1
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 description 1
- 101001098805 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4A Proteins 0.000 description 1
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 1
- 102000030513 Homogentisate 1,2-Dioxygenase Human genes 0.000 description 1
- 108700023439 Homogentisate 1,2-dioxygenases Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 1
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010020562 Hyperadrenalism Diseases 0.000 description 1
- 206010020564 Hyperadrenocorticism Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- USXAYNCLFSUSBA-MGHWNKPDSA-N Ile-Phe-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N USXAYNCLFSUSBA-MGHWNKPDSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 241000186984 Kitasatospora aureofaciens Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 description 1
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- 206010062062 Large intestinal obstruction Diseases 0.000 description 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
- 108700005090 Lethal Genes Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 101710170970 Leukotoxin Proteins 0.000 description 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
- 208000026709 Liddle syndrome Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- BYPMOIFBQPEWOH-CIUDSAMLSA-N Lys-Asn-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N BYPMOIFBQPEWOH-CIUDSAMLSA-N 0.000 description 1
- 108010062166 Lys-Asn-Asp Proteins 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 239000005949 Malathion Substances 0.000 description 1
- 102100038560 Maleylacetoacetate isomerase Human genes 0.000 description 1
- 206010026712 Mallory-Weiss syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000027933 Mannosidase Deficiency disease Diseases 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
- SIGQQUBJQXSAMW-LURJTMIESA-N Mevalonic acid 5-pyrophosphate Chemical compound OC(=O)C[C@](O)(C)CCOP(O)(=O)OP(O)(O)=O SIGQQUBJQXSAMW-LURJTMIESA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108010064998 N-acetyltransferase 1 Proteins 0.000 description 1
- 108030006803 N-acylmannosamine 1-dehydrogenases Proteins 0.000 description 1
- UIAYVIIHMORPSJ-UHFFFAOYSA-N N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide Chemical compound C=1C=C2NC(=O)C=CC2=CC=1OCCCC(=O)N(C)C1CCCCC1 UIAYVIIHMORPSJ-UHFFFAOYSA-N 0.000 description 1
- 125000000815 N-oxide group Chemical group 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 description 1
- 101710197978 NADPH-dependent oxidoreductase Proteins 0.000 description 1
- 101150019103 NAT2 gene Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 108090001145 Nuclear Receptor Coactivator 3 Proteins 0.000 description 1
- 102100022883 Nuclear receptor coactivator 3 Human genes 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010030184 Oesophageal spasm Diseases 0.000 description 1
- 206010030194 Oesophageal stenosis Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 102000039033 PDE3 family Human genes 0.000 description 1
- 108091065683 PDE3 family Proteins 0.000 description 1
- 101150085386 PDE6B gene Proteins 0.000 description 1
- 102000039035 PDE7 family Human genes 0.000 description 1
- 108091065699 PDE7 family Proteins 0.000 description 1
- 108010035473 Palmitoyl-CoA Hydrolase Proteins 0.000 description 1
- 102000008172 Palmitoyl-CoA Hydrolase Human genes 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 201000004602 Peliosis Hepatis Diseases 0.000 description 1
- 108700001574 Pentosuria Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100038124 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 208000021738 Plummer disease Diseases 0.000 description 1
- 241000881705 Porcine endogenous retrovirus Species 0.000 description 1
- 206010058989 Portal vein occlusion Diseases 0.000 description 1
- 201000009454 Portal vein thrombosis Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 206010036297 Postpartum hypopituitarism Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010036783 Proctitis ulcerative Diseases 0.000 description 1
- 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 1
- 206010071019 Prostatic dysplasia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 101100231693 Rattus norvegicus Hpgds gene Proteins 0.000 description 1
- 101100539374 Rattus norvegicus Ugt2b gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 101000744001 Ruminococcus gnavus (strain ATCC 29149 / VPI C7-9) 3beta-hydroxysteroid dehydrogenase Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- VQBLHWSPVYYZTB-DCAQKATOSA-N Ser-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N VQBLHWSPVYYZTB-DCAQKATOSA-N 0.000 description 1
- CDVFZMOFNJPUDD-ACZMJKKPSA-N Ser-Gln-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CDVFZMOFNJPUDD-ACZMJKKPSA-N 0.000 description 1
- 102100026842 Serine-pyruvate aminotransferase Human genes 0.000 description 1
- 206010066833 Sertoli cell-only syndrome Diseases 0.000 description 1
- 201000009895 Sheehan syndrome Diseases 0.000 description 1
- 102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 description 1
- 108010048287 Short Chain Dehydrogenase-Reductases Proteins 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 201000001388 Smith-Magenis syndrome Diseases 0.000 description 1
- 102100033869 Sodium-coupled neutral amino acid transporter 4 Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 108030007031 Sorbitol-6-phosphate 2-dehydrogenases Proteins 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 102000005566 Succinate-Semialdehyde Dehydrogenase Human genes 0.000 description 1
- 108010084086 Succinate-Semialdehyde Dehydrogenase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102100029867 Sulfotransferase 2A1 Human genes 0.000 description 1
- 102100028031 Sulfotransferase 2B1 Human genes 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 206010069771 Thyroid dermatopathy Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010043780 Thyroiditis acute Diseases 0.000 description 1
- 206010043784 Thyroiditis subacute Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 1
- 231100000265 Toxic optic neuropathy Toxicity 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000006612 Transducin Human genes 0.000 description 1
- 108010087042 Transducin Proteins 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- SWSUXOKZKQRADK-FDARSICLSA-N Trp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N SWSUXOKZKQRADK-FDARSICLSA-N 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- KWKJGBHDYJOVCR-SRVKXCTJSA-N Tyr-Ser-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O KWKJGBHDYJOVCR-SRVKXCTJSA-N 0.000 description 1
- AFWXOGHZEKARFH-ACRUOGEOSA-N Tyr-Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=C(O)C=C1 AFWXOGHZEKARFH-ACRUOGEOSA-N 0.000 description 1
- 102000016540 Tyrosine aminotransferases Human genes 0.000 description 1
- 108010042606 Tyrosine transaminase Proteins 0.000 description 1
- 108010090271 Tyrosine-ester sulfotransferase Proteins 0.000 description 1
- 108010075920 UDP-galactose translocator Proteins 0.000 description 1
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 description 1
- 208000006038 Urogenital Abnormalities Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
- LZRWTJSPTJSWDN-FKBYEOEOSA-N Val-Trp-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)N LZRWTJSPTJSWDN-FKBYEOEOSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- 208000012346 Venoocclusive disease Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 201000007960 WAGR syndrome Diseases 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 201000011032 Werner Syndrome Diseases 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 108700029631 X-Linked Genes Proteins 0.000 description 1
- 208000028247 X-linked inheritance Diseases 0.000 description 1
- 241000589506 Xanthobacter Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108091000039 acetoacetyl-CoA reductase Proteins 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NUFNQYOELLVIPL-UHFFFAOYSA-N acifluorfen Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 NUFNQYOELLVIPL-UHFFFAOYSA-N 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 201000006498 acute thyroiditis Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000015234 adrenal cortex adenoma Diseases 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 239000002115 aflatoxin B1 Substances 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 229930020125 aflatoxin-B1 Natural products 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000002340 alkalosis Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000000975 allocortex Anatomy 0.000 description 1
- 230000008856 allosteric binding Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 208000007957 amaurosis fugax Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- NVWAMZLSFUBOGT-UHFFFAOYSA-N amino nitrite Chemical class NON=O NVWAMZLSFUBOGT-UHFFFAOYSA-N 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 206010002320 anencephaly Diseases 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 208000008303 aniridia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003858 bile acid conjugate Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- VWYQKFLLGRBICZ-UHFFFAOYSA-N butanilicaine Chemical compound CCCCNCC(=O)NC1=C(C)C=CC=C1Cl VWYQKFLLGRBICZ-UHFFFAOYSA-N 0.000 description 1
- 229960001290 butanilicaine Drugs 0.000 description 1
- 102100037092 cAMP-specific 3',5'-cyclic phosphodiesterase 4A Human genes 0.000 description 1
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000002894 chemical waste Substances 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950002934 cilostamide Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 108010065657 cis-1,2-dihydrobenzene-1,2-diol dehydrogenase Proteins 0.000 description 1
- 108010016012 cis-toluene dihydrodiol dehydrogenase Proteins 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- JSRLJPSBLDHEIO-SHYZEUOFSA-N dUMP Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- VBLJFQYCTRKKKF-UHFFFAOYSA-N diazoxon Chemical compound CCOP(=O)(OCC)OC1=CC(C)=NC(C(C)C)=N1 VBLJFQYCTRKKKF-UHFFFAOYSA-N 0.000 description 1
- SIEILFNCEFEENQ-UHFFFAOYSA-N dibromo-acetic acid Natural products OC(=O)C(Br)Br SIEILFNCEFEENQ-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- OTMOUPHCTWPNSL-UHFFFAOYSA-N diethyl (3,5,6-trichloropyridin-2-yl) phosphate Chemical compound CCOP(=O)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl OTMOUPHCTWPNSL-UHFFFAOYSA-N 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- VKFAUCPBMAGVRG-UHFFFAOYSA-N dipivefrin hydrochloride Chemical compound [Cl-].C[NH2+]CC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 VKFAUCPBMAGVRG-UHFFFAOYSA-N 0.000 description 1
- 229940090570 dipivefrin hydrochloride Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000016001 distal arthrogryposis type 3 Diseases 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 description 1
- 229960000972 enoximone Drugs 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 108010017796 epoxidase Proteins 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 description 1
- 229960002724 fenoldopam Drugs 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 208000001031 fetal erythroblastosis Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 201000004098 fibrolamellar carcinoma Diseases 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000007914 freezing tolerance Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010087974 gliotactin Proteins 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108010040856 glutamyl-cysteinyl-alanine Proteins 0.000 description 1
- LLCSXHMJULHSJN-UHFFFAOYSA-N glycerophosphoglycerol Chemical compound OCC(O)COP(O)(=O)OCC(O)CO LLCSXHMJULHSJN-UHFFFAOYSA-N 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 108010011677 glyoxylate aminotransferase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000002566 gonadal dysgenesis Diseases 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 208000017367 hand-Schuller-Christian disease Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 206010019680 hepatic infarction Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 208000007000 hereditary hyperbilirubinemia Diseases 0.000 description 1
- 208000013057 hereditary mucoepithelial dysplasia Diseases 0.000 description 1
- 201000005611 hermaphroditism Diseases 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 101150113423 hisD gene Proteins 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000044787 human EP300 Human genes 0.000 description 1
- 108091003098 human bone sialoprotein (35-62) Proteins 0.000 description 1
- 102000027012 human bone sialoprotein (35-62) Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 238000006912 hydrolase reaction Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- HBMCQTHGYMTCOF-UHFFFAOYSA-N hydroquinone monoacetate Natural products CC(=O)OC1=CC=C(O)C=C1 HBMCQTHGYMTCOF-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 208000007357 hyperpituitarism Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000027139 infectious colitis Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000027884 letterer-Siwe disease Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 229950009035 lixazinone Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 101710130522 mRNA export factor Proteins 0.000 description 1
- 201000005139 macular corneal dystrophy Diseases 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 229960000453 malathion Drugs 0.000 description 1
- 108010035293 maleylacetoacetate isomerase Proteins 0.000 description 1
- 201000002742 malignant choroid melanoma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- WUECXCBONAGRSA-UHFFFAOYSA-N n-cyclohexyl-n-methyl-4-[(2-oxo-5,10-dihydro-3h-imidazo[2,1-b]quinazolin-7-yl)oxy]butanamide Chemical compound C=1C=C2NC3=NC(=O)CN3CC2=CC=1OCCCC(=O)N(C)C1CCCCC1 WUECXCBONAGRSA-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-L oxaloacetate(2-) Chemical compound [O-]C(=O)CC(=O)C([O-])=O KHPXUQMNIQBQEV-UHFFFAOYSA-L 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 238000012753 partial hepatectomy Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 101150037969 pde-6 gene Proteins 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 208000001893 pentosuria Diseases 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010025593 phenylalanine (histidine) aminotransferase Proteins 0.000 description 1
- BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000016732 phototransduction Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 201000006672 primary congenital glaucoma Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 208000000891 primary hyperoxaluria type 1 Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 208000024981 pyrosis Diseases 0.000 description 1
- ADRDEXBBJTUCND-UHFFFAOYSA-N pyrrolizidine Chemical class C1CCN2CCCC21 ADRDEXBBJTUCND-UHFFFAOYSA-N 0.000 description 1
- 229930002356 pyrrolizidine alkaloid Natural products 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000010666 regulation of catalytic activity Effects 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000012865 response to insecticide Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 108010020957 ribitol 2-dehydrogenase Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 150000003346 selenoethers Chemical class 0.000 description 1
- 150000003349 semicarbazides Chemical class 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- BMVUIWJCUQSHLZ-YFZGBAIXSA-N sn-Glycero-3-phosphoinositol Chemical compound OC[C@@H](O)COP(O)(=O)OC1[C@H](O)[C@@H](O)C(O)[C@@H](O)[C@H]1O BMVUIWJCUQSHLZ-YFZGBAIXSA-N 0.000 description 1
- JZNWSCPGTDBMEW-YFKPBYRVSA-N sn-glycero-3-phosphoethanolamine Chemical compound NCCO[P@@](O)(=O)OC[C@@H](O)CO JZNWSCPGTDBMEW-YFKPBYRVSA-N 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000010009 steroidogenesis Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 201000007497 subacute thyroiditis Diseases 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000005460 tetrahydrofolate Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108010014677 transcription factor TFIIE Proteins 0.000 description 1
- 108010014678 transcription factor TFIIF Proteins 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
- 101150081616 trpB gene Proteins 0.000 description 1
- 101150111232 trpB-1 gene Proteins 0.000 description 1
- 208000013327 true hermaphroditism Diseases 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000006130 type 1B vitamin D hydroxylation-deficient rickets Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 108020005400 tyrosyl-DNA phosphodiesterase Proteins 0.000 description 1
- 102000007405 tyrosyl-DNA phosphodiesterase Human genes 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- CCPPLLJZDQAOHD-UHFFFAOYSA-N vernolic acid Natural products CCCCCC1OC1CC=CCCCCCCCC(O)=O CCPPLLJZDQAOHD-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 208000000318 vitreous detachment Diseases 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
- QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01021—Aldehyde reductase (1.1.1.21), i.e. aldose-reductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01017—Glucuronosyltransferase (2.4.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01045—2-Hydroxyacylsphingosine 1-beta-galactosyltransferase (2.4.1.45)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides human drug metabolizing enzymes (DME) and polynucleotides which identify and encode DME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of DME.
Description
DRUG METABOLIZING ENZYMES
TECHNICAL FIELD
This invention relates to nucleic acid and amino acid sequences of drug metabolizing enzymes and to the use of these sequences in the diagnosis, treatment, and prevention of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of drug metabolizing enzymes.
BACKGROUND OF THE INVENTION
The metabolism of a drug and its movement through the body (pharmacokinetics) are important in determining its effects, toxicity, and interactions with other drugs. The three processes governing pharmacokinetics are the absorption of the drug, distribution to various tissues, and elimination of drug metabolites. These processes are intimately coupled to drug metabolism, since a variety of metabolic modifications alter most of the physicochemical and pharmacological properties of drugs, including solubility, binding to receptors, and excretion rates. The metabolic pathways which modify drugs also accept a variety of naturally occurring substrates such as steroids, fatty acids, prostaglandins, leukotrienes, and vitamins. The enzymes in these pathways are therefore important sites of biochemical and pharmacological interaction between natural compounds, drugs, carcinogens, mutagens, and xenobiotics.
It has long been appreciated that inherited differences in drug metabolism lead to drastically different levels of drug efficacy and toxicity among individuals. For drugs with narrow therapeutic indices, or drugs which require bioactivation (such as codeine), these polymorphisms can be critical.
Moreover, promising new drugs are frequently eliminated in clinical trials based on toxicities which may only affect a segment of the patient group. Advances in pharmacogenomics research, of which drug metabolizing enzymes constitute an important part, are promising to expand the tools and information that can be brought to bear on questions of drug efficacy and toxicity (See Evans, W.E.
and R.V. Relling (1999) Science 286:487-491).
Drug metabolic reactions are categorized as Phase I, which functionalize the drug molecule and prepare it for further metabolism, and Phase II, which are conjugative. In general, Phase I
reaction products are partially or fully inactive, and Phase II reaction products are the chief excreted species. However, Phase I reaction products are sometimes more active than the original administered drugs; this metabolic activation principle is exploited by pro-drugs (e.g. L-dopa).
Additionally, some nontoxic compounds (e.g. aflatoxin, benzo[a]pyrene) are metabolized to toxic intermediates through these pathways. Phase I reactions are usually rate-limiting in drug metabolism.
Prior exposure to the compound, or other compounds, can induce the expression of Phase I enzymes however, and thereby increase substrate flux through the metabolic pathways.
(See Klaassen, C.D., Amdur, M.O. and J. Doull (1996) Casarett and Doull's Toxicol~y: The Basic Science of Poisons, McGraw-Hill, New York, NY, pp. 113-186; B.G. Katzung (1995) Basic and Clinical Pharmacolo~y, Appleton and Lange, Norwalk, CT, pp. 48-59; G.G. Gibson and P. Skett (1994) Introduction to Drug Metabolism, Blackie Academic and Professional, London.) Drug metabolizing enzymes (DMEs) have broad substrate specificities. This can be contrasted to the immune system, where a large and diverse population of antibodies are highly specific for their antigens. The ability of DMEs to metabolize a wide variety of molecules creates the potential for drug interactions at the level of metabolism. For example, the induction of a DME by one compound may affect the metabolism of another compound by the enzyme.
DMEs have been classified according to the type of reaction they catalyze and the cofactors involved. The major classes of Phase I enzymes include, but are not limited to, cytochrome P450 and flavin-containing monooxygenase. Other enzyme classes involved in Phase I-type catalytic cycles and reactions include, but are not limited to, NADPH cytochrome P450 reductase (CPR), the microsomal cytochrome b5/NADH cytochrome b5 reductase system, the ferredoxin/ferredoxin reductase redox pair, aldo/keto reductases, and alcohol dehydrogenases. The major classes of Phase II enzymes include, but are not limited to, UDP glucuronyltransferase, sulfotransferase, glutathione S-transferase, N-acyltransferase, and N-acetyl transferase.
Cytochrome P450 and P450 catalytic cvcle-associated enz Members of the cytochrome P450 superfamily of enzymes catalyze the oxidative metabolism of a variety of substrates, including natural compounds such as steroids, fatty acids, prostaglandins, leukotrienes, and vitamins, as well as drugs, carcinogens, mutagens, and xenobiotics. Cytochromes P450, also known as P450 heme-thiolate proteins, usually act as terminal oxidases in multi-component electron transfer chains, called P450-containing monooxygenase systems. Specific reactions catalyzed include hydroxylation, epoxidation, N-oxidation, sulfooxidation, N-, S-, and O-dealkylations, desulfation, deamination, and reduction of azo, nitro, and N-oxide groups. These reactions are involved in steroidogenesis of glucocorticoids, cortisols, estrogens, and androgens in animals; insecticide resistance in insects; herbicide resistance and flower coloring in plants; and environmental bioremediation by microorganisms. Cytochrome P450 actions on drugs, carcinogens, mutagens, and xenobiotics can result in detoxification or in conversion of the substance to a more toxic product. Cytochromes P450 are abundant in the liver, but also occur in other tissues; the enzymes are located in microsomes. (See ExPASY ENZYME EC 1.14.14.1; Prosite Cytochrome P450 cysteine heme-iron ligand signature; PRINTS EP450I E-Class P450 Group I
TECHNICAL FIELD
This invention relates to nucleic acid and amino acid sequences of drug metabolizing enzymes and to the use of these sequences in the diagnosis, treatment, and prevention of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of drug metabolizing enzymes.
BACKGROUND OF THE INVENTION
The metabolism of a drug and its movement through the body (pharmacokinetics) are important in determining its effects, toxicity, and interactions with other drugs. The three processes governing pharmacokinetics are the absorption of the drug, distribution to various tissues, and elimination of drug metabolites. These processes are intimately coupled to drug metabolism, since a variety of metabolic modifications alter most of the physicochemical and pharmacological properties of drugs, including solubility, binding to receptors, and excretion rates. The metabolic pathways which modify drugs also accept a variety of naturally occurring substrates such as steroids, fatty acids, prostaglandins, leukotrienes, and vitamins. The enzymes in these pathways are therefore important sites of biochemical and pharmacological interaction between natural compounds, drugs, carcinogens, mutagens, and xenobiotics.
It has long been appreciated that inherited differences in drug metabolism lead to drastically different levels of drug efficacy and toxicity among individuals. For drugs with narrow therapeutic indices, or drugs which require bioactivation (such as codeine), these polymorphisms can be critical.
Moreover, promising new drugs are frequently eliminated in clinical trials based on toxicities which may only affect a segment of the patient group. Advances in pharmacogenomics research, of which drug metabolizing enzymes constitute an important part, are promising to expand the tools and information that can be brought to bear on questions of drug efficacy and toxicity (See Evans, W.E.
and R.V. Relling (1999) Science 286:487-491).
Drug metabolic reactions are categorized as Phase I, which functionalize the drug molecule and prepare it for further metabolism, and Phase II, which are conjugative. In general, Phase I
reaction products are partially or fully inactive, and Phase II reaction products are the chief excreted species. However, Phase I reaction products are sometimes more active than the original administered drugs; this metabolic activation principle is exploited by pro-drugs (e.g. L-dopa).
Additionally, some nontoxic compounds (e.g. aflatoxin, benzo[a]pyrene) are metabolized to toxic intermediates through these pathways. Phase I reactions are usually rate-limiting in drug metabolism.
Prior exposure to the compound, or other compounds, can induce the expression of Phase I enzymes however, and thereby increase substrate flux through the metabolic pathways.
(See Klaassen, C.D., Amdur, M.O. and J. Doull (1996) Casarett and Doull's Toxicol~y: The Basic Science of Poisons, McGraw-Hill, New York, NY, pp. 113-186; B.G. Katzung (1995) Basic and Clinical Pharmacolo~y, Appleton and Lange, Norwalk, CT, pp. 48-59; G.G. Gibson and P. Skett (1994) Introduction to Drug Metabolism, Blackie Academic and Professional, London.) Drug metabolizing enzymes (DMEs) have broad substrate specificities. This can be contrasted to the immune system, where a large and diverse population of antibodies are highly specific for their antigens. The ability of DMEs to metabolize a wide variety of molecules creates the potential for drug interactions at the level of metabolism. For example, the induction of a DME by one compound may affect the metabolism of another compound by the enzyme.
DMEs have been classified according to the type of reaction they catalyze and the cofactors involved. The major classes of Phase I enzymes include, but are not limited to, cytochrome P450 and flavin-containing monooxygenase. Other enzyme classes involved in Phase I-type catalytic cycles and reactions include, but are not limited to, NADPH cytochrome P450 reductase (CPR), the microsomal cytochrome b5/NADH cytochrome b5 reductase system, the ferredoxin/ferredoxin reductase redox pair, aldo/keto reductases, and alcohol dehydrogenases. The major classes of Phase II enzymes include, but are not limited to, UDP glucuronyltransferase, sulfotransferase, glutathione S-transferase, N-acyltransferase, and N-acetyl transferase.
Cytochrome P450 and P450 catalytic cvcle-associated enz Members of the cytochrome P450 superfamily of enzymes catalyze the oxidative metabolism of a variety of substrates, including natural compounds such as steroids, fatty acids, prostaglandins, leukotrienes, and vitamins, as well as drugs, carcinogens, mutagens, and xenobiotics. Cytochromes P450, also known as P450 heme-thiolate proteins, usually act as terminal oxidases in multi-component electron transfer chains, called P450-containing monooxygenase systems. Specific reactions catalyzed include hydroxylation, epoxidation, N-oxidation, sulfooxidation, N-, S-, and O-dealkylations, desulfation, deamination, and reduction of azo, nitro, and N-oxide groups. These reactions are involved in steroidogenesis of glucocorticoids, cortisols, estrogens, and androgens in animals; insecticide resistance in insects; herbicide resistance and flower coloring in plants; and environmental bioremediation by microorganisms. Cytochrome P450 actions on drugs, carcinogens, mutagens, and xenobiotics can result in detoxification or in conversion of the substance to a more toxic product. Cytochromes P450 are abundant in the liver, but also occur in other tissues; the enzymes are located in microsomes. (See ExPASY ENZYME EC 1.14.14.1; Prosite Cytochrome P450 cysteine heme-iron ligand signature; PRINTS EP450I E-Class P450 Group I
signature; Graham-Lorence, S. and Peterson, J.A. ( 1996) FASEB J. 10:206-214.) Four hundred cytochromes P450 have been identified in diverse organisms including bacteria, fungi, plants, and animals (Graham-Lorence, supra). The B-class is found in prokaryotes and fungi, while the E-class is found in bacteria, plants, insects, vertebrates, and mammals. Five subclasses or groups are found within the larger family of E-class cytochromes P450 (PRINTS
EP450I E-Class P450 Group I signature).
All cytochromes P450 use a heme cofactor and share structural attributes. Most cytochromes P450 are 400 to 530 amino acids in length. The secondary structure of the enzyme is about 70%
alpha-helical and about 22% beta-sheet. The region around the heme-binding site in the C-terminal part of the protein is conserved among cytochromes P450. A ten amino acid signature sequence in this heme-iron ligand region has been identified which includes a conserved cysteine involved in binding the heme iron in the fifth coordination site. In eukaryotic cytochromes P450, a membrane-spanning region is usually found in the first 15-20 amino acids of the protein, generally consisting of approximately 15 hydrophobic residues followed by a positively charged residue. (See Prosite PDOC00081, supra; Graham-Lorence, supra.) Cytochrome P450 enzymes are involved in cell proliferation and development.
The enzymes have roles in chemical mutagenesis and carcinogenesis by metabolizing chemicals to reactive intermediates that form adducts with DNA (Nebert, D.W. and Gonzalez, F.J.
(1987) Ann. Rev.
Biochem. 56:945-993). These adducts can cause nucleotide changes and DNA
rearrangements that lead to oncogenesis. Cytochrome P450 expression in liver and other tissues is induced by xenobiotics such as polycyclic aromatic hydrocarbons, peroxisomal proliferators, phenobarbital, and the glucocorticoid dexamethasone (Dogra, S.C. et al. (1998) Clin. Exp. Pharmacol.
Physiol. 25:1-9). A
cytochrome P450 protein may participate in eye development as mutations in the P450 gene CYP1B1 cause primary congenital glaucoma (Online Mendelian Inheritance in Man (OMIM) *601771 Cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1; CYP1B1).
Cytochromes P450 are associated with inflammation and infection. Hepatic cytochrome P450 activities are profoundly affected by various infections and inflammatory stimuli, some of which are suppressed and some induced (Morgan, E.T. (1997) Drug Metab. Rev.
29:1129-1188).
Effects observed in vivo can be mimicked by proinflammatory cytokines and interferons.
Autoantibodies to two cytochrome P450 proteins were found in patients with autoimmune polyenodocrinopathy-candidiasis-ectodermal dystrophy (APECED), a polyglandular autoimmune syndrome (OMIM *240300 Autoimmune polyenodocrinopathy-candidiasis-ectodermal dystrophy).
Mutations in cytochromes P450 have been linked to metabolic disorders, including congenital adrenal hyperplasia, the most common adrenal disorder of infancy and childhood; pseudovitamin D-deficiency rickets; cerebrotendinous xanthomatosis, a lipid storage disease characterized by progressive neurologic dysfunction, premature atherosclerosis, and cataracts;
and an inherited resistance to the anticoagulant drugs coumarin and warfarin (Isselbacher, K.J.
et al. ( 1994) Harrison's Principles of Internal Medicine, McGraw-Hill, Inc. New York, NY, pp. 1968-1970; Takeyama, K. et al. (1997) Science 277:1827-1830; Kitanaka, S. et al. (1998) N. Engl. J. Med.
338:653-661; OMIM
*213700 Cerebrotendinous xanthomatosis; and OMIM #122700 Coumarin resistance).
Extremely high levels of expression of the cytochrome P450 protein aromatase were found in a fibrolamellar hepatocellular carcinoma from a boy with severe gynecomastia (feminization) (Agarwal, V.R. ( 1998) J. Clip. Endocrinol. Metab. 83:1797-1800).
The cytochrome P450 catalytic cycle is completed through reduction of cytochrome P450 by NADPH cytochrome P450 reductase (CPR). Another microsomal electron transport system consisting of cytochrome b5 and NADPH cytochrome b5 reductase has been widely viewed as a minor contributor of electrons to the cytochrome P450 catalytic cycle.
However, a recent report by Lamb, D.C. et al. (1999; FEBS Lett. 462:283-288) identifies a Candida albicans cytochrome P450 (CYP51) which can be efficiently reduced and supported by the microsomal cytochrome b5/NADPH
cytochrome b5 reductase system. Therefore, there are likely many cytochromes P450 which are supported by this alternative electron donor system.
Cytochrome b5 reductase is also responsible for the reduction of oxidized hemoglobin (methemoglobin, or ferrihemoglobin, which is unable to carry oxygen) to the active hemoglobin (ferrohemoglobin) in red blood cells. Methemoglobinemia results when there is a high level of oxidant drugs or an abnormal hemoglobin (hemoglobin M) which is not efficiently reduced.
Methemoglobinemia can also result from a hereditary deficiency in red cell cytochrome b5 reductase (Reviewed in Mansour, A. and Lurie, A.A. (1993) Am. J. Hematol. 42:7-12).
Members of the cytochrome P450 family are also closely associated with vitamin D synthesis and catabolism. Vitamin D exists as two biologically equivalent prohormones, ergocalciferol (vitamin DZ), produced in plant tissues, and cholecalciferol (vitamin D3), produced in animal tissues.
The latter form, cholecalciferol, is formed upon the exposure of 7-dehydrocholesterol to near ultraviolet light (i.e., 290-310 nm), normally resulting from even minimal periods of skin exposure to sunlight (reviewed in Miller, W.L. and Portale, A.A. (2000) Trends Endocrinol.
Metab. 11:315-319).
Both prohormone forms are further metabolized in the liver to 25-hydroxyvitamin D
(25(OH)D) by the enzyme 25-hydroxylase. 25(OH)D is the most abundant precursor form of vitamin D which must be further metabolized in the kidney to the active form, 1a,25-dihydroxyvitamin D
(1a,25(OH)ZD), by the enzyme 25-hydroxyvitamin D la-hydroxylase (la-hydroxylase). Regulation of 1a,25(OH)ZD production is primarily at this final step in the synthetic pathway. The activity of la-hydroxylase depends upon several physiological factors including the circulating level of the enzyme product (1a,25(OH)ZD) and the levels of parathyroid hormone (PTH), calcitonin, insulin, calcium, phosphorus, growth hormone, and prolactin. Furthermore, extrarenal la-hydroxylase activity has been reported, suggesting that tissue-specific, local regulation of 1a,25(OH)2D
production may also be biologically important. The catalysis of 1a,25(OH)ZD to 24,25-dihydroxyvitamin D (24,25(OH)ZD), involving the enzyme 25-hydroxyvitamin D
24-hydroxylase (24-hydroxylase), also occurs in the kidney. 24-hydroxylase can also use 25(OH)D as a substrate (Shinki, T. et al. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:12920-12925; Miller, W.L. and Portale, A.A. supra; and references within).
Vitamin D 25-hydroxylase, 1 a-hydroxylase, and 24-hydroxylase are all NADPH-dependent, type I (mitochondrial) cytochrome P450 enzymes that show a high degree of homology with other members of the family. Vitamin D 25-hydroxylase also shows a broad substrate specificity and may also perform 26-hydroxylation of bile acid intermediates and 25, 26, and 27-hydroxylation of cholesterol (Dilworth, F.J. et al. (1995) J. Biol. Chem. 270:16766-16774;
Miller, W.L. and Portale, A.A. supra; and references within).
The active form of vitamin D (1a,25(OH)ZD) is involved in calcium and phosphate homeostasis and promotes the differentiation of myeloid and skin cells.
Vitamin D deficiency resulting from deficiencies in the enzymes involved in vitamin D metabolism (e.g., la-hydroxylase) causes hypocalcemia, hypophosphatemia, and vitamin D-dependent (sensitive) rickets, a disease characterized by loss of bone density and distinctive clinical features, including bandy or bow leggedness accompanied by a waddling gait. Deficiencies in vitamin D 25-hydroxylase cause cerebrotendinous xanthomatosis, a lipid-storage disease characterized by the deposition of cholesterol and cholestanol in the Achilles' tendons, brain, lungs, and many other tissues. The disease presents with progressive neurologic dysfunction, including postpubescent cerebellar ataxia, atherosclerosis, and cataracts. Vitamin D 25-hydroxylase deficiency does not result in rickets, suggesting the existence of alternative pathways for the synthesis of 25(OH)D (Griffin, J.E.
and Zerwekh, J.E.
(1983) J. Clin. Invest. 72:1190-1199; Gamblin, G.T. et al. (1985) J. Clin.
Invest. 75:954-960; and W.L. and Portale, A.A. supra).
Ferredoxin and ferredoxin reductase are electron transport accessory proteins which support at least one human cytochrome P450 species, cytochrome P450c27 encoded by the CYP27 gene (Dilworth, F.J. et al. (1996) Biochem. J. 320:267-71). A Streptomyces ng ~seus cytochrome P450, CYP104D1, was heterologously expressed in E. coli and found to be reduced by the endogenous ferredoxin and ferredoxin reductase enzymes (Taylor, M. et al. (1999) Biochem.
Biophys. Res.
Commun. 263:838-42), suggesting that many cytochrome P450 species may be supported by the ferredoxin/ferredoxin reductase pair. Ferredoxin reductase has also been found in a model drug metabolism system to reduce actinomycin D, an antitumor antibiotic, to a reactive free radical species (Flitter, W.D. and Mason, R.P. (1988) Arch. Biochem. Biophys. 267:632-639).
Flavin-containing monooxygenase (FMO) Flavin-containing monooxygenases oxidize the nucleophilic nitrogen, sulfur, and phosphorus heteroatom of an exceptional range of substrates. Like cytochromes P450, FMOs are microsomal and use NADPH and OZ; there is also a great deal of substrate overlap with cytochromes P450. The tissue distribution of FMOs includes liver, kidney, and lung.
There are five different known isoforms of FMO in mammals (FMO1, FM02, FM03, FM04, and FM05), which are expressed in a tissue-specific manner. The isoforms differ in their substrate specificities and other properties such as inhibition by various compounds and stereospecificity of reaction. FMOs have a 13 amino acid signature sequence, the components of which span the N-terminal two-thirds of the sequences and include the FAD binding region and the FATGY motif which has been found in many N-hydroxylating enzymes (Stehr, M. et al. (1998) Trends Biochem.
Sci. 23:56-57; PRINTS FMOXYGENASE Flavin-containing monooxygenase signature).
Specific reactions include oxidation of nucleophilic tertiary amines to N-oxides, secondary amines to hydroxylamines and nitrones, primary amines to hydroxylamines and oximes, and sulfur-containing compounds and phosphines to S- and P-oxides. Hydrazines, iodides, selenides, and boron-containing compounds are also substrates. Although FMOs appear similar to cytochromes P450 in their chemistry, they can generally be distinguished from cytochromes P450 in vitro based on, for example, the higher heat lability of FMOs and the nonionic detergent sensitivity of cytochromes P450; however, use of these properties in identification is complicated by further variation among FMO isoforms with respect to thermal stability and detergent sensitivity.
FMOs play important roles in the metabolism of several drugs and xenobiotics.
FMO (FM03 in liver) is predominantly responsible for metabolizing (S)-nicotine to (S)-nicotine N-1=oxide, which is excreted in urine. FMO is also involved in S-oxygenation of cimetidine, an HZ-antagonist widely used for the treatment of gastric ulcers. Liver-expressed forms of FMO are not under the same regulatory control as cytochrome P450. In rats, for example, phenobarbital treatment leads to the induction of cytochrome P450, but the repression of FMO1.
Endogenous substrates of FMO include cysteamine, which is oxidized to the disulfide, cystamine, and trimethylamine (TMA), which is metabolized to trimethylamine N-oxide. TMA
smells like rotting fish, and mutations in the FM03 isoform lead to large amounts of the malodorous free amine being excreted in sweat, urine, and breath. These symptoms have led to the designation fish-odor syndrome (OMIM 602079 Trimethylaminuria).
Lysyl oxidase:
Lysyl oxidase (lysine 6-oxidase, LO) is a copper-dependent amine oxidase involved in the formation of connective.tissue matrices by crosslinking collagen and elastin.
LO is secreted as a N-glycosylated precuror protein of approximately 50 kDa Levels and cleaved to the mature form of the enzyme by a metalloprotease, although the precursor form is also active. The copper atom in LO is involved in the transport of electron to and from oxygen to facilitate the oxidative deamination of lysine residues in these extracellular matrix proteins. While the coordination of copper is essential to LO activity, insufficient dietary intake of copper does not influence the expression of the apoenzyme.
However, the absence of the functional LO is linked to the skeletal and vascular tissue disorders that are associated with dietary copper deficiency. LO is also inhibited by a variety of semicarbazides, hydrazines, and amino nitrites, as well as heparin. Beta-aminopropionitrile is a commonly used inhibitor. LO activity is increased in response to ozone, cadmium, and elevated levels of hormones released in response to local tissue trauma, such as transforming growth factor-beta, platelet-derived growth factor, angiotensin II, and fibroblast growth factor. Abnormalities in LO activity has been linked to Menkes syndrome and occipital horn syndrome. Cytosolic forms of the enzyme hae been implicated in abnormal cell proliferation (reviewed in Rucker, R.B. et al.
(1998) Am. J. Clin. Nutr.
67:9965-1002S and Smith-Mungo, L.I. and Kagan, H.M. (1998) Matrix Biol. 16:387-398).
Dihydrofolate reductases Dihydrofolate reductases (DHFR) are ubiquitous enzymes that catalyze the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate, an essential step in the de novo synthesis of glycine and purines as well as the conversion of deoxyuridine monophosphate (dLTMP) to deoxythymidine monophosphate (dTMP). The basic reaction is as follows:
7,8-dihydrofolate + NADPH -~ 5,6,7,8-tetrahydrofolate + NADP+
The enzymes can be inhibited by a number of dihydrofolate analogs, including trimethroprim and methotrexate. Since an abundance of TMP is required for DNA synthesis, rapidly dividing cells require the activity of DHFR. The replication of DNA viruses (i.e., herpesvirus) also requires high levels of DHFR activity. As a result, drugs that target DHFR have been used for cancer chemotherapy and to inhibit DNA virus replication. (For similar reasons, thymidylate synthetases are also target enzymes.) Drugs that inhibit DHFR are preferentially cytotoxic for rapidly dividing cells (or DNA virus-infected cells) but have no specificity, resulting in the indiscriminate destruction of dividing cells. Furthermore, cancer cells may become resistant to drugs such as methotrexate as a result of acquired transport defects or the duplication of one or more DHFR
genes (Stryer, L. ( 1988) Biochemistry. W.H Freeman and Co., Inc. New York. pp. 511-5619).
Aldo/keto reductases Aldo/keto reductases are monomeric NADPH-dependent oxidoreductases with broad substrate specificities (Bohren, K.M. et al. (1989) J. Biol. Chem. 264:9547-9551). These enzymes catalyze the reduction of carbonyl-containing compounds, including carbonyl-containing sugars and aromatic compounds, to the corresponding alcohols. Therefore, a variety of carbonyl-containing drugs and xenobiotics are likely metabolized by enzymes of this class.
One known reaction catalyzed by a family member, aldose reductase, is the reduction of glucose to sorbitol, which is then further metabolized to fructose by sorbitol dehydrogenase. Under normal conditions, the reduction of glucose to sorbitol is a minor pathway. In hyperglycemic states, however, the accumulation of sorbitol is implicated in the development of diabetic complications (OMIM * 103880 Aldo-keto reductase family 1, member B1). Members of this enzyme family are also highly expressed in some liver cancers (Cao, D. et al. (1998) J. Biol.
Chem. 273:11429-11435).
Alcoholdehydro eg eases Alcohol dehydrogenases (ADHs) oxidize simple alcohols to the corresponding aldehydes.
ADH is a cytosolic enzyme, prefers the cofactor NAD+, and also binds zinc ion.
Liver contains the highest levels of ADH, with lower levels in kidney, lung, and the gastric mucosa.
Known ADH isoforms are dimeric proteins composed of 40 kDa subunits. There are five known gene loci which encode these subunits (a, b, g, p, c), and some of the loci have characterized allelic variants (b" b2, b3, g,, g2). The subunits can form homodimers and heterodimers; the subunit composition determines the specific properties of the active enzyme. The holoenzymes have therefore been categorized as Class I (subunit compositions aa, ab, ag, bg, gg), Class II (pp), and Class III (cc). Class I ADH isozymes oxidize ethanol and other small aliphatic alcohols, and are inhibited by pyrazole. Class II isozymes prefer longer chain aliphatic and aromatic alcohols, are unable to oxidize methanol, and are not inhibited by pyrazole. Class III
isozymes prefer even longer chain aliphatic alcohols (five carbons and longer) and aromatic alcohols, and are not inhibited by pyrazole.
The short-chain alcohol dehydrogenases include a number of related enzymes with a variety of substrate specificities. Included in this group are the mammalian enzymes D-beta-hydroxybutyrate dehydrogenase, (R)-3-hydroxybutyrate dehydrogenase, 15-hydroxyprostaglandin dehydrogenase, NADPH-dependent carbonyl reductase, corticosteroid 11-beta-dehydrogenase, and estradiol 17-beta-dehydrogenase, as well as the bacterial enzymes acetoacetyl-CoA reductase, glucose 1-dehydrogenase, 3-beta-hydroxysteroid dehydrogenase, 20-beta-hydroxysteroid dehydrogenase, ribitol dehydrogenase, 3-oxoacyl reductase, 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase, sorbitol-6-phosphate 2-dehydrogenase, 7-alpha-hydroxysteroid dehydrogenase, cis-1,2-dihydroxy-3,4-cyclohexadiene-1-carboxylate dehydrogenase, cis-toluene dihydrodiol dehydrogenase, cis-benzene glycol dehydrogenase, biphenyl-2,3-dihydro-2,3-diol dehydrogenase, N-acylmannosamine 1-dehydrogenase, and 2-deoxy-D-gluconate 3-dehydrogenase (Krozowski, Z. (1994) J. Steroid Biochem. Mol. Biol. 51:125-130; Krozowski, Z. (1992) Mol. Cell Endocrinol.
84:C25-31; and Marks, A.R. et al. (1992) J. Biol. Chem. 267:15459-15463).
UDP glucuronyltransferase Members of the UDP glucuronyltransferase family (UGTs) catalyze the transfer of a glucuronic acid group from the cofactor uridine diphosphate-glucuronic acid (UDP-glucuronic acid) to a substrate. The transfer is generally to a nucleophilic heteroatom (O, N, or S). Substrates include xenobiotics which have been functionalized by Phase I reactions, as well as endogenous compounds such as bilirubin, steroid hormones, and thyroid hormones. Products of glucuronidation are excreted in urine if the molecular weight of the substrate is less than about 250 g/mol, whereas larger glucuronidated substrates are excreted in bile.
UGTs are located in the microsomes of liver, kidney, intestine, skin, brain, spleen, and nasal mucosa, where they are on the same side of the endoplasmic reticulum membrane as cytochrome P450 enzymes and flavin-containing monooxygenases, and therefore are ideally located to access products of Phase I drug metabolism. UGTs have a C-terminal membrane-spanning domain which anchors them in the endoplasmic reticulum membrane, and a conserved signature domain of about 50 amino acid residues in their C terminal section (Prosite PDOC00359 UDP-glycosyltransferase signature).
UGTs involved in drug metabolism are encoded by two gene families, UGT1 and UGT2.
Members of the UGT1 family result from alternative splicing of a single gene locus, which has a variable substrate binding domain and constant region involved in cofactor binding and membrane insertion. Members of the UGT2 family are encoded by separate gene loci, and are divided into two families, UGT2A and UGT2B. The 2A subfamily is expressed in olfactory epithelium, and the 2B
subfamily is expressed in liver microsomes. Mutations in UGT genes are associated with hyperbilirubinemia (OMIM #143500 Hyperbilirubinemia I); Crigler-Najjar syndrome, characterized by intense hyperbilirubinemia from birth (OMIM #218800 Crigler-Najjar syndrome); and a milder form of hyperbilirubinemia termed Gilbert's disease (OMIM *191740 UGT1).
Sulfotransferase Sulfate conjugation occurs on many of the same substrates which undergo O-glucuronidation to produce a highly water-soluble sulfuric acid ester. Sulfotransferases (ST) catalyze this reaction by transferring S03- from the cofactor 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to the substrate.
ST substrates are predominantly phenols and aliphatic alcohols, but also include aromatic amines and aliphatic amines, which are conjugated to produce the corresponding sulfamates. The products of these reactions are excreted mainly in urine.
STs are found in a wide range of tissues, including liver, kidney, intestinal tract, lung, platelets; and brain. The enzymes are generally cytosolic, and multiple forms are often co-expressed.
For example, there are more than a dozen forms of ST in rat liver cytosol.
These biochemically characterized STs fall into five classes based on their substrate preference:
arylsulfotransferase, alcohol sulfotransferase, estrogen sulfotransferase, tyrosine ester sulfotransferase, and bile salt sulfotransferase.
ST enzyme activity varies greatly with sex and age in rats. The combined effects of developmental cues and sex-related hormones are thought to lead to these differences in ST
expression profiles, as well as the profiles of other DMEs such as cytochromes P450. Notably, the high expression of STs in cats partially compensates for their low level of UDP glucuronyltransferase activity.
Several forms of ST have been purified from human liver cytosol and cloned.
There are two phenol sulfotransferases with different thermal stabilities and substrate preferences. The thermostable enzyme catalyzes the sulfation of phenols such as para-nitrophenol, minoxidil, and acetaminophen; the thermolabile enzyme prefers monoamine substrates such as dopamine, epinephrine, and levadopa. Other cloned STs include an estrogen sulfotransferase and an N-acetylglucosamine-6-O-sulfotransferase. This last enzyme is illustrative of the other major role of STs in cellular biochemistry, the modification of carbohydrate structures that may be important in cellular differentiation and maturation of proteoglycans. Indeed, an inherited defect in a sulfotransferase has been implicated in macular corneal dystrophy, a disorder characterized by a failure to synthesize mature keratan sulfate proteoglycans (Nakazawa, K. et al. (1984) J. Biol. Chem.
259:13751-13757; OMIM *217800 Macular dystrophy, corneal).
Galactosyltransferases Galactosyltransferases are a subset of glycosyltransferases that transfer galactose (Gal) to the terminal N-acetylglucosamine (GIcNAc) oligosaccharide chains that are part of glycoproteins or glycolipids that are free in solution (Kolbinger, F. et al. (1998) J. Biol.
Chem. 273:433-440; Amado, M. et al. (1999) Biochim. Biophys. Acta 1473:35-53). Galactosyltransferases have been detected on the cell surface and as soluble extracellular proteins, in addition to being present in the Golgi. (31,3-galactosyltransferases form Type I carbohydrate chains with Gal (ail-3)GIcNAc linkages. Known human and mouse (31,3-galactosyltransferases appear to have a short cytosolic domain, a single transmembrane domain, and a catalytic domain with eight conserved regions.
(Kolbinger, F., supra and Hennet, T. et al. (1998) J. Biol. Chem. 273:58-65). In mouse UDP-galactose:(3-N-acetylglucosamine (31,3-galactosyltransferase-I region 1 is located at amino acid residues 78-83, region 2 is located at amino acid residues 93-102, region 3 is located at amino acid residues 116-119, region 4 is located at amino acid residues 147-158, region 5 is located at amino acid residues 172-183, region 6 is located at amino acid residues 203-206, region 7 is located at amino acid residues 236-246, and region 8 is located at amino acid residues 264-275. A variant of a sequence found within mouse UDP-galactose:(3-N-acetylglucosamine (31,3-galactosyltransferase-I region 8 is also found in bacterial galactosyltransferases, suggesting that this sequence defines a galactosyltransferase sequence motif (Hennet, T. supra). Recent work suggests that brainiac protein is a (31,3-galactosyltransferase (Yuan, Y. et al. (1997) Cell 88:9-11; and Hennet, T.
supra).
UDP-Gal:GlcNAc-1,4-galactosyltransferase (-1,4-GaIT) (Sato, T. et al., (1997) EMBO J.
16:1850-1857) catalyzes the formation of Type II carbohydrate chains with Gal ((31-4)GIcNAc linkages. As is the case with the (31,3-galactosyltransferase, a soluble form of the enzyme is formed by cleavage of the membrane-bound form. Amino acids conserved among (31,4-galactosyltransferases include two cysteines linked through a disulfide-bonded and a putative UDP-galactose-binding site in the catalytic domain (Yadav, S. and Brew, K. (1990) J. Biol. Chem. 265:14163-14169; Yadav, S.P.
and Brew, K. (1991) J. Biol. Chem. 266:698-703; and Shaper, N.L. et al. (1997) J. Biol. Chem.
272:31389-31399). (31,4-galactosyltransferases have several specialized roles in addition to synthesizing carbohydrate chains on glycoproteins or glycolipids. In mammals a ~i1,4-galactosyltransferase, as part of a heterodimer with a-lactalbumin, functions in lactating mammary gland lactose production. A ~i1,4-galactosyltransferase on the surface of sperm functions as a receptor that specifically recognizes the egg. Cell surface (31,4-galactosyltransferases also function in cell adhesion, cell/basal lamina interaction, 'and normal and metastatic cell migration. (Shur, B.
(1993) Curr. Opin. Cell Biol. 5:854-863; and Shaper, J. (1995) Adv. Exp. Med.
Biol. 376:95-104).
Glutathione S-transferase The basic reaction catalyzed by glutathione S-transferases (GST) is the conjugation of an electrophile with reduced glutathione (GSH). GSTs are homodimeric or heterodimeric proteins localized mainly in the cytosol, but some level of activity is present in microsomes as well. The major isozymes share common structural and catalytic properties; in humans they have been classified into four major classes, Alpha, Mu, Pi, and Theta. The two largest classes, Alpha and Mu, are identified by their respective protein isoelectric points; pI ~ 7.5-9.0 (Alpha), and pI ~ 6.6 (Mu).
Each GST possesses a common binding site for GSH and a variable hydrophobic binding site. The hydrophobic binding site in each isozyme is specific for particular electrophilic substrates. Specific amino acid residues within GSTs have been identified as important for these binding sites and for catalytic activity. Residues Q67, T68, D101, E104, and 8131 are important for the binding of GSH
(Lee, H.-C. et al. (1995) J. Biol. Chem. 270:99-109). Residues R13, R20, and R69 are important for the catalytic activity of GST (Stenberg, G. et al. (1991) Biochem. J. 274:549-555).
In most cases, GSTs perform the beneficial function of deactivation and detoxification of potentially mutagenic and carcinogenic chemicals. However, in some cases their action is detrimental and results in activation of chemicals with consequent mutagenic and carcinogenic effects. Some forms of rat and human GSTs are reliable preneoplastic markers that aid in the detection of carcinogenesis. Expression of human GSTs in bacterial strains, such as Salmonella t~phimurium used in the well-known Ames test for mutagenicity, has helped to establish the role of these enzymes in mutagenesis. Dihalomethanes, which produce liver tumors in mice, are believed to be activated by GST. This view is supported by the finding that dihalomethanes are more mutagenic in bacterial cells expressing human GST than in untransfected cells (Thier, R. et al. ( 1993) Proc. Natl. Acad. Sci. USA
90:8567-8580). The mutagenicity of ethylene dibromide and ethylene dichloride is increased in bacterial cells expressing the human Alpha GST, A1-1, while the mutagenicity of aflatoxin B1 is substantially reduced by enhancing the expression of GST (Simula, T.P. et al.
(1993) Carcinogenesis 14:1371-1376). Thus, control of GST activity may be useful in the control of mutagenesis and carcinogenesis.
GST has been implicated in the acquired resistance of many cancers to drug treatment, the phenomenon known as multi-drug resistance (MDR). MDR occurs when a cancer patient is treated with a cytotoxic drug such as cyclophosphamide and subsequently becomes resistant to this drug and to a variety of other cytotoxic agents as well. Increased GST levels are associated with some of these drug resistant cancers, and it is believed that this increase occurs in response to the drug agent which is then deactivated by the GST catalyzed GSH conjugation reaction. The increased GST levels then protect the cancer cells from other cytotoxic agents which bind to GST.
Increased levels of A1-1 in tumors has been linked to drug resistance induced by cyclophosphamide treatment (Dirven H.A. et al.
(1994) Cancer Res. 54: 6215-6220). Thus control of GST activity in cancerous tissues may be useful in treating MDR in cancer patients.
Gamma-. lug tamvl transpeptidase Gamma-glutamyl transpeptidases are ubiquitously expressed enzymes that initiate extracellular glutathione (GSH) breakdown by cleaving gamma-glutamyl amide bonds. The breakdown of GSH provides cells with a regional cysteine pool for biosynthetic pathways.
Gamma-glutamyl transpeptidases also contribute to cellular antioxidant defenses and expression is induced by oxidative steress. The cell surface-localized glycoproteins.are expressed at high levels in cancer cells. Studies have suggested that the high level of gamma-glutamyl transpeptidases activity present on the surface of cancer cells could be exploited to activate precursor drugs, resulting in high local concentrations of anti-cancer therapeutic agents (Hanigan, M.H. (1998) Chem. Biol. Interact.
111-112:333-42; Taniguchi, N. and Ikeda, Y. (1998) Adv. Enzymol. Relat. Areas Mol. Biol.
72:239-78; Chikhi, N. et al. (1999) Comp. Biochem. Physiol. B. Biochem. Mol.
Biol. 122:367-380).
Acyltransferase N-acyltransferase enzymes catalyze the transfer of an amino acid conjugate to an activated carboxylic group. Endogenous compounds and xenobiotics are activated by acyl-CoA synthetases in the cytosol, microsomes, and mitochondria. The acyl-CoA intermediates are then conjugated with an amino acid (typically glycine, glutamine, or taurine, but also ornithine, arginine, histidine, serine, aspartic acid, and several dipeptides) by N-acyltransferases in the cytosol or mitochondria to form a metabolite with an amide bond. This reaction is complementary to O-glucuronidation, but amino acid conjugation does not produce the reactive and toxic metabolites which often result from glucuronidation.
One well-characterized enzyme of this class is the bile acid-CoA:amino acid N-acyltransferase (BAT) responsible for generating the bile acid conjugates which serve as detergents in the gastrointestinal tract (Falany, C.N. et al. (1994) J. Biol. Chem.
269:19375-19379; Johnson, M.R.
et al. (1991) J. Biol. Chem. 266:10227-10233). BAT is also useful as a predictive indicator for prognosis of hepatocellular carcinoma patients after partial hepatectomy (Furutani, M. et al. (1996) Hepatology 24:1441-1445).
Acetyltransferases Acetyltransferases have been extensively studied for their role in histone acetylation. Histone acetylation results in the relaxing of the chromatin structure in eukaryotic cells, allowing transcription factors to gain access to promoter elements of the DNA templates in the affected region of the genome (or the genome in general). In contrast, histone deacetylation results in a reduction in transcription by closing the chromatin structure and limiting access of transcription factors. To this end, a common means of stimulating cell transcription is the use of chemical agents that inhibit the deacetylation of histones (e.g., sodium butyrate), resulting in a global (albeit artifactual) increase in gene expression. The modulation of gene expression by acetylation also results from the acetylation of other proteins, including but not limited to, p53, GATA-1, MyoD, ACTR, TFIIE, TFIIF and the high mobility group proteins (HMG). In the case of p53, acetylation results in increased DNA
binding, leading to the stimulation of transcription of genes regulated by p53. The prototypic histone acetylase (HAT) is GcnS from Saccharomyces cerevisiae. GcnS is a member of a family of acetylases that includes Tetrahymena p55, human GcnS, and human p300/CBP. Histone acetylation is reviewed in (Cheung, W.L. et al. (2000) Curr. Opin. Cell Biol. 12:326-333 and Bergen S.L (1999) Curr. Opin.
Cell Biol. 11:336-341). Some acetyltransferase enzymes posses the alpha/beta hydrolase fold (Center of Applied Molecular Engineering Inst. of Chemistry and Biochemistry -University of Salzburg, http://predict.sanger.ac.uk/irbm-course97/Docs/ms/) common to several other major classes of enzymes, including but not limited to, acetylcholinesterases and carboxylesterases (Structural Classification of Proteins, http://scop.mrc-Imb.cam.ac.uk/scop/index.html).
N-acetyltransferase Aromatic amines and hydrazine-containing compounds are subject to N-acetylation by the N-acetyltransferase enzymes of liver and other tissues. Some xenobiotics can be O-acetylated to some extent by the same enzymes. N-acetyltransferases are cytosolic enzymes which utilize the cofactor acetyl-coenzyme A (acetyl-CoA) to transfer the acetyl group in a two step process. In the first step, the acetyl group is transferred from acetyl-CoA to an active site cysteine residue; in the second step, the acetyl group is transferred to the substrate amino group and the enzyme is regenerated.
In contrast to most other DME classes, there are a limited number of known N-acetyltransferases. In humans, there are two highly similar enzymes, NATI and NAT2; mice appear to have a third form of the enzyme, NAT3. The human forms of N-acetyltransferase have independent regulation (NAT1 is widely-expressed, whereas NAT2 is in liver and gut only) and overlapping substrate preferences. Both enzymes appear to accept most substrates to some extent, but NAT1 does prefer some substrates (para-aminobenzoic acid, para-aminosalicylic acid, sulfamethoxazole, and sulfanilamide), while NAT2 prefers others (isoniazid, hydralazine, procainamide, dapsone, aminoglutethimide, and sulfamethazine).
Clinical observations of patients taking the antituberculosis drug isoniazid in the 1950s led to the description of fast and slow acetylators of the compound. These phenotypes were shown subsequently to be due to mutations in the NAT2 gene which affected enzyme activity or stability.
The slow isoniazid acetylator phenotype is very prevalent in Middle Eastern populations (approx.
70%), and is less prevalent in Caucasian (approx. 50%) and Asian (<25%) populations. More recently, functional polymorphism in NAT1 has been detected, with approximately 8% of the population tested showing a slow acetylator phenotype (Butcher, N. J. et al.
(1998) Pharmacogenetics 8:67-72). Since NAT1 can activate some known aromatic amine carcinogens, polymorphism in the widely-expressed NAT1 enzyme may be important in determining cancer risk (OMIM
*108345 N-acetyltransferase 1).
Aminotransferases Aminotransferases comprise a family of pyridoxal 5 =phosphate (PLP) -dependent enzymes that catalyze transformations of amino acids. Aspartate aminotransferase (AspAT) is the most extensively studied PLP-containing enzyme. It catalyzes the reversible transamination of dicarboxylic L-amino acids, aspartate and glutamate, and the corresponding 2-oxo acids, oxalacetate and 2-oxoglutarate. Other members of the family included pyruvate aminotransferase, branched-chain amino acid aminotransferase, tyrosine aminotransferase, aromatic aminotransferase, alanine:glyoxylate aminotransferase (AGT), and kynurenine aminotransferase (Vacca, R.A. et al.
(1997) J. Biol. Chem. 272:21932-21937).
Primary hyperoxaluria type-1 is an autosomal recessive disorder resulting in a deficiency in the liver-specific peroxisomal enzyme, alanine:glyoxylate aminotransferase-1.
The phenotype of the disorder is a deficiency in glyoxylate metabolism. In the absence of AGT, glyoxylate is oxidized to oxalate rather than being transaminated to glycine. The result is the deposition of insoluble calcium oxalate in the kidneys and urinary tract, ultimately causing renal failure (Lumb, M.J. et al. (1999) J.
Biol. Chem. 274:20587-20596).
Kynurenine aminotransferase catalyzes the irreversible transamination of the L-tryptophan metabolite L-kynurenine to form kynurenic acid. The enzyme may also catalyzes the reversible transamination reaction between L-2-aminoadipate and 2-oxoglutarate to produce 2-oxoadipate and L-glutamate. Kynurenic acid is a putative modulator of glutamatergic neurotransmission, thus a deficiency in kynurenine aminotransferase may be associated with pleotrophic effects (Buchli, R. et al. (1995) J. Biol. Chem. 270:29330-29335).
Catechol-O-methyltransferase Catechol-O-methyltransferase (COMT) catalyzes the transfer of the methyl group of S-adenosyl-L-methionine (AdoMet; SAM) donor to one of the hydroxyl groups of the catechol substrate (e.g., L-dopa, dopamine, or DBA). Methylation of the 3 =hydroxyl group is favored over methylation of the 4'-hydroxyl group and the membrane bound isoform of COMT is more regiospecific than the soluble form. Translation of the soluble form of the enzyme results from utilization of an internal start codon in a full-length mRNA (1.5 kb) or from the translation of a shorter mRNA (1.3 kb), transcribed from an internal promoter. The proposed SN2-like methylation reaction requires Mg++ and is inhibited by Ca''-". The binding of the donor and substrate to COMT occurs sequentially. AdoMet first binds COMT in a Mg**-independent manner, followed by the binding of Mg**
and the binding of the catechol substrate.
The amount of COMT in tissues is relatively high compared to the amount of activity normally required, thus inhibition is problematic. Nonetheless, inhibitors have been developed for in vitro use (e.g., gallates, tropolone, U-0521, and 3',4=dihydroxy-2-methyl-propiophetropolone) and for clinical use (e.g., nitrocatechol-based compounds and tolcapone).
Administration of these inhibitors results in the increased half-life of L-dopa and the consequent formation of dopamine. Inhibition of COMT is also likely to increase the half-life of various other catechol-structure compounds, including but not limited to epinephrine/norepinephrine, isoprenaline, rimiterol, dobutamine, fenoldopam, apomorphine, and a-methyldopa. A deficiency in norepinephrine has been linked to clinical depression, hence the use of COMT inhibitors could be usefull in the treatment of depression.
COMT inhibitors are generally well tolerated with minimal side effects and are ultimately metabolized in the liver with only minor accumulation of metabolites in the body (Mannisto, P.T. and Kaakkola, S. (1999) Pharmacol. Rev. 51:593-628).
Copper-zinc superoxide dismutases Copper-zinc superoxide dismutases are compact homodimeric metalloenzymes involved in cellular defenses against oxidative damage. The enzymes contain one atom of zinc and one atom of copper per subunit and catalyze the dismutation of superoxide anions into OZ
and HZO2. The rate of dismutation is diffusion-limited and consequently enhanced by the presence of favorable electrostatic interactions between the substrate and enzyme active site. Examples of this class of enzyme have been identified in the cytoplasm of all the eukaryotic cells as well as in the periplasm of several bacterial species. Copper-zinc superoxide dismutases are robust enzymes that are highly resistant to proteolytic digestion and denaturing by urea and SDS. In addition to the compact structure of the enzymes, the presence of the metal ions and intrasubunit disulfide bonds is believed to be responsible for enzyme stability. The enzymes undergo reversible denaturation at temperatures as high as 70°C
(Battistoni; A. et al. (1998) J. Biol. Chem. 273:5655-5661).
Overexpression of superoxide dismutase has been implicated in enhancing freezing tolerance of transgenic Alfalfa as well as providing resistance to environmental toxins such as the diphenyl ether herbicide, acifluorfen (McKersie, B.D. et al. ( 1993) Plant Physiol.
103:1155-1163). In addtion, yeast cells become more resistant to freeze-thaw damage following exposure to hydrogen peroxide which causes the yeast cells to adapt to further peroxide stress by upregulating expression of superoxide dismutases. In this study, mutations to yeast superoxide dismutase genes had a more detrimental effect on freeze-thaw resistance than mutations which affected the regulation of glutathione metabolism, long suspected of being important in determining an organisms survival through the process of cryopreservation (Jong-In Park, J.-I. et al. (1998) J.
Biol. Chem.
273:22921-22928).
Expression of superoxide dismutase is also associated with Mycobacterium tuberculosis, the organism that causes tuberculosis. Superoxide dismutase is one of the ten major proteins secreted by M. tuberculosis and its expression is upregulated approximately 5-fold in response to oxidative stress.
M. tuberculosis expresses almost two orders of magnitude more superoxide dismutase than the nonpathogenic mycobacterium M. smegmatis, and secretes a much higher proportion of the expressed enzyme. The result is the secretion of --350-fold more enzyme by M.
tuberculosis than M. smegmaris, providing substantial resistance to oxidative stress (Harth, G. and Horwitz, M.A. (1999) J. Biol.
Chem. 274:4281-4292).
The reduced expression of copper-zinc superoxide dismutases, as well as other enzymes with anti-oxidant capabilities, has been implicated in the early stages of cancer.
The expression of copper-zinc superoxide dismutases has been shown to be lower in prostatic intraepithelial neoplasia and prostate carcinomas, compared to normal prostate tissue (Bostwick, D.G. (2000) Cancer 89:123-134).
Phosphodiesterases Phosphodiesterases make up a class of enzymes which catalyze the hydrolysis of one of the two ester bonds in a phosphodiester compound. Phosphodiesterases are therefore crucial to a variety of cellular processes. Phosphodiesterases include DNA and RNA endonucleases and exonucleases, which are essential for cell growth and replication, and topoisomerases, which break and rejoin nucleic acid strands during topological rearrangement of DNA. A Tyr-DNA
phosphodiesterase functions in DNA repair by hydrolyzing dead-end covalent intermediates formed between topoisomerase I and DNA (Pouliot, J.J. et al. (1999) Science 286:552-555;
Yang, S.-W. (1996) Proc.
Natl. Acad. Sci. USA 93:11534-11539).
Acid sphingomyelinase is a phosphodiesterase which hydrolyzes the membrane phospholipid sphingomyelin to produce ceramide and phosphorylcholine. Phosphorylcholine is used in the synthesis of phosphatidylcholine, which is involved in numerous intracellular signaling pathways, while ceramide is an essential precursor for the generation of gangliosides, membrane lipids found in high concentration in neural tissue. Defective acid sphingomyelinase leads to a build-up of sphingomyelin molecules in lysosomes, resulting in Niemann-Pick disease (Schuchman, E.H. and S.R. Miranda (1997) Genet. Test. 1:13-19).
Glycerophosphoryl diester phosphodiesterase (also known as glycerophosphodiester phosphodiesterase) is a phosphodiesterase which hydrolyzes deacetylated phospholipid glycerophosphodiesters to produce sn-glycerol-3-phosphate and an alcohol.
Glycerophosphocholine, glycerophosphoethanolamine, glycerophosphoglycerol, and glycerophosphoinositol are examples of substrates for glycerophosphoryl diester phosphodiesterases. A
glycerophosphoryl diester phosphodiesterase from E. coli has broad specificity for glycerophosphodiester substrates (Larson, T.J. et al. (1983) J. Biol: Chem. 248:5428-5432).
Cyclic nucleotide phosphodiesterases (PDEs) are crucial enzymes in the regulation of the cyclic nucleotides cAMP and cGMP. cAMP and cGMP function as intracellular second messengers to transduce a variety of extracellular signals including hormones, light, and neurotransmitters. PDEs degrade cyclic nucleotides to their corresponding monophosphates, thereby regulating the intracellular concentrations of cyclic nucleotides and their effects on signal transduction. Due to their roles as regulators of signal transduction, PDEs have been extensively studied as chemotherapeutic targets (Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481;
Torphy, J.T. (1998) Am. J. Resp. Crit. Care Med. 157:351-370).
Families of mammalian PDEs have been classified based on their substrate specificity and affinity, sensitivity to cofactors, and sensitivity to inhibitory agents (Beavo, J.A. (1995) Physiol. Rev.
75:725-748; Conti, M. et al. (1995) Endocrine Rev. 16:370-389). Several of these families contain distinct genes, many of which are expressed in different tissues as splice variants. Within PDE
families, there are multiple isozymes and multiple splice variants of these isozymes (Conti, M. and S.-L.C. Jin (1999) Prog. Nucleic Acid Res. Mol. Biol. 63:1-38). The existence of multiple PDE
families, isozymes, and splice variants is an indication of the variety and complexity of the regulatory pathways involving cyclic nucleotides (Houslay, M.D. and G. Milligan (1997) Trends Biochem. Sci.
22:217-224).
Type 1 PDEs (PDEls) are Caz+/calmodulin-dependent and appear to be encoded by at least three different genes, each having at least two different splice variants (Kakkar, R. et al. ( 1999) Cell Mol. Life Sci. 55:1164-1186). PDEIs have been found in the lung, heart, and brain. Some PDE1 isozymes are regulated in vitro by phosphorylation/dephosphorylation.
Phosphorylation of these PDE1 isozymes decreases the affinity of the enzyme for calmodulin, decreases PDE activity, and increases steady state levels of cAMP (Kakkar, supra). PDEls may provide useful therapeutic targets for disorders of the central nervous system, and the cardiovascular and immune systems due to the involvement of PDEls in both cyclic nucleotide and calcium signaling (Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481).
PDE2s are cGMP-stimulated PDEs that have been found in the cerebellum, neocortex, heart, kidney, lung, pulmonary artery, and skeletal muscle (Sadhu, K. et al. (1999) J. Histochem. Cytochem.
47:895-906). PDE2s are thought to mediate the effects of cAMP on catecholamine secretion, participate in the regulation of aldosterone (Beavo, supra), and play a role in olfactory signal transduction (Juilfs, D.M. et al. (1997) Proc. Natl. Acad. Sci. USA 94:3388-3395).
PDE3s have high affinity for both cGMP and cAMP, and so these cyclic nucleotides act as competitive substrates for PDE3s. PDE3s play roles in stimulating myocardial contractility, inhibiting platelet aggregation, relaxing vascular and airway smooth muscle, inhibiting proliferation of T-lymphocytes and cultured vascular smooth muscle cells, and regulating catecholamine-induced.
release of free fatty acids from adipose tissue. The PDE3 family of phosphodiesterases are sensitive to specific inhibitors such as cilostamide, enoximone, and lixazinone.
Isozymes of PDE3 can be regulated by cAMP-dependent protein kinase, or by insulin-dependent kinases (Degerman, E. et al.
(1997) J. Biol. Chem. 272:6823-6826).
PDE4s are specific for cAMP; are localized to airway smooth muscle, the vascular endothelium, and all inflammatory cells; and can be activated by cAMP-dependent phosphorylation.
Since elevation of cAMP levels can lead to suppression of inflammatory cell activation and to relaxation of bronchial smooth muscle, PDE4s have been studied extensively as possible targets for novel anti-inflammatory agents, with special emphasis placed on the discovery of asthma treatments.
PDE4 inhibitors are currently undergoing clinical trials as treatments for asthma, chronic obstructive pulmonary disease, and atopic eczema. All four known isozymes of PDE4 are susceptible to the inhibitor rolipram, a compound which has been shown to improve behavioral memory in mice (Barad, M. et al. (1998) Proc. Natl. Acad. Sci. USA 95:15020-15025). PDE4 inhibitors have also been studied as possible therapeutic agents against acute lung injury, endotoxemia, rheumatoid arthritis, multiple sclerosis, and various neurological and gastrointestinal indications (Doherty, A.M. (1999) Curr. Opin. Chem. Biol. 3:466=473).
PDES is highly selective for cGMP as a substrate (Turko, LV. et al. (1998) Biochemistry 37:4200-4205), and has two allosteric cGMP-specific binding sites (McAllister-Lucas, L.M. et al.
(1995) J. Biol. Chem. 270:30671-30679). Binding of cGMP to these allosteric binding sites seems to be important for phosphorylation of PDES by cGMP-dependent protein kinase rather than for direct regulation of catalytic activity. High levels of PDES are found in vascular smooth muscle, platelets, lung, and kidney. The inhibitor zaprinast is effective against PDES and PDEls.
Modification of zaprinast to provide specificity against PDES has resulted in sildenafil (VIAGRA; Pfizer, Inc., New York NY), a treatment for male erectile dysfunction (Terrett, N. et al. (1996) Bioorg. Med. Chem.
Lett. 6:1819-1824). Inhibitors of PDES are currently being studied as agents for cardiovascular therapy (Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481).
PDE6s, the photoreceptor cyclic nucleotide phosphodiesterases, are crucial components of the phototransduction cascade. In association with the G-protein transducin, PDE6s hydrolyze cGMP
to regulate cGMP-gated canon channels in photoreceptor membranes. In addition to the cGMP-binding active site, PDE6s also have two high-affinity cGMP-binding sites which are thought to play a regulatory role in PDE6 function (Artemyev, N.O. et al. (1998) Methods 14:93-104). Defects in PDE6s have been associated with retinal disease. Retinal degeneration in the rd mouse (Yan, W. et al. (1998) Invest. Opthalmol. Vis. Sci. 39:2529-2536), autosomal recessive retinitis pigmentosa in humans (Danciger, M. et al. (1995) Genomics 30:1-7), and rod/cone dysplasia 1 in Irish Setter dogs (Suber, M.L. et al. ( 1993) Proc. Natl. Acad. Sci. USA 90:3968-3972) have been attributed to mutations in the PDE6B gene.
The PDE7 family of PDEs consists of only one known member having multiple splice variants (Bloom, T.J. and J.A. Beavo (1996) Proc. Natl. Acad. Sci. USA
93:14188-14192). PDE7s are cAMP specific, but little else is known about their physiological function. Although mRNAs encoding PDE7s are found in skeletal muscle, heart, brain, lung, kidney, and pancreas, expression of PDE7 proteins is restricted to specific tissue types (Han, P. et al. (1997) J.
Biol. Chem. 272:16152-16157; Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481).
PDE7s are very closely related to the PDE4 family; however, PDE7s are not inhibited by rolipram, a specific inhibitor of PDE4s (Beavo, supra).
PDEBs are cAMP specific, and are closely related to the PDE4 family. PDEBs are expressed in thyroid gland, testis, eye, liver, skeletal muscle, heart, kidney, ovary, and brain. The cAMP-hydrolyzing activity of PDEBs is not inhibited by the PDE inhibitors rolipram, vinpocetine, milrinone, IBMX (3-isobutyl-1-methylxanthine), or zaprinast, but PDEBs are inhibited by dipyridamole (Fisher, D.A. et al. (1998) Biochem. Biophys. Res. Commun. 246:570-577; Hayashi, M. et al. (1998) Biochem. Biophys. Res. Commun. 250:751-756; Soderling, S.H. et al. (1998) Proc. Natl. Acad. Sci.
USA 95:8991-8996).
PDE9s are cGMP specific and most closely resemble the PDEB family of PDEs.
PDE9s are expressed in kidney, liver, lung, brain, spleen, and small intestine. PDE9s are not inhibited by sildenafil (VIAGRA; Pfizer, Inc., New York NY), rolipram, vinpocetine, dipyridamole, or IBMX (3-isobutyl-1-methylxanthine), but they are sensitive to the PDES inhibitor zaprinast (Fisher, D.A. et al.
(1998) J. Biol. Chem. 273:15559-15564; Soderling, S.H. et al. (1998) J. Biol.
Chem. 273:15553-15558).
PDEIOs are dual-substrate PDEs, hydrolyzing both cAMP and cGMP. PDElOs are expressed in brain, thyroid, and testis. (Soderling, S.H. et al. (1999) Proc. Natl.
Acad. Sci. USA 96:7071-7076;
Fujishige, K. et al. (1999) J. Biol. Chem. 274:18438-18445; Loughney, K. et al (1999) Gene 234:109 117).
PDEs are composed of a catalytic domain of about 270-300 amino acids, an N-terminal regulatory domain responsible for binding cofactors, and, in some cases, a hydrophilic C-terminal domain of unknown function (Conti, M. and S.-L.C. Jin (1999) Prog. Nucleic Acid Res. Mol. Biol.
63:1-38). A conserved, putative zinc-binding motif, HDXXHXGXXN, has been identified in the catalytic domain of all PDEs. N-terminal regulatory domains include non-catalytic cGMP-binding domains in PDE2s, PDESs, and PDE6s; calmodulin-binding domains in PDEls; and domains containing phosphorylation sites in PDE3s and PDE4s. In PDES, the N-terminal cGMP-binding domain spans about 380 amino acid residues and comprises tandem repeats of the conserved sequence motif N(R/K)XnFX3DE (McAllister-Lucas, L.M. et al. (1993) J. Biol. Chem.
268:22863-22873). The NKXnD motif has been shown by mutagenesis to be important for cGMP binding (Turko, LV. et al.
(1996) J. Biol. Chem. 271:22240-22244). PDE families display approximately 30%
amino acid identity within the catalytic domain; however, isozymes within the same family typically display about 85-95% identity in this region (e.g. PDE4A vs PDE4B). Furthermore, within a family there is extensive similarity (>60%) outside the catalytic domain; while across families, there is little or no sequence similarity outside this domain.
Many of the constituent functions of immune and inflammatory responses are inhibited by agents that increase intracellular levels of cAMP (Verghese, M.W. et al.
(1995) Mol. Pharmacol.
47:1164-1171). A variety of diseases have been attributed to increased PDE
activity and associated with decreased levels of cyclic nucleotides. For example, a form of diabetes insipidus in mice has been associated with increased PDE4 activity, an increase in low-Km cAMP PDE
activity has been reported in leukocytes of atopic patients, and PDE3 has been associated with cardiac disease.
Many inhibitors of PDEs have been identified and have undergone clinical evaluation (Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481; Torphy, T.J.
(1998) Am. J. Respir.
Crit. Care Med. 157:351-370). PDE3 inhibitors are being developed as antithrombotic agents, antihypertensive agents, and as cardiotonic agents useful in the treatment of congestive heart failure.
Rolipram, a PDE4 inhibitor, has been used in the treatment of depression, and other inhibitors of PDE4 are undergoing evaluation as anti-inflammatory agents. Rolipram has also been shown to inhibit lipopolysaccharide (LPS) induced TNF-a which has been shown to enhance HIV-1 replication in vitro. Therefore, rolipram may inhibit HIV-1 replication (Angel, J.B. et al. (1995) AIDS
9:1137-1144). Additionally, rolipram, based on its ability to suppress the production of cytokines such as TNF-a and b and interferon g, has been shown to be effective in the treatment of encephalomyelitis. Rolipram may also be effective in treating tardive dyskinesia and was effective in treating multiple sclerosis in an experimental animal model (Sommer, N. et al.
(1995) Nat. Med.
1:244-248; Sasaki, H. et al. ( 1995) Eur. J. Pharmacol. 282:71-76).
Theophylline is a nonspecific PDE inhibitor used in the treatment of bronchial asthma and other respiratory diseases. Theophylline is believed to act on airway smooth muscle function and in an anti-inflammatory or immunomodulatory capacity in the treatment of respiratory diseases (Banner, K.H. and C.P. Page (1995) Eur. Respir. J. 8:996-1000). Pentoxifylline is another nonspecific PDE
inhibitor used in the treatment of intermittent claudication and diabetes-induced peripheral vascular disease. Pentoxifylline is also known to block TNF-a production and may inhibit HIV-1 replication (Angel et al., supra).
PDEs have been reported to affect cellular proliferation of a variety of cell types (Conti et al.
(1995) Endocrine Rev. 16:370-389) and have been implicated in various cancers.
Growth of prostate carcinoma cell lines DU145 and LNCaP was inhibited by delivery of cAMP
derivatives and PDE
inhibitors (Bang, Y.J. et al. (1994) Proc. Natl. Acad. Sci. USA 91:5330-5334).
These cells also showed a permanent conversion in phenotype from epithelial to neuronal morphology. It has also been suggested that PDE inhibitors have the potential to regulate mesangial cell proliferation (Matousovic, K. et al. (1995) J. Clin. Invest. 96:401-410) and lymphocyte proliferation (Joulain, C. et al. ( 1995) J. Lipid Mediat. Cell Signal. 11:63-79). A cancer treatment has been described that involves intracellular delivery of PDEs to particular cellular compartments of tumors, resulting in cell death (Deonarain, M.P. and A.A. Epenetos (1994) Br. J. Cancer 70:786-794).
Phosphotriesterases Phosphotriesterases (PTE, paraoxonases) are enzymes that hydrolyze toxic organophosphorus compounds and have been isolated from a variety of tissues. The enzymes appear to be lacking in birds and insects and abundant in mammals, explaining the reduced tolerance of birds and insects to organophosphorus compound (Vilanova, E. and Sogorb, M.A. (1999) Crit. Rev.
Toxicol. 29:21-57).
Phosphotriesterases play a central role in the detoxification of insecticides by mammals.
Phosphotriesterase activity varies among individuals and is lower in infants than adults. Knockout mice are markedly more sensitive to the organophosphate-based toxins diazoxon and chlorpyrifos oxon (Furlong, C.E., et al. (2000) Neurotoxicology 21:91-100). PTEs have attracted interest as enzymes capable of the detoxification of organophosphate-containing chemical waste and warfare reagents (e.g., parathion), in addition to pesticides and insecticides. Some studies have also implicated phosphotriesterase in atherosclerosis and diseases involving lipoprotein metabolism.
Thioesterases Two soluble thioesterases involved in fatty acid biosynthesis have been isolated from mammalian tissues, one which is active only toward long-chain fatty-acyl thioesters and one which is active toward thioesters with a wide range of fatty-acyl chain-lengths. These thioesterases catalyze the chain-terminating step in the de novo biosynthesis of fatty acids. Chain termination involves the hydrolysis of the thioester bond which links the fatty acyl chain to the 4'-phosphopantetheine prosthetic group of the acyl Garner protein (ACP) subunit of the fatty acid synthase (Smith, S. (1981a) Methods Enzymol. 71:181-188; Smith, S. (1981b) Methods Enzymol. 71:188-200).
~E. coli contains two soluble thioesterases, thioesterase I which is active only toward long-chain acyl thioesters, and thioesterase II (TEII) which has a broad chain-length specificity (Naggert, J., et al. (1991) J. Biol. Chem. 266:11044-11050). E. coli TEII does not exhibit sequence similarity with either of the two types of mammalian thioesterases which function as chain-terminating enzymes in de novo fatty acid biosynthesis. Unlike the mammalian thioesterases, E. coli TEII lacks the characteristic serine active site gly-X-ser-X-gly sequence motif and is not inactivated by the serine modifying agent diisopropyl fluorophosphate. However, modification of histidine 58 by iodoacetamide and diethylpyrocarbonate abolished TEII activity. Overexpression of TEII did not alter fatty acid content in E. coli, which suggests that it does not function as a chain-terminating enzyme in fatty acid biosynthesis (Naggert et al., supra). For that reason, Naggert et al. (supra) proposed that the physiological substrates for E. coli TEII may be coenzyme A
(CoA)-fatty acid esters instead of ACP-phosphopanthetheine-fatty acid esters.
Carboxylesterases Mammalian carboxylesterases constitute a multigene family expressed in a variety of tissues and cell types. Isozymes have significant sequence homology and are classified primarily on the basis of amino acid sequence. Acetylcholinesterase, butyrylcholinesterase, and carboxylesterase are grouped into the serine super family of esterases (B-esterases). Other carboxylesterases included thyroglobulin, thrombin, Factor IX, gliotactin, and plasminogen.
Carboxylesterases catalyze the hydrolysis of ester- and amide- groups from molecules and are involved in detoxification of drugs, environmental toxins, and carcinogens. Substrates for carboxylesterases include short- and long-chain acyl-glycerols, acylcarnitine, carbonates, dipivefrin hydrochloride, cocaine, salicylates, capsaicin, palmitoyl-coenzyme A, imidapril, haloperidol, pyrrolizidine alkaloids, steroids, p-nitrophenyl acetate, malathion, butanilicaine, and isocarboxazide. The enzymes often demonstrate low substrate specificity. Carboxylesterases are also important for the conversion of prodrugs to their respective free acids, which may be the active form of the drug (e.g., lovastatin, used to lower blood cholesterol) (reviewed in Satoh, T. and Hosokawa, M. ( 1998) Annu. Rev.
Pharmacol.
Toxico1.38:257-288).
Neuroligins are a class of molecules that (i) have N-terminal signal sequences, (ii) resemble cell-surface receptors, (iii) contain carboxylesterase domains, (iv) are highly expressed in the brain, and (v) bind to neurexins in a calcium-dependent manner. Despite the homology to carboxylesterases, neuroligins lack the active site serine residue, implying a role in substrate binding rather than catalysis (Ichtchenko, K. et al. (1996) J. Biol. Chem. 271:2676-2682).
Sgualene epoxidase Squalene epoxidase (squalene monooxygenase, SE) is a microsomal membrane-bound, FAD-dependent oxidoreductase that catalyzes the first oxygenation step in the sterol biosynthetic pathway of eukaryotic cells. Cholesterol is an essential structural component of cytoplasmic membranes acquired via the LDL receptor-mediated pathway or the biosynthetic pathway. In the latter case, all 27 carbon atoms in the cholesterol molecule are derived from acetyl-CoA
(Stryer, L., supra). SE
converts squalene to 2,3(S~-oxidosqualene, which is then converted to lanosterol and then cholesterol.
The steps involved in cholesterol biosynthesis are summarized below (Stryer, L
(1988) Biochemistry.
W.H Freeman and Co., Inc. New York. pp. 554-560 and Sakakibara, J. et al. ( 1995) 270:17-20):
acetate (from Acetyl-CoA) ~ 3-hydoxy-3-methyl-glutaryl CoA ~ mevalonate ~ 5-phosphomevalonate ~ 5-pyrophosphomevalonate ~ isopentenyl pyrophosphate ~ dimethylallyl pyrophosphate ~ geranyl pyrophosphate ~ farnesyl pyrophosphate ~ squalene ~ squalene epoxide ~
lanosterol ~ cholesterol While cholesterol is essential for the viability of eukaryotic cells, inordinately high serum cholesterol levels results in the formation of atherosclerotic plaques in the arteries of higher organisms. This deposition of highly insoluble lipid material onto the walls of essential blood vessels (e.g., coronary arteries) results in decreased blood flow and potential necrosis of the tissues deprived of adequate blood flow. HMG-CoA reductase is responsible for the conversion of 3-hydroxyl-3-methyl-glutaryl CoA (HMG-CoA) to mevalonate, which represents the first committed step in cholesterol biosynthesis. HMG-CoA is the target of a number of pharmaceutical compounds designed to lower plasma cholesterol levels. However, inhibition of MHG-CoA
also results in the reduced synthesis of non-sterol intermediates (e.g., mevalonate) required for other biochemical pathways. SE catalyzes a rate-limiting reaction that occurs later in the sterol synthesis pathway and cholesterol in the only end product of the pathway following the step catalyzed by SE. As a result, SE is the ideal target for the design of anti-hyperlipidemic drugs that do not cause a reduction in other necessary intermediates (Nakamura, Y. et al. (1996) 271:8053-8056).
Epoxide hydrolases Epoxide hydrolases catalyze the addition of water to epoxide-containing compounds, thereby hydrolyzing epoxides to their corresponding 1,2-diols. They are related to bacterial haloalkane dehalogenases and show sequence similarity to other members of the aJ~i hydrolase fold family of enzymes (e.g., bromoperoxidase A2 from Streptomyces aureofaciens, hydroxymuconic semialdehyde hydrolases from Pseudomonas putida, and haloalkane dehalogenase from Xanthobacter autotro~hicus). Epoxide hydrolases are ubiquitous in nature and have been found in mammals, invertebrates, plants, fungi, and bacteria. This family of enzymes is important for the detoxification of xenobiotic epoxide compounds which are often highly electrophilic and destructive when introduced into an organism. Examples of epoxide hydrolase reactions include the hydrolysis of cis-9,10-epoxyoctadec-9(Z)-enoic acid (leukotoxin) to form its corresponding diol, threo-9,10-dihydroxyoctadec-12(Z)-enoic acid (leukotoxin diol), and the hydrolysis of cis-12,13-epoxyoctadec-9(Z)-enoic acid (isoleukotoxin) to form its corresponding diol threo-12,13-dihydroxyoctadec-9(Z)-enoic acid (isoleukotoxin diol). Leukotoxins alter membrane permeability and ion transport and cause inflammatory responses. In addition, epoxide carcinogens are known to be produced by cytochrome P450 as intermediates in the detoxification of drugs and environmental toxins.
The enzymes possess a catalytic triad composed of Asp (the nucleophile), Asp (the histidine-supporting acid), and His (the water-activating histidine). The reaction mechanism of epoxide hydrolase proceeds via a covalently bound ester intermediate initiated by the nucleophilic attack of one of the Asp residues on the primary carbon atom of the epoxide ring of the target molecule, leading to a covalently bound ester intermediate (Michael Arand, M.
et al. (1996) J. Biol.
Chem. 271:4223-4229; Rink, R. et al. (1997) J. Biol. Chem. 272:14650-14657;
Argiriadi, M.A. et al.
(2000) J. Biol. Chem. 275:15265-15270).
Enzymes involved in tyrosine catalysis The degradation of the amino acid tyrosine to either succinate and pyruvate or fumarate and acetoacetate, requires a large number of enzymes and generates a large number of intermediate compounds. In addition, many xenobiotic compounds may be metabolized using one or more reactions that are part of the tyrosine catabolic pathway. While the pathway has been studied primarily in bacteria, tyrosine degradation is known to occur in a variety of organisms and is likely to involve many of the same biological reactions.
The enzymes involved in the degradation of tyrosine to succinate and pyruvate (e.g., in Arthrobacter species) include 4-hydroxyphenylpyruvate oxidase, 4-hydroxyphenylacetate 3-hydroxylase, 3,4-dihydroxyphenylacetate 2,3-dioxygenase, 5-carboxymethyl-2-hydroxymuconic semialdehyde dehydrogenase, traps,cis-5-carboxymethyl-2-hydroxymuconate isomerase, homoprotocatechuate isomerase/decarboxylase, cis-2-oxohept-3-ene-1,7-dioate hydratase, 2,4-dihydroxyhept-traps-2-ene-1,7-dioate aldolase, and succinic semialdehyde dehydrogenase.
The enzymes involved in the degradation of tyrosine to fumarate and acetoacetate (e.g., in Pseudomonas species) include 4-hydroxyphenylpyruvate dioxygenase, homogentisate 1,2-dioxygenase, maleylacetoacetate isomerase, and fumarylacetoacetase. 4-hydroxyphenylacetate 1-hydroxylase may also be involved if intermediates from the succinate/pyruvate pathway are accepted.
Additional enzymes associated with tyrosine metabolism in different organisms include 4-chlorophenylacetate-3,4-dioxygenase, aromatic aminotransferase, 5-oxopent-3-ene-1,2,5-tricarboxylate decarboxylase, 2-oxo-kept-3-ene-1,7-dioate hydratase, and 5-carboxymethyl-2-hydroxymuconate isomerase (Elks, L.B.M. et al. (1999) Nucleic Acids Res.
27:373-376; Wackett, L.P. and Ellis, L.B.M. (1996) J. Microbiol. Meth. 25:91-93; and Schmidt, M.
(1996) Amer. Soc. Microbiol. News 62:102).
In humans, acquired or inherited genetic defects in enzymes of the tyrosine degradation pathway may result in hereditary tyrosinemia. One form of this disease, hereditary tyrosinemia 1 (HT1) is caused by a deficiency in the enzyme fumarylacetoacetate hydrolase, the last enzyme in the pathway in organisms that metabolize tyrosine to fumarate and acetoacetate.
HT1 is characterized by progressive liver damage beginning at infancy, and increased risk for liver cancer (Endo, F. et al.
(1997) J. Biol. Chem. 272:24426-24432).
The discovery of new drug metabolizing enzymes and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of drug metabolizing enzymes.
SUMMARY OF THE INVENTION
The invention features purified polypeptides, drug metabolizing enzymes, referred to collectively as "DME" and individually as "DME-1," "DME-2," "DME-3," "DME-4,"
"DME-5,"
"DME-6," "DME-7," "DME-8," "DME-9," and "DME-10." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: l-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-10.
The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ
117 NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10.
In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ )D NO:1-10. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:11-20.
Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:I-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.
The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.
Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10.
The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ )D NO:11-20, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ m NO:11-20, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d).
In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.
Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ )D NO:11-20, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:11-20, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA
equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.
The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:11-20, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ l~
NO:11-20, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d).
The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:I-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:l-10. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment the composition.
The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment the composition.
Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample.
In one alternative, the invention provides a composition comprising an antagonist compound identified by~ the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional DME, comprising administering to a patient in need of such treatment the composition.
The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ )D NO:I-10, b) a naturally occurring polypeptide cmoprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ >D NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:l-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.
The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:I-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.
The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:11-20, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.
The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ
ID NO:11-20, ii) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:11-20, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID
NO:11-20, ii) a naturally occurnng polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:11-20, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv).
Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex;
and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
BRIEF DESCRIPTION OF THE TABLES
Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.
Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.
Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.
Table 4 lists the cDNA and genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.
Table 5 shows the representative cDNA library for polynucleotides of the invention.
Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.
Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.
DESCRIPTION OF THE INVENTION
Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
It must be noted that as used herein and in the appended claims, the singular forms "a," "an,"
and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs.
Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
DEFINITIONS
"DME" refers to the amino acid sequences of substantially purified DME
obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.
The term "agonist" refers to a molecule which intensifies or mimics the biological activity of DME. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of DME either by directly interacting with DME or by acting on components of the biological pathway in which DME
participates.
An "allelic variant" is an alternative form of the gene encoding DME. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.
Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
"Altered" nucleic acid sequences encoding DME include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as DME or a polypeptide with at least one functional characteristic of DME. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding DME, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding DME. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent DME. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of DME is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged , amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine.
Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.
The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.
"Amplification" relates to the production of additional copies of a nucleic acid sequence.
Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.
The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of DME. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of DME either by directly interacting with DME or by acting on components of the biological pathway in which DME participates.
The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')2, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind DME polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired.
Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.
The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.
The term "antisense" refers to any composition capable of base-pairing with the "sense"
(coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA;
RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.
The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic DME, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.
"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.
A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding DME or fragments of DME may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCI), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).
"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.
"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions.
The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.
Original Residue Conservative Substitution Ala Gly, Ser Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln, Glu Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile, Leu, Thr Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.
A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.
The term "derivative" refers to a chemically modified polynucleotide or polypeptide.
Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.
A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.
A "fragment" is a unique portion of DME or the polynucleotide encoding DME
which is identical in sequence to but shorter in length than the parent sequence. A
fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule.
For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.
A fragment of SEQ ID NO:11-20 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:11-20, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:11-20 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:11-20 from related polynucleotide sequences. The precise length of a fragment of SEQ
ID NO:11-20 and the region of SEQ ID NO:11-20 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.
A fragment of SEQ ID NO:1-10 is encoded by a fragment of SEQ ID NO:11-20. A
fragment of SEQ ID NO:1-10 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-10. For example, a fragment of SEQ ID NO:1-10 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-10. The precise length of a fragment of SEQ ID NO:1-10 and the region of SEQ
ID NO:1-10 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.
A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A
"full length" polynucleotide sequence encodes a "full length" polypeptide sequence.
"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.
The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.
Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN
version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted"
residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.
Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol.
215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST
2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2.html.
The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST
programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2Ø12 (April-21-2000) set at default parameters. Such default parameters may be, for example:
Matrix: BLOSUM62 heward for match: I
Penalty for mismatch: -2 Open Gap: 5 and Extension Gap: 2 penalties Gap x drop-off.' S0 Expect: l0 Word Size: Il Filter: on Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.
' Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.
The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions.
Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.
Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN
version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.
Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences"
tool Version 2Ø12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:
Matrix: BLOSUM62 Open Gap: 11 and Extension Gap: 1 penalties Cap x drop-off. 50 Expect: 10 Word Size: 3 Filter: on Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ m number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.
"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.
The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.
"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing steps) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 pg/ml sheared, denatured salmon sperm DNA.
Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50°l0 of the target sequence hybridizes to a perfectly matched probe. An equation for calculating Tm and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al.
( 1989) Molecular Cloning: A Laboratory Manual, 2"d ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.
High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1 % SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC
concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1 %.
Typically, blocking reagents are used to block non-specific hybridization.
Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 pg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art.
Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.
The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A
hybridization complex may be formed in solution (e.g., Cot or Rot analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).
The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.
"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.
An "immunogenic fragment" is a polypeptide or oligopeptide fragment of DME
which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of DME which is useful in any of the antibody production methods disclosed herein or known in the art.
The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.
The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.
The term "modulate" refers to a change in the activity of DME. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of DME.
The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA
of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.
"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.
"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition.
PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.
"Post-translational modification" of an DME may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of DME.
"Probe" refers to nucleic acid sequences encoding DME, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule.
Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.
"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).
Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.
Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laborator~Manual, 2"d ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biolo~y, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR
Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA.
PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).
Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR
primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases.
Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.
A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence.
This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, s-bra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.
Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.
A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.
"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes;
fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors;
magnetic particles; and other moieties known in the art.
An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.
The term "sample" is used in its broadest sense. A sample suspected of containing DME, nucleic acids encoding DME, or fragments thereof may comprise a bodily fluid;
an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.
The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A
and the antibody will reduce the amount of labeled A that binds to the antibody.
The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.
A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.
"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.
A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.
"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment.
The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA
for limited periods of time.
A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or mote of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA
of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al.
(1989), s_ upra.
A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences"
tool Version 2Ø9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.
A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2Ø9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%
or greater sequence identity over a certain defined length of one of the polypeptides.
THE INVENTION
The invention is based on the discovery of new human drug metabolizing enzymes (DME), the polynucleotides encoding DME, and the use of these compositions for the diagnosis, treatment, or prevention of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders.
Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project m). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ
ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ
ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.
Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ )D NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog.
Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where applicable, all of which are expressly incorporated by reference herein.
Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ff~) for each polypeptide of the invention.
Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.
Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are drug metabolizing enzymes. For example, SEQ ID N0:9 is 32% identical to human putative N-acetyltransferase Camello 2 (GenBank ID 86651438) as determined by the Basic Local Alignment Search Tool (BLAST).
(See Table 2.) The BLAST probability score is 6.50E-23, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID N0:9 also contains a signal peptide signature sequence as determined by the SPScan program, and an acetyltransferase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM
database of conserved protein family domains. The probability value of the HMM
comparison to acetyltransferase domain is 3.2e-12. (See Table 3.) Based on BLAST and HMM
analyses, the protein of SEQ )D N0:9 is an N-acetyltransferase which N-acetylates aromatic amines and hvrlra~ina-rnntainino rnmnnnnrlc inrlnrlina hnt not limitPrl tn nara-aminnhPn~nir arid nara-database (See Table 7 for descriptions). All of these signature sequence identifications are highly statistically significant (see Table 7 for threshold values); for example, the probability value of the HMM comparison to the aldo-keto reductase family signature sequence is 5.6e-170. Based on BLAST, HMM, BLIMPS, MOTIFS, and ProfileScan analyses, the protein of SEQ ID
NO:10 is an aldo/keto reductase which reduces carbonyl-containing sugars and aromatic compounds, including, but not limited to, glucose, and carbonyl-containing drug molecules and xenobiotics. SEQ ID NO:1-8 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-10 are described in Table 7.
As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide )D) for each polynucleotide of the invention.
Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:I 1-20 or that distinguish between SEQ ID
NO:11-20 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA
sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (S') and stop (3') positions of the cDNA and genomic sequences in column 5 relative to their respective full length sequences.
The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 3700065F6 is the identification number of an Incyte cDNA sequence, and SININOTOS is the cDNA
library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., 71447910V 1 ). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs (e.g., g5663459) which contributed to the assembly of the full length polynucleotide sequences. Alternatively, the identification numbers in column 5 may refer to coding regions predicted by Genscan analysis of genomic DNA. For example, GNN.g7025744_000055 002 is the identification number of a Genscan-predicted coding sequence, with g7025744 being the GenBank identification number of the sequence to which Genscan was applied. The Genscan-predicted coding sequences may have been edited prior to assembly. (See Example IV.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching"
algorithm. For example, FL,152824_00001 represents a "stitched" sequence in which 152824 is the identification number of the cluster of sequences to which the algorithm was applied, and 00001 is the number of the prediction generated by the algorithm. (See Example V.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon-stretching" algorithm. (See Example V.) In some cases, Incyte cDNA
coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.
Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.
The invention also encompasses DME variants. A preferred DME variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the DME amino acid sequence, and which contains at least one functional or structural characteristic of DME.
The invention also encompasses polynucleotides which encode DME. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:11-20, which encodes DME. The polynucleotide sequences of SEQ ID NO:11-20, as presented in the Sequence Listing, embrace the equivalent RNA
sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.
The invention also encompasses a variant of a polynucleotide sequence encoding DME. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding DME. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID
NO:11-20 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:11-20. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of DME.
It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding DME, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring DME, and all such variations are to be considered as being specifically disclosed.
Although nucleotide sequences which encode DME and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring DME under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding DME or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding DME and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.
The invention also encompasses production of DNA sequences which encode DME
and DME derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding DME or any fragment thereof.
Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID
NO:11-20 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol.
152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."
Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE
amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA
sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art.
(See, e.g., Ausubel, F.M.
(1997) Short Protocols in Molecular BioloQV, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and BiotechnoloQV, Wiley VCH, New York NY, pp.
856-853.) The nucleic acid sequences encoding DME may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic.
2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR
amplification of DNA
fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. ( 1991 ) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res.
19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.
When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.
Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.
In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode DME may be cloned in recombinant DNA molecules that direct expression of DME, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express DME.
The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter DME-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences.
For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.
The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat.
Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of DME, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial"
breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.
In another embodiment, sequences encoding DME may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp.
Ser. 7:225-232.) Alternatively, DME itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques.
(See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems).
Additionally, the amino acid sequence of DME, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.
The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.) In order to express a biologically active DME, the nucleotide sequences encoding DME or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding DME. Such elements may vary in their strength and specificity.
Specific initiation signals may also be used to achieve more efficient translation of sequences encoding DME. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding DME and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG
initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.) Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding DME and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA
techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biolo~y, John Wiley & Sons, New York NY, ch. 9, 13, and 16.) A variety of expression vector/host systems may be utilized to contain and express sequences encoding DME. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra;
Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl.
Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technolo~y (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc.
Natl. Acad. Sci.
USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al.
(1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226;
and Verma, LM.
and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.
In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding DME. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding DME can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding DME into the vector's multiple cloning site disrupts the lacZ gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M.
Schuster (1989) J. Biol.
Chem. 264:5503-5509.) When large quantities of DME are needed, e.g. for the production of antibodies, vectors which direct high level expression of DME may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.
Yeast expression systems may be used for production of DME. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH
promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation.
(See, e.g., Ausubel, 1995, suura; Bitter, G.A. et al. ( 1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. ( 1994) Bio/Technology 12:181-184.) Plant systems may also be used for expression of DME. Transcription of sequences encoding DME may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N.
(1987) EMBO J.
EP450I E-Class P450 Group I signature).
All cytochromes P450 use a heme cofactor and share structural attributes. Most cytochromes P450 are 400 to 530 amino acids in length. The secondary structure of the enzyme is about 70%
alpha-helical and about 22% beta-sheet. The region around the heme-binding site in the C-terminal part of the protein is conserved among cytochromes P450. A ten amino acid signature sequence in this heme-iron ligand region has been identified which includes a conserved cysteine involved in binding the heme iron in the fifth coordination site. In eukaryotic cytochromes P450, a membrane-spanning region is usually found in the first 15-20 amino acids of the protein, generally consisting of approximately 15 hydrophobic residues followed by a positively charged residue. (See Prosite PDOC00081, supra; Graham-Lorence, supra.) Cytochrome P450 enzymes are involved in cell proliferation and development.
The enzymes have roles in chemical mutagenesis and carcinogenesis by metabolizing chemicals to reactive intermediates that form adducts with DNA (Nebert, D.W. and Gonzalez, F.J.
(1987) Ann. Rev.
Biochem. 56:945-993). These adducts can cause nucleotide changes and DNA
rearrangements that lead to oncogenesis. Cytochrome P450 expression in liver and other tissues is induced by xenobiotics such as polycyclic aromatic hydrocarbons, peroxisomal proliferators, phenobarbital, and the glucocorticoid dexamethasone (Dogra, S.C. et al. (1998) Clin. Exp. Pharmacol.
Physiol. 25:1-9). A
cytochrome P450 protein may participate in eye development as mutations in the P450 gene CYP1B1 cause primary congenital glaucoma (Online Mendelian Inheritance in Man (OMIM) *601771 Cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1; CYP1B1).
Cytochromes P450 are associated with inflammation and infection. Hepatic cytochrome P450 activities are profoundly affected by various infections and inflammatory stimuli, some of which are suppressed and some induced (Morgan, E.T. (1997) Drug Metab. Rev.
29:1129-1188).
Effects observed in vivo can be mimicked by proinflammatory cytokines and interferons.
Autoantibodies to two cytochrome P450 proteins were found in patients with autoimmune polyenodocrinopathy-candidiasis-ectodermal dystrophy (APECED), a polyglandular autoimmune syndrome (OMIM *240300 Autoimmune polyenodocrinopathy-candidiasis-ectodermal dystrophy).
Mutations in cytochromes P450 have been linked to metabolic disorders, including congenital adrenal hyperplasia, the most common adrenal disorder of infancy and childhood; pseudovitamin D-deficiency rickets; cerebrotendinous xanthomatosis, a lipid storage disease characterized by progressive neurologic dysfunction, premature atherosclerosis, and cataracts;
and an inherited resistance to the anticoagulant drugs coumarin and warfarin (Isselbacher, K.J.
et al. ( 1994) Harrison's Principles of Internal Medicine, McGraw-Hill, Inc. New York, NY, pp. 1968-1970; Takeyama, K. et al. (1997) Science 277:1827-1830; Kitanaka, S. et al. (1998) N. Engl. J. Med.
338:653-661; OMIM
*213700 Cerebrotendinous xanthomatosis; and OMIM #122700 Coumarin resistance).
Extremely high levels of expression of the cytochrome P450 protein aromatase were found in a fibrolamellar hepatocellular carcinoma from a boy with severe gynecomastia (feminization) (Agarwal, V.R. ( 1998) J. Clip. Endocrinol. Metab. 83:1797-1800).
The cytochrome P450 catalytic cycle is completed through reduction of cytochrome P450 by NADPH cytochrome P450 reductase (CPR). Another microsomal electron transport system consisting of cytochrome b5 and NADPH cytochrome b5 reductase has been widely viewed as a minor contributor of electrons to the cytochrome P450 catalytic cycle.
However, a recent report by Lamb, D.C. et al. (1999; FEBS Lett. 462:283-288) identifies a Candida albicans cytochrome P450 (CYP51) which can be efficiently reduced and supported by the microsomal cytochrome b5/NADPH
cytochrome b5 reductase system. Therefore, there are likely many cytochromes P450 which are supported by this alternative electron donor system.
Cytochrome b5 reductase is also responsible for the reduction of oxidized hemoglobin (methemoglobin, or ferrihemoglobin, which is unable to carry oxygen) to the active hemoglobin (ferrohemoglobin) in red blood cells. Methemoglobinemia results when there is a high level of oxidant drugs or an abnormal hemoglobin (hemoglobin M) which is not efficiently reduced.
Methemoglobinemia can also result from a hereditary deficiency in red cell cytochrome b5 reductase (Reviewed in Mansour, A. and Lurie, A.A. (1993) Am. J. Hematol. 42:7-12).
Members of the cytochrome P450 family are also closely associated with vitamin D synthesis and catabolism. Vitamin D exists as two biologically equivalent prohormones, ergocalciferol (vitamin DZ), produced in plant tissues, and cholecalciferol (vitamin D3), produced in animal tissues.
The latter form, cholecalciferol, is formed upon the exposure of 7-dehydrocholesterol to near ultraviolet light (i.e., 290-310 nm), normally resulting from even minimal periods of skin exposure to sunlight (reviewed in Miller, W.L. and Portale, A.A. (2000) Trends Endocrinol.
Metab. 11:315-319).
Both prohormone forms are further metabolized in the liver to 25-hydroxyvitamin D
(25(OH)D) by the enzyme 25-hydroxylase. 25(OH)D is the most abundant precursor form of vitamin D which must be further metabolized in the kidney to the active form, 1a,25-dihydroxyvitamin D
(1a,25(OH)ZD), by the enzyme 25-hydroxyvitamin D la-hydroxylase (la-hydroxylase). Regulation of 1a,25(OH)ZD production is primarily at this final step in the synthetic pathway. The activity of la-hydroxylase depends upon several physiological factors including the circulating level of the enzyme product (1a,25(OH)ZD) and the levels of parathyroid hormone (PTH), calcitonin, insulin, calcium, phosphorus, growth hormone, and prolactin. Furthermore, extrarenal la-hydroxylase activity has been reported, suggesting that tissue-specific, local regulation of 1a,25(OH)2D
production may also be biologically important. The catalysis of 1a,25(OH)ZD to 24,25-dihydroxyvitamin D (24,25(OH)ZD), involving the enzyme 25-hydroxyvitamin D
24-hydroxylase (24-hydroxylase), also occurs in the kidney. 24-hydroxylase can also use 25(OH)D as a substrate (Shinki, T. et al. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:12920-12925; Miller, W.L. and Portale, A.A. supra; and references within).
Vitamin D 25-hydroxylase, 1 a-hydroxylase, and 24-hydroxylase are all NADPH-dependent, type I (mitochondrial) cytochrome P450 enzymes that show a high degree of homology with other members of the family. Vitamin D 25-hydroxylase also shows a broad substrate specificity and may also perform 26-hydroxylation of bile acid intermediates and 25, 26, and 27-hydroxylation of cholesterol (Dilworth, F.J. et al. (1995) J. Biol. Chem. 270:16766-16774;
Miller, W.L. and Portale, A.A. supra; and references within).
The active form of vitamin D (1a,25(OH)ZD) is involved in calcium and phosphate homeostasis and promotes the differentiation of myeloid and skin cells.
Vitamin D deficiency resulting from deficiencies in the enzymes involved in vitamin D metabolism (e.g., la-hydroxylase) causes hypocalcemia, hypophosphatemia, and vitamin D-dependent (sensitive) rickets, a disease characterized by loss of bone density and distinctive clinical features, including bandy or bow leggedness accompanied by a waddling gait. Deficiencies in vitamin D 25-hydroxylase cause cerebrotendinous xanthomatosis, a lipid-storage disease characterized by the deposition of cholesterol and cholestanol in the Achilles' tendons, brain, lungs, and many other tissues. The disease presents with progressive neurologic dysfunction, including postpubescent cerebellar ataxia, atherosclerosis, and cataracts. Vitamin D 25-hydroxylase deficiency does not result in rickets, suggesting the existence of alternative pathways for the synthesis of 25(OH)D (Griffin, J.E.
and Zerwekh, J.E.
(1983) J. Clin. Invest. 72:1190-1199; Gamblin, G.T. et al. (1985) J. Clin.
Invest. 75:954-960; and W.L. and Portale, A.A. supra).
Ferredoxin and ferredoxin reductase are electron transport accessory proteins which support at least one human cytochrome P450 species, cytochrome P450c27 encoded by the CYP27 gene (Dilworth, F.J. et al. (1996) Biochem. J. 320:267-71). A Streptomyces ng ~seus cytochrome P450, CYP104D1, was heterologously expressed in E. coli and found to be reduced by the endogenous ferredoxin and ferredoxin reductase enzymes (Taylor, M. et al. (1999) Biochem.
Biophys. Res.
Commun. 263:838-42), suggesting that many cytochrome P450 species may be supported by the ferredoxin/ferredoxin reductase pair. Ferredoxin reductase has also been found in a model drug metabolism system to reduce actinomycin D, an antitumor antibiotic, to a reactive free radical species (Flitter, W.D. and Mason, R.P. (1988) Arch. Biochem. Biophys. 267:632-639).
Flavin-containing monooxygenase (FMO) Flavin-containing monooxygenases oxidize the nucleophilic nitrogen, sulfur, and phosphorus heteroatom of an exceptional range of substrates. Like cytochromes P450, FMOs are microsomal and use NADPH and OZ; there is also a great deal of substrate overlap with cytochromes P450. The tissue distribution of FMOs includes liver, kidney, and lung.
There are five different known isoforms of FMO in mammals (FMO1, FM02, FM03, FM04, and FM05), which are expressed in a tissue-specific manner. The isoforms differ in their substrate specificities and other properties such as inhibition by various compounds and stereospecificity of reaction. FMOs have a 13 amino acid signature sequence, the components of which span the N-terminal two-thirds of the sequences and include the FAD binding region and the FATGY motif which has been found in many N-hydroxylating enzymes (Stehr, M. et al. (1998) Trends Biochem.
Sci. 23:56-57; PRINTS FMOXYGENASE Flavin-containing monooxygenase signature).
Specific reactions include oxidation of nucleophilic tertiary amines to N-oxides, secondary amines to hydroxylamines and nitrones, primary amines to hydroxylamines and oximes, and sulfur-containing compounds and phosphines to S- and P-oxides. Hydrazines, iodides, selenides, and boron-containing compounds are also substrates. Although FMOs appear similar to cytochromes P450 in their chemistry, they can generally be distinguished from cytochromes P450 in vitro based on, for example, the higher heat lability of FMOs and the nonionic detergent sensitivity of cytochromes P450; however, use of these properties in identification is complicated by further variation among FMO isoforms with respect to thermal stability and detergent sensitivity.
FMOs play important roles in the metabolism of several drugs and xenobiotics.
FMO (FM03 in liver) is predominantly responsible for metabolizing (S)-nicotine to (S)-nicotine N-1=oxide, which is excreted in urine. FMO is also involved in S-oxygenation of cimetidine, an HZ-antagonist widely used for the treatment of gastric ulcers. Liver-expressed forms of FMO are not under the same regulatory control as cytochrome P450. In rats, for example, phenobarbital treatment leads to the induction of cytochrome P450, but the repression of FMO1.
Endogenous substrates of FMO include cysteamine, which is oxidized to the disulfide, cystamine, and trimethylamine (TMA), which is metabolized to trimethylamine N-oxide. TMA
smells like rotting fish, and mutations in the FM03 isoform lead to large amounts of the malodorous free amine being excreted in sweat, urine, and breath. These symptoms have led to the designation fish-odor syndrome (OMIM 602079 Trimethylaminuria).
Lysyl oxidase:
Lysyl oxidase (lysine 6-oxidase, LO) is a copper-dependent amine oxidase involved in the formation of connective.tissue matrices by crosslinking collagen and elastin.
LO is secreted as a N-glycosylated precuror protein of approximately 50 kDa Levels and cleaved to the mature form of the enzyme by a metalloprotease, although the precursor form is also active. The copper atom in LO is involved in the transport of electron to and from oxygen to facilitate the oxidative deamination of lysine residues in these extracellular matrix proteins. While the coordination of copper is essential to LO activity, insufficient dietary intake of copper does not influence the expression of the apoenzyme.
However, the absence of the functional LO is linked to the skeletal and vascular tissue disorders that are associated with dietary copper deficiency. LO is also inhibited by a variety of semicarbazides, hydrazines, and amino nitrites, as well as heparin. Beta-aminopropionitrile is a commonly used inhibitor. LO activity is increased in response to ozone, cadmium, and elevated levels of hormones released in response to local tissue trauma, such as transforming growth factor-beta, platelet-derived growth factor, angiotensin II, and fibroblast growth factor. Abnormalities in LO activity has been linked to Menkes syndrome and occipital horn syndrome. Cytosolic forms of the enzyme hae been implicated in abnormal cell proliferation (reviewed in Rucker, R.B. et al.
(1998) Am. J. Clin. Nutr.
67:9965-1002S and Smith-Mungo, L.I. and Kagan, H.M. (1998) Matrix Biol. 16:387-398).
Dihydrofolate reductases Dihydrofolate reductases (DHFR) are ubiquitous enzymes that catalyze the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate, an essential step in the de novo synthesis of glycine and purines as well as the conversion of deoxyuridine monophosphate (dLTMP) to deoxythymidine monophosphate (dTMP). The basic reaction is as follows:
7,8-dihydrofolate + NADPH -~ 5,6,7,8-tetrahydrofolate + NADP+
The enzymes can be inhibited by a number of dihydrofolate analogs, including trimethroprim and methotrexate. Since an abundance of TMP is required for DNA synthesis, rapidly dividing cells require the activity of DHFR. The replication of DNA viruses (i.e., herpesvirus) also requires high levels of DHFR activity. As a result, drugs that target DHFR have been used for cancer chemotherapy and to inhibit DNA virus replication. (For similar reasons, thymidylate synthetases are also target enzymes.) Drugs that inhibit DHFR are preferentially cytotoxic for rapidly dividing cells (or DNA virus-infected cells) but have no specificity, resulting in the indiscriminate destruction of dividing cells. Furthermore, cancer cells may become resistant to drugs such as methotrexate as a result of acquired transport defects or the duplication of one or more DHFR
genes (Stryer, L. ( 1988) Biochemistry. W.H Freeman and Co., Inc. New York. pp. 511-5619).
Aldo/keto reductases Aldo/keto reductases are monomeric NADPH-dependent oxidoreductases with broad substrate specificities (Bohren, K.M. et al. (1989) J. Biol. Chem. 264:9547-9551). These enzymes catalyze the reduction of carbonyl-containing compounds, including carbonyl-containing sugars and aromatic compounds, to the corresponding alcohols. Therefore, a variety of carbonyl-containing drugs and xenobiotics are likely metabolized by enzymes of this class.
One known reaction catalyzed by a family member, aldose reductase, is the reduction of glucose to sorbitol, which is then further metabolized to fructose by sorbitol dehydrogenase. Under normal conditions, the reduction of glucose to sorbitol is a minor pathway. In hyperglycemic states, however, the accumulation of sorbitol is implicated in the development of diabetic complications (OMIM * 103880 Aldo-keto reductase family 1, member B1). Members of this enzyme family are also highly expressed in some liver cancers (Cao, D. et al. (1998) J. Biol.
Chem. 273:11429-11435).
Alcoholdehydro eg eases Alcohol dehydrogenases (ADHs) oxidize simple alcohols to the corresponding aldehydes.
ADH is a cytosolic enzyme, prefers the cofactor NAD+, and also binds zinc ion.
Liver contains the highest levels of ADH, with lower levels in kidney, lung, and the gastric mucosa.
Known ADH isoforms are dimeric proteins composed of 40 kDa subunits. There are five known gene loci which encode these subunits (a, b, g, p, c), and some of the loci have characterized allelic variants (b" b2, b3, g,, g2). The subunits can form homodimers and heterodimers; the subunit composition determines the specific properties of the active enzyme. The holoenzymes have therefore been categorized as Class I (subunit compositions aa, ab, ag, bg, gg), Class II (pp), and Class III (cc). Class I ADH isozymes oxidize ethanol and other small aliphatic alcohols, and are inhibited by pyrazole. Class II isozymes prefer longer chain aliphatic and aromatic alcohols, are unable to oxidize methanol, and are not inhibited by pyrazole. Class III
isozymes prefer even longer chain aliphatic alcohols (five carbons and longer) and aromatic alcohols, and are not inhibited by pyrazole.
The short-chain alcohol dehydrogenases include a number of related enzymes with a variety of substrate specificities. Included in this group are the mammalian enzymes D-beta-hydroxybutyrate dehydrogenase, (R)-3-hydroxybutyrate dehydrogenase, 15-hydroxyprostaglandin dehydrogenase, NADPH-dependent carbonyl reductase, corticosteroid 11-beta-dehydrogenase, and estradiol 17-beta-dehydrogenase, as well as the bacterial enzymes acetoacetyl-CoA reductase, glucose 1-dehydrogenase, 3-beta-hydroxysteroid dehydrogenase, 20-beta-hydroxysteroid dehydrogenase, ribitol dehydrogenase, 3-oxoacyl reductase, 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase, sorbitol-6-phosphate 2-dehydrogenase, 7-alpha-hydroxysteroid dehydrogenase, cis-1,2-dihydroxy-3,4-cyclohexadiene-1-carboxylate dehydrogenase, cis-toluene dihydrodiol dehydrogenase, cis-benzene glycol dehydrogenase, biphenyl-2,3-dihydro-2,3-diol dehydrogenase, N-acylmannosamine 1-dehydrogenase, and 2-deoxy-D-gluconate 3-dehydrogenase (Krozowski, Z. (1994) J. Steroid Biochem. Mol. Biol. 51:125-130; Krozowski, Z. (1992) Mol. Cell Endocrinol.
84:C25-31; and Marks, A.R. et al. (1992) J. Biol. Chem. 267:15459-15463).
UDP glucuronyltransferase Members of the UDP glucuronyltransferase family (UGTs) catalyze the transfer of a glucuronic acid group from the cofactor uridine diphosphate-glucuronic acid (UDP-glucuronic acid) to a substrate. The transfer is generally to a nucleophilic heteroatom (O, N, or S). Substrates include xenobiotics which have been functionalized by Phase I reactions, as well as endogenous compounds such as bilirubin, steroid hormones, and thyroid hormones. Products of glucuronidation are excreted in urine if the molecular weight of the substrate is less than about 250 g/mol, whereas larger glucuronidated substrates are excreted in bile.
UGTs are located in the microsomes of liver, kidney, intestine, skin, brain, spleen, and nasal mucosa, where they are on the same side of the endoplasmic reticulum membrane as cytochrome P450 enzymes and flavin-containing monooxygenases, and therefore are ideally located to access products of Phase I drug metabolism. UGTs have a C-terminal membrane-spanning domain which anchors them in the endoplasmic reticulum membrane, and a conserved signature domain of about 50 amino acid residues in their C terminal section (Prosite PDOC00359 UDP-glycosyltransferase signature).
UGTs involved in drug metabolism are encoded by two gene families, UGT1 and UGT2.
Members of the UGT1 family result from alternative splicing of a single gene locus, which has a variable substrate binding domain and constant region involved in cofactor binding and membrane insertion. Members of the UGT2 family are encoded by separate gene loci, and are divided into two families, UGT2A and UGT2B. The 2A subfamily is expressed in olfactory epithelium, and the 2B
subfamily is expressed in liver microsomes. Mutations in UGT genes are associated with hyperbilirubinemia (OMIM #143500 Hyperbilirubinemia I); Crigler-Najjar syndrome, characterized by intense hyperbilirubinemia from birth (OMIM #218800 Crigler-Najjar syndrome); and a milder form of hyperbilirubinemia termed Gilbert's disease (OMIM *191740 UGT1).
Sulfotransferase Sulfate conjugation occurs on many of the same substrates which undergo O-glucuronidation to produce a highly water-soluble sulfuric acid ester. Sulfotransferases (ST) catalyze this reaction by transferring S03- from the cofactor 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to the substrate.
ST substrates are predominantly phenols and aliphatic alcohols, but also include aromatic amines and aliphatic amines, which are conjugated to produce the corresponding sulfamates. The products of these reactions are excreted mainly in urine.
STs are found in a wide range of tissues, including liver, kidney, intestinal tract, lung, platelets; and brain. The enzymes are generally cytosolic, and multiple forms are often co-expressed.
For example, there are more than a dozen forms of ST in rat liver cytosol.
These biochemically characterized STs fall into five classes based on their substrate preference:
arylsulfotransferase, alcohol sulfotransferase, estrogen sulfotransferase, tyrosine ester sulfotransferase, and bile salt sulfotransferase.
ST enzyme activity varies greatly with sex and age in rats. The combined effects of developmental cues and sex-related hormones are thought to lead to these differences in ST
expression profiles, as well as the profiles of other DMEs such as cytochromes P450. Notably, the high expression of STs in cats partially compensates for their low level of UDP glucuronyltransferase activity.
Several forms of ST have been purified from human liver cytosol and cloned.
There are two phenol sulfotransferases with different thermal stabilities and substrate preferences. The thermostable enzyme catalyzes the sulfation of phenols such as para-nitrophenol, minoxidil, and acetaminophen; the thermolabile enzyme prefers monoamine substrates such as dopamine, epinephrine, and levadopa. Other cloned STs include an estrogen sulfotransferase and an N-acetylglucosamine-6-O-sulfotransferase. This last enzyme is illustrative of the other major role of STs in cellular biochemistry, the modification of carbohydrate structures that may be important in cellular differentiation and maturation of proteoglycans. Indeed, an inherited defect in a sulfotransferase has been implicated in macular corneal dystrophy, a disorder characterized by a failure to synthesize mature keratan sulfate proteoglycans (Nakazawa, K. et al. (1984) J. Biol. Chem.
259:13751-13757; OMIM *217800 Macular dystrophy, corneal).
Galactosyltransferases Galactosyltransferases are a subset of glycosyltransferases that transfer galactose (Gal) to the terminal N-acetylglucosamine (GIcNAc) oligosaccharide chains that are part of glycoproteins or glycolipids that are free in solution (Kolbinger, F. et al. (1998) J. Biol.
Chem. 273:433-440; Amado, M. et al. (1999) Biochim. Biophys. Acta 1473:35-53). Galactosyltransferases have been detected on the cell surface and as soluble extracellular proteins, in addition to being present in the Golgi. (31,3-galactosyltransferases form Type I carbohydrate chains with Gal (ail-3)GIcNAc linkages. Known human and mouse (31,3-galactosyltransferases appear to have a short cytosolic domain, a single transmembrane domain, and a catalytic domain with eight conserved regions.
(Kolbinger, F., supra and Hennet, T. et al. (1998) J. Biol. Chem. 273:58-65). In mouse UDP-galactose:(3-N-acetylglucosamine (31,3-galactosyltransferase-I region 1 is located at amino acid residues 78-83, region 2 is located at amino acid residues 93-102, region 3 is located at amino acid residues 116-119, region 4 is located at amino acid residues 147-158, region 5 is located at amino acid residues 172-183, region 6 is located at amino acid residues 203-206, region 7 is located at amino acid residues 236-246, and region 8 is located at amino acid residues 264-275. A variant of a sequence found within mouse UDP-galactose:(3-N-acetylglucosamine (31,3-galactosyltransferase-I region 8 is also found in bacterial galactosyltransferases, suggesting that this sequence defines a galactosyltransferase sequence motif (Hennet, T. supra). Recent work suggests that brainiac protein is a (31,3-galactosyltransferase (Yuan, Y. et al. (1997) Cell 88:9-11; and Hennet, T.
supra).
UDP-Gal:GlcNAc-1,4-galactosyltransferase (-1,4-GaIT) (Sato, T. et al., (1997) EMBO J.
16:1850-1857) catalyzes the formation of Type II carbohydrate chains with Gal ((31-4)GIcNAc linkages. As is the case with the (31,3-galactosyltransferase, a soluble form of the enzyme is formed by cleavage of the membrane-bound form. Amino acids conserved among (31,4-galactosyltransferases include two cysteines linked through a disulfide-bonded and a putative UDP-galactose-binding site in the catalytic domain (Yadav, S. and Brew, K. (1990) J. Biol. Chem. 265:14163-14169; Yadav, S.P.
and Brew, K. (1991) J. Biol. Chem. 266:698-703; and Shaper, N.L. et al. (1997) J. Biol. Chem.
272:31389-31399). (31,4-galactosyltransferases have several specialized roles in addition to synthesizing carbohydrate chains on glycoproteins or glycolipids. In mammals a ~i1,4-galactosyltransferase, as part of a heterodimer with a-lactalbumin, functions in lactating mammary gland lactose production. A ~i1,4-galactosyltransferase on the surface of sperm functions as a receptor that specifically recognizes the egg. Cell surface (31,4-galactosyltransferases also function in cell adhesion, cell/basal lamina interaction, 'and normal and metastatic cell migration. (Shur, B.
(1993) Curr. Opin. Cell Biol. 5:854-863; and Shaper, J. (1995) Adv. Exp. Med.
Biol. 376:95-104).
Glutathione S-transferase The basic reaction catalyzed by glutathione S-transferases (GST) is the conjugation of an electrophile with reduced glutathione (GSH). GSTs are homodimeric or heterodimeric proteins localized mainly in the cytosol, but some level of activity is present in microsomes as well. The major isozymes share common structural and catalytic properties; in humans they have been classified into four major classes, Alpha, Mu, Pi, and Theta. The two largest classes, Alpha and Mu, are identified by their respective protein isoelectric points; pI ~ 7.5-9.0 (Alpha), and pI ~ 6.6 (Mu).
Each GST possesses a common binding site for GSH and a variable hydrophobic binding site. The hydrophobic binding site in each isozyme is specific for particular electrophilic substrates. Specific amino acid residues within GSTs have been identified as important for these binding sites and for catalytic activity. Residues Q67, T68, D101, E104, and 8131 are important for the binding of GSH
(Lee, H.-C. et al. (1995) J. Biol. Chem. 270:99-109). Residues R13, R20, and R69 are important for the catalytic activity of GST (Stenberg, G. et al. (1991) Biochem. J. 274:549-555).
In most cases, GSTs perform the beneficial function of deactivation and detoxification of potentially mutagenic and carcinogenic chemicals. However, in some cases their action is detrimental and results in activation of chemicals with consequent mutagenic and carcinogenic effects. Some forms of rat and human GSTs are reliable preneoplastic markers that aid in the detection of carcinogenesis. Expression of human GSTs in bacterial strains, such as Salmonella t~phimurium used in the well-known Ames test for mutagenicity, has helped to establish the role of these enzymes in mutagenesis. Dihalomethanes, which produce liver tumors in mice, are believed to be activated by GST. This view is supported by the finding that dihalomethanes are more mutagenic in bacterial cells expressing human GST than in untransfected cells (Thier, R. et al. ( 1993) Proc. Natl. Acad. Sci. USA
90:8567-8580). The mutagenicity of ethylene dibromide and ethylene dichloride is increased in bacterial cells expressing the human Alpha GST, A1-1, while the mutagenicity of aflatoxin B1 is substantially reduced by enhancing the expression of GST (Simula, T.P. et al.
(1993) Carcinogenesis 14:1371-1376). Thus, control of GST activity may be useful in the control of mutagenesis and carcinogenesis.
GST has been implicated in the acquired resistance of many cancers to drug treatment, the phenomenon known as multi-drug resistance (MDR). MDR occurs when a cancer patient is treated with a cytotoxic drug such as cyclophosphamide and subsequently becomes resistant to this drug and to a variety of other cytotoxic agents as well. Increased GST levels are associated with some of these drug resistant cancers, and it is believed that this increase occurs in response to the drug agent which is then deactivated by the GST catalyzed GSH conjugation reaction. The increased GST levels then protect the cancer cells from other cytotoxic agents which bind to GST.
Increased levels of A1-1 in tumors has been linked to drug resistance induced by cyclophosphamide treatment (Dirven H.A. et al.
(1994) Cancer Res. 54: 6215-6220). Thus control of GST activity in cancerous tissues may be useful in treating MDR in cancer patients.
Gamma-. lug tamvl transpeptidase Gamma-glutamyl transpeptidases are ubiquitously expressed enzymes that initiate extracellular glutathione (GSH) breakdown by cleaving gamma-glutamyl amide bonds. The breakdown of GSH provides cells with a regional cysteine pool for biosynthetic pathways.
Gamma-glutamyl transpeptidases also contribute to cellular antioxidant defenses and expression is induced by oxidative steress. The cell surface-localized glycoproteins.are expressed at high levels in cancer cells. Studies have suggested that the high level of gamma-glutamyl transpeptidases activity present on the surface of cancer cells could be exploited to activate precursor drugs, resulting in high local concentrations of anti-cancer therapeutic agents (Hanigan, M.H. (1998) Chem. Biol. Interact.
111-112:333-42; Taniguchi, N. and Ikeda, Y. (1998) Adv. Enzymol. Relat. Areas Mol. Biol.
72:239-78; Chikhi, N. et al. (1999) Comp. Biochem. Physiol. B. Biochem. Mol.
Biol. 122:367-380).
Acyltransferase N-acyltransferase enzymes catalyze the transfer of an amino acid conjugate to an activated carboxylic group. Endogenous compounds and xenobiotics are activated by acyl-CoA synthetases in the cytosol, microsomes, and mitochondria. The acyl-CoA intermediates are then conjugated with an amino acid (typically glycine, glutamine, or taurine, but also ornithine, arginine, histidine, serine, aspartic acid, and several dipeptides) by N-acyltransferases in the cytosol or mitochondria to form a metabolite with an amide bond. This reaction is complementary to O-glucuronidation, but amino acid conjugation does not produce the reactive and toxic metabolites which often result from glucuronidation.
One well-characterized enzyme of this class is the bile acid-CoA:amino acid N-acyltransferase (BAT) responsible for generating the bile acid conjugates which serve as detergents in the gastrointestinal tract (Falany, C.N. et al. (1994) J. Biol. Chem.
269:19375-19379; Johnson, M.R.
et al. (1991) J. Biol. Chem. 266:10227-10233). BAT is also useful as a predictive indicator for prognosis of hepatocellular carcinoma patients after partial hepatectomy (Furutani, M. et al. (1996) Hepatology 24:1441-1445).
Acetyltransferases Acetyltransferases have been extensively studied for their role in histone acetylation. Histone acetylation results in the relaxing of the chromatin structure in eukaryotic cells, allowing transcription factors to gain access to promoter elements of the DNA templates in the affected region of the genome (or the genome in general). In contrast, histone deacetylation results in a reduction in transcription by closing the chromatin structure and limiting access of transcription factors. To this end, a common means of stimulating cell transcription is the use of chemical agents that inhibit the deacetylation of histones (e.g., sodium butyrate), resulting in a global (albeit artifactual) increase in gene expression. The modulation of gene expression by acetylation also results from the acetylation of other proteins, including but not limited to, p53, GATA-1, MyoD, ACTR, TFIIE, TFIIF and the high mobility group proteins (HMG). In the case of p53, acetylation results in increased DNA
binding, leading to the stimulation of transcription of genes regulated by p53. The prototypic histone acetylase (HAT) is GcnS from Saccharomyces cerevisiae. GcnS is a member of a family of acetylases that includes Tetrahymena p55, human GcnS, and human p300/CBP. Histone acetylation is reviewed in (Cheung, W.L. et al. (2000) Curr. Opin. Cell Biol. 12:326-333 and Bergen S.L (1999) Curr. Opin.
Cell Biol. 11:336-341). Some acetyltransferase enzymes posses the alpha/beta hydrolase fold (Center of Applied Molecular Engineering Inst. of Chemistry and Biochemistry -University of Salzburg, http://predict.sanger.ac.uk/irbm-course97/Docs/ms/) common to several other major classes of enzymes, including but not limited to, acetylcholinesterases and carboxylesterases (Structural Classification of Proteins, http://scop.mrc-Imb.cam.ac.uk/scop/index.html).
N-acetyltransferase Aromatic amines and hydrazine-containing compounds are subject to N-acetylation by the N-acetyltransferase enzymes of liver and other tissues. Some xenobiotics can be O-acetylated to some extent by the same enzymes. N-acetyltransferases are cytosolic enzymes which utilize the cofactor acetyl-coenzyme A (acetyl-CoA) to transfer the acetyl group in a two step process. In the first step, the acetyl group is transferred from acetyl-CoA to an active site cysteine residue; in the second step, the acetyl group is transferred to the substrate amino group and the enzyme is regenerated.
In contrast to most other DME classes, there are a limited number of known N-acetyltransferases. In humans, there are two highly similar enzymes, NATI and NAT2; mice appear to have a third form of the enzyme, NAT3. The human forms of N-acetyltransferase have independent regulation (NAT1 is widely-expressed, whereas NAT2 is in liver and gut only) and overlapping substrate preferences. Both enzymes appear to accept most substrates to some extent, but NAT1 does prefer some substrates (para-aminobenzoic acid, para-aminosalicylic acid, sulfamethoxazole, and sulfanilamide), while NAT2 prefers others (isoniazid, hydralazine, procainamide, dapsone, aminoglutethimide, and sulfamethazine).
Clinical observations of patients taking the antituberculosis drug isoniazid in the 1950s led to the description of fast and slow acetylators of the compound. These phenotypes were shown subsequently to be due to mutations in the NAT2 gene which affected enzyme activity or stability.
The slow isoniazid acetylator phenotype is very prevalent in Middle Eastern populations (approx.
70%), and is less prevalent in Caucasian (approx. 50%) and Asian (<25%) populations. More recently, functional polymorphism in NAT1 has been detected, with approximately 8% of the population tested showing a slow acetylator phenotype (Butcher, N. J. et al.
(1998) Pharmacogenetics 8:67-72). Since NAT1 can activate some known aromatic amine carcinogens, polymorphism in the widely-expressed NAT1 enzyme may be important in determining cancer risk (OMIM
*108345 N-acetyltransferase 1).
Aminotransferases Aminotransferases comprise a family of pyridoxal 5 =phosphate (PLP) -dependent enzymes that catalyze transformations of amino acids. Aspartate aminotransferase (AspAT) is the most extensively studied PLP-containing enzyme. It catalyzes the reversible transamination of dicarboxylic L-amino acids, aspartate and glutamate, and the corresponding 2-oxo acids, oxalacetate and 2-oxoglutarate. Other members of the family included pyruvate aminotransferase, branched-chain amino acid aminotransferase, tyrosine aminotransferase, aromatic aminotransferase, alanine:glyoxylate aminotransferase (AGT), and kynurenine aminotransferase (Vacca, R.A. et al.
(1997) J. Biol. Chem. 272:21932-21937).
Primary hyperoxaluria type-1 is an autosomal recessive disorder resulting in a deficiency in the liver-specific peroxisomal enzyme, alanine:glyoxylate aminotransferase-1.
The phenotype of the disorder is a deficiency in glyoxylate metabolism. In the absence of AGT, glyoxylate is oxidized to oxalate rather than being transaminated to glycine. The result is the deposition of insoluble calcium oxalate in the kidneys and urinary tract, ultimately causing renal failure (Lumb, M.J. et al. (1999) J.
Biol. Chem. 274:20587-20596).
Kynurenine aminotransferase catalyzes the irreversible transamination of the L-tryptophan metabolite L-kynurenine to form kynurenic acid. The enzyme may also catalyzes the reversible transamination reaction between L-2-aminoadipate and 2-oxoglutarate to produce 2-oxoadipate and L-glutamate. Kynurenic acid is a putative modulator of glutamatergic neurotransmission, thus a deficiency in kynurenine aminotransferase may be associated with pleotrophic effects (Buchli, R. et al. (1995) J. Biol. Chem. 270:29330-29335).
Catechol-O-methyltransferase Catechol-O-methyltransferase (COMT) catalyzes the transfer of the methyl group of S-adenosyl-L-methionine (AdoMet; SAM) donor to one of the hydroxyl groups of the catechol substrate (e.g., L-dopa, dopamine, or DBA). Methylation of the 3 =hydroxyl group is favored over methylation of the 4'-hydroxyl group and the membrane bound isoform of COMT is more regiospecific than the soluble form. Translation of the soluble form of the enzyme results from utilization of an internal start codon in a full-length mRNA (1.5 kb) or from the translation of a shorter mRNA (1.3 kb), transcribed from an internal promoter. The proposed SN2-like methylation reaction requires Mg++ and is inhibited by Ca''-". The binding of the donor and substrate to COMT occurs sequentially. AdoMet first binds COMT in a Mg**-independent manner, followed by the binding of Mg**
and the binding of the catechol substrate.
The amount of COMT in tissues is relatively high compared to the amount of activity normally required, thus inhibition is problematic. Nonetheless, inhibitors have been developed for in vitro use (e.g., gallates, tropolone, U-0521, and 3',4=dihydroxy-2-methyl-propiophetropolone) and for clinical use (e.g., nitrocatechol-based compounds and tolcapone).
Administration of these inhibitors results in the increased half-life of L-dopa and the consequent formation of dopamine. Inhibition of COMT is also likely to increase the half-life of various other catechol-structure compounds, including but not limited to epinephrine/norepinephrine, isoprenaline, rimiterol, dobutamine, fenoldopam, apomorphine, and a-methyldopa. A deficiency in norepinephrine has been linked to clinical depression, hence the use of COMT inhibitors could be usefull in the treatment of depression.
COMT inhibitors are generally well tolerated with minimal side effects and are ultimately metabolized in the liver with only minor accumulation of metabolites in the body (Mannisto, P.T. and Kaakkola, S. (1999) Pharmacol. Rev. 51:593-628).
Copper-zinc superoxide dismutases Copper-zinc superoxide dismutases are compact homodimeric metalloenzymes involved in cellular defenses against oxidative damage. The enzymes contain one atom of zinc and one atom of copper per subunit and catalyze the dismutation of superoxide anions into OZ
and HZO2. The rate of dismutation is diffusion-limited and consequently enhanced by the presence of favorable electrostatic interactions between the substrate and enzyme active site. Examples of this class of enzyme have been identified in the cytoplasm of all the eukaryotic cells as well as in the periplasm of several bacterial species. Copper-zinc superoxide dismutases are robust enzymes that are highly resistant to proteolytic digestion and denaturing by urea and SDS. In addition to the compact structure of the enzymes, the presence of the metal ions and intrasubunit disulfide bonds is believed to be responsible for enzyme stability. The enzymes undergo reversible denaturation at temperatures as high as 70°C
(Battistoni; A. et al. (1998) J. Biol. Chem. 273:5655-5661).
Overexpression of superoxide dismutase has been implicated in enhancing freezing tolerance of transgenic Alfalfa as well as providing resistance to environmental toxins such as the diphenyl ether herbicide, acifluorfen (McKersie, B.D. et al. ( 1993) Plant Physiol.
103:1155-1163). In addtion, yeast cells become more resistant to freeze-thaw damage following exposure to hydrogen peroxide which causes the yeast cells to adapt to further peroxide stress by upregulating expression of superoxide dismutases. In this study, mutations to yeast superoxide dismutase genes had a more detrimental effect on freeze-thaw resistance than mutations which affected the regulation of glutathione metabolism, long suspected of being important in determining an organisms survival through the process of cryopreservation (Jong-In Park, J.-I. et al. (1998) J.
Biol. Chem.
273:22921-22928).
Expression of superoxide dismutase is also associated with Mycobacterium tuberculosis, the organism that causes tuberculosis. Superoxide dismutase is one of the ten major proteins secreted by M. tuberculosis and its expression is upregulated approximately 5-fold in response to oxidative stress.
M. tuberculosis expresses almost two orders of magnitude more superoxide dismutase than the nonpathogenic mycobacterium M. smegmatis, and secretes a much higher proportion of the expressed enzyme. The result is the secretion of --350-fold more enzyme by M.
tuberculosis than M. smegmaris, providing substantial resistance to oxidative stress (Harth, G. and Horwitz, M.A. (1999) J. Biol.
Chem. 274:4281-4292).
The reduced expression of copper-zinc superoxide dismutases, as well as other enzymes with anti-oxidant capabilities, has been implicated in the early stages of cancer.
The expression of copper-zinc superoxide dismutases has been shown to be lower in prostatic intraepithelial neoplasia and prostate carcinomas, compared to normal prostate tissue (Bostwick, D.G. (2000) Cancer 89:123-134).
Phosphodiesterases Phosphodiesterases make up a class of enzymes which catalyze the hydrolysis of one of the two ester bonds in a phosphodiester compound. Phosphodiesterases are therefore crucial to a variety of cellular processes. Phosphodiesterases include DNA and RNA endonucleases and exonucleases, which are essential for cell growth and replication, and topoisomerases, which break and rejoin nucleic acid strands during topological rearrangement of DNA. A Tyr-DNA
phosphodiesterase functions in DNA repair by hydrolyzing dead-end covalent intermediates formed between topoisomerase I and DNA (Pouliot, J.J. et al. (1999) Science 286:552-555;
Yang, S.-W. (1996) Proc.
Natl. Acad. Sci. USA 93:11534-11539).
Acid sphingomyelinase is a phosphodiesterase which hydrolyzes the membrane phospholipid sphingomyelin to produce ceramide and phosphorylcholine. Phosphorylcholine is used in the synthesis of phosphatidylcholine, which is involved in numerous intracellular signaling pathways, while ceramide is an essential precursor for the generation of gangliosides, membrane lipids found in high concentration in neural tissue. Defective acid sphingomyelinase leads to a build-up of sphingomyelin molecules in lysosomes, resulting in Niemann-Pick disease (Schuchman, E.H. and S.R. Miranda (1997) Genet. Test. 1:13-19).
Glycerophosphoryl diester phosphodiesterase (also known as glycerophosphodiester phosphodiesterase) is a phosphodiesterase which hydrolyzes deacetylated phospholipid glycerophosphodiesters to produce sn-glycerol-3-phosphate and an alcohol.
Glycerophosphocholine, glycerophosphoethanolamine, glycerophosphoglycerol, and glycerophosphoinositol are examples of substrates for glycerophosphoryl diester phosphodiesterases. A
glycerophosphoryl diester phosphodiesterase from E. coli has broad specificity for glycerophosphodiester substrates (Larson, T.J. et al. (1983) J. Biol: Chem. 248:5428-5432).
Cyclic nucleotide phosphodiesterases (PDEs) are crucial enzymes in the regulation of the cyclic nucleotides cAMP and cGMP. cAMP and cGMP function as intracellular second messengers to transduce a variety of extracellular signals including hormones, light, and neurotransmitters. PDEs degrade cyclic nucleotides to their corresponding monophosphates, thereby regulating the intracellular concentrations of cyclic nucleotides and their effects on signal transduction. Due to their roles as regulators of signal transduction, PDEs have been extensively studied as chemotherapeutic targets (Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481;
Torphy, J.T. (1998) Am. J. Resp. Crit. Care Med. 157:351-370).
Families of mammalian PDEs have been classified based on their substrate specificity and affinity, sensitivity to cofactors, and sensitivity to inhibitory agents (Beavo, J.A. (1995) Physiol. Rev.
75:725-748; Conti, M. et al. (1995) Endocrine Rev. 16:370-389). Several of these families contain distinct genes, many of which are expressed in different tissues as splice variants. Within PDE
families, there are multiple isozymes and multiple splice variants of these isozymes (Conti, M. and S.-L.C. Jin (1999) Prog. Nucleic Acid Res. Mol. Biol. 63:1-38). The existence of multiple PDE
families, isozymes, and splice variants is an indication of the variety and complexity of the regulatory pathways involving cyclic nucleotides (Houslay, M.D. and G. Milligan (1997) Trends Biochem. Sci.
22:217-224).
Type 1 PDEs (PDEls) are Caz+/calmodulin-dependent and appear to be encoded by at least three different genes, each having at least two different splice variants (Kakkar, R. et al. ( 1999) Cell Mol. Life Sci. 55:1164-1186). PDEIs have been found in the lung, heart, and brain. Some PDE1 isozymes are regulated in vitro by phosphorylation/dephosphorylation.
Phosphorylation of these PDE1 isozymes decreases the affinity of the enzyme for calmodulin, decreases PDE activity, and increases steady state levels of cAMP (Kakkar, supra). PDEls may provide useful therapeutic targets for disorders of the central nervous system, and the cardiovascular and immune systems due to the involvement of PDEls in both cyclic nucleotide and calcium signaling (Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481).
PDE2s are cGMP-stimulated PDEs that have been found in the cerebellum, neocortex, heart, kidney, lung, pulmonary artery, and skeletal muscle (Sadhu, K. et al. (1999) J. Histochem. Cytochem.
47:895-906). PDE2s are thought to mediate the effects of cAMP on catecholamine secretion, participate in the regulation of aldosterone (Beavo, supra), and play a role in olfactory signal transduction (Juilfs, D.M. et al. (1997) Proc. Natl. Acad. Sci. USA 94:3388-3395).
PDE3s have high affinity for both cGMP and cAMP, and so these cyclic nucleotides act as competitive substrates for PDE3s. PDE3s play roles in stimulating myocardial contractility, inhibiting platelet aggregation, relaxing vascular and airway smooth muscle, inhibiting proliferation of T-lymphocytes and cultured vascular smooth muscle cells, and regulating catecholamine-induced.
release of free fatty acids from adipose tissue. The PDE3 family of phosphodiesterases are sensitive to specific inhibitors such as cilostamide, enoximone, and lixazinone.
Isozymes of PDE3 can be regulated by cAMP-dependent protein kinase, or by insulin-dependent kinases (Degerman, E. et al.
(1997) J. Biol. Chem. 272:6823-6826).
PDE4s are specific for cAMP; are localized to airway smooth muscle, the vascular endothelium, and all inflammatory cells; and can be activated by cAMP-dependent phosphorylation.
Since elevation of cAMP levels can lead to suppression of inflammatory cell activation and to relaxation of bronchial smooth muscle, PDE4s have been studied extensively as possible targets for novel anti-inflammatory agents, with special emphasis placed on the discovery of asthma treatments.
PDE4 inhibitors are currently undergoing clinical trials as treatments for asthma, chronic obstructive pulmonary disease, and atopic eczema. All four known isozymes of PDE4 are susceptible to the inhibitor rolipram, a compound which has been shown to improve behavioral memory in mice (Barad, M. et al. (1998) Proc. Natl. Acad. Sci. USA 95:15020-15025). PDE4 inhibitors have also been studied as possible therapeutic agents against acute lung injury, endotoxemia, rheumatoid arthritis, multiple sclerosis, and various neurological and gastrointestinal indications (Doherty, A.M. (1999) Curr. Opin. Chem. Biol. 3:466=473).
PDES is highly selective for cGMP as a substrate (Turko, LV. et al. (1998) Biochemistry 37:4200-4205), and has two allosteric cGMP-specific binding sites (McAllister-Lucas, L.M. et al.
(1995) J. Biol. Chem. 270:30671-30679). Binding of cGMP to these allosteric binding sites seems to be important for phosphorylation of PDES by cGMP-dependent protein kinase rather than for direct regulation of catalytic activity. High levels of PDES are found in vascular smooth muscle, platelets, lung, and kidney. The inhibitor zaprinast is effective against PDES and PDEls.
Modification of zaprinast to provide specificity against PDES has resulted in sildenafil (VIAGRA; Pfizer, Inc., New York NY), a treatment for male erectile dysfunction (Terrett, N. et al. (1996) Bioorg. Med. Chem.
Lett. 6:1819-1824). Inhibitors of PDES are currently being studied as agents for cardiovascular therapy (Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481).
PDE6s, the photoreceptor cyclic nucleotide phosphodiesterases, are crucial components of the phototransduction cascade. In association with the G-protein transducin, PDE6s hydrolyze cGMP
to regulate cGMP-gated canon channels in photoreceptor membranes. In addition to the cGMP-binding active site, PDE6s also have two high-affinity cGMP-binding sites which are thought to play a regulatory role in PDE6 function (Artemyev, N.O. et al. (1998) Methods 14:93-104). Defects in PDE6s have been associated with retinal disease. Retinal degeneration in the rd mouse (Yan, W. et al. (1998) Invest. Opthalmol. Vis. Sci. 39:2529-2536), autosomal recessive retinitis pigmentosa in humans (Danciger, M. et al. (1995) Genomics 30:1-7), and rod/cone dysplasia 1 in Irish Setter dogs (Suber, M.L. et al. ( 1993) Proc. Natl. Acad. Sci. USA 90:3968-3972) have been attributed to mutations in the PDE6B gene.
The PDE7 family of PDEs consists of only one known member having multiple splice variants (Bloom, T.J. and J.A. Beavo (1996) Proc. Natl. Acad. Sci. USA
93:14188-14192). PDE7s are cAMP specific, but little else is known about their physiological function. Although mRNAs encoding PDE7s are found in skeletal muscle, heart, brain, lung, kidney, and pancreas, expression of PDE7 proteins is restricted to specific tissue types (Han, P. et al. (1997) J.
Biol. Chem. 272:16152-16157; Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481).
PDE7s are very closely related to the PDE4 family; however, PDE7s are not inhibited by rolipram, a specific inhibitor of PDE4s (Beavo, supra).
PDEBs are cAMP specific, and are closely related to the PDE4 family. PDEBs are expressed in thyroid gland, testis, eye, liver, skeletal muscle, heart, kidney, ovary, and brain. The cAMP-hydrolyzing activity of PDEBs is not inhibited by the PDE inhibitors rolipram, vinpocetine, milrinone, IBMX (3-isobutyl-1-methylxanthine), or zaprinast, but PDEBs are inhibited by dipyridamole (Fisher, D.A. et al. (1998) Biochem. Biophys. Res. Commun. 246:570-577; Hayashi, M. et al. (1998) Biochem. Biophys. Res. Commun. 250:751-756; Soderling, S.H. et al. (1998) Proc. Natl. Acad. Sci.
USA 95:8991-8996).
PDE9s are cGMP specific and most closely resemble the PDEB family of PDEs.
PDE9s are expressed in kidney, liver, lung, brain, spleen, and small intestine. PDE9s are not inhibited by sildenafil (VIAGRA; Pfizer, Inc., New York NY), rolipram, vinpocetine, dipyridamole, or IBMX (3-isobutyl-1-methylxanthine), but they are sensitive to the PDES inhibitor zaprinast (Fisher, D.A. et al.
(1998) J. Biol. Chem. 273:15559-15564; Soderling, S.H. et al. (1998) J. Biol.
Chem. 273:15553-15558).
PDEIOs are dual-substrate PDEs, hydrolyzing both cAMP and cGMP. PDElOs are expressed in brain, thyroid, and testis. (Soderling, S.H. et al. (1999) Proc. Natl.
Acad. Sci. USA 96:7071-7076;
Fujishige, K. et al. (1999) J. Biol. Chem. 274:18438-18445; Loughney, K. et al (1999) Gene 234:109 117).
PDEs are composed of a catalytic domain of about 270-300 amino acids, an N-terminal regulatory domain responsible for binding cofactors, and, in some cases, a hydrophilic C-terminal domain of unknown function (Conti, M. and S.-L.C. Jin (1999) Prog. Nucleic Acid Res. Mol. Biol.
63:1-38). A conserved, putative zinc-binding motif, HDXXHXGXXN, has been identified in the catalytic domain of all PDEs. N-terminal regulatory domains include non-catalytic cGMP-binding domains in PDE2s, PDESs, and PDE6s; calmodulin-binding domains in PDEls; and domains containing phosphorylation sites in PDE3s and PDE4s. In PDES, the N-terminal cGMP-binding domain spans about 380 amino acid residues and comprises tandem repeats of the conserved sequence motif N(R/K)XnFX3DE (McAllister-Lucas, L.M. et al. (1993) J. Biol. Chem.
268:22863-22873). The NKXnD motif has been shown by mutagenesis to be important for cGMP binding (Turko, LV. et al.
(1996) J. Biol. Chem. 271:22240-22244). PDE families display approximately 30%
amino acid identity within the catalytic domain; however, isozymes within the same family typically display about 85-95% identity in this region (e.g. PDE4A vs PDE4B). Furthermore, within a family there is extensive similarity (>60%) outside the catalytic domain; while across families, there is little or no sequence similarity outside this domain.
Many of the constituent functions of immune and inflammatory responses are inhibited by agents that increase intracellular levels of cAMP (Verghese, M.W. et al.
(1995) Mol. Pharmacol.
47:1164-1171). A variety of diseases have been attributed to increased PDE
activity and associated with decreased levels of cyclic nucleotides. For example, a form of diabetes insipidus in mice has been associated with increased PDE4 activity, an increase in low-Km cAMP PDE
activity has been reported in leukocytes of atopic patients, and PDE3 has been associated with cardiac disease.
Many inhibitors of PDEs have been identified and have undergone clinical evaluation (Perry, M.J. and G.A. Higgs (1998) Curr. Opin. Chem. Biol. 2:472-481; Torphy, T.J.
(1998) Am. J. Respir.
Crit. Care Med. 157:351-370). PDE3 inhibitors are being developed as antithrombotic agents, antihypertensive agents, and as cardiotonic agents useful in the treatment of congestive heart failure.
Rolipram, a PDE4 inhibitor, has been used in the treatment of depression, and other inhibitors of PDE4 are undergoing evaluation as anti-inflammatory agents. Rolipram has also been shown to inhibit lipopolysaccharide (LPS) induced TNF-a which has been shown to enhance HIV-1 replication in vitro. Therefore, rolipram may inhibit HIV-1 replication (Angel, J.B. et al. (1995) AIDS
9:1137-1144). Additionally, rolipram, based on its ability to suppress the production of cytokines such as TNF-a and b and interferon g, has been shown to be effective in the treatment of encephalomyelitis. Rolipram may also be effective in treating tardive dyskinesia and was effective in treating multiple sclerosis in an experimental animal model (Sommer, N. et al.
(1995) Nat. Med.
1:244-248; Sasaki, H. et al. ( 1995) Eur. J. Pharmacol. 282:71-76).
Theophylline is a nonspecific PDE inhibitor used in the treatment of bronchial asthma and other respiratory diseases. Theophylline is believed to act on airway smooth muscle function and in an anti-inflammatory or immunomodulatory capacity in the treatment of respiratory diseases (Banner, K.H. and C.P. Page (1995) Eur. Respir. J. 8:996-1000). Pentoxifylline is another nonspecific PDE
inhibitor used in the treatment of intermittent claudication and diabetes-induced peripheral vascular disease. Pentoxifylline is also known to block TNF-a production and may inhibit HIV-1 replication (Angel et al., supra).
PDEs have been reported to affect cellular proliferation of a variety of cell types (Conti et al.
(1995) Endocrine Rev. 16:370-389) and have been implicated in various cancers.
Growth of prostate carcinoma cell lines DU145 and LNCaP was inhibited by delivery of cAMP
derivatives and PDE
inhibitors (Bang, Y.J. et al. (1994) Proc. Natl. Acad. Sci. USA 91:5330-5334).
These cells also showed a permanent conversion in phenotype from epithelial to neuronal morphology. It has also been suggested that PDE inhibitors have the potential to regulate mesangial cell proliferation (Matousovic, K. et al. (1995) J. Clin. Invest. 96:401-410) and lymphocyte proliferation (Joulain, C. et al. ( 1995) J. Lipid Mediat. Cell Signal. 11:63-79). A cancer treatment has been described that involves intracellular delivery of PDEs to particular cellular compartments of tumors, resulting in cell death (Deonarain, M.P. and A.A. Epenetos (1994) Br. J. Cancer 70:786-794).
Phosphotriesterases Phosphotriesterases (PTE, paraoxonases) are enzymes that hydrolyze toxic organophosphorus compounds and have been isolated from a variety of tissues. The enzymes appear to be lacking in birds and insects and abundant in mammals, explaining the reduced tolerance of birds and insects to organophosphorus compound (Vilanova, E. and Sogorb, M.A. (1999) Crit. Rev.
Toxicol. 29:21-57).
Phosphotriesterases play a central role in the detoxification of insecticides by mammals.
Phosphotriesterase activity varies among individuals and is lower in infants than adults. Knockout mice are markedly more sensitive to the organophosphate-based toxins diazoxon and chlorpyrifos oxon (Furlong, C.E., et al. (2000) Neurotoxicology 21:91-100). PTEs have attracted interest as enzymes capable of the detoxification of organophosphate-containing chemical waste and warfare reagents (e.g., parathion), in addition to pesticides and insecticides. Some studies have also implicated phosphotriesterase in atherosclerosis and diseases involving lipoprotein metabolism.
Thioesterases Two soluble thioesterases involved in fatty acid biosynthesis have been isolated from mammalian tissues, one which is active only toward long-chain fatty-acyl thioesters and one which is active toward thioesters with a wide range of fatty-acyl chain-lengths. These thioesterases catalyze the chain-terminating step in the de novo biosynthesis of fatty acids. Chain termination involves the hydrolysis of the thioester bond which links the fatty acyl chain to the 4'-phosphopantetheine prosthetic group of the acyl Garner protein (ACP) subunit of the fatty acid synthase (Smith, S. (1981a) Methods Enzymol. 71:181-188; Smith, S. (1981b) Methods Enzymol. 71:188-200).
~E. coli contains two soluble thioesterases, thioesterase I which is active only toward long-chain acyl thioesters, and thioesterase II (TEII) which has a broad chain-length specificity (Naggert, J., et al. (1991) J. Biol. Chem. 266:11044-11050). E. coli TEII does not exhibit sequence similarity with either of the two types of mammalian thioesterases which function as chain-terminating enzymes in de novo fatty acid biosynthesis. Unlike the mammalian thioesterases, E. coli TEII lacks the characteristic serine active site gly-X-ser-X-gly sequence motif and is not inactivated by the serine modifying agent diisopropyl fluorophosphate. However, modification of histidine 58 by iodoacetamide and diethylpyrocarbonate abolished TEII activity. Overexpression of TEII did not alter fatty acid content in E. coli, which suggests that it does not function as a chain-terminating enzyme in fatty acid biosynthesis (Naggert et al., supra). For that reason, Naggert et al. (supra) proposed that the physiological substrates for E. coli TEII may be coenzyme A
(CoA)-fatty acid esters instead of ACP-phosphopanthetheine-fatty acid esters.
Carboxylesterases Mammalian carboxylesterases constitute a multigene family expressed in a variety of tissues and cell types. Isozymes have significant sequence homology and are classified primarily on the basis of amino acid sequence. Acetylcholinesterase, butyrylcholinesterase, and carboxylesterase are grouped into the serine super family of esterases (B-esterases). Other carboxylesterases included thyroglobulin, thrombin, Factor IX, gliotactin, and plasminogen.
Carboxylesterases catalyze the hydrolysis of ester- and amide- groups from molecules and are involved in detoxification of drugs, environmental toxins, and carcinogens. Substrates for carboxylesterases include short- and long-chain acyl-glycerols, acylcarnitine, carbonates, dipivefrin hydrochloride, cocaine, salicylates, capsaicin, palmitoyl-coenzyme A, imidapril, haloperidol, pyrrolizidine alkaloids, steroids, p-nitrophenyl acetate, malathion, butanilicaine, and isocarboxazide. The enzymes often demonstrate low substrate specificity. Carboxylesterases are also important for the conversion of prodrugs to their respective free acids, which may be the active form of the drug (e.g., lovastatin, used to lower blood cholesterol) (reviewed in Satoh, T. and Hosokawa, M. ( 1998) Annu. Rev.
Pharmacol.
Toxico1.38:257-288).
Neuroligins are a class of molecules that (i) have N-terminal signal sequences, (ii) resemble cell-surface receptors, (iii) contain carboxylesterase domains, (iv) are highly expressed in the brain, and (v) bind to neurexins in a calcium-dependent manner. Despite the homology to carboxylesterases, neuroligins lack the active site serine residue, implying a role in substrate binding rather than catalysis (Ichtchenko, K. et al. (1996) J. Biol. Chem. 271:2676-2682).
Sgualene epoxidase Squalene epoxidase (squalene monooxygenase, SE) is a microsomal membrane-bound, FAD-dependent oxidoreductase that catalyzes the first oxygenation step in the sterol biosynthetic pathway of eukaryotic cells. Cholesterol is an essential structural component of cytoplasmic membranes acquired via the LDL receptor-mediated pathway or the biosynthetic pathway. In the latter case, all 27 carbon atoms in the cholesterol molecule are derived from acetyl-CoA
(Stryer, L., supra). SE
converts squalene to 2,3(S~-oxidosqualene, which is then converted to lanosterol and then cholesterol.
The steps involved in cholesterol biosynthesis are summarized below (Stryer, L
(1988) Biochemistry.
W.H Freeman and Co., Inc. New York. pp. 554-560 and Sakakibara, J. et al. ( 1995) 270:17-20):
acetate (from Acetyl-CoA) ~ 3-hydoxy-3-methyl-glutaryl CoA ~ mevalonate ~ 5-phosphomevalonate ~ 5-pyrophosphomevalonate ~ isopentenyl pyrophosphate ~ dimethylallyl pyrophosphate ~ geranyl pyrophosphate ~ farnesyl pyrophosphate ~ squalene ~ squalene epoxide ~
lanosterol ~ cholesterol While cholesterol is essential for the viability of eukaryotic cells, inordinately high serum cholesterol levels results in the formation of atherosclerotic plaques in the arteries of higher organisms. This deposition of highly insoluble lipid material onto the walls of essential blood vessels (e.g., coronary arteries) results in decreased blood flow and potential necrosis of the tissues deprived of adequate blood flow. HMG-CoA reductase is responsible for the conversion of 3-hydroxyl-3-methyl-glutaryl CoA (HMG-CoA) to mevalonate, which represents the first committed step in cholesterol biosynthesis. HMG-CoA is the target of a number of pharmaceutical compounds designed to lower plasma cholesterol levels. However, inhibition of MHG-CoA
also results in the reduced synthesis of non-sterol intermediates (e.g., mevalonate) required for other biochemical pathways. SE catalyzes a rate-limiting reaction that occurs later in the sterol synthesis pathway and cholesterol in the only end product of the pathway following the step catalyzed by SE. As a result, SE is the ideal target for the design of anti-hyperlipidemic drugs that do not cause a reduction in other necessary intermediates (Nakamura, Y. et al. (1996) 271:8053-8056).
Epoxide hydrolases Epoxide hydrolases catalyze the addition of water to epoxide-containing compounds, thereby hydrolyzing epoxides to their corresponding 1,2-diols. They are related to bacterial haloalkane dehalogenases and show sequence similarity to other members of the aJ~i hydrolase fold family of enzymes (e.g., bromoperoxidase A2 from Streptomyces aureofaciens, hydroxymuconic semialdehyde hydrolases from Pseudomonas putida, and haloalkane dehalogenase from Xanthobacter autotro~hicus). Epoxide hydrolases are ubiquitous in nature and have been found in mammals, invertebrates, plants, fungi, and bacteria. This family of enzymes is important for the detoxification of xenobiotic epoxide compounds which are often highly electrophilic and destructive when introduced into an organism. Examples of epoxide hydrolase reactions include the hydrolysis of cis-9,10-epoxyoctadec-9(Z)-enoic acid (leukotoxin) to form its corresponding diol, threo-9,10-dihydroxyoctadec-12(Z)-enoic acid (leukotoxin diol), and the hydrolysis of cis-12,13-epoxyoctadec-9(Z)-enoic acid (isoleukotoxin) to form its corresponding diol threo-12,13-dihydroxyoctadec-9(Z)-enoic acid (isoleukotoxin diol). Leukotoxins alter membrane permeability and ion transport and cause inflammatory responses. In addition, epoxide carcinogens are known to be produced by cytochrome P450 as intermediates in the detoxification of drugs and environmental toxins.
The enzymes possess a catalytic triad composed of Asp (the nucleophile), Asp (the histidine-supporting acid), and His (the water-activating histidine). The reaction mechanism of epoxide hydrolase proceeds via a covalently bound ester intermediate initiated by the nucleophilic attack of one of the Asp residues on the primary carbon atom of the epoxide ring of the target molecule, leading to a covalently bound ester intermediate (Michael Arand, M.
et al. (1996) J. Biol.
Chem. 271:4223-4229; Rink, R. et al. (1997) J. Biol. Chem. 272:14650-14657;
Argiriadi, M.A. et al.
(2000) J. Biol. Chem. 275:15265-15270).
Enzymes involved in tyrosine catalysis The degradation of the amino acid tyrosine to either succinate and pyruvate or fumarate and acetoacetate, requires a large number of enzymes and generates a large number of intermediate compounds. In addition, many xenobiotic compounds may be metabolized using one or more reactions that are part of the tyrosine catabolic pathway. While the pathway has been studied primarily in bacteria, tyrosine degradation is known to occur in a variety of organisms and is likely to involve many of the same biological reactions.
The enzymes involved in the degradation of tyrosine to succinate and pyruvate (e.g., in Arthrobacter species) include 4-hydroxyphenylpyruvate oxidase, 4-hydroxyphenylacetate 3-hydroxylase, 3,4-dihydroxyphenylacetate 2,3-dioxygenase, 5-carboxymethyl-2-hydroxymuconic semialdehyde dehydrogenase, traps,cis-5-carboxymethyl-2-hydroxymuconate isomerase, homoprotocatechuate isomerase/decarboxylase, cis-2-oxohept-3-ene-1,7-dioate hydratase, 2,4-dihydroxyhept-traps-2-ene-1,7-dioate aldolase, and succinic semialdehyde dehydrogenase.
The enzymes involved in the degradation of tyrosine to fumarate and acetoacetate (e.g., in Pseudomonas species) include 4-hydroxyphenylpyruvate dioxygenase, homogentisate 1,2-dioxygenase, maleylacetoacetate isomerase, and fumarylacetoacetase. 4-hydroxyphenylacetate 1-hydroxylase may also be involved if intermediates from the succinate/pyruvate pathway are accepted.
Additional enzymes associated with tyrosine metabolism in different organisms include 4-chlorophenylacetate-3,4-dioxygenase, aromatic aminotransferase, 5-oxopent-3-ene-1,2,5-tricarboxylate decarboxylase, 2-oxo-kept-3-ene-1,7-dioate hydratase, and 5-carboxymethyl-2-hydroxymuconate isomerase (Elks, L.B.M. et al. (1999) Nucleic Acids Res.
27:373-376; Wackett, L.P. and Ellis, L.B.M. (1996) J. Microbiol. Meth. 25:91-93; and Schmidt, M.
(1996) Amer. Soc. Microbiol. News 62:102).
In humans, acquired or inherited genetic defects in enzymes of the tyrosine degradation pathway may result in hereditary tyrosinemia. One form of this disease, hereditary tyrosinemia 1 (HT1) is caused by a deficiency in the enzyme fumarylacetoacetate hydrolase, the last enzyme in the pathway in organisms that metabolize tyrosine to fumarate and acetoacetate.
HT1 is characterized by progressive liver damage beginning at infancy, and increased risk for liver cancer (Endo, F. et al.
(1997) J. Biol. Chem. 272:24426-24432).
The discovery of new drug metabolizing enzymes and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of drug metabolizing enzymes.
SUMMARY OF THE INVENTION
The invention features purified polypeptides, drug metabolizing enzymes, referred to collectively as "DME" and individually as "DME-1," "DME-2," "DME-3," "DME-4,"
"DME-5,"
"DME-6," "DME-7," "DME-8," "DME-9," and "DME-10." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: l-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-10.
The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ
117 NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10.
In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ )D NO:1-10. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:11-20.
Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:I-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.
The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.
Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10.
The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ )D NO:11-20, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ m NO:11-20, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d).
In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.
Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ )D NO:11-20, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:11-20, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA
equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.
The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:11-20, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ l~
NO:11-20, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d).
The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:I-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:l-10. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment the composition.
The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment the composition.
Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample.
In one alternative, the invention provides a composition comprising an antagonist compound identified by~ the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional DME, comprising administering to a patient in need of such treatment the composition.
The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ )D NO:I-10, b) a naturally occurring polypeptide cmoprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ >D NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:l-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.
The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:I-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.
The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:11-20, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.
The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ
ID NO:11-20, ii) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:11-20, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID
NO:11-20, ii) a naturally occurnng polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:11-20, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv).
Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex;
and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
BRIEF DESCRIPTION OF THE TABLES
Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.
Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.
Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.
Table 4 lists the cDNA and genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.
Table 5 shows the representative cDNA library for polynucleotides of the invention.
Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.
Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.
DESCRIPTION OF THE INVENTION
Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
It must be noted that as used herein and in the appended claims, the singular forms "a," "an,"
and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs.
Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
DEFINITIONS
"DME" refers to the amino acid sequences of substantially purified DME
obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.
The term "agonist" refers to a molecule which intensifies or mimics the biological activity of DME. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of DME either by directly interacting with DME or by acting on components of the biological pathway in which DME
participates.
An "allelic variant" is an alternative form of the gene encoding DME. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.
Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
"Altered" nucleic acid sequences encoding DME include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as DME or a polypeptide with at least one functional characteristic of DME. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding DME, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding DME. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent DME. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of DME is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged , amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine.
Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.
The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.
"Amplification" relates to the production of additional copies of a nucleic acid sequence.
Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.
The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of DME. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of DME either by directly interacting with DME or by acting on components of the biological pathway in which DME participates.
The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')2, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind DME polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired.
Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.
The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.
The term "antisense" refers to any composition capable of base-pairing with the "sense"
(coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA;
RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.
The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic DME, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.
"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.
A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding DME or fragments of DME may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCI), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).
"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.
"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions.
The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.
Original Residue Conservative Substitution Ala Gly, Ser Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln, Glu Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile, Leu, Thr Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.
A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.
The term "derivative" refers to a chemically modified polynucleotide or polypeptide.
Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.
A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.
A "fragment" is a unique portion of DME or the polynucleotide encoding DME
which is identical in sequence to but shorter in length than the parent sequence. A
fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule.
For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.
A fragment of SEQ ID NO:11-20 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:11-20, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:11-20 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:11-20 from related polynucleotide sequences. The precise length of a fragment of SEQ
ID NO:11-20 and the region of SEQ ID NO:11-20 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.
A fragment of SEQ ID NO:1-10 is encoded by a fragment of SEQ ID NO:11-20. A
fragment of SEQ ID NO:1-10 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-10. For example, a fragment of SEQ ID NO:1-10 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-10. The precise length of a fragment of SEQ ID NO:1-10 and the region of SEQ
ID NO:1-10 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.
A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A
"full length" polynucleotide sequence encodes a "full length" polypeptide sequence.
"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.
The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.
Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN
version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted"
residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.
Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol.
215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST
2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2.html.
The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST
programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2Ø12 (April-21-2000) set at default parameters. Such default parameters may be, for example:
Matrix: BLOSUM62 heward for match: I
Penalty for mismatch: -2 Open Gap: 5 and Extension Gap: 2 penalties Gap x drop-off.' S0 Expect: l0 Word Size: Il Filter: on Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.
' Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.
The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions.
Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.
Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN
version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.
Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences"
tool Version 2Ø12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:
Matrix: BLOSUM62 Open Gap: 11 and Extension Gap: 1 penalties Cap x drop-off. 50 Expect: 10 Word Size: 3 Filter: on Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ m number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.
"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.
The term "humanized antibody" refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.
"Hybridization" refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the "washing" step(s). The washing steps) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 pg/ml sheared, denatured salmon sperm DNA.
Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50°l0 of the target sequence hybridizes to a perfectly matched probe. An equation for calculating Tm and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al.
( 1989) Molecular Cloning: A Laboratory Manual, 2"d ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.
High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1 % SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC
concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1 %.
Typically, blocking reagents are used to block non-specific hybridization.
Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 pg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art.
Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.
The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A
hybridization complex may be formed in solution (e.g., Cot or Rot analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).
The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.
"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.
An "immunogenic fragment" is a polypeptide or oligopeptide fragment of DME
which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of DME which is useful in any of the antibody production methods disclosed herein or known in the art.
The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.
The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.
The term "modulate" refers to a change in the activity of DME. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of DME.
The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA
of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.
"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.
"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition.
PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.
"Post-translational modification" of an DME may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of DME.
"Probe" refers to nucleic acid sequences encoding DME, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule.
Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.
"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).
Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.
Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laborator~Manual, 2"d ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biolo~y, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR
Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA.
PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).
Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR
primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases.
Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.
A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence.
This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, s-bra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.
Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.
A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.
"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes;
fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors;
magnetic particles; and other moieties known in the art.
An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.
The term "sample" is used in its broadest sense. A sample suspected of containing DME, nucleic acids encoding DME, or fragments thereof may comprise a bodily fluid;
an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.
The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A
and the antibody will reduce the amount of labeled A that binds to the antibody.
The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.
A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.
"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.
A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.
"Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment.
The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA
for limited periods of time.
A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or mote of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA
of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al.
(1989), s_ upra.
A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences"
tool Version 2Ø9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.
A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2Ø9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%
or greater sequence identity over a certain defined length of one of the polypeptides.
THE INVENTION
The invention is based on the discovery of new human drug metabolizing enzymes (DME), the polynucleotides encoding DME, and the use of these compositions for the diagnosis, treatment, or prevention of autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders.
Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project m). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ
ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ
ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.
Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ )D NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog.
Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where applicable, all of which are expressly incorporated by reference herein.
Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ff~) for each polypeptide of the invention.
Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.
Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are drug metabolizing enzymes. For example, SEQ ID N0:9 is 32% identical to human putative N-acetyltransferase Camello 2 (GenBank ID 86651438) as determined by the Basic Local Alignment Search Tool (BLAST).
(See Table 2.) The BLAST probability score is 6.50E-23, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID N0:9 also contains a signal peptide signature sequence as determined by the SPScan program, and an acetyltransferase domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM
database of conserved protein family domains. The probability value of the HMM
comparison to acetyltransferase domain is 3.2e-12. (See Table 3.) Based on BLAST and HMM
analyses, the protein of SEQ )D N0:9 is an N-acetyltransferase which N-acetylates aromatic amines and hvrlra~ina-rnntainino rnmnnnnrlc inrlnrlina hnt not limitPrl tn nara-aminnhPn~nir arid nara-database (See Table 7 for descriptions). All of these signature sequence identifications are highly statistically significant (see Table 7 for threshold values); for example, the probability value of the HMM comparison to the aldo-keto reductase family signature sequence is 5.6e-170. Based on BLAST, HMM, BLIMPS, MOTIFS, and ProfileScan analyses, the protein of SEQ ID
NO:10 is an aldo/keto reductase which reduces carbonyl-containing sugars and aromatic compounds, including, but not limited to, glucose, and carbonyl-containing drug molecules and xenobiotics. SEQ ID NO:1-8 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-10 are described in Table 7.
As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide )D) for each polynucleotide of the invention.
Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:I 1-20 or that distinguish between SEQ ID
NO:11-20 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA
sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (S') and stop (3') positions of the cDNA and genomic sequences in column 5 relative to their respective full length sequences.
The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 3700065F6 is the identification number of an Incyte cDNA sequence, and SININOTOS is the cDNA
library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., 71447910V 1 ). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs (e.g., g5663459) which contributed to the assembly of the full length polynucleotide sequences. Alternatively, the identification numbers in column 5 may refer to coding regions predicted by Genscan analysis of genomic DNA. For example, GNN.g7025744_000055 002 is the identification number of a Genscan-predicted coding sequence, with g7025744 being the GenBank identification number of the sequence to which Genscan was applied. The Genscan-predicted coding sequences may have been edited prior to assembly. (See Example IV.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching"
algorithm. For example, FL,152824_00001 represents a "stitched" sequence in which 152824 is the identification number of the cluster of sequences to which the algorithm was applied, and 00001 is the number of the prediction generated by the algorithm. (See Example V.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon-stretching" algorithm. (See Example V.) In some cases, Incyte cDNA
coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.
Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.
The invention also encompasses DME variants. A preferred DME variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the DME amino acid sequence, and which contains at least one functional or structural characteristic of DME.
The invention also encompasses polynucleotides which encode DME. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:11-20, which encodes DME. The polynucleotide sequences of SEQ ID NO:11-20, as presented in the Sequence Listing, embrace the equivalent RNA
sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.
The invention also encompasses a variant of a polynucleotide sequence encoding DME. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding DME. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID
NO:11-20 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:11-20. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of DME.
It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding DME, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring DME, and all such variations are to be considered as being specifically disclosed.
Although nucleotide sequences which encode DME and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring DME under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding DME or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding DME and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.
The invention also encompasses production of DNA sequences which encode DME
and DME derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding DME or any fragment thereof.
Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID
NO:11-20 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A.R. (1987) Methods Enzymol.
152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."
Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE
amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA
sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art.
(See, e.g., Ausubel, F.M.
(1997) Short Protocols in Molecular BioloQV, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and BiotechnoloQV, Wiley VCH, New York NY, pp.
856-853.) The nucleic acid sequences encoding DME may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic.
2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR
amplification of DNA
fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. ( 1991 ) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res.
19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.
When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.
Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.
In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode DME may be cloned in recombinant DNA molecules that direct expression of DME, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express DME.
The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter DME-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences.
For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.
The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat.
Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of DME, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial"
breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.
In another embodiment, sequences encoding DME may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp.
Ser. 7:225-232.) Alternatively, DME itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques.
(See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems).
Additionally, the amino acid sequence of DME, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.
The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.) In order to express a biologically active DME, the nucleotide sequences encoding DME or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding DME. Such elements may vary in their strength and specificity.
Specific initiation signals may also be used to achieve more efficient translation of sequences encoding DME. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding DME and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG
initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.) Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding DME and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA
techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biolo~y, John Wiley & Sons, New York NY, ch. 9, 13, and 16.) A variety of expression vector/host systems may be utilized to contain and express sequences encoding DME. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra;
Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl.
Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technolo~y (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc.
Natl. Acad. Sci.
USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al.
(1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226;
and Verma, LM.
and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.
In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding DME. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding DME can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding DME into the vector's multiple cloning site disrupts the lacZ gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M.
Schuster (1989) J. Biol.
Chem. 264:5503-5509.) When large quantities of DME are needed, e.g. for the production of antibodies, vectors which direct high level expression of DME may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.
Yeast expression systems may be used for production of DME. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH
promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation.
(See, e.g., Ausubel, 1995, suura; Bitter, G.A. et al. ( 1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. ( 1994) Bio/Technology 12:181-184.) Plant systems may also be used for expression of DME. Transcription of sequences encoding DME may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N.
(1987) EMBO J.
6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Brogue, R. et al.
(1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA
transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technolo~y (1992) McGraw Hill, New York NY, pp. 191-196.) In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding DME
may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses DME in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc.
Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.
Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J.
et al. ( 1997) Nat. Genet.
15:345-355.) For long term production of recombinant proteins in mammalian systems, stable expression of DME in cell lines is preferred. For example, sequences encoding DME can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.
Any number of selection systems may be used to recover transformed cell lines.
These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in tk- and apr cells, respectively.
(See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate; neo confers resistance to the aminoglycosides neomycin and G-418; and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., trpB and hisD, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc.
Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), (3 glucuronidase and its substrate f3-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system.
(See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.) Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding DME is inserted within a marker gene sequence, transformed cells containing sequences encoding DME can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding DME under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.
In general, host cells that contain the nucleic acid sequence encoding DME and that express DME may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR
amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.
Immunological methods for detecting and measuring the expression of DME using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on DME is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art.
(See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in ImmunoloQV, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.) A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding DME
include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding DME, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides.
These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.
Host cells transformed with nucleotide sequences encoding DME may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode DME may be designed to contain signal sequences which direct secretion of DME through a prokaryotic or eukaryotic cell membrane.
In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion.
Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity.
Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.
In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding DME may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric DME protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of DME activity.
Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, c-niyc, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the DME encoding sequence and the heterologous protein sequence, so that DME may be cleaved away from the heterologous moiety following purification.
Methods for fusion protein expression and purification are discussed in Ausubel ( 1995, s. unra, ch.
10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.
In a further embodiment of the invention, synthesis of radiolabeled DME may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, 35S-methionine.
DME of the present invention or fragments thereof may be used to screen for compounds that specifically bind to DME. At least one and up to a plurality of test compounds may be screened for specific binding to DME. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.
In one embodiment, the compound thus identified is closely related to the natural ligand of DME, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunolo~y 1(2):
Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which DME
binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express DME, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing DME or cell membrane fractions which contain DME are then contacted with a test compound and binding, stimulation, or inhibition of activity of either DME or the compound is analyzed.
An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with DME, either in solution or affixed to a solid support, and detecting the binding of DME to the compound.
Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compounds) may be free in solution or affixed to a solid support.
DME of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of DME. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for DME
activity, wherein DME is combined with at least one test compound, and the activity of DME in the presence of a test compound is compared with the activity of DME in the absence of the test compound. A change in the activity of DME in the presence of the test compound is indicative of a compound that modulates the activity of DME. Alternatively, a test compound is combined with an in vitro or cell-free system comprising DME under conditions suitable for DME
activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of DME
may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.
In another embodiment, polynucleotides encoding DME or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S.
Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo;
Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U.
et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.
Polynucleotides encoding DME may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al.
( 1998) Science 282:1145-1147).
Polynucleotides encoding DME can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding DME is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease.
Alternatively, a mammal inbred to overexpress DME, e.g., by secreting DME in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).
THERAPEUTICS
Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of DME and drug metabolizing enzymes. In addition, the expression of DME is closely associated with a liver tumor cell line, liver tumor tissue, pancreatic tissue, pituitary gland tissue, brain tissue, small intestine tissue, fetal brain tissue, and allocortex brain tissue. Therefore, DME appears to play a role in autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders. In the treatment of disorders associated with increased DME expression or activity, it is desirable to decrease the expression or activity of DME. In the treatment of disorders associated with decreased DME
expression or activity, it is desirable to increase the expression or activity of DME.
Therefore, in one embodiment, DME or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME. Examples of such disorders include, but are not limited to, an autoimmune/inflammatory disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a developmental disorder, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; an endocrine disorder, such as disorders of the hypothalamus and pituitary resulting from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma; disorders associated with hypopituitarism including hypogonadism, Sheehan syndrome, diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and dwarfism; disorders associated with hyperpituitarism including acromegaly, giantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma;
disorders associated with hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection, subacute thyroiditis associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism; disorders associated with hyperthyroidism including thyrotoxicosis and its various forms, Grave's disease, pretibial myxedema, toxic multinodular goiter, thyroid carcinoma, and Plummer's disease; disorders associated with hyperparathyroidism including Conn disease (chronic hypercalemia); pancreatic disorders such as Type I or Type II diabetes mellitus and associated complications; disorders associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis, amyloidosis, hypokalemia, Cushing's disease, Liddle's syndrome, and Arnold-Healy-Gordon syndrome, pheochromocytoma tumors, and Addison's disease; disorders associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbations of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, hypergonadal disorders associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5 a-reductase, and gynecomastia; an eye disorder, such as conjunctivitis, keratoconjunctivitis sicca, keratitis, episcleritis, iritis, posterior uveitis, glaucoma, amaurosis fugax, ischemic optic neuropathy, optic neuritis, Leber's hereditary optic neuropathy, toxic optic neuropathy, vitreous detachment, retinal detachment, cataract, macular degeneration, central serous chorioretinopathy, retinitis pigmentosa, melanoma of the choroid, retrobulbar tumor, and chiasmal tumor; a metabolic disorder, such as Addison's disease, cerebrotendinous xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, diabetes, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalism, hypoadrenalism, hyperparathyroidism, hypoparathyroidism, hypercholesterolemia, hyperthyroidism, hypoglycemia, hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage diseases, Menkes syndrome, occipital horn syndrome, mannosidosis, neuraminidase deficiency, obesity, pentosuria phenylketonuria, pseudovitamin D-deficiency rickets; hypocalcemia, hypophosphatemia, and postpubescent cerebellar ataxia, tyrosinemia, and a gastrointestinal disorder, such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecysfitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, hereditary hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha,-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas.
In another embodiment, a vector capable of expressing DME or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME including, but not limited to, those described above.
In a further embodiment, a composition comprising a substantially purified DME
in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME
including, but not limited to, those provided above.
In still another embodiment, an agonist which modulates the activity of DME
may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME including, but not limited to, those listed above.
In a further embodiment, an antagonist of DME may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of DME.
Examples of such disorders include, but are not limited to, those autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders, described above. In one aspect, an antibody which specifically binds DME may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express DME.
In an additional embodiment, a vector expressing the complement of the polynucleotide encoding DME may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of DME including, but not limited to, those described above.
In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
An antagonist of DME may be produced using methods which are generally known in the art. In particular, purified DME may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind DME.
Antibodies to DME may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.
For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with DME or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol.
Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium narvum are especially preferable.
It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to DME have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of DME amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.
Monoclonal antibodies to DME may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497;
Kozbor, D. et al.
(1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl.
Acad. Sci. USA
80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.) In addition, techniques developed for the production of "chimeric antibodies,"
such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc.
Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce DME-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.) Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl.
Acad. Sci. USA
86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.) Antibody fragments which contain specific binding sites for DME may also be generated.
For example, such fragments include, but are not limited to, F(ab')2 fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
(See, e.g., Huse, W.D.
et al. (1989) Science 246:1275-1281.) Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between DME and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering DME epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).
Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for DME. Affinity is expressed as an association constant, K~, which is defined as the molar concentration of DME-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions.
The K~ determined for a preparation of polyclonal antibodies, which are heterogeneous in their IS affinities for multiple DME epitopes, represents the average affinity, or avidity, of the antibodies for DME. The Ka determined for a preparation of monoclonal antibodies, which are monospecific for a particular DME epitope, represents a true measure of affinity. High-affinity antibody preparations with K~ ranging from about 109 to 10'2 L/mole are preferred for use in immunoassays in which the DME-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with Ka ranging from about 106 to 10' L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of DME, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL
Press, Washington DC;
Liddell, J.E. and A. Cryer (1991 ) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).
The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of DME-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. s_u~ra.) In another embodiment of the invention, the polynucleotides encoding DME, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding DME. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding DME. (See, e.g., Agrawal, S., ed. (1996) Antisense Theraueutics, Humana Press Inc., Totawa NJ.) In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) J. Allergy Cli. Immunol. 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) Blood 76:271; Ausubel, su ra; Uckert, W. and W. Walther (1994) Pharmacol.
Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull.
51(1):217-225; Boado, R.J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M.C. et al.
(1997) Nucleic Acids Res.
25(14):2730-2736.) In another embodiment of the invention, polynucleotides encoding DME may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, LM. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc.
Natl. Acad. Sci. USA.
93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in DME expression or regulation causes disease, the expression of DME from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.
In a further embodiment of the invention, diseases or disorders caused by deficiencies in DME are treated by constructing mammalian expression vectors encoding DME and introducing these vectors by mechanical means into DME-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev.
Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H.
Recipon (1998) Curr.
Opin. Biotechnol. 9:445-450).
Expression vectors that may be effective for the expression of DME include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). DME may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or ~i-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl.
Acad. Sci. USA
89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V.
and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX
plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND;
Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding DME from a normal individual.
Commercially available liposome transformation kits (e.g., the PERFECT LIPID
TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al.
(1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.
In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to DME expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding DME under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc.
Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al.
(1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol.
72:8463-8471; Zufferey, R.
et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4+ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J.
Virol. 71:4707-4716;
Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).
In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding DME to cells which have one or more genetic abnormalities with respect to the expression of DME. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al.
(1999) Annu. Rev. Nutr. 19:511-544 and Verma, LM. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.
In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding DME to target cells which have one or more genetic abnormalities with respect to the expression of DME. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing DME to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res.
169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S.
Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol.
73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.
In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding DME to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol.
9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for DME into the alphavirus genome in place of the capsid-coding region results in the production of a large number of DME-coding RNAs and the synthesis of high levels of DME in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of DME into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA
transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.
Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E.
and B.I. Carr, Molecular and Immunolo i~c Approaches, Futura Publishing, Mt.
Kisco NY, pp. 163-177.) A complementary sequence oc antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.
Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage.
For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding DME.
Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable.
The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.
Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules.
These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding DME. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.
RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thin-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.
An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding DME. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased DME
expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding DME may be therapeutically useful, and in the treament of disorders associated with decreased DME expression or activity, a compound which specifically promotes expression of the polynucleotide encoding DME may be therapeutically useful.
At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds;
rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A
sample comprising a polynucleotide encoding DME is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding DME are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding DME. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E 15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No.
5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).
Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient.
Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.) Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.
An additional embodiment of the invention.relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins.
Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of DME, antibodies to DME, and mimetics, agonists, antagonists, or inhibitors of DME.
The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.
Compositions for pulmonary administration may be prepared in liquid or dry powder form.
These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.
Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.
Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising DME or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, DME or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R.
et al. (1999) Science 285:1569-1572).
For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
A therapeutically effective dose refers to that amount of active ingredient, for example DME
or fragments thereof, antibodies of DME, and agonists, antagonists or inhibitors of DME, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the EDSO (the dose therapeutically effective in 50% of the population) or LDso (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LDso/EDSO ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the EDSO
with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.
The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half life and clearance rate of the particular formulation.
Normal dosage amounts may vary from about 0.1 ~cg to 100,000 fig, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art.
Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.
DIAGNOSTICS
In another embodiment, antibodies which specifically bind DME may be used for the diagnosis of disorders characterized by expression of DME, or in assays to monitor patients being treated with DME or agonists, antagonists, or inhibitors of DME. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for DME include methods which utilize the antibody and a label to detect DME in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A
wide variety of reporter molecules, several of which are described above, are known in the art and may be used.
A variety of protocols for measuring DME, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of DME expression. Normal or standard values for DME expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to DME under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of DME
expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values.
Deviation between standard and subject values establishes the parameters for diagnosing disease.
In another embodiment of the invention, the polynucleotides encoding DME may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of DME
may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of DME, and to monitor regulation of DME levels during therapeutic intervention.
In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding DME or closely related molecules may be used to identify nucleic acid sequences which encode DME. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5'regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding DME, allelic variants, or related sequences.
Probes may also be used for the detection of related sequences, and may have at least 50%
sequence identity to any of the DME encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID
NO:11-20 or from genomic sequences including promoters, enhancers, and introns of the DME gene.
Means for producing specific hybridization probes for DNAs encoding DME
include the cloning of polynucleotide sequences encoding DME or DME derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA
polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as 32P or 35S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.
Polynucleotide sequences encoding DME may be used for the diagnosis of disorders associated with expression of DME. Examples of such disorders include, but are not limited to, an autoimmune/inflammatory disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a developmental disorder, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; an endocrine disorder, such as disorders of the hypothalamus and pituitary resulting from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma; disorders associated with hypopituitarism including hypogonadism, Sheehan syndrome, diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and dwarfism; disorders associated with hyperpituitarism including acromegaly, giantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma;
disorders associated with hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection, subacute thyroiditis associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism; disorders associated with hyperthyroidism including thyrotoxicosis and its various forms, Grave's disease, pretibial myxedema, toxic multinodular goiter, thyroid carcinoma, and Plummer's disease; disorders associated with hyperparathyroidism including Conn disease (chronic hypercalemia); pancreatic disorders such as Type I or Type II diabetes mellitus and associated complications; disorders associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis, amyloidosis, hypokalemia, Cushing's disease, Liddle's syndrome, and Arnold-Healy-Gordon syndrome, pheochromocytoma tumors, and Addison's disease; disorders associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbations of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, hypergonadal disorders associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5 a-reductase, and gynecomastia; an eye disorder, such as conjunctivitis, keratoconjunctivitis sicca, keratitis, episcleritis, iritis, posterior uveitis, glaucoma, amaurosis fugax, ischemic optic neuropathy, optic neuritis, Leber's hereditary optic neuropathy, toxic optic neuropathy, vitreous detachment, retinal detachment, cataract, macular degeneration, central serous chorioretinopathy, retinitis pigmentosa, melanoma of the choroid, retrobulbar tumor, and chiasmal tumor; a metabolic disorder, such as Addison's disease, cerebrotendinous xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, diabetes, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalism, hypoadrenalism, hyperparathyroidism, hypoparathyroidism, hypercholesterolemia, hyperthyroidism, hypoglycemia, hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage diseases, Menkes syndrome, occipital horn syndrome, mannosidosis, neuraminidase deficiency, obesity, pentosuria phenylketonuria, pseudovitamin D-deficiency rickets; hypocalcemia, hypophosphatemia, and postpubescent cerebellar ataxia, tyrosinemia, and a gastrointestinal disorder, such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, hereditary hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha,-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas. The polynucleotide sequences encoding DME may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered DME
expression. Such qualitative or quantitative methods are well known in the art.
In a particular aspect, the nucleotide sequences encoding DME may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding DME may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding DME in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.
In order to provide a basis for the diagnosis of a disorder associated with expression of DME, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding DME, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder.
Deviation from standard values is used to establish the presence of a disorder.
Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject.
The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.
With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.
Additional diagnostic uses for oligonucleotides designed from the sequences encoding DME
may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding DME, or a fragment of a polynucleotide complementary to the polynucleotide encoding DME, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.
In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding DME may be used to detect single nucleotide polymorphisms (SNPs).
SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding DME
are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like.
SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA
sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).
Methods which may also be used to quantify the expression of DME include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. ( 1993) J. Immunol. Methods 159:235-244; Duplaa, C.
et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.
In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.
In another embodiment, DME, fragments of DME, or antibodies specific for DME
may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.
A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.
Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.
Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S.
and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families.
Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.
In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.
Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type.
In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, suera). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.
A proteomic profile may also be generated using antibodies specific for DME to quantify the levels of DME expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoze, L.G. et al. ( 1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol-or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.
Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.
In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.
In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A
difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.
Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al.
(1996) Proc. Natl.
Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application W095/251116;
Shalom D. et al. (1995) PCT application W095/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad.
Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No.
5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A
Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.
In another embodiment of the invention, nucleic acid sequences encoding DME
may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harnngton, J.J. et al. ( 1997) Nat.
Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J.
(1991) Trends Genet.
(1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA
transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technolo~y (1992) McGraw Hill, New York NY, pp. 191-196.) In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding DME
may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses DME in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc.
Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.
Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J.
et al. ( 1997) Nat. Genet.
15:345-355.) For long term production of recombinant proteins in mammalian systems, stable expression of DME in cell lines is preferred. For example, sequences encoding DME can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.
Any number of selection systems may be used to recover transformed cell lines.
These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in tk- and apr cells, respectively.
(See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate; neo confers resistance to the aminoglycosides neomycin and G-418; and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., trpB and hisD, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc.
Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), (3 glucuronidase and its substrate f3-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system.
(See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.) Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding DME is inserted within a marker gene sequence, transformed cells containing sequences encoding DME can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding DME under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.
In general, host cells that contain the nucleic acid sequence encoding DME and that express DME may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR
amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.
Immunological methods for detecting and measuring the expression of DME using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on DME is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art.
(See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in ImmunoloQV, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.) A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding DME
include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding DME, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides.
These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.
Host cells transformed with nucleotide sequences encoding DME may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode DME may be designed to contain signal sequences which direct secretion of DME through a prokaryotic or eukaryotic cell membrane.
In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion.
Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity.
Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.
In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding DME may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric DME protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of DME activity.
Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, c-niyc, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the DME encoding sequence and the heterologous protein sequence, so that DME may be cleaved away from the heterologous moiety following purification.
Methods for fusion protein expression and purification are discussed in Ausubel ( 1995, s. unra, ch.
10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.
In a further embodiment of the invention, synthesis of radiolabeled DME may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, 35S-methionine.
DME of the present invention or fragments thereof may be used to screen for compounds that specifically bind to DME. At least one and up to a plurality of test compounds may be screened for specific binding to DME. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.
In one embodiment, the compound thus identified is closely related to the natural ligand of DME, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunolo~y 1(2):
Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which DME
binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express DME, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing DME or cell membrane fractions which contain DME are then contacted with a test compound and binding, stimulation, or inhibition of activity of either DME or the compound is analyzed.
An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with DME, either in solution or affixed to a solid support, and detecting the binding of DME to the compound.
Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compounds) may be free in solution or affixed to a solid support.
DME of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of DME. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for DME
activity, wherein DME is combined with at least one test compound, and the activity of DME in the presence of a test compound is compared with the activity of DME in the absence of the test compound. A change in the activity of DME in the presence of the test compound is indicative of a compound that modulates the activity of DME. Alternatively, a test compound is combined with an in vitro or cell-free system comprising DME under conditions suitable for DME
activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of DME
may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.
In another embodiment, polynucleotides encoding DME or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S.
Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo;
Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U.
et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.
Polynucleotides encoding DME may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al.
( 1998) Science 282:1145-1147).
Polynucleotides encoding DME can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding DME is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease.
Alternatively, a mammal inbred to overexpress DME, e.g., by secreting DME in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).
THERAPEUTICS
Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of DME and drug metabolizing enzymes. In addition, the expression of DME is closely associated with a liver tumor cell line, liver tumor tissue, pancreatic tissue, pituitary gland tissue, brain tissue, small intestine tissue, fetal brain tissue, and allocortex brain tissue. Therefore, DME appears to play a role in autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders. In the treatment of disorders associated with increased DME expression or activity, it is desirable to decrease the expression or activity of DME. In the treatment of disorders associated with decreased DME
expression or activity, it is desirable to increase the expression or activity of DME.
Therefore, in one embodiment, DME or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME. Examples of such disorders include, but are not limited to, an autoimmune/inflammatory disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a developmental disorder, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; an endocrine disorder, such as disorders of the hypothalamus and pituitary resulting from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma; disorders associated with hypopituitarism including hypogonadism, Sheehan syndrome, diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and dwarfism; disorders associated with hyperpituitarism including acromegaly, giantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma;
disorders associated with hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection, subacute thyroiditis associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism; disorders associated with hyperthyroidism including thyrotoxicosis and its various forms, Grave's disease, pretibial myxedema, toxic multinodular goiter, thyroid carcinoma, and Plummer's disease; disorders associated with hyperparathyroidism including Conn disease (chronic hypercalemia); pancreatic disorders such as Type I or Type II diabetes mellitus and associated complications; disorders associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis, amyloidosis, hypokalemia, Cushing's disease, Liddle's syndrome, and Arnold-Healy-Gordon syndrome, pheochromocytoma tumors, and Addison's disease; disorders associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbations of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, hypergonadal disorders associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5 a-reductase, and gynecomastia; an eye disorder, such as conjunctivitis, keratoconjunctivitis sicca, keratitis, episcleritis, iritis, posterior uveitis, glaucoma, amaurosis fugax, ischemic optic neuropathy, optic neuritis, Leber's hereditary optic neuropathy, toxic optic neuropathy, vitreous detachment, retinal detachment, cataract, macular degeneration, central serous chorioretinopathy, retinitis pigmentosa, melanoma of the choroid, retrobulbar tumor, and chiasmal tumor; a metabolic disorder, such as Addison's disease, cerebrotendinous xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, diabetes, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalism, hypoadrenalism, hyperparathyroidism, hypoparathyroidism, hypercholesterolemia, hyperthyroidism, hypoglycemia, hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage diseases, Menkes syndrome, occipital horn syndrome, mannosidosis, neuraminidase deficiency, obesity, pentosuria phenylketonuria, pseudovitamin D-deficiency rickets; hypocalcemia, hypophosphatemia, and postpubescent cerebellar ataxia, tyrosinemia, and a gastrointestinal disorder, such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecysfitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, hereditary hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha,-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas.
In another embodiment, a vector capable of expressing DME or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME including, but not limited to, those described above.
In a further embodiment, a composition comprising a substantially purified DME
in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME
including, but not limited to, those provided above.
In still another embodiment, an agonist which modulates the activity of DME
may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of DME including, but not limited to, those listed above.
In a further embodiment, an antagonist of DME may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of DME.
Examples of such disorders include, but are not limited to, those autoimmune/inflammatory, cell proliferative, developmental, endocrine, eye, metabolic, and gastrointestinal disorders, including liver disorders, described above. In one aspect, an antibody which specifically binds DME may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express DME.
In an additional embodiment, a vector expressing the complement of the polynucleotide encoding DME may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of DME including, but not limited to, those described above.
In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
An antagonist of DME may be produced using methods which are generally known in the art. In particular, purified DME may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind DME.
Antibodies to DME may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.
For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with DME or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol.
Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium narvum are especially preferable.
It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to DME have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of DME amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.
Monoclonal antibodies to DME may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497;
Kozbor, D. et al.
(1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl.
Acad. Sci. USA
80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.) In addition, techniques developed for the production of "chimeric antibodies,"
such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc.
Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce DME-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.) Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl.
Acad. Sci. USA
86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.) Antibody fragments which contain specific binding sites for DME may also be generated.
For example, such fragments include, but are not limited to, F(ab')2 fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
(See, e.g., Huse, W.D.
et al. (1989) Science 246:1275-1281.) Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between DME and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering DME epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).
Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for DME. Affinity is expressed as an association constant, K~, which is defined as the molar concentration of DME-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions.
The K~ determined for a preparation of polyclonal antibodies, which are heterogeneous in their IS affinities for multiple DME epitopes, represents the average affinity, or avidity, of the antibodies for DME. The Ka determined for a preparation of monoclonal antibodies, which are monospecific for a particular DME epitope, represents a true measure of affinity. High-affinity antibody preparations with K~ ranging from about 109 to 10'2 L/mole are preferred for use in immunoassays in which the DME-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with Ka ranging from about 106 to 10' L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of DME, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL
Press, Washington DC;
Liddell, J.E. and A. Cryer (1991 ) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).
The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of DME-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. s_u~ra.) In another embodiment of the invention, the polynucleotides encoding DME, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding DME. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding DME. (See, e.g., Agrawal, S., ed. (1996) Antisense Theraueutics, Humana Press Inc., Totawa NJ.) In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) J. Allergy Cli. Immunol. 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) Blood 76:271; Ausubel, su ra; Uckert, W. and W. Walther (1994) Pharmacol.
Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) Br. Med. Bull.
51(1):217-225; Boado, R.J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M.C. et al.
(1997) Nucleic Acids Res.
25(14):2730-2736.) In another embodiment of the invention, polynucleotides encoding DME may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, LM. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc.
Natl. Acad. Sci. USA.
93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in DME expression or regulation causes disease, the expression of DME from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.
In a further embodiment of the invention, diseases or disorders caused by deficiencies in DME are treated by constructing mammalian expression vectors encoding DME and introducing these vectors by mechanical means into DME-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev.
Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H.
Recipon (1998) Curr.
Opin. Biotechnol. 9:445-450).
Expression vectors that may be effective for the expression of DME include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). DME may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or ~i-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl.
Acad. Sci. USA
89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V.
and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX
plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND;
Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding DME from a normal individual.
Commercially available liposome transformation kits (e.g., the PERFECT LIPID
TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al.
(1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.
In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to DME expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding DME under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc.
Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al.
(1987) J. Virol. 61:1647-1650; Bender, M.A. et al. (1987) J. Virol. 61:1639-1646; Adam, M.A. and A.D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol.
72:8463-8471; Zufferey, R.
et al. (1998) J. Virol. 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4+ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M.L. (1997) J.
Virol. 71:4707-4716;
Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).
In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding DME to cells which have one or more genetic abnormalities with respect to the expression of DME. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al.
(1999) Annu. Rev. Nutr. 19:511-544 and Verma, LM. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.
In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding DME to target cells which have one or more genetic abnormalities with respect to the expression of DME. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing DME to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res.
169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S.
Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol.
73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.
In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding DME to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol.
9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for DME into the alphavirus genome in place of the capsid-coding region results in the production of a large number of DME-coding RNAs and the synthesis of high levels of DME in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of DME into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA
transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.
Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E.
and B.I. Carr, Molecular and Immunolo i~c Approaches, Futura Publishing, Mt.
Kisco NY, pp. 163-177.) A complementary sequence oc antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.
Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage.
For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding DME.
Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable.
The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.
Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules.
These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding DME. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.
RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thin-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.
An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding DME. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased DME
expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding DME may be therapeutically useful, and in the treament of disorders associated with decreased DME expression or activity, a compound which specifically promotes expression of the polynucleotide encoding DME may be therapeutically useful.
At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds;
rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A
sample comprising a polynucleotide encoding DME is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding DME are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding DME. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E 15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No.
5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).
Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient.
Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.) Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.
An additional embodiment of the invention.relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins.
Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of DME, antibodies to DME, and mimetics, agonists, antagonists, or inhibitors of DME.
The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.
Compositions for pulmonary administration may be prepared in liquid or dry powder form.
These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.
Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.
Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising DME or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, DME or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R.
et al. (1999) Science 285:1569-1572).
For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
A therapeutically effective dose refers to that amount of active ingredient, for example DME
or fragments thereof, antibodies of DME, and agonists, antagonists or inhibitors of DME, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the EDSO (the dose therapeutically effective in 50% of the population) or LDso (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LDso/EDSO ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the EDSO
with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.
The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half life and clearance rate of the particular formulation.
Normal dosage amounts may vary from about 0.1 ~cg to 100,000 fig, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art.
Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.
DIAGNOSTICS
In another embodiment, antibodies which specifically bind DME may be used for the diagnosis of disorders characterized by expression of DME, or in assays to monitor patients being treated with DME or agonists, antagonists, or inhibitors of DME. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for DME include methods which utilize the antibody and a label to detect DME in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A
wide variety of reporter molecules, several of which are described above, are known in the art and may be used.
A variety of protocols for measuring DME, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of DME expression. Normal or standard values for DME expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to DME under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of DME
expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values.
Deviation between standard and subject values establishes the parameters for diagnosing disease.
In another embodiment of the invention, the polynucleotides encoding DME may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of DME
may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of DME, and to monitor regulation of DME levels during therapeutic intervention.
In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding DME or closely related molecules may be used to identify nucleic acid sequences which encode DME. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5'regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding DME, allelic variants, or related sequences.
Probes may also be used for the detection of related sequences, and may have at least 50%
sequence identity to any of the DME encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID
NO:11-20 or from genomic sequences including promoters, enhancers, and introns of the DME gene.
Means for producing specific hybridization probes for DNAs encoding DME
include the cloning of polynucleotide sequences encoding DME or DME derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA
polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as 32P or 35S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.
Polynucleotide sequences encoding DME may be used for the diagnosis of disorders associated with expression of DME. Examples of such disorders include, but are not limited to, an autoimmune/inflammatory disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a developmental disorder, such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; an endocrine disorder, such as disorders of the hypothalamus and pituitary resulting from lesions such as primary brain tumors, adenomas, infarction associated with pregnancy, hypophysectomy, aneurysms, vascular malformations, thrombosis, infections, immunological disorders, and complications due to head trauma; disorders associated with hypopituitarism including hypogonadism, Sheehan syndrome, diabetes insipidus, Kallman's disease, Hand-Schuller-Christian disease, Letterer-Siwe disease, sarcoidosis, empty sella syndrome, and dwarfism; disorders associated with hyperpituitarism including acromegaly, giantism, and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) often caused by benign adenoma;
disorders associated with hypothyroidism including goiter, myxedema, acute thyroiditis associated with bacterial infection, subacute thyroiditis associated with viral infection, autoimmune thyroiditis (Hashimoto's disease), and cretinism; disorders associated with hyperthyroidism including thyrotoxicosis and its various forms, Grave's disease, pretibial myxedema, toxic multinodular goiter, thyroid carcinoma, and Plummer's disease; disorders associated with hyperparathyroidism including Conn disease (chronic hypercalemia); pancreatic disorders such as Type I or Type II diabetes mellitus and associated complications; disorders associated with the adrenals such as hyperplasia, carcinoma, or adenoma of the adrenal cortex, hypertension associated with alkalosis, amyloidosis, hypokalemia, Cushing's disease, Liddle's syndrome, and Arnold-Healy-Gordon syndrome, pheochromocytoma tumors, and Addison's disease; disorders associated with gonadal steroid hormones such as: in women, abnormal prolactin production, infertility, endometriosis, perturbations of the menstrual cycle, polycystic ovarian disease, hyperprolactinemia, isolated gonadotropin deficiency, amenorrhea, galactorrhea, hermaphroditism, hirsutism and virilization, breast cancer, and, in post-menopausal women, osteoporosis; and, in men, Leydig cell deficiency, male climacteric phase, and germinal cell aplasia, hypergonadal disorders associated with Leydig cell tumors, androgen resistance associated with absence of androgen receptors, syndrome of 5 a-reductase, and gynecomastia; an eye disorder, such as conjunctivitis, keratoconjunctivitis sicca, keratitis, episcleritis, iritis, posterior uveitis, glaucoma, amaurosis fugax, ischemic optic neuropathy, optic neuritis, Leber's hereditary optic neuropathy, toxic optic neuropathy, vitreous detachment, retinal detachment, cataract, macular degeneration, central serous chorioretinopathy, retinitis pigmentosa, melanoma of the choroid, retrobulbar tumor, and chiasmal tumor; a metabolic disorder, such as Addison's disease, cerebrotendinous xanthomatosis, congenital adrenal hyperplasia, coumarin resistance, cystic fibrosis, diabetes, fatty hepatocirrhosis, fructose-1,6-diphosphatase deficiency, galactosemia, goiter, glucagonoma, glycogen storage diseases, hereditary fructose intolerance, hyperadrenalism, hypoadrenalism, hyperparathyroidism, hypoparathyroidism, hypercholesterolemia, hyperthyroidism, hypoglycemia, hypothyroidism, hyperlipidemia, hyperlipemia, lipid myopathies, lipodystrophies, lysosomal storage diseases, Menkes syndrome, occipital horn syndrome, mannosidosis, neuraminidase deficiency, obesity, pentosuria phenylketonuria, pseudovitamin D-deficiency rickets; hypocalcemia, hypophosphatemia, and postpubescent cerebellar ataxia, tyrosinemia, and a gastrointestinal disorder, such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, hereditary hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha,-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas. The polynucleotide sequences encoding DME may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered DME
expression. Such qualitative or quantitative methods are well known in the art.
In a particular aspect, the nucleotide sequences encoding DME may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding DME may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding DME in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.
In order to provide a basis for the diagnosis of a disorder associated with expression of DME, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding DME, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder.
Deviation from standard values is used to establish the presence of a disorder.
Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject.
The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.
With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.
Additional diagnostic uses for oligonucleotides designed from the sequences encoding DME
may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding DME, or a fragment of a polynucleotide complementary to the polynucleotide encoding DME, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.
In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding DME may be used to detect single nucleotide polymorphisms (SNPs).
SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding DME
are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like.
SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA
sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).
Methods which may also be used to quantify the expression of DME include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. ( 1993) J. Immunol. Methods 159:235-244; Duplaa, C.
et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.
In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.
In another embodiment, DME, fragments of DME, or antibodies specific for DME
may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.
A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.
Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.
Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S.
and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families.
Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.
In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.
Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type.
In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, suera). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.
A proteomic profile may also be generated using antibodies specific for DME to quantify the levels of DME expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoze, L.G. et al. ( 1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol-or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.
Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.
In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.
In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A
difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.
Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al.
(1996) Proc. Natl.
Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application W095/251116;
Shalom D. et al. (1995) PCT application W095/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad.
Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No.
5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A
Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.
In another embodiment of the invention, nucleic acid sequences encoding DME
may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harnngton, J.J. et al. ( 1997) Nat.
Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J.
(1991) Trends Genet.
7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP).
(See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci.
USA 83:7353-7357.) Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding DME
on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.
In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps.
Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to l 1q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.
In another embodiment of the invention, DME, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between DME and the agent being tested may be measured.
Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT
application W084/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with DME, or fragments thereof, and washed. Bound DME is then detected by methods well known in the art.
Purified DME can also be coated directly onto plates for use in the aforementioned drug screening techniques.
Alternatively,.non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.
In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding DME specifically compete with a test compound for binding DME. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with DME.
In additional embodiments, the nucleotide sequences which encode DME may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
The disclosures of all patents, applications and publications, mentioned above and below, including U.S. Ser. No. 60/197,590, U.S. Ser. No. 601198,403, U.S. Ser. No.
60/200,185, U.S. Ser.
No. 60/202,234, and U.S. Ser. No. 60/203,509, are expressly incorporated by reference herein.
EXAMPLES
I. ~ Construction of cDNA Libraries Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD
database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCI cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.
Phenol extraction and~precipitation of RNA were repeated as necessary to increase RNA
purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX
latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN).
Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).
In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA
libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP
vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA
was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA
was size-selected (300-1000 bp) using SEPHACRYL S 1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BIueMRF, or SOLR from Stratagene or DHSa, DH10B, or ElectroMAX
DH10B from Life Technologies.
II. Isolation of cDNA Clones Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis.
Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega);
an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.
Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II
fluorescence scanner (Labsystems Oy, Helsinki, Finland).
III. Sequencing and Analysis Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows.
Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI
sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI
protocols and base calling software; or other sequence analysis systems known iri the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, s-unra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.
The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) Curr.
Opin. Struct. Biol.
6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences.
Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS
PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).
Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN
multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.
Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).
The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ
B7 NO:11-20. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.
IV. Identification and Editing of Coding Sequences from Genomic DNA
Putative drug metabolizing enzymes were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA
sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin ( 1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon..
The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode drug metabolizing enzymes, the encoded polypeptides were analyzed by querying against PFAM models for drug metabolizing enzymes.
Potential drug metabolizing enzymes were also identified by homology to Incyte cDNA sequences that had been annotated as drug metabolizing enzymes. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST
hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST
analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA
coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.
V. Assembly of Genomic Sequence Data with cDNA Sequence Data "Stitched" Sequences Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example 1V. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent.
This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases.
Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.
"Stretched" Sequences Partial DNA sequences were extended to full length with an algorithm based on BLAST
analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST
analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog.
Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.
VI. Chromosomal Mapping of DME Encoding Polynucleotides The sequences which were used to assemble SEQ ID NO:11-20 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:11-20 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Genethon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.
Map locations are represented by ranges, or intervals, of human chromosomes.
The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM
distances are based on genetic markers mapped by Genethon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap~, can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.
VII. Analysis of Polynucleotide Expression Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.) Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:
BLAST Score x Percent Identity 5 x minimum { length(Seq. 1 ), length(Seq. 2) }
The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP
(separated by gaps). If there is more than one HSP, then the pair with the highest BLAST
score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A
product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88%
identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.
Alternatively, polynucleotide sequences encoding DME are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA
sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female;
genitalia, male; germ cells; heroic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed;
or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding DME. cDNA sequences and cDNA
library/tissue information are found in the LIFESEQ GOLD database (Incyte Genorriics, Palo Alto CA).
VIII. Extension of DME Encoding Polynucleotides Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.
Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.
High fidelity amplification was obtained by PCR using methods well known in the art. PCR
was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg2+, (NH4)ZS04, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE
enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2:
94°C, 15 sec; Step 3: 60°C, 1 min;
Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+
were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4:
68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.
The concentration of DNA in each well was determined by dispensing 100 p1 PICOGREEN
quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE
and 0.5 p1 of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II
(Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 ,u1 to 10 ~l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.
The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to relegation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE
(Promega). Extended clones were relegated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerise (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37 °C in 384-well plates in LB/2x carb liquid media.
The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerise (Amersham Pharmacia Biotech) and Pfu DNA polymerise (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3:
60°C, 1 min; Step 4: 72°C, 2 min;
Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA
recoveries were reamplified using the same conditions as described above.
Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI
PRISM
BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.
IX. Labeling and Use of Individual Hybridization Probes Hybridization probes derived from SEQ ID NO:11-20 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 ,uCi of [y-32P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25' superfine size exclusion dextran bead column (Amersham Pharmacia Biotech).
An aliquot containing 10' counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases:
Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).
The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5%
sodium dodecyl sulfate.
Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.
X. Microarrays The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink jet printing, See, e.g., Baldeschweiler, supra.), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), su ra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers.
Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645;
Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.) Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization.
The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.
Tissue or Cell Sample Preparation Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)+ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)+
RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/pl oligo-(dT) primer (2lmer), 1X
first strand buffer, 0.03 units/pl RNase inhibitor, 500 E.~M dATP, 500 pM
dGTP, 500 NM dTTP, 40 E.~M dCTP, 40 l.~M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech).
The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)+ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)+ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37 ° C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of O.SM sodium hydroxide and incubated for 20 minutes at 85°C to the stop the reaction and degrade the RNA.
Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC
(Savant Instruments Inc., Holbrook NY) and resuspended in 14 p1 SX SSC/0.2% SDS.
Microarrav Preparation Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts.
PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert.
Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 pg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).
Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1 % SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4%
hydrofluoric acid (VWR
Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.
Array elements are applied to the coated glass substrate using a procedure described in US
Patent No. 5,807,522, incorporated herein by reference. 1 p1 of the array element DNA, at an average concentration of 100 ng/pl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 n1 of array element sample per slide.
Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene).
Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water.
Non-specific binding sites are blocked by incubation of microarrays in 0.2%
casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C
followed by washes in 0.2% SDS and distilled water as before.
Hybridization Hybridization reactions contain 9 p1 of sample mixture consisting of 0.2 pg each of Cy3 and Cy5 labeled cDNA synthesis products in SX SSC, 0.2% SDS hybridization buffer.
The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an I .8 cmz coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 p1 of SX SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X
SSC), and dried.
Detection Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of CyS. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.
In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially.
Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT 81477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores.
Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for CyS.
Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.
The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A
specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are _ differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.
The output of the photomultiplier tube is digitized using a 12-bit RTI-835H
analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC
computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.
A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).
XI. Complementary Polynucleotides Sequences complementary to the DME-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring DME. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of DME. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the DME-encoding transcript.
XII. Expression of DME
Expression and purification of DME is achieved using bacterial or virus-based expression systems. For expression of DME in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA
transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the TS or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3).
Antibiotic resistant bacteria express DME upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of DME in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Auto~raphica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding DME by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect ~odoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases.
Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K.
et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al.
(1996) Hum. Gene Ther.
7:1937-1945.) In most expression systems, DME is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma Laponicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from DME at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG
antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified DME obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, and XVIII, where applicable.
XIII. Functional Assays DME function is assessed by expressing the sequences encoding DME at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA
expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 ~g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 ~cg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP;
Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP
or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM
detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA
with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface.
Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.
The influence of DME on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding DME and either CD64 or CD64-GFP.
CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art.
Expression of mRNA encoding DME and other genes of interest can be analyzed by northern analysis or microarray techniques.
XIV. Production of DME Specific Antibodies DME substantially purified using polyacrylamide gel electrophoresis (PAGE;
see, e.g., Harnngton, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.
Alternatively, the DME amino acid sequence is analyzed using LASERGENE
software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.) Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A
peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KL,H complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-DME activity by, for example, binding the peptide or DME
to a substrate, blocking with 1°lo BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.
XV. Purification of Naturally Occurring DME Using Specific Antibodies Naturally occurring or recombinant DME is substantially purified by immunoaffinity chromatography using antibodies specific for DME. An immunoaffinity column is constructed by covalently coupling anti-DME antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.
Media containing DME are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of DME (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/DME binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and DME is collected.
XVI. Identification of Molecules Which Interact with DME
DME, or biologically active fragments thereof, are labeled with'ZSI Bolton-Hunter reagent.
(See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled DME, washed, and any wells with labeled DME complex are assayed. Data obtained using different concentrations of DME are used to calculate values for the number, affinity, and association of DME with the candidate molecules.
Alternatively, molecules interacting with DME are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).
DME may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al.
(2000) U.S. Patent No. 6,057,101).
XVII. Demonstration of DME Activity Cytochrome P450 activity of DME is measured using the 4-hydroxylation of aniline. Aniline is converted to 4-aminophenol by the enzyme, and has an absorption maximum at 630 nm (Gibson and Skett, supra). This assay is a convenient measure, but underestimates the total hydroxylation, which also occurs at the 2- and 3- positions. Assays are performed at 37°C and contain an aliquot of the enzyme and a suitable amount of aniline (approximately 2 mM) in reaction buffer. For this reaction, the buffer must contain NADPH or an NADPH-generating cofactor system. One formulation for this reaction buffer includes 85 mM Tris pH 7.4, 15 mM MgClz, 50 mM
nicotinamide, 40 mg trisodium isocitrate, and 2 units isocitrate dehydrogenase, with 8 mg NADP+
added to a 10 mL reaction buffer stock just prior to assay. Reactions are carried out in an optical cuvette, and the absorbance at 630 nm is measured. The rate of increase in absorbance is proportional to the enzyme activity in the assay. A standard curve can be constructed using known concentrations of 4-aminophenol.
1a,25-dihydroxyvitamin D 24-hydroxylase activity of DME is determined by monitoring the conversion of 3H-labeled 1a,25-dihydroxyvitamin D (1a,25(OH)ZD) to 24,25-dihydroxyvitamin D
(24,25(OH)zD) in transgenic rats expressing DME. 1 pg of 1a,25(OH)ZD dissolved in ethanol (or ethanol alone as a control) is administered intravenously to approximately 6-week-old male transgenic rats expressing DME or otherwise identical control rats expressing either a defective variant of DME or not expressing DME. The rats are killed by decapitation after 8 hrs, and the kidneys are rapidly removed, rinsed, and homogenized in 9 volumes of ice-cold buffer (15 mM Tris-acetate (pH 7.4), 0.19 M sucrose, 2 mM magnesium acetate, and 5 mM sodium succinate). A portion (e.g., 3 ml) of each homogenate is then incubated with 0.25 nM 1a,25(OH)2[1 3H]D, with a specific activity of approximately 3.5 GBq/mmol, for 15 min at 37 °C under oxygen with constant shaking.
Total lipids are extracted as described (Bligh, E.G. and W.J. Dyer (1959) Can.
J. Biochem. Physiol.
37: 911-917) and the chloroform phase is analyzed by HPLC using a FINEPAK SIL
column (JASCO, Tokyo, Japan) with a n-hexane/chloroform/methanol (10:2.5:1.5) solvent system at a flow rate of 1 ml/min. In the alternative, the chloroform phase is analyzed by reverse phase HPLC using a J SPHERE ODS-AM column (YMC Co. Ltd., Kyoto, Japan) with an acetonitrile buffer system (40 to 100%, in water, in 30 min) at a flow rate of 1 ml/min. The eluates are collected in fractions of 30 seconds (or less) and the amount of 3H present in each fraction is measured using a scintillation counter. By comparing the chromatograms of control samples (i.e., samples comprising 1a,25-dihydroxyvitamin D or 24,25-dihydroxyvitamin D (24,25(OH)zD), with the chromatograms of the reaction products, the relative mobilities of.the substrate (1a,25(OH)z[1-;H]D) and product (24,25(0H)2[1 3H]D) are determined and correlated with the fractions collected. The amount of 24,25(0H)2[1 3H]D produced in control rats is subtracted from that of transgenic rats expressing DME. The difference in the production of 24,25(0H)2[1 3H]D in the transgenic and control animals is proportional to the amount of 25-hydrolase activity of DME present in the sample. Confirmation of the identity of the substrate and products) is confirmed by means of mass spectroscopy (Miyamoto, Y. et al. (1997) J. Biol. Chem. 272:14115-14119).
Flavin-containing monooxygenase activity of DME is measured by chromatographic analysis of metabolic products. For example, Ring, B.J. et al. (1999; Drug Metab. Dis.
27:1099-1103) incubated FMO in 0.1 M sodium phosphate buffer (pH 7.4 or 8.3) and 1 mM NADPH
at 37°C, stopped the reaction with an organic solvent, and determined product formation by HPLC.
Alternatively, activity is measured by monitoring oxygen uptake using a Clark-type electrode. For example, Ziegler, D.M. and Poulsen, L.L. (1978; Methods Enzymol. 52:142-151) incubated the enzyme at 37°C in an NADPH-generating cofactor system (similar to the one described above) containing the substrate methimazole. The rate of oxygen uptake is proportional to enzyme activity.
UDP glucuronyltransferase activity of DME is measured using a colorimetric determination of free amine groups (Gibson and Skett, suera). An amine-containing substrate, such as 2-aminophenol, is incubated at 37°C with an aliquot of the enzyme in a reaction buffer containing the necessary cofactors (40 mM Tris pH 8.0, 7.5 mM MgCIZ, 0.025% Triton X-100, 1 mM ascorbic acid, 0.75 mM UDP-glucuronic acid). After sufficient time, the reaction is stopped by addition of ice-cold 20% trichloroacetic acid in 0.1 M phosphate buffer pH 2.7, incubated on ice, and centrifuged to clarify the supernatant. Any unreacted 2-aminophenol is destroyed in this step. Sufficient freshly-prepared sodium nitrite is then added; this step allows formation of the diazonium salt of the glucuronidated product. Excess nitrite is removed by addition of sufficient ammonium sulfamate, and the diazonium salt is reacted with an aromatic amine (for example, N-naphthylethylene diamine) to produce a colored azo compound which can be assayed spectrophotometrically (at 540 nm for the example). A standard curve can be constructed using known concentrations of aniline, which will form a chromophore with similar properties to 2-aminophenol glucuronide.
Glutathione S-transferase activity of DME is measured using a model substrate, such as 2,4-dinitro-1-chlorobenzene, which reacts with glutathione to form a product, 2,4-dinitrophenyl-glutathione, that has an absorbance maximum at 340 nm. It is important to note that GSTs have differing substrate specificities, and the model substrate should be selected based on the substrate preferences of the GST of interest. Assays are performed at ambient temperature and contain an aliquot of the enzyme in a suitable reaction buffer (for example, 1 mM
glutathione, 1 mM
dinitrochlorobenzene, 90 mM potassium phosphate buffer pH 6.5). Reactions are carried out in an optical cuvette, and the absorbance at 340 nm is measured. The rate of increase in absorbance is proportional to the enzyme activity in the assay.
N-acyltransferase activity of DME is measured using radiolabeled amino acid substrates and measuring radiolabel incorporation into conjugated products. Enzyme is incubated in a reaction buffer containing an unlabeled acyl-CoA compound and radiolabeled amino acid, and the radiolabeled acyl-conjugates are separated from the unreacted amino acid by extraction into n-butanol or other appropriate organic solvent. For example, Johnson, M.R. et al. (1990; J. Biol. Chem.
266:10227-10233) measured bile acid-CoA:amino acid N-acyltransferase activity by incubating the enzyme with cholyl-CoA and 3H-glycine or 3H-taurine, separating the tritiated cholate conjugate by extraction into n-butanol, and measuring the radioactivity in the extracted product by scintillation.
Alternatively, N-acyltransferase activity is measured using the spectrophotometric determination of reduced CoA (CoASH) described below.
N-acetyltransferase activity of DME is measured using the transfer of radiolabel from ['4C]acetyl-CoA to a substrate molecule (for example, see Deguchi, T. (1975) J. Neurochem.
24:1083-5). Alternatively, a spectrophotometric assay based on DTNB (5,5'-dithio-bis(2-nitrobenzoic acid; Ellman's reagent) reaction with CoASH may be used. Free thiol-containing CoASH is formed during N-acetyltransferase catalyzed transfer of an acetyl group to a substrate. CoASH is detected using the absorbance of DTNB conjugate at 412 nm (De Angelis, J. et al. (1997) J. Biol. Chem.
273:3045-3050). Enzyme activity is proportional to the rate of radioactivity incorporation into substrate, or the rate of absorbance increase in the spectrophotometric assay.
Protein arginine methyltransferase activity of DME is measured at 37 °C
for various periods of time. S-adenosyl-L-[methyl 3H]methionine ([3H]AdoMet; specific activity =
75 Ci/mmol; NEN
Life Science Products) is used as the methyl-donor substrate. Useful methyl-accepting substrates include glutathione S-transferase fibrillarin glycine-arginine domain fusion protein (GST-GAR), heterogeneous nuclear ribonucleoprotein (hnRNP), or hypomethylated proteins present in lysates from adenosine dialdehyde-treated cells. Methylation reactions are stopped by adding SDS-PAGE
sample buffer. The products of the reactions are resolved by SDS-PAGE and visualized by fluorography. The presence of 3H-labeled methyl-donor substrates is indicative of protein arginine methyltransferase activity of DME (Tang, J. et al. (2000) J. Biol. Chem.
275:7723-7730 and Tang, J.
et al. (2000) J. Biol. Chem.275:19866-19876).
Catechol-O-methyltransferase activity of DME is measured in a reaction mixture consisting of 50 mM Tris-HCl (pH 7.4), 1.2 mM MgCIZ, 200 pM SAM (S-adenosyl-L-methionine) iodide (containing 0.5 pCi of methyl-[H3]SAM), 1 mM dithiothreitol, and varying concentrations of catechol substrate (e.g., L-dopa, dopamine, or DBA) in a final volume of 1.0 ml. The reaction is initiated by the addition of 250-500 pg of purified DME or crude DME-containing sample and performed at 37 °C for 30 min. The reaction is arrested by rapidly cooling on ice and immediately extracting with 7 ml of ice-cold n-heptane. Following centrifugation at 1000 x g for 10 min, 3-ml aliquots of the organic extracts are analyzed for radioactivity content by liquid scintillation counting.
The level of catechol-associated radioactivity in the organic phase is proportional to the catechol-O-methyltransferase activity of DME (Zhu, B.T. and J.G. Liehr (1996) 271:1357-1363).
DHFR activity of DME is determined spectrophotometrically at 15 °C by following the disappearance of NADPH at 340 nm (e3ao = 11,800 M-'~crri'). The standard assay mixture contains 100 pM NADPH, 14 mM 2-mercaptoethanol, MTEN buffer (50 mM 2-morpholinoethanesulfonic acid, 25 mM tris(hydroxymethyl)aminomethane, 25 mM ethanolamine, and 100 mM
NaCI, pH 7.0), and DME in a final volume of 2.0 ml. The reaction is started by the addition of 50 pM dihydrofolate (as substrate). The oxidation of NADPH to NADP+ corresponds to the reduction of dihydrofolate in the reaction and is proportional to the amount of DHFR activity in the sample (Nakamura, T. and Iwakura, M. (1999) J. Biol. Chem. 274:19041-19047).
Aldo/keto reductase activity of DME is measured using the decrease in absorbance at 340 nm as NADPH is consumed. A standard reaction mixture is 135 mM sodium phosphate buffer (pH
6.2-7.2 depending on enzyme), 0.2 mM NADPH, 0.3 M lithium sulfate, 0.5-2.5 mg enzyme and an appropriate level of substrate. The reaction is incubated at 30°C and the reaction is monitored continuously with a spectrophotometer. Enzyme activity is calculated as mol NADPH consumed /
mg of enzyme.
Alcohol dehydrogenase activity of DME is measured using the increase in absorbance at 340 nm as NAD+ is reduced to NADH. A standard reaction mixture is 50 mM sodium phosphate, pH 7.5, and 0.25 mM EDTA. The reaction is incubated at 25°C and monitored using a spectrophotometer.
Enzyme activity is calculated as mol NADH produced / mg of enzyme.
Carboxylesterase activity of DME activity is determined using 4-methylumbelliferyl acetate as a substrate. The enzymatic reaction is initiated by adding approximately 10 p1 of DME-containing sample to 1 ml of reaction buffer (90 mM KHZP04, 40 mM KCI, pH 7.3) with 0.5 mM
4-methylumbelliferyl acetate at 37°C. The production of 4-methylumbelliferone is monitored with a spectrophotometer (s3so = 12.2 mM-' cm') for 1.5 min. Specific activity is expressed as micromoles of product formed per minute per milligram of protein and corresponds to the activity of DME in the sample (Evgenia, V. et al. (1997) J. Biol. Chem. 272:14769-14775).
In the alternative, the cocaine benzoyl ester hydrolase activity of DME is measured by incubating approximately 0.1 ml of enzyme and 3.3 mM cocaine in reaction buffer (50 mM
NaH2P04, pH 7.4) with 1 mM benzamidine, 1 mM EDTA, and 1 mM dithiothreitol at 37°C. The reaction is incubated for 1 h in a total volume of 0.4 ml then terminated with an equal volume of 5%
trichloroacetic acid. 0.1 ml of the internal standard 3,4-dimethylbenzoic acid (10 pg/ml) is added.
Precipitated protein is separated by centrifugation at 12,000 x g for 10 min.
The supernatant is transferred to a clean tube and extracted twice with 0.4 ml of methylene chloride. The two extracts are combined and dried under a stream of nitrogen. The residue is resuspended in 14% acetonitrile, 250 mM KHzP04, pH 4.0, with 8 p1 of diethylamine per 100 ml and injected onto a C18 reverse-phase HPLC column for separation. The column eluate is monitored at 235 nm.
DME activity is quantified by comparing peak area ratios of the analyte to the internal standard. A standard curve is generated with benzoic acid standards prepared in a trichloroacetic acid-treated protein matrix (Evgenia, V. et al. (1997) J. Biol. Chem. 272:14769-14775).
In another alternative, DME carboxyl esterase activity against the water-soluble substrate para-nitrophenyl butyric acid is determined by spectrophotometric methods well known to those skilled in the art. In this procedure, the DME-containing samples are diluted with 0.5 M Tris-HCl (pH 7.4 or 8.0) or sodium acetate (pH 5.0) in the presence of 6 mM
taurocholate. The assay is initiated by adding a freshly prepared para-nitrophenyl butyric acid solution (100 pg/ml in sodium acetate, pH 5.0). Carboxyl esterase activity is then monitored and compared with control autohydrolysis of the substrate using a spectrophotometer set at 405 nm (Wan, L. et al. (2000) J.
Biol. Chem. 275:10041-10046).
Sulfotransferase activity of DME is measured using the incorporation of 35S
from [35S]PAPS
into a model substrate such as phenol (Folds, A. and J.L. Meek (1973) Biochim.
Biophys. Acta 327:365-374). An aliquot of enzyme is incubated at 37°C with 1 mL of 10 mM phosphate buffer, pH
6.4, 50 mM phenol, and 0.4-4.0 mM [35S]PAPS. After sufficient time for 5-20%
of the radiolabel to be transferred to the substrate, 0.2 mL of 0.1 M barium acetate is added to precipitate protein and phosphate buffer. Then 0.2 mL of 0.1 M Ba(OH)Z-is added, followed by 0.2 mL
ZnS04. The supernatant is cleared by centrifugation, which removes proteins as well as unreacted [35S]PAPS.
Radioactivity in the supernatant is measured by scintillation. The enzyme activity is determined from the number of moles of radioactivity in the reaction product.
Heparan sulfate 6-sulfotransferase activity of DME is measured in vitro by incubating a sample containing DME along with 2.5 pmol imidazole HCl (pH 6.8), 3.75 ~tg of protamine chloride, nmol (as hexosamine) of completely desulfated and N-resulfated heparin, and 50 pmol (about 5 x 105 cpm) of ['SS] adenosine 3'-phosphate 5'-phosphosulfate (PAPS) in a final reaction volume of 50 p1 at 37°C for 20 min. The reaction is stopped by immersing the reaction tubes in a boiling water bath for 1 min. 0.1 pmol (as glucuronic acid) of chondroitin sulfate A is added to the reaction 20 mixture as a carrier. 35S-Labeled polysaccharides are precipitated with 3 volumes of cold ethanol containing 1.3% potassium acetate and separated completely from unincorporated [35S]PAPS and its degradation products by gel chromatography using desalting columns. One unit of enzyme activity is defined as the amount required to transfer 1 pmol of sulfate/min., determined by the amount of [35S]PADS incorporated into the precipitated polysaccharides (Habuchi, H. et al. (1995) J. Biol.
25 Chem.270:4172-4179).
In the alternative, heparan sulfate 6-sulfotransferase activity of DME is measured by extraction and renaturation of enzyme from gels following separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Following separation, the gel is washed with buffer (0.05 M Tris-HCI, pH 8.0), cut into 3-S mm segments and subjected to agitation at 4 °C with 100 ~1 of the same buffer containing 0.15 M NaCI for 48 h. The eluted enzyme is collected by centrifugation and assayed for the sulfotransferase activity as described above (Habuchi, H. et al.
(1995) J. Biol. Chem. 270:4172-4179).
In another alternative, DME sulfotransferase activity is determined by measuring the transfer of [35S]sulfate from [35S]PAPS to an immobilized peptide that represents the N-terminal 15 residues of the mature P-selectin glycoprotein ligand-1 polypeptide to which a C-terminal cysteine residue is added. The peptide spans three potential tyrosine sulfation sites. The peptide is linked via the cysteine residue to iodoacetamide-activated resin at a density of 1.5-3.0 pmol peptide/ml of resin.
The enzyme assay is performed by combining 10 p1 of peptide-derivitized beads with 2-20 p1 of DME-containing sample in 40 mM Pipes (pH 6.8), 0.3 M NaCI, 20 mM MnCl2, 50 mM
NaF, 1 %
Triton X-100, and I mM 5'-AMP in a final volume of 130 p1. The assay is initiated by addition of 0.5 pCi of [35S]PAPS (1.7 pM; 1 Ci = 37 GBq). After 30 min at 37°C, the reaction beads are washed with 6 M guanidine at 65°C and the.radioactivity incorporated into the beads is determined by liquid scintillation counting. Transfer of [35S]sulfate to the bead-associated peptide is measured to determine the DME activity in the sample. One unit of activity is defined as 1 pmol of product formed per min (Ouyang, Y.-B. et al. (1998) Biochemistry 95:2896-2901).
In another alternative, DME sulfotransferase assays are performed using [35S]PAPS as the sulfate donor in a final volume of 30 p1, containing 50 mM Hepes-NaOH (pH
7.0), 250 mM sucrose, 1 mM dithiothreitol, 14 pM[35S]PAPS (15 Ci/mmol), and dopamine (25 pM), p-nitrophenol (5 pM), or other candidate substrates. Assay reactions are started by the addition of a purified DME enzyme preparation or a sample containing DME activity, allowed to proceed for 15 min at 37°C, and terminated by heating at 100°C for 3 min. The precipitates formed are cleared by centrifugation.
The supernatants are then subjected to the analysis of 'SS-sulfated product by either thin-layer chromatography or a two-dimensional thin layer separation procedure.
Appropriate standards are run in parallel with the supernatants to allow the identification of the 35S-sulfated products and determine the enzyme specificity of the DME-containing samples based on relative rates of migration of reaction products (Sakakibara, Y. et al. (1998) J. Biol. Chem.
273:6242-6247).
Squalene epoxidase activity of DME is assayed in a mixture comprising purified DME (or a crude mixture comprising DME), 20 mM Tris-HCI (pH 7.5), 0.01 mM FAD, 0.2 unit of NADPH-cytochrome C (P-450) reductase, 0.01 mM ['4C]squalene (dispersed with the aid of 20 p1 of Tween 80), and 0.2% Triton X-100. 1 mM NADPH is added to initiate the reaction followed by incubation at 37 °C for 30 min. The nonsaponifiable lipids are analyzed by silica gel TLC developed with ethyl acetate/benzene (0.5:99.5, v/v). The reaction products are compared to those from a reaction mixture without DME. The presence of 2,3(S~-oxidosqualene is confirmed using appropriate lipid standards (Sakakibara, J. et al. (1995) 270:17-20).
Epoxide hydrolase activity of DME is determined by following substrate depletion using gas chromatographic (GC) analysis of ethereal extracts or by following substrate depletion and diol production by GC analysis of reaction mixtures quenched in acetone. A sample containing DME or an epoxide hydrolase control sample is incubated in 10 mM Tris-HCl (pH 8.0), 1 mM
ethylenediaminetetraacetate (EDTA), and 5 mM epoxide substrate (e.g., ethylene oxide, styrene oxide, propylene oxide, isoprene monoxide, epichlorohydrin, epibromohydrin, epifluorohydrin, glycidol, 1,2-epoxybutane, 1,2-epoxyhexane, or 1,2-epoxyoctane). A portion of the sample is withdrawn from the reaction mixture at various time points, and added to 1 ml of ice-cold acetone containing an internal standard for GC analysis (e.g., 1-nonanol). Protein and salts are removed by centrifugation (15 min, 4000 x g) and the extract is analyzed by GC using a 0.2 mm x 25-m CP-Wax57-CB column (CHROMPACK, Middelburg, The Netherlands) and a flame-ionization detector. The identification of GC products is performed using appropriate standards and controls well known to those skilled in the art. 1 Unit of DME activity is defined as the amount of enzyme that catalyzes the production of 1 pmol of diol/min (Rink, R. et al. (1997) J.
Biol. Chem.
272:14650-14657).
Aminotransferase activity of DME is assayed by incubating samples containing DME for 1 hour at 37°C in the presence of 1 mM L-kynurenine and 1 mM 2-oxoglutarate in a final volume of 200 p1 of 150 mM Tris acetate buffer (pH 8.0) containing 70 pM PLP. The formation of kynurenic acid is quantified by HPLC with spectrophotometric detection at 330 nm using the appropriate standards and controls well known to those skilled in the art. In the alternative, L-3-hydroxykynurenine is used as substrate and the production of xanthurenic acid is determined by HPLC analysis of the products with UV detection at 340 nm. The production of kynurenic acid and xanthurenic acid, respectively, is indicative of aminotransferase activity (Buchli, R. et al. (1995) J.
Biol. Chem. 270:29330-29335).
In another alternative, aminotransferase activity of DME is measured by determining the activity of purified DME or crude samples containing DME toward various amino and oxo acid substrates under single turnover conditions by monitoring the changes in the UV/VIS absorption spectrum of the enzyme-bound cofactor, pyridoxal 5'-phosphate (PLP). The reactions are performed at 25°C in SO mM 4-methylmorpholine (pH 7.5) containing 9 pM purified DME or DME containing samples and substrate to be tested (amino and oxo acid substrates). The half reaction from amino acid to oxo acid is followed by measuring the decrease in absorbance at 360 nm and the increase in absorbance at 330 nm due to the conversion of enzyme-bound PLP to pyridoxamine 5' phosphate (PMP). The specificity and relative activity of DME is determined by the activity of the enzyme preparation against specific substrates (Vacca, R.A. et al. (1997) J. Biol.
Chem. 272:21932-21937).
Superoxide dismutase activity of DME is assayed from cell pellets, culture supernatants, or purified protein preparations. Samples or lysates are resolved by electrophoresis on 15%
non-denaturing polyacrylamide gels. The gels are incubated for 30 min in 2.5 mM nitro blue tetrazolium, followed by incubation for 20 min in 30 mM potassium phosphate, 30 mM TEMED, and 30 pM riboflavin (pH 7.8). Superoxide dismutase activity is visualized as white bands against a blue background, following illumination of the gels on a lightbox.
Quantitation of superoxide dismutase activity is performed by densitometric scanning of the activity gels using the appropriate superoxide dismutase positive and negative controls (e.g., various amounts of commercially available E. coli superoxide dismutase (Harth, G. and Horwitz, M.A. (1999) J.
Biol. Chem.
274:4281-4292).
XVIII. Identification of DME Inhibitors Compounds to be tested are arrayed in the wells of a multi-well plate in varying concentrations along with an appropriate buffer and substrate, as described in the assays in Example XVII. DME activity is measured for each well and the ability of each compound to inhibit DME
activity can be determined, as well as the dose-response profiles. This assay could also be used to identify molecules which enhance DME activity.
Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.
A
H I
Q r-Ir-Ir1rir1~-IH ~-Ic-i.-i ~ 0~1P~lW P4POW GOPOW W
N U UU U UU U UU U
~
1J Lf1l~1nM l~M O Crl0[~
O Lf1d~(~N I~~ 01~M N
U
~ l0I~(~M l~ODl~01v-iM
d~l~N M NN N Md~d!
U
H M r1t~I~I~I~I~I~d~I~
y f1d~d~d~N d~~N d~
N Nl~L~L~r1I~I~N t r1 O
LL
N
.,1 ..
~O
O
,'~-, N
r-I-iNM d~~l0f~OO01O
(W
U r1r1r1r1~-1r1r1r1riN
H
?, W
r~i U~
O
Pa A
H
ri.--IH H r-1r-I.--I.--Ir-Ir-I
~--1N CaCaCaCaC1A CaCaCaq N'dU UU U UU U UU U
.I-1Lf1L~Lf1M I~M O d'l0f~
-.-i 1.1t17d~L~N L~V~O1~M N
U ~DL~L~M L~00l~01r1M
V~~ON M NN N Md~d~
H M lf~C~f~L~I~(~d'l~
d~r~ ~ ~N d~d'N d~
Ln r1 N NL~L~L~r1I~(~N L~
O
W
N
O
z ~, r1NM ~ Lf7l0I~0001 r-I
W
O
~
W
H Lf1(~1f1M l~M O ~l0L~
Q II1d~L~N L~d~01d~M N
J~
l0I~t~M L~00l~01r1M
d~~ON M NN N MV~~
M r1C~L~t~L~l L~d~I
H d~~d~d'd~N d~d~N d~
O
N NC~L~C~r1L~L~N L~
W
.u +~ ~ ui N N N ~ O
I ~, (n t~ to [-~ ~.1N O ~ -r1 ~
r N x U7 x N ~ x N f'.
~
I N ~ N ,~ r1 U U1 ~
ao ~O M i-1FC S-I H CZ ~I ~-i (~ c~S N
O
-1 m U z N Id ~ A u~ ~ -~I
N U
,~ ~ x ,-Ix m x ro c~v~
oo N ~
yo ~ x N x ~ -- r.>:o ~ cat~
..
U ~ cd C7 rt '~ O N ~ u1' m U7 M I
S-I M W al ~ ~ rl N O
O a~ N x O ~ ~a x m Oro .~ x ~ ~ ~
f~ cn o x -~I -~I - ~
c~ ~n ,-, ~ ~
1.1 td r O U UJ r1 r1 OI
U ~ V a '-' .-I
c0 ~1 u~ m m ~n ~ .~1 ~ ~ xuW
N .~1.o ~ I oo n ~ c~ ~ r-.N ~ a -~IU
cr ~r ?~ oo -o, ,7 w U ~-IU U7 U7 ~' N N u7 L~
O o1 a1 .~ r-I 00 cp U7 .riN -r1 O t0 .r1 S-1 J-1~ Nb~
~',01 01 ~ CA rtS ~ I d~
U ~ Cn W C71 N N I N O ~ ~ G
1~ N N N M O ~ Ln r1 N td N u1 N .r1N rl U S.1t~ U7O~
C7 I I .-I.r1 U
G' ~I N ~ N C.~4-t c0 CL U7 ~'.,r-I,~
~ ~ W l0 fY1 N N 01 -Id~
1 l0 M l d N H c0 UI J- U ~ N rU
N ~ O S-1O O ~ -rl U7 ''O00 .,~O~
FC r-I01 01 U7 r1 ~', N
C7 1~ d~ ..
N 't i."l~ ~"'-,1 (a ,p N -' C~
~ 01 01 ~ fx J~ t17 E-r U7 N O N O 1-1 S-I 4-1 11 L~ c~c0 ~ In O O
C7 O u1 w U7 ~ N rt O cd N u1U~n ~--Irl o .~ ~ ~ N
'.7 J~ ~ r1 ~ O O ~ r-Iu1 ~''., O -- N N ~O U ~' N N
M
~ U 1W ~ 1~ x 4-I O b~ N ca O NN
~ L~ O O WO C7 ~
C7 N N 1~ U1 1-1 '-'r-I ~', O S-IS-11~Ul-rl x N N V~ -r1 ~t ~ U
d~
U7 rl (~ I rd ~ U r1 .-.N O ~0~
~ rl fY1 G~.' N
I
~ c~ x o x N m ,~ o a~ W x ~Icd o, rt In -- ~ ,~
d~
S-I W7 - I -' U1 I C~ ~ U7 U7 ~ NUI
a ~' ~ L~ .-. In 01 U r-I
N J-1N d~ N lIjO ~ O flj.~, 4-1O
01 N 01 d~ 01 4-1 N N N i-II U1 ~'.,S.~ttfN U7O
r-I N ~ .~. o1 r-I ..-i U7 'LStl7N U1 N ~o ~C N 1-IN ~~
v U U a1 ~ '-'rl (Y1 d~
p -riId s~ ~ w ,-I PI7 4.-,1~ cdc0O
~ r-I O
o ~a ~ s~ -~1s~ cn a~ I ai ~n o ~I~Ix ~C a~ -- ~ . ..~
M
S-I td N .~.,N C",C', PI7 U1 ~",W N !~~
ri r-I .-I .~" U ri PI7 h +~ N w ~ w t0 -ri N c0 ~0 r1 4-I~1 10 - O O V -~1 ~d -1 N tn u1 U7 Sa ~ ~ ~I S.~~ u~>,N
O -rl .~1 r1 cn 1~ U >~ O ~ .1~ca O N 1~ U1 ~ -UU1 -rlW (.n N ~ 1~ r7 01 'r U7 U7 10 .L-Ic~ O U7 tn 4-I N I ctiNt6 N -, r-1 U 00 .~' O N ~I U ~-I 4-1O d~ U7 rl ~ ~IU1~
O u1 O 1~ CL ~ av U7 +~ ~ 1~ r-IU Pa ~ 'r O +~ctjU
LO h ~ ~7 -rlN t~ ri ~ O
O O O .H O ~ ~ ~ ai +~ G O I~
FC ~ N 0.l~ -rl ~ o --~I 1-1W (~ 4-W.N r-i N ~-1 N .r1W '-7.,''O
~ -rl ~1 O
d~ f~
U1 U r1 b) ~ I b1 ~ +~ U 1~ r1 ~ L~ CL I~ ".~ td ~ N
u1 U t~ ~ r1 ~ d~ r-1 O r-I (~ .r1~ NS-I
U7 o\ c0 ~ f7 r-1 r, S-I~- r-i I
r-Itn 5, U7 ?, ~I ~t I O N ,~O
~ o1 tn 01 I7 O U7 N
M ~
r-I ~ -i yJ ~-i U t~ ,L',1~ z ~I .riO
,~ r1 ~ d~ J~ ~,' .~"., 'O
N
~ b1 H N .-I FC N U N O '-Or11~U7 1~ ~ '-'O v O ~ U N r-I
u1 ,~
W C4 x to p4 rZ-Ica 1~ c0 f~ O x ~'ZS
~ U7 O o N 1~ fl, N ~
M O
~ ~ x z ~ I~ I ~, I x ~ z ~~
cn ~ ~ x r1 N a o ~ vv +~ x wca c~ ~o .~I z ~ U ~
-- z ~ ~n ~- a~ a -- w ~s N U
J, O 01 O [v 00 ~ d~ L~ 01MM
~ d~ M ~ ~ M N
r-I N I 1 1 -I r1 r1 I I I
N , -r-II 1 I I I
,~ W 0 o O o O W W W o O o oW
O O
c~ O ~ ~ ~ O o O d, H ~
U
O I~ I~ L~ O a0 ~I di N '-'I M N r-i M M l0 r1 LL
~H IW O '1 to ~ t0 ~ r-IIW O o0 x O O M O
O OJ r-1 c-I O ~O ~ O M
~ ~ ~
O ~ t~ t~ ~ t~ ~ ~ ~ ~ ~0 0o M d~
N l>7O O L~ N O l l ~ r r O d~ l0 lD ri O d N
Ca 00 N l0 N t0 ~ Q1 ~ N M M 01l0 H f1 i Lf1 l L~ N 10 U I- r N N ~ r is ~ ~ ~ Cs ~ Js ~ t5~b~ ~ b~
W -1 r-Ir1 r-I r-I r-I r-I r-I r1r-i G1 A A Ca Ca Ca Ca Ca ACa ~ U U U UU
N U V U V U
1W fl (~ II1 M l~ M O d~ l0t~
(~ Lf1 ~ I~ N (~ ~ O~ ~ MN
H ~O ~ ~ ~ 00 ~ 01 -IM
U I I M t l .
Ca' d~ l0 N M N N N M ~d~
H M r-iL~ I~ l~ l~ L~ I~ d~(~
H
O d~ t11d~ d~ d~ N d~ d~ Nd~
N N (~ C~ t~ r1 L~ I~ Nl~
O
.~
z "
r1 N M d~ In l0 I~ 00 01 a ,~
W
o ~' w yd ~ ~ O
N
U U
U7 fsa U2 O f~ U1 O
~ ~ ~ ~
('., I U1 Ul r1I I U1 C,' I r-iU1 I I
~' ,~", U1 '~", O ~c~f~ ~ W x ~IH H C~,tWd CLCx -~IPa H H
i0 O x O
~
~ WU W W ~ U u-Iu7 U7 I-aWU WW w ~ U U1 U7 ~ fa Ca ~ ~ ~
t ~ ~ W ~ ~ ~ U W f l~ W 1 -0 ~
o ~o r r-i ~ r1 r-I N r-I
ri r-I
u~ I Om cn t~ N m H O H I
O O
I I
M NO M
.. x O ON ~~ ~ U~ ~l~O MM I ~
~ '-i U7 N a ~ 00 ,~N N Q ~r1 r1 a ~ Q N ~
N 01 M ~-' M r a O cn~ ~ V ~ ~n o u~ oob~ ~ ~ ~ N ~ b~
u-I w z z w o U f~ I (0 U HIS d~I I a (0 I
-ri r1 I " ' '~ a ..
I ~ I N
I
~, MM ~-IU7 pa1-I ~ ?-1N01r~ LL ~A ~ ~
J-1 N N O ~ M N r1 N r1!~~ . Q W Q A
N OD ~ l0 l0 O V~ ~
~
NU " 4-IN I ~ N 4-I a1 4-1Na r1 N ~ ~ ~ ~
N ~ L~ ~ ' U1 O d ~ N M I I I
V
'~
N
d~
UI UI U1~ ~ N '~ U7 F4I ..N ~-If~ ~ M ,~
I ~ N H Z' '~N ~ L~ Ii "'' '~ N a ~ 00 ~ i j ~ a 0 1 ~
~r1Fi ~i-I ~ S-i s~ 1 ,~r ~[ a -1 ~a~'s~
z ~ ~sa~ ~ >~~a ~' G z .,Lf ~ a~ ~
~' ~ ~ ~a -~Is~ ~
M x 6 ~ N N '~ U N ~I ~0 ~I ~ ~N rt w U S~q c~
~j' c~W ~ OI I c0 ,-i ~ F~ 1.1f7 C~. Gi.L~ J-1 .~,M S-iA ~ JJ
N U1 I fn ~I ' O .-1~ r-I~ r1 r-1 Or--Ir-I~ r-I~ r-I
U7 N ~ O d~ N C37. ~ M
-I f~ -i N '~~7r~Pa... ~-~~ y ~~ ..tv''(~Sr~~-r-I. ~ N y ~ l N l0 N ~ . 1f1 M f~
M ~
J~ v N U7y..1 N U7 UI U7 Q~ NUl UI ~-I U7a ~
r1 ~ H O r U7O O M '~ O U1 ~ ., O O
~ . r1 O ~ . O p o d~ 00 ~ ~ 0o '~N S' ~ y ~ f'i . S~ -rl'>>~>~ ~ .1 ~ ~' ~ l ~ N U1 f, U7 -1 UI
M ~ U7 ~ M
M N
M
~ ~~a, o r Q o o o ~r ,o o r o ~ , o ~a ~ ~, a a~.. a~ ~acaa~ a~ 5, o o ~ z w ~ ~ a a~
x z ~
~
-r-I N ~.I~I~ ~IS~ N ~I N ~-I~.IS~ tn S~ ~I
~1 '~ N I oo u~-- m ~n cn O I a~o~N
M t~ M ~ o O
m ~
t' u7 N.-t~ O O O O O O N~ ~O O U~~~ O N U
U '~ UNU~o~d' rtfO c~ N U c0 ~0 U'~ S~I~
U Uo~M U I U U
S. ~~ U ~ S
~ I I
z x MrINd~ -I'y' 7 - - - MrIM X0(,7~
M N ' ~M
~ ~ ~, ~ ~ri N ~ O~ ~ ~ o I o .-Ir-1~ ri1n W N I : ~ ,--Ir-I~r1 N u1 ri r-I
~ d'C7., r1r1 o r-I 4-1.-,w ~ u-I
x 4-Io r-I +.1 4..1z r-i d' u-. r-I
rt~ m asas asu~aO b~m b~~N~Otnb~~nbarnb~ b~ ~tn I I I I I ~' '' I I I
' ~ I ~
W r-C U ~ ~ f~ 1 ~ ~~ W FC CL W
W C7 W P q W caC4 c~ U td W c0A CL ~d Crn t~ C4 -r-I-~If-I ~1~ ~1 A -r-I-~I~I~I ~-IG1 fa u ~Iw ~I -~ uu~~~ S-I
-- ~ ~
p u~~ H ~ , m 1 +,.
a O
M
-r1 M
(0 11 r1 r~
N
~, M
~t ~
' z o in W M N
'r .-I
zz z Q O d~
M
I~
M
N M
d~ C~
a1 N
V~ d~
~
01 Ll1 t!1 r1 N M
N ~O
N L
v-I o~
~o N
H u~
~o M
H ~
u~
y~
-ri ,--I V1 r~ Cl~ Ul .1.1 [~ d~
N tf1 M
d~
l0 O
M .-I
M l0 O N
M N
d~ N
d~ N
N M
N d' .-1 ~' N v~
~ u~ ,-I
~ M H
H r1 u~ H
~
N
H
O O O
~ ~
~ 01 r1 O
~ M
i ~
M r1 lW N
-1 Lf1 N d V d cn u~
H H
tn ~
E-~ ~
H cn H ~
O
'~
S=i f~ M
'~
-rl N N
U Ln u1 -~
~
N
O ri r-I
a Ca N U U
~
1 1 C~
~ u~ ~r a ~
, 1D L
() H
~H v0 H M ~-i ~
O
N N
wqz ,~ N
U O ~ ~ 0 ~
a 1 O O ~ U 0 ~ ~ W W A WO W I I I
'd .~
I I C.'I I Ir-II U7U1 Cl~ U1 U1 U7 ~"., ' U7 ~ H E-~ rxcoH H x-~ H u.,w H a~ r-. a, x rox ~ E-~
~
~ u~ cn w U~n un ww cnH~ z ~ z ~ w Uw ~ Q' FC U1FC ~, O ~ EnH H H H z U7 H
H
, a ~ wa a ~s~ a oax arx ax a 0o a~ x ~ncn oa w oo~m w oa w m x cn al p o -~ a ..
I I ~
.
. ..
M N M ' .' ~ l0 l0 N M M 00 N O r1 O ~
~
O L~ d~ .' 01 1p O W Nd~ d~ Lf1 t0 O
a ~ ~u w~ ~a~ aw a o " ~~ ..~o ~ ~ O
~I ~p ~O ~ ~~' O I ~ M ~
U I I I I I I
-rl I
~.," NV~ ~ fx~ , ILL ~ r-I ~', y~ 00N
l~ N N d~ O N ~ .' ~
O
l O .. .. t11MN ~ 1-riO Ma ~ ~ I 00 ~ N ~..
O e-1 M N ~
t!1 d .~-n N N ~ M UlCr ~ M~ O M' ~ Z '~ 01 ' ~ IN
O ' d~ C~ G4 C7-i U ' C~ '~' ~
Q
U7 N Fi,IO ~ M11 O d~H H , I r1S., ~ ~ [2, O N t51 '~
M -' ' fa (O I r1Ca '~ L4U7 O Ci.,~ a -rl -I~,-rl ~, y ~a ~w ~ z' ~..~ Ar~x ~
~' w~ l v w w I ..~ ..~..~ ..p .. p .. ~ "pa I ~ ~ ~ ' . U . ..
~ ' . ' ' . ..
' ~-I U7 N NUl O OO O O~ ~ ~ , O
U1 ' O ~ S-I ~ L~ 01 ~O 00 M , L~
M N M
O
S-, O t51~ L!7Lf7Ln lf11f1~ ~ ,~ O 01 a ~ ~ " ~ M . l0 ~
r1 ~O .-I M
Lfl d~
N 'CfNS-1d~ V~d~ d~d~O H M OD M ~ r~j(aN
' M 1J d~ V~ ~' M N
d~ d~
!O ~-1 SJ -r1,N W WG4 W QIO O ~ "1~~
~ w .. ~~~ v~ (O ~AC~aa ~aaa ~zU H
a ~ " " ,~4-I p ,.r, ,r, w, " b~
~ ~ ~ ~ ~ I I ' I
I I ~ I I
I I
CT o o OU7 N NN N Nd~ ~ ~ O
o 4-I w N N r-i~ ~ ~~ ~ ~(1, I , O p~r-I
-rl N ~ M N -.-i I~ r1 ~ I O o C~ ~ ~ N Ln O O O r1 '~ t r1 O N
01 V~ In u1 M
O d~
u7 r-1 r1 U(0 O OO O OI M M 1~ M ~ UN
I O u1 ~ d~ ..
~ d~ M
~
S-11-IS-I~-IS~I~1~ ~ ~ O
N U1 u~aaU ~ H
~~>au xa r1~I~ .~ ,~.~ro,~.~u~ ~, ~,~ ~,,~~
~ I
W A W 0O U UU U Ucti c~ M r~NU7 N ~ G . .. .. .. .. ..
.. .. ..
..
.-i -i ~ ~4-1O OO O Ori ~ o x~ x'~ -,~+~A~ca ~ ~U~UW~H owAwx ~ ,~,pwq z ~Z -~-~, ~1 ~, I I ~r -~,-.~~I
C~u1~ .,~ W W x U7v1E-~
v1 U C4 l W
x U Ur U U
O M
r1 N
O .ri z ~a ~
V -~I ~o o, c~ t~ 00 m J-1 00 l0 N
ri Ill N N
N N M N
Ci M
'' ~
M t z zz zz ~
o~
O N o O1 l0 U tf1 P
a d~ O M .-I
'r L!l zz O
~ zz zz >~
O r1 V~ M N
M l0 00 U7 V~ (~ 01 M N l0 L~
~f1 00 M d~ If1 r1 ~O M r1 M 01 ((S N M
~O ~-i N Ul -r-1 E-~ Ul C/~ 01 r-I M ~ E-~ E~
tn e--I Ul Ul [~
11 ~ 1D r1 01 N In N 00 H M t11 d~ r1 LI1 N M r1 N ~ M r1 00 M M N r1 Ld 10 N
E ~ E-~ U7 N u1 H
W ~ ~ [-a ~ -~
c I~ 01 N r1 n r1 O M
M
O Ill d~ OD M
~i OO d~ N d~
d~ 01 d~
lfl OO C~
~
01 r1 ~ r1 N H M M
~ M N
N d ~
N
~ 00 ~o I!1 d~
~
,~
-ri V1 01 01 O
M M M Lf1 N
O
A ~ A
U U U U U
~
y t~ N L~ d' ~
~1 , t~ M I~ 00 U
H
N M N N
H C~ C~ L~ L
H
O d~ d~ V~ N
r1 M d~ t!) 10 m G4 O C~.w O
~
~ O N ~ W O w c R: E-~E-~ CGH ttxP: W :4 E-~ H E ~I
W W W W -~ FC aC U~ ~C ~ H O H H FC ~C l~O
~a~A~ O a wo O a~~ ~ as ax O a os~
ax ax ax x mw w v vow ~nx x mm mw ovwm ~w N '- W
DN
O
r1f.L
r1 M
U H N U ~
r1 ~o I
W I N ~ ' ~ 1J ~ d'~r '~ N N
N ~ x y r ~ H
W
U
r1 ODU Ml -rlr1 -$-'., -r-1,~,'-ri N H " M l0M ~ ~ b1 O M ' ~
!x C7~ Id N -r-1 ~0 ~0 ~ ' a W W ~ WN ~
' ~~ N W
~
~
r ~ ~ ~ ~ O .MI ~ N~
O
L
f U rl ,~ d~ 01 O O 01 r1 a1 I
cn ~- H I-~ ~ o N N r1 N v N
~ W ~ '' N N N l o~
-I ~ OD a~
-I U1 ~' Ln l G
~ C
.. .. rtf~ ..N w r ~ ~U7 ~ , ~ r I
~ . 4 ~
N N !v ~ .. Q (IS~ N H ~ a I I .. ~ U~(a I a ~ I I I z M ~
I ~ I I I of H I
I I l~
M O
Q ..N y~ y~ ~ Q ~ ~~
M N N I u'1 a0 In u1 00 d~ N
N L V~ d~ a0 M
cts~ c<jN'QU7 NrtSU U U ~ U ~U
'1 N ~ ~ M l0 M 01 N 01 .-i 01 r1 c-I
N w1 N
J-1 ~-I~I 1-1a (d C51S-1~ ~ ~ ~ ~ ~ro -rl H ~ ~ s va~~~xN .o~x~~a "~ .~~
a ' ' ' ~a~l ~aa~~ o '' ~
W W W ~>~N ~W N N N U N OO
.. .. .. .. .. .. .. (1, .. .. .. ..
~ W ~~ ~ ~ ~ ~ ~ Q~, '~ ~ FC 00 U ~C PO oo ..
Ca W f~ U ~1 .
W
t~ >~ t~ N~Iu7 N>~ ~ y~u7 U1 (O N ~O r1 ~,' r-ifaO O O O 00 O 01 O O O
~ ~ ~ N ~ 00 OD 01 01 OO N Q
~-i~1 ~-IU flS US-1.!~J-1 ~ Q1 y, l0 ~, ~ Q1~
N ~ N ~ ~ 01 01 l0 l0 N 01 S-1 ~ ~ ~ ~ O1 01 l0 l0 O l ~ L~ L~ O O O
L~ O O
~
1~ J-1J-1 N ~-I J-1N L Q Q y~Q
' ' d~ ~ N N ~ L ooooo o r a t~ x oooooo o ,~ ,~ ,~ ,~~ " r-,r,,x ,,~ x ~ x o o I oooooo o000o o o ?, ?, c~u~0 cd? m ~ I N ~ x~
M a z p ~ aaaaaa xxxxx a z cd >, ~ ~ ~s~W ar,o o o o Q Qo ff w A w . moowcncnm wwwww w . a a . A .
o ~, ~, ~ ,~ ~,, ~ .~y , , ,o, o o o o U U U r-1~I~ r-1U r-Ir-I .-I r-ir-ir-Ir-I
-rl ~C ~C FC u~N u~ v~~Cr.CFC FC ~ FC FC~C
~
n s~
O
r-i -r-I
V
1-1 .-i r1 M d~
N N
>~ M
't ~
M ' zz ~, o n o o ~o z U io ., o uo rl ,-I r1 01 N z z M
zz ~
c 0 N V~ 01 Ln r1 d' O
O M N
O
M N d~
N l0 N
M
(a c-i ~--I N
4S U7 E-~ U1 e-I
E-~
~
1~ ~p C W
N /7 o ~o ~D
>~ ~r ov m n ~ o0 oo r-I
t~
oo N H O 01 r1 O H r1 N
-r1 01 N
M
O ~ E'' ~ E-~
~ E
u1 H~ ~ ~
~
W ~ ~ 00 d~
OO M O
O ~
d~
.-I
00 00 l0 t r1 u-I M
M
N
N
N
(' ~ O
ri N d~ r1 v-i U
-~
N N M N M
N
P.' N
A
A A Ca N U U U U
~
+~ o dm o ~
~ 01 d~ M N
'r L~ 01 r1 M
O
(~
U
H
N M d~ d~
H L~ C~ d~ L~
~, O ~ d~ N d~
L~ L~ N f~
o, G
.r1 O l001l0MO r-i 01 tn d~ I~~O M I~O
~ I
11 V~~ MN 00LfW-id~~M M 00 ~ c-iN01O MODM Lf1 '~ ~~ H ~ '~ '1 M O ~Od~O L~l0r1 O r1 00 f~00 N l0l0 .r1 ~~ ~ O O ~
(JI r1W -ir1N .-irir1 ~-i ~-I r1 '-Ir1 r1~-ir1 O
W
O
-r1 O C~~ II1d1O N M .-IO L~~ I~~ ~ t W -I
1J 111 d~00d~O 00 ~~ l N LI1~ W -i l Ld O H Nr L(1r1O r1 r1l01 r t!~ r1M N r O
.ri ~ O ~ N 10r1 tf1 M 00 U7 r1 ~-ic-Iv-i ~ ~ H
O
I
O
I
<i N
O
.-.~..~ .-.~O .~ .-. ..
U LI1N~-I M riI H r1 <-I
N
~' H
cr z Hm z o z z H O
H ~H PGI f3.' O ~H
U1P0U1 V7lY1l0 PI7 W O W
r1r1~-ic-i.-I~-I~ '-'N O '-' v v H ~ ~~ ~ ~ W O r1 O
',>l0lfl10O 00M u'7r100l0w-Id~ r1 ~1D y-I
O CLfxCs-iN d~OOM tnN Ct-ix01 x 00NC~01 00d~
r1LdMO r-il0O L~d~Lf1l0Lf1O r1l0OL(~tIWI701N 00 01l0Nr1O r1O N w1v-ilf~L~lO N r1d~M d~O0100r1 L~O ~f100O OO O OO M 01~7 N I~0001M M01N OD
d~o ~oo U UV FCUU a~o~o o~t~o~o~000~Int~
V'O 01O l~f~I~U1(~fWl1d~L~ 00O NlD10t0l0'-101 ~
- m~o~n>C5C>CU 5C~Coou,,~ ,-IN o.~u,do.oa ~I
L~M N'-IU1(!~U1U1UlU1N MC7 ~ ~ l0d~b7CrC51G410 rl v--I'~ 1D , d~
~ CO l0 -1 J~ V~ l0 r l0 O 00 M
O . to ,-I
U O\ N I d~
.-I r1 r1 I
N
N
I
I
r-i O~ 1 Lf~ ~O
~ I 01 ~i c-I
r1 ~ 01 l0 l0 M
M
I~
U1 I lO I~ I
~ O~ O
t!7 N
-I 01 r1 r1 c-i N
.-I
.-I
N
U
,~
1W O l0 ~ O
N M 00 v-i In LT
l0 0 00 ~D
W -i N r1 r1 a~
a m -I
a r~ w m on N U U U U
O
J-1 In L~ II1 M
O
'r Lf1 d~ I~ N
r1 q U tD t~ t M
U
H
VW O N M
H M r1 I~ l~
~ d~ Lf1 ~ d~
r1 N N L~ I~
O
W
N
l~
oz r1 H N M d~
(~
U ri r1 r1 ri H
Ga ~w r-, u~
w t~
-ri l~r100N OdlO 00 O M riO h r100Lf1NN
1 ~ O ~ N ~ ~ O
J-I d~O 00M N01l001' ~ l0~ r100r1~ N01~ O01Lf1Lf1Lf1~ l0 M l~M r10010InLf1Lf1M O~ r1ctt1.f1~ ~01~ lW-iI~MM ~
-rl O
U7 r1r1r1w-INN r1N N v-1 rlr1.-I rl MM N Nv-1 O
~, O
r1 O O Ml0 l0 Lf1<i 01 M01If1N
~ H ~ r l ~ ~
J-1 01 Inr101 M W -100 lf~ Nd~d~M
1 -I 0 O l I~l l -I-I Q1 10-i-I
f1 Lf1 r1. ~r1d~l~1 00N r Mr r O'~. .N M O~Dr1L~ ~ .
-ri O ~ N M
U7 ~-I r1N.-i r1 r1r1 r1 MN N r1 O
W
N N N
O O O
~ ~
d N I HN Ne-Ir1riI N ~M .-Ir1InN ~-1r-Id InN M I
-' -f .-IO 111 OO OO O OO O Lf1O O OO O OO O OO O d~
, H z ~ HH v~x x x,-1w oz w HH w U~ x r~x x o O O O ~p pO O OO W E-~faO HO ~ ~O Ca~H LaO
z z o HH Hz z zo w oH Az H ~z H Ha H p ~
N H C7o r.~E-~ xF E-~E-~o fxz~1 E-~E-~E-~N p U H o ~ o a~n az z zo ~ Hx ~ ~ ~n~n a o w I OW OH H HI H U1W W x~ W R:~ ~ a I
m cn~r UH Uu~cncn~,a xz ~nHr~H cncncncnw cnIn .rd, .rN .~pp~.
v v L~d W -i O 00 v l0r1111,'~r1l0,'W-ir1r1r1d~r1 N .-Ir1OO.-INr1r1l0r-iriI~
w x NM xH o xx x hN x ~-1x x xw x xx x wx h O
O r-1Ol0MM ~ I~l0M ~OO N f.2,'~-IN 01L~00Ol0r10000l0~H
r1tnL~00Nd~r1toN O NL~N N00ri00L~111v-1M I~00l0Lf1t~
01l0(77N InOOt~01Lf101Ind7(~l~M t11L~O N OD00N ~DL~01t51 M O1 01tDN ~Dl0O M O r1Od~riNr1N OM ~ 01L~00 0110 L~InL~LfIL~N N N,~0110O N ~1~ON (~C~1~01M 00 Lf100 O ON O L(10000OD M l0M M t!101M l01O l0l000 -1~ t7m n,-1~ ~~ w ot7c~01~or ~ou1~ ru1t~.-to~ot7 ~
U
b W o o ,-i ro .
~
.-i O
O
J Ln OD r1 In ~ ' L(1 N
~
~
N - O1 N O .1.f7 O1 U -W 0 l N
U f 01 l l M
N
d~
l ~ . . 1 r r"1 N N . l0I r ~ O l M
r-i N I
d~ 1 r-I
I
I
N L!1 I M d~ N
I N OD
M N
I
C~
N
41 e-i Ill 00v-I V~ N
~ N N L~ I
U7 I .-i O
I V~
C~
O
l~
f1 I
W O '-I 01N I
I , 1 r1 ri d~'r-1 M r1 00 r1 r1 r1 N
~O
r1 N
O
U
,~
~ ~ o 0 0 ,--I o 1y N d~ N ~ r1 O
t57 ~D vD X11 L~
~
C3' r1 N r1 M
U
a~
a ro w cn m w cn w ~ U U U U U U
O
J-1 L~ M O d~ l0 L~
N
?I L~ 'd~ 01d~ M N
r-i Ca U t~ ao I~a1 rl M
U I
H
N N N M V~
H L~ t~ I~l~ dl l~
~
V~ N d~d~ N
r1 f~ r1 l~I~ N l~
O
Oa O
'O
+~
O
oz A ~1 ~ ~ ~ ~ o U .-I r1 r1r1 .-I N
H
a ~
w w a~
r1d~r1.-Id~..-I01M
O ON O ~-IO O O
U HN z Nx H x O W
O H ; H[Z-iiH H
!] ~
, RU
.,~z ~z ~z ~ ~
'~ ~
~, v aw w mi cncn v x q H f~alPOW f~P~7COCO
N U UU U UU U U
J-1t17CWI7M L~M d~l0 ~t ~ ~(~N L~d~d~M
U
U ~o~~ M I~aoa~r1 N
C,''d~1DN M NN M
' H M r-I(~t~L~l~IW1' O
~1 d~u'7d~d~~HN d~N
f3~N NI~C~I~r1L~N
N
Oz N
ri .-iNM ~ Lf~l00001 f~
U r1r1~-ir1r1r1r1.-I
H
~r W
O
W
v rov a~
>~ ro r1~ ro v I
G
ro v ~ 1J ro ',~ OI 1 N
r1 b) C31 x '~ -r-I Lf7M OD
~-I r1 J~
m ~~ C S~ N N r1 +~ NN
x O G
ro w~I -~Iv ~ ~ . rov a am v r1 -.~
v U N~ U ~ N ro v 'L5 ro -r1ro U 1~ ro .t~
N r1 .-tN O O U ~ ~ro .-i ~-I~ ~ ro ,~
ro ~ U .-IO O~-I ~
a-I O N CL
t~ ro U N~ x ?, U '~ S-1 S-Ib1 O N~
'O ~-I N
R~
,~r-I N r-iN G 'O W~ Sa 1-~
ro 1~ro +~N ~ ~ N ro w ~U
O .H m O N
s~ ~.I~ ro a ~ ~~ ~,r-I
~ .~ ro ~
~,Q O O rl N N N'O 'O S-I
m ro ~ ro ~ O
dP ~
O ON U ~-I~ ~ U ~N N r1~
-rl ~ -r1~ Ln ro ~-I S-I1-I O w b~ U1 -rl O~ ~ r-IUI
~ rl ,~ v ro ~
ao 4-I wv r1~ ~,'U1 ~-I ~ro O roro N ~1 ~-I C~' -.-I
U ~-I'O rl -rlro NU ~ ~tT
b1 O O ''O O
'Lf 'Ty roN U ~ rl S-Ir1 N tJ~
'~ +~ S~-IO ~-I
O ~
v Nca -rl>~ O ~ r0 ~-I
d~ N ro U7 ~
~ ''ON ~ U NG ~I
~I N >~ ~
N
O Ow O p, ,~ O I ~.-i v O~
v r1 ro v O N
O ~IO ~ ro '-d U7+-I ~ ~-Iv 'd N -rl N
-r1 v vro w ,~ ,~ ~ ~ m~I N wI
N ~I ~I
~ ~
s~ ~IG 3 va +~ ~ ~Iv N x s~ -~I+~ ~ ~ s~
U
o roN o -~Ioo +~o a, ~
v v N.-i N v >~ 'd r1 rl y vO
O N a~ ~
N
N ~ r1 ~I v v s~o rd s~ -~ v .--, ,~
v ro N N-~I roro v ~ ~ o~ U ro v ~a s~ o 3 ~I
W U7U WI ~ 1J ro .-I +-I -r1 r1b1 1- -rlUI ~.~", x o v -a -~I~ ro ~ os~
ro w v ~ . ~
rd >~
1J 1~N N W ro U ro J~W ro U1-rl U ri J--I~ -rl ~ N
-r1 ~Ir-I~ O ~-I ~ N
b1 -rlO ~
ro s~tn G ~ N v ~Iv ~I
~ ro 3 -~I -~I
.,1r-1 r1~.," FCro N U1 f.~ N~r U FC'C3 ~ N ro 1J ,~
'y J-1 ro ro-rl .-i+~ ro O ~~ f~
rl as +.IS-a-r1 l~ ro N
u I N ~ O
I 'a O ro ~ 7 -.-v .I -r; a r, v t~ ,~ > .u r1~
ro ~ ~ v -~I ~
Z3 b1U 3 ~ U1 U b1ro ~ ~ -rl~ ''O
U N
U7 ~"~ ro +~ O ~v ~ >~
v ~-I~., ~
v U
NO ON -rlro N p, O+~ O -r1N
N ~ rl r-1 r1 +~ ro OSa Sari u1U .~ ~I ro Nro Sa m4-I
ri r1 v u1 U
4-t q4-I wro ~ ''~1~ O ~ 4-IRW,' 4-a +~ r1 .C,~, 1-I
'Z~l-I4-Iro N .(~', r--I J-tU ri ~
'O 'bN 'drl ~''., ~ '~~' ''O ''Oro O S-I r-I,S~ U7 N
~,v vw v o ~I ~ o v~ v v-~I
-~I o ~ -~Iw ~ ~, r1 a I w o >~ ~r1 a ro~N
o w ~
o ro roG U ?-IU1 O .-I roro ro-riUro ro ~ '~ O -.-I O -ri ,~
~~-I r1ro ~ ro '~ r-IU rl-rl r-Ix ~U
J--I J..I v ~-Iro J~ J~ Ul U UI
.,~O O-rl ~IN r1 O S.I O1~ O O 1-I~
U1 +~ ~ ~ ro U7 v r1 au1 NN ~ ~, o x ro N~I N s~~ro v ~ ro v o s~ -~I ~
~ ~
r1 r1ro U7I i-IJ~ U -rlro -rlroU7U
01 v U ~.'t~.,'LS .~. O
N -r1 U ~ 111N ro O CL >~
+~ r1 --I~ ~
FC ~C~ O In ~ P, -ri r.>;~ FC~ O'~
~ ro z3 '~ U ~ ro r1 ~ ' U7 ro U 1~ CL ~-Ib~ ro O Ur-i G ~-rl ro N ro N ~ ro l U r-I f-~
~ ' ' f U
? U N -r 7 >~ C C51 4-I
v aU -I U , v b roS
O v L ~ ~
~ ro I
~
l b1 3~u1 ro~ r1 O -rl b1~ ~ -I
N ~ ~ O r ~ >
3 s~r1 3 0 ro ~I o ~-~ a d 3ro m ~ -~Ix ro ~I
rd I -~Io ~I ~ ~ ~ ~I~I -~Iv v ro o ro ~ ro a~ r1 N ~
U7 U1I ~ w O N U U1~ U7wi~~
ch r1 U S~ ?-I ro U
v ~ ~Sa O x ~I O ~''d ~ 'OS.II
N N N ro ~
rox ro~~ ro ~ ro~ N ro~~
~ ~
~ 'Ltv S~v 3 ~. v 'dv rdo ~r1 ~ ~ O ~ N v v v v v~, a ~ ro ro ~d vr1 v .~~~
ro ro v ,~ >~ ro rn ~1 ~Io v ~I ~ ~ro ~ 3 -~ro w w v o ~ ~
~I -~I
U UO r-I~ S1 b1 r1 U~ U r-Ir1 ''~ O ''~ 1~
~
N ~~ N N ''OU ~ro ~ N ~
4-I ro ?, f~ U
N
I s~ b ~I ~ r-Is~ ~Ia ~Ir1fdo -~ ro v .a ro a a aro v ~ +~ ro -~I ~ro ~ rov~I
~ ~, ~ ~ m ~ -~I
m m~, ~ v ro ~ . N-~I N ~
o >~ ro ~ s~
v O >~w -~I~ U U >, s~cn G -rl>, O t~ ro -r1u1 r1 O ~I
o oo saN N ~ ~ oro o x s~~
~ r1 -~ ~ v ~ ~I
-~ o U UO G1U1 '~ O UU U U ~1,v 3 U 1~ +~ ~-I O
N -r1U7 N .u ~ ro ,~ ~-I v -.-I O
N
U7 U7~ ro~ 1J U7 ~ U7 U7ro U7r-I~O
1J ro ~ S-1U W U7 ~-1 W
ro roO ~O U N CS'-rl roU roW O~
cn ro ~ N U7 -rI
W
3 3~ o~ ~I -~Iro ,~ 3~ 3 Zsv ~ w O ro w ro N ~
~ o ~ -~I ~a ro ~I r1 w ro -~
~ ~ - ?' ~
-I S-ro U~I~-Ix N S~ ~O ~-O ~-IN
-I I~ f~ ~ ''O~ O I >~
4 ~-I -rl ?
ro ro>J O N N CA v roI roI ~
O ro ~ I ro 1~ N
~ ~r ~I s-I~ s~m ~ ~ r-I~I s~~ ~Is~
v -r-I ~-I -~I ro r-I ro r-I ~O +~-riU7 ~ N 1.1 ,~ro ,~ro U7 O N r1 r-1 CL
.-~I f.~
ro -rl~-I tn.>~O O ~ ro rlv -rlN ~r1 N .~ ~ N --i N ro ro v a aw roH f.~U ,-~C4 a~, a ~,H~
~ r1 U .u 3 ~ ~ w w x ~z z q z z ~' >?' U Q' R' U
GL GL
01 V~ M d~ r1 r1 O r1 O O N O
H H ~ C~ H
H
~z z A z z H H H R; U E-~
H ~ H
a r~ cn w a w ~n v m ~I
~ ~
~ ,~ 5 - u~ N ~ R~
ca~ r-I ~, .uoas~ ro ~U ~ 3 S l - U O ~ s~ N N ~ o N -i to O
U a r 7 o t o~ ~ a~ ~ , n ~ ~ ~ ~ ~ ~ ~ ~ m rd i 4-m..~~ U7 a O ~ 'L3of~N N rl- O ~ N ~ N
.t~ O 1~ U '~ ~d ~0 'y,'O 'rCa ~ -..1 I ~ Oa ~ ~",c~ 11 b1 u) ~-IU7 d~ N ,5 -r1 U
~ ~ ~ ~ ~ ~-~ v ~~ ~ ~ o v o v --~ . ~ t 3 a 3 ~d , v ~ ~ -o r-I U7r1~ .--IW I 1~ a -f,a a N S~-I-r1 U7 t0 rd S- ~ ro N NO ~ --I'~r-Ito U v ~ O ~, ctSG S-ab~ v '~
s~ ~ N
.rt -~~ G ~ I 'd.-~-I-r1S-I ~N -rlU N i-1 N
wi U N O a ~., 1.1S-ICi S1 '$..,' O C,"c~U O r-I'J O ~I a '~
u1 U~ fa U7 O ~I ~ t0 N U7 .("., 1J
~a -~IO v a ,~ s~ s~ rd~~.,v ~,~w a ~ a ' O ro O r~ rd M ~I ~
N ~ t~~ a ~ c~ w va ~ ~o o v v r~ ~ Zs 3 U z ~ ~d ~ ~ m ~I ~
ov N .~-rim .rl W ~ 4-1O 1.~ ~ '-d~ U v ,~ r1 1-~ U 'Lf v FC ~ N 1~ t~ r-I U7 r.>;?~ U ~d ~ W O O ~I ~ 'U
U w 'O v i~ f-I
o s~ ~I 3 s~ . z N s~m v v-~I-~I~ o -~ ~ ro .~I~ ~r ~ ~ Zs o O U u1 N N N fa a rtfO ~ U ~ N >~ r1 >~
~ a O N N E-~
O v ~ U O x ~0 ~
w H
tr ~ a a ~I E-~ cd -~U~rtf. 4U caN ~ U7 A
Sa ~I U ~0 -I1 ~ A
s~ coo u~ v ~ x 3 b ,~~a~ ~Ir1~ ~ m o -~I
~ o U v .~I
w w U ~I ~ ~-I v UO ~ ~c0 c0 U7 ~
-rl -~ .t~ 'U -r1O ~
v 1~ N U7N 11 -rl (d r-I1-I~U ~ N U7?-I.ri (0 UI
'(j N 1.-~N .~'., v '~ 11 r-I?, .r1 '-O U7O ~ N ~ -ri O N ~S~ N N ~ C7~1-~ ~ -rl ~-I ~ ' O ~ G c~ ~-I i-~
v O S W ~ G' U1 O ,5U~-ir1 r1S.aO 'J O f.' O
~ i a r1 ..~ O a-I to rt -rl Ei 1J ~IU -rltd '~ N a .r1 7i 1 (~v S-1N N >~' 1~
1J G' N o1 ~ a r-I
'~ 1.1 U ~ ~I~n .~ v ~I v .-I~a d mg o ~ ~n -~ ~
u~ as ~I ~ r1 ~n v a ca ~ ~ O O ~ ~
~
?-I O 4-Iv N a O .(",(,"OU (d U7 U7 N
.~ vo .ri 'O U a ~I N ,~
,~
3 s~~ o u~ v o u~ -~Iv Iu~ ~ ~v ~ ~s ..~ ~a ~
o ~ rd v ~I ~ v ~ >~
U7 ~ r-IccS~ N ~ N a S-IO -.~ ~'-C5I ~ ''d U +~
1~ .,~ ~ O N U UI td a v v s~ 3 v ~ Wo ~ o caro ~ o s~s~ rt o ~a it ~I u~ ~ ~ o . ~I t~
v 0 0 s~~Iv w ~I ~ u~ v.~Ix v>~o .~ ~ w on -~
~I r1 o o, o v .~I
r1 ~
.~,U v ~a~u ~ U ~, ro ~o v .~ s~r1 r1 v 5 ,x ,~ o o~ ~, ~~I ~ v as ~~I 3 a ~ ~ u~ 4-I v >,I,- ~, ~,,~ rd ~ ~ ~I
~ ~ ~ ,-I ~ ~ o~ 'U d .~Im m ~ ,~ ~ N m N u~ o H ~ ~-.,-i. N a ~ t r1 ''O U O L~.-1N Oa ~ t~ O ~ t~ N
c>3 ~ ~ O r-I''U ~ u N >~ ~~ ~ N 1~
'd s O b~ ~n ~ ~ o a l v ~ ~
I ~ ~
3 I ~ c r ~ . ~ ~s + cd I U o v -~ v , , , -r1 >~
' N O c6 ~ ~ 1~ ~-IU caU7 1~ r-IN U N -rl 1~
4-It5)U r1 N .1~
N ' ~, ,~f~' N ~7 ~ J..1N U7 1.1 a 1~-r-IN 1.1 a U7 a ~-I r-I N ("., I r-I
U N ~ Sa O N r1 U7 r1~'-,~ ~~ N ''Oc0 ~ 'O
u7 N ~I ~ to .r1 -rlc~ O ~
N t0 q c0 m O ~ ~I U t~ O Ou7 -rl N U >~ v 1~ N -r1 -rl ,~ 'LS 1-~w 1~ -.-1 ca v v l-I '~(~w W1 v .~'., O U ~-Ia r1---rlr1 i,'' U1 1~ 1 t~'7to U7 ~ U7 U7 a N ~', r-I
,~ N 3 ~0 U -.-i U wO b1 r-i '~r-I1~ c0 ~
?, ~C N >~ O S-IU -rl c0 r1 1J J~ U U7 P4 ~I r1 .r1C' (a~-IG'~ ~ U ~ r-I
''~ !~ b O -rl ~0 I
W ~fv a U v s~ m ~ ~~ .~I 3~ -~m o v -~I
n -~ v w ~ ~I ~ ~ h ~' ~
~d U ~Iv -~Io v ~a -~v m s~ ~n ~ ~ ~ v In v I v ~a x v -,~v U a ~ o -,~ 3 ~ ~s~ .~I r1o a1~
r1 ?~ ~ ~ ~ ~ ~ -~ ~
-,~~ ~ ~ x o ~ ~ o v ~Iov s~ v-~I o -~I w v ~ ~ ~ ~ 3 a ~ u o ~a S ~ ro o ~
m s~E-~v U w ~n ?~ ~ ~5 ai 3~ I ~ a .
~ .~I ~ z v ~ >~
~
m -~I rt u~ o -~ ~I a v-~ u~ o.~o o +~ ~ o ~s >, ,~ ro v c~ v ~
~ s~
U ~' ~ ~~ _ '~o~o ~o ~'~v i '~~ o ~~ i i ~~ ~ ~~ a~
~
c ~,+ N U u~ - ~,NS~ a Nr.C'~rd v a LT>~U U7 ~ t~ ~ f~ +~ ~ 'n U >~
~ U ' U7 ~ N U7 w S-I
..-iO N f~ -rlO >~ --i-ri~v O ,~ !-IO -.-1 1-~
'' -r1~ w -ri to N ~ ~ -rl ~ ' ~ ~
'~
O ~-i~ -ri~ -r1 v r1 i-1U1a 1~ 1 S-IO c0 w ~
~ o v 1 O b) r1 ~C ~ cn~ ~ s~o 1 N 1 O ~ x u7 o -~I ~ .~ o o >~
~ ~I +~ -~ ~ -~Isa .~
~ s~ ~
v ~I
Q] rl ~ b~c0 ~ U 1~ 'd '~w1N U ,~O w ~ ~I S-I 'z3 -~I ~ ca -.-i U2 t~ c0 S-I
~ ~
~ ~ S-Ix v W 0 U7 ~ 1~,~ 1-I ~ 1~ a U ,~ -rl a a 1~ O O ,~
O
tdt0N ,~ N W ~ 1~ ~ ~, c0 ~ ~ O .. i cd ~ N .~ ~ 1~ w O 'd 1~
c~ a ~ 1~ b FC~~ U O1-~C7~'Zf~-I ~ U
N N G UI S-r O ~ N O U U7 ~ ~O -rl ~I O N a z3 U H
~ ~ b~ .H O oo b~ ~I '~ m ~
O ~ N ~ 'Ci ~ ~
Wit' ~ ~
.
N ~ N ~.,a . O r1U ~ uO O U ,~ v - O . 4-Ir1 ~ ~n -..~ v ~I~I r1 0 7, ~ t~-~Iv -,~ w ,~~ -~ ~I w ~I ~ 3 ~ ca m r1 o v ~ ~
~~ z ~ ~-~o~ U rt~~ ~, v3 ~ ~ ~~ ~, ~ ~~o~ o~ ~~v~~o r ~ r-IN c ~-I.~~U O ''dv 0 +~ r-I N ''O
n a n 'd OO ~ c U
-rl O W b~ W
-rI
a N U rt N ~-I .H w 1.-I-rld ~.r1 N ~ N a G
N u1 ~ O ~ N r1 .H ~ ' N
~
U7-rlU .~ U r-I I N 4-I~ >~ N1~ ~ U ~ N ca O 3 'Ci 1~ O c0 Sa ~I w O
'd td~-I-r-IE-~-r-I N ri N v +-~..-i~ r, U7 ...i O N U7 N a ~ ,~ N N ~ ~ N r-I
'~ ~ r-I
N N .U11 ~'., N (d'-O,~,'O xrJ7O U ~ JJ ~
ri J-1 U ((j ~-I .J~r-1 U1 '~ x ~., N u7~''.,~-I~,'~"., .rl~ ~c~ S-a vO -ri~-1~ -rl u7 U .-i ~, N -r1 r1 (~ 1-I
ca O
-., -~Iv O a v -~, ~n v ro~ ~ a ~nO ~n rd .~I
r1 s~ ~ N r1 >~ a~ ~ ~ O ~
r-I 'LS'JU N N -n N w .G N S-1 ~'w N O ~ N
1~ ''d-rtr1 1~ N a U7 cd t7~
co o ~ ~ ~ d v ~ ~ ov v ,~ ,~ a ~a ~ ~ 3 N s~ tn ,~ o o -~I
~
~ ~ ~ v -~ a -~ ~ ,~~w ~ ~~I~ ~ ~ -~ v ~
v ~ I v v o, ~ ~~, as ~ s 5, ro co ~
s I ~
~ x s ~ I ~ s~ ~ N -I ~a I ,-~ v x m ~ ca-~I ~ U U7 -.~oo ,~ +~3 v o ~ s~
o ~I ~ , rt b~ ,~ ca ~
~ >~ ca ~I rt ~ ~ v ~ -~ eo .~I
s~ a ~ v v U ~ r-I r1 m ~as v r-I~ 3 -~ v v ~ -~ N w g ~ ~ a ~ .~ ~
~
~ ~ . ~
. ~
O
O
U1 ~ >~U N a U1 U O.r1~ ~-1v O .~ v t ~ --IG r->r O O ~ f1 ~ ~ ~ ~0 ~-I r -I
..-Ir-I(a.r1'd a N ~-1 -r1~ r1i-1~I N'~~ .i-~~I '~ ~
'-C~ rtf b1 '-~,' rl id ~-I'~ N ', !--~ U
,.t~~ .Gw ~ rl ~ ~ ~ O~ ~ ~O ~ ~ ~ O rl G
~ a ~ O ~-I fa O ~ O Sa ~ !~
-rI -i H , J~O ~ ~ +~ H U U'~ '-' 3Ci1~W +y' w N
-rl t0 U7 .~., U U +~ w ~ J-1 -r-I
, 01 U1 ~ z z ~ a a .-~ r-I
~Iz U
aso ,!~ H
H z H H
w cn i ' ~ ~>, '' ~ a O
o p D ~ ~
w o ~b ~, O~. W ~" M '~
6.1 N
O
~
, y , >
~ ~D t-.
2f O
C ~ ~s.~.
V c~a v~
~
O _ > ~ W ~ ~
~y -o ao ~ w ~~
O ~ o 'S a ~1 y a' O N
c ti cGG
O
~
. 0 ~ ~
~ t "
n ~ ~ W ~ ' d., ~ ~ > ~
m ar 'ts .c ai W
o ~~ ~
~
' c o~
y ~. ~ .~ ~ ~ .= ,.~
.... o O
~ sy ao >
'g ni W 'J coo ~
~ ~' r' ~ y ~ a ~i w ~ ~
~
~
.~
~
ea ~ ~, ~ ~ ~ ~, w ~ ~ ~ ~ a c W o W ~; W ~o > '~ t a ~ a w ~
o.
~
w ... , , U
~.
~~~ M
N
~j N
.~
d d d ~ ~ W
M
>
o pa v M o~ w .
U U U . _, N C ' o ~ .~
_' ~ o ~ .-7 o~o 0 ~o ' ' >' ~ '~ O '~ .~C Pa y G I~ W
N N
O
~ t'~n . ~ C M ~;
.. U U M ~ w G W ~' :
U ~ ~
' ~ ~ ~ ~ ~ ~ ~r ~
~
~
~
~
p~ C~j ~ C O p M w ~ ~ N o N ~
N
a C
o, M ~ ~, ~;
w w w . . . ~, ~
~a " ~
A ~ ' a\
' d y C
~ -d ~ ~
'~' a~
b b ~ ~ ~ ~ ~, _ a~ ~ ~ d ~ ~
, "., ~
~ v ~ v~
.~ d ~
w o W N ~ ~ ~ ~ ' >> c~ >, t~ U ~C"" ~ U
>, ~ O~ b ~ cG
~ ~ O C
j ~!
~ c~ 01 v c b fx CG M
u'' ~ .
~ ~ _ N
O_ O_ O ~ ~ p ~/j ~ ~ . 4w., v-j ' a W f~ f~ ~ ~ d ~ ~ ,~.; ~ Q
~ y' O o ~ o G. ~
., r.
,~ o ~ ~ ~
d ~
d b ~
x d da, d aNz r~z3 xd~NU x ~d N..~z . w O
W ~ ~
O O
d .
U vi U C c~ U U bp a v~
~
C
G N U C _ .O N U c0 Cn ~ ~
> tn CO G 'O G -p '~ tn E-, U
' N O C by O tn crs ~ ,."' ' ~
C
U
~n U C p~ C ~ N w C
U U O N y ~, O N
~ tn 'O c S ~ N C
O" ~ cC ca .
~
a . ~ b -d c b ~ ~ ~ '~ a~
~' U w b ~' a ~
'~
b b , ~ ~ P, ~ ~ v~
V ~ ~ y ~
~
~ d ~
~ _ ~ ~ ' ~ C ~ ' U ~ /~ cV ,'"
U U ~ '''..' ~ O
~ b 0 ~
( ~ U ~ N
~
C
d ,.,~'O .~ U ~ '~ O ~ a' " ' U ~ ~ " O G
U ; ''~' s tn U ~
~ C .. y~ ~ a '~ cG
~ , ~
w a ~. Q' 'n ~
C . _ ~ . Op ~ ~ j >, U GG w C N U
~ N G' U ~ ~ ~ C . C
t, ~ ~ C cn Y
~ ~ ~ ~ b U
b ~ C C/~ N ~
p~ ~
O c~G ~ ~ N 'C1 p ~ ~
V y cG .b G tn U '~ y c0 N _ > 'rJ
cG b A
>' N "n C ~ ~ G. O O
C ~ a- ~ ~
~ rn O
~
d O
" ~
.
~
G.' ~, ~ C ~ .~ ,, p . .~
_ C
c N
V ~ ~ w ~
~ b .a ~ O
~
O
w O .ac~ ~ C w c ctf oU ~ j N v n ~ w C .
C, ~ > .
U
r p~ ~ brp'~ C ..U..L' ~. bp ~ s'~' C O C C
C C
~
w t~.t~Lt.i O. C1C1 ~ fir ~1 a Q C O
C U p- ~ ~ ~O
p ~
y L d ~ d d d ~ ~ d d ~ ~1 d ~ w ~~ w 'w~ :~
~ o.
?:
~
A
w w Q
U ~
a w d ~ ~ d d rn ' ~ Q Q a w w a a U -~
i N
w v.N.
N '~
O
~ ~ ~.. v..
t' Y > ~ cd p y rr N cC
~ ~
U
i,' ~ [~ b~
~ cn E~ ~' .~"" O .y ..
, o ~
~ O
~ O
y 'C c~ N M
~' II II
U ' U f"" a.UJ ~ N
U
a ;z "~ ~ ~
' ~
"
GL v~ rn ~ N a.
N _ N ' O ~ U
, V
N , 00 7 O~
~ ~ w r., N G
~O O > f ~
~G ~ 'O ''~'~ O~ G ~ O .C ~ ~ .O
Ov ~ O
>, Q~~ ~ ~ Via, C ~ ~.-~ C C ~ p Cn W 'v~0 ~ .r0 G w ~ >
~ U
G ' ~ G -- p p a O ~ ~ a ~ ~
o ~ p; ~ " ~ ~ w ~ ~' p. G o ~ ~ U
~1 ~ '' C7 ~ ~ a ~ ~ o a ~~
. .~ 0~, ~ ~ c~; ~
o ~ ~:~ ~3 ~ o~ ~ ~''~ ~ ~, N ~ G f~ ~ f~ O U ~ ~ ~ C ~
~ '~ ~ ~ G :~
cC
y~ C7 a w z 0 o Q ~j C ~ ~ . . ~ ~ ~ a~ ~, N ~ Y ~ ~ c o.
. ...
-.~~ 3~:
w ~ U N Oyl ~ U ~ ~ ~ ~ y~ ~ O~
~ ~ p ~ '~
~
Cn _ _ cn ~~
M N
~ U
cCcC.~N ~G~r ~ON . ~ ~
~ ~ a C ~
O~ N N~O ~ ~..U.
1 N ~ ~ , a5 ctt ~ ~ ~ V
~ U ~. M w .
6 ~ ~ ~
. ~ ~ ~ U ~' ~ ",~ _ 3 ~ N cG y iC U
w ~ N w ~
G ~ ~ ~ N ~ ~ p N Q ~ ~ ~ N
> > i~ V1 N w ~ G ~ xi U ~ a C
~' G ~ V C4 G C7 ~ N ~
O O ~O ~ ~ [~ C/~ V7 ~ ~ ~ ~ C G 0 C c~ O ~ ~
~ N 3 U O\
x x v ~ ' O ~O G ' i ~--i 0 N ~ ~
rwn .~ ~ U Y .~ ~ ~ t~ G O ~ .~
.fl ~ . .~ Y y O y ~
~ ~ ~ ~ . m ~ cC 'D
iG
3 ~ ~ . N
x ~~ ~~ a3 ~~ ~ z wNa ~ 3~
z ~~
~ w ~ c U , U x, G
.b G N
G ~
vi UN H.cG ~~
~i ~ G ~ b c~
~
a b~ 3~~~ N W~. ~ ~- o ' ~ N ~
~ ' Q Y ~ ~ O :~ ~ a~ w y ~ U ' ca ~
U cG p N s"' cGcn C ~ p bD p ~ O ~ N U '-' G N
~ ~
0 p , ~ C G ~ C N .N
G w C ~
, .
~ ~ C1 U p U
~
~ > G 'n O O a, G ~ G N tU-~ U 'x ~ '~
~ m .., ~ b N y ~ ~ c~
~ .~ O
G c O ~ ~
~ 0 O , . ~ O f G
w cd cUn C~ b by O O G N b0 C
O U
, 3 ~ on vv G
_ .
U y L ~ C G N .v~ U .C N w U G G
.O
~o .Y a~~~~c '> T; 3~~ c ,y G
~s~.~
y .c ~ ~ .b o ~ e ~ o ~ ~ o N o . ~ ~
y0 ~U cOnO"O O _ _ Wny iCy ~ _ ~G
~i~..s.,O
O ~-" G c~ i .~ ~ O . ~ C G t -p y cd s:.
y ~ U~ ~ ~ ~~ ~ ~ ~U
~ i U
Y
G1 s:.G y ~ ~
O A- G
c C
n ~ ~p N C ,~ ~ ~ C. ~ G by ~ ~ " ~ cc5 U C U U
~
~
fn y~ m N N cC '~ O O U O
~ N
v c o '~ ~ c . o ~ ou 3 a. a a. v a ~
Q. c -b a' ~
fa a ~-v a ~ aU o ~' a a ~' a a-o ~ a~
b-o U
p 'C CL ~ V W
a ~ ~ H
f~. w .~ ., U ~
p <110> INCYTE GENOMICS, INC.
POLICKY, Jennifer L.
HAFALIA, April BURFORD, Neil RING, Huijun Z.
LAL, Preeti TRIBOULEY, Catherine M.
YAO, Monique G.
YUE, Henry TANG, Y. Tom PATTERSON, Chandra DAS, Debopriya SANJANWALA, Madhu S.
GANDHI, Ameena R.
REDDY, Roopa KHAN, Farrah A.
BAUGHN, Mariah R.
RAMKUMAR, Jaya GRIFFIN, Jennifer A.
AU-YOUNG, Janice <120> DRUG METABOLIZING ENZYMES
<130> PI-0070 PCT
<140> To Be Assigned <141> Herewith <150> 60/197,590; 60/198,403; 60/200,185; 60/202,234; 60/203,509 <151> 2000-04-13; 2000-04-19; 2000-04-28; 2000-05-05; 2000-05-11 <160> 20 <170> PERL Program <210> 1 <211> 527 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 2434655CD1 <400> 1 Met Arg Ser Asp Lys Ser Ala Leu Val Phe Leu Leu Leu Gln Leu Phe Cys Val Gly Cys Gly Phe Cys Gly Lys Val Leu Val Trp Pro Cys Asp Met Ser His Trp Leu Asn Val Lys Val Ile Leu Glu Glu Leu Ile Val Arg Gly His Glu Val Thr Val Leu Thr His Ser Lys Pro Ser Leu Ile Asp Tyr Arg Lys Pro Ser Ala Leu Lys Phe Glu Val Val His Met Pro Gln Asp Arg Thr Glu Glu Asn Glu Ile Phe Val Asp Leu Ala Leu Asn Val Leu Pro,Gly Leu Ser Thr Trp Gln Ser Val Ile Lys Leu Asn Asp Phe Phe Val Glu Ile Arg Gly Thr Leu Lys Met Met Cys Glu Ser Phe Ile Tyr Asn Gln Thr Leu Met Lys Lys Leu Gln Glu Thr Asn Tyr Asp Val Met Leu Ile Asp Pro Val Ile Pro Cys Gly Asp Leu Met Ala Glu Leu Leu Ala Val Pro Phe Val Leu Thr Leu Arg Ile Ser Val Gly Gly Asn Met Glu Arg Ser Cys Gly Lys Leu Pro Ala Pro Leu Ser Tyr Val Pro Val Pro Met Thr Gly Leu Thr Asp Arg Met Thr Phe Leu Glu Arg Val Lys Asn Ser Met Leu Ser Val Leu Phe His Phe Trp Ile Gln Asp Tyr Asp Tyr His Phe Trp Glu Glu Phe Tyr Ser Lys Ala Leu Gly Arg Pro Thr Thr Leu Cys Glu Thr Val Gly Lys Ala Glu Ile Trp Leu Ile Arg Thr Tyr Trp Asp Phe Glu Phe Pro Gln Pro Tyr Gln Pro Asn Phe Glu Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Ala Leu Pro Lys Glu Met Glu Asn Phe Val Gln Ser Ser Gly Glu Asp Gly Ile Val Val Phe Ser Leu Gly Ser Leu Phe Gln Asn Val Thr Glu Glu Lys Ala Asn Ile Ile Ala Ser Ala Leu Ala Gln Ile Pro Gln Lys Val Leu Trp Arg Tyr Lys Gly Lys Lys Pro Ser Thr Leu Gly Ala Asn Thr Arg Leu Tyr Asp Trp Ile Pro Gln Asn Asp Leu Leu Gly His Pro Lys Thr Lys Ala Phe Ile Thr His Gly Gly Met Asn Gly Ile Tyr Glu Ala Ile Tyr His Gly Val Pro Met Val Gly Val Pro Ile Phe Gly Asp Gln Leu Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Val Glu Ile Asn Phe Lys Thr Met Thr Ser Glu Asp Leu Leu Arg Ala Leu Arg Thr Val Ile Thr Asp Ser Ser Tyr Lys Glu Asn Ala Met Arg Leu Ser Arg Ile His His Asp Gln Pro.Val Lys Pro Leu Asp Arg Ala Val Phe Trp Ile Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Ser Ala Ala His Asp Leu Thr Trp Phe Gln His Tyr Ser Ile Asp Val Ile Gly Phe Leu Leu Thr Cys Val Ala Thr Ala Ile Phe Leu Phe Thr Lys Cys Phe Leu Phe Ser Cys Gln Lys Phe Asn Lys Thr Arg Lys Ile Glu Lys Arg Glu <210> 2 <211> 523 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 2516747CD1 <400> 2 Met Val Gly Gln Arg Val Leu Leu Leu Val Ala Phe Leu Leu Ser Gly Val Leu Leu Ser Glu Ala Ala Lys Ile Leu Thr Ile Ser Thr Leu Gly Gly Ser His Tyr Leu Leu Leu Asp Arg Val Ser Gln Ile Leu Gln Glu His Gly His Asn Val Thr Met Leu His Gln Ser Gly Lys Phe Leu Ile Pro Asp Ile Lys Glu Glu Glu Lys Ser Tyr Gln Val Ile Arg Trp Phe Ser Pro Glu Asp His Gln Lys Arg Ile Lys Lys His Phe Asp Ser Tyr Ile Glu Thr Ala Leu Asp Gly Arg Lys Glu Ser Glu Ala Leu Val Lys Leu Met Glu Ile Phe Gly Thr Gln Cys Ser Tyr Leu Leu Ser Arg Lys Asp Ile Met Asp Ser Leu Lys Asn Glu Asn Tyr Asp Leu Val Phe Val Glu Ala Phe Asp Phe Cys Ser Phe Leu Ile Ala Glu Lys Leu Val Lys Pro Phe Val Ala Ile Leu Pro Thr Thr Phe Gly Ser Leu Asp Phe Gly Leu Pro Ser Pro Leu Ser Tyr Val Pro Val Phe Pro Ser Leu Leu Thr Asp His Met Asp Phe Trp Gly Arg Val Lys Asn Phe Leu Met Phe Phe Ser Phe Ser Arg Ser Gln Trp Asp Met Gln Ser Thr Phe Asp Asn Thr Ile Lys Glu His Phe Pro Glu Gly Ser Arg Pro Val Leu Ser His Leu Leu Leu Lys Ala Glu Leu Trp Phe Val Asn Ser Asp Phe Ala Phe Asp Phe Ala Arg Pro Leu Leu Pro Asn Thr Val Tyr Ile Gly Gly Leu Met Glu Lys Pro Ile Lys Pro Val Pro Gln Asp Leu Asp Asn Phe Ile Ala Asn Phe Gly Asp Ala Gly Phe Val Leu Val Ala Phe Gly Ser Met Leu Asn Thr His Gln Ser Gln Glu Val Leu Lys Lys Met His Asn Ala Phe Ala His Leu Pro Gln Gly Val Ile Trp Thr Cys Gln Ser Ser His Trp Pro Arg Asp Val His Leu Ala Thr Asn Val Lys Ile Val Asp Trp Leu Pro Arg Ser Asp Leu Leu Ala His Pro Ser Ile Arg Leu Phe Val Thr His Gly Gly Gln Asn Ser Val Met Glu Ala Ile Arg His Gly Val Pro Met Val Gly Leu Pro Val Asn Gly Asp Gln His Gly Asn Met Val Arg Val Val Ala Lys Asn Tyr Gly Val Ser Ile Arg Leu Asn Gln Val Thr Ala Asp Thr Leu Thr Leu Thr Met Lys Gln Val Ile Glu Asp Lys Arg Tyr Lys Ser Ala Val Val Ala Ala Ser Val Ile Leu His Ser Gln Pro Leu Ser Pro Ala Gln Arg Leu Val Gly Trp Ile Asp His Ile Leu Gln Thr Gly Gly Ala Thr His Leu Lys Pro Tyr Ala Phe Gln Gln Pro Trp His Glu Gln Tyr Leu Ile Asp Val Phe Val Phe Leu Leu Gly Leu Thr Leu Gly Thr Met Trp Leu Cys Gly Lys Leu Leu Gly Val Val 500' 505 510 Ala Arg Trp Leu Arg Gly Ala Arg Lys Val Lys Lys Thr <210> 3 <211> 358 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7472775CD1 <400> 3 Met Pro Glu Asp Val Arg Glu Lys Lys Glu Asn Leu Leu Leu Asn Ser Glu Arg Ser Thr Arg Leu Leu Thr Lys Thr Ser His Ser Gln Gly Gly Asp Gln Ala Leu Ser Lys Ser Thr Gly Ser Pro Thr Glu Lys Leu Ile Glu Lys Arg Gln Gly Ala Lys Thr Val Phe Asn Lys Phe Ser Asn Met Asn Trp Pro Val Asp Ile His Pro Leu Asn Lys Ser Leu Val Lys Asp Asn Lys Trp Lys Lys Thr Glu Glu Thr Gln Glu Lys Arg Arg Ser Phe Leu Gln Glu Phe Cys Lys Lys Tyr Gly Gly Val Ser His His Gln Ser His Leu Phe His Thr Val Ser Arg Ile Tyr Val Glu Asp Lys His Lys Ile Leu Tyr Cys Glu Val Pro Lys Ala Gly Cys Ser Asn Trp Lys Arg Ile Leu Met Val Leu Asn Gly Leu Ala Ser Ser Ala Tyr Asn Ile Ser His Asn Ala Val His Tyr Gly Lys His Leu Lys Lys Leu Asp Ser Phe Asp Leu Lys Gly Ile Tyr Thr Arg Leu Asn Thr Tyr Thr Lys Ala Val Phe Val Arg Asp Pro Met Glu Arg Leu Val Ser Ala Phe Arg Asp Lys Phe Glu His Pro Asn Ser Tyr Tyr His Pro Val Phe Gly Lys Ala Ile Ile Lys Lys Tyr Arg Pro Asn Ala Cys Glu Glu Ala Leu Ile Asn Gly Ser Gly Val Lys Phe Lys Glu Phe Ile His Tyr Leu Leu Asp Ser His Arg Pro Val Gly Met Asp Ile His Trp Glu Lys Val Ser Lys Leu Cys Tyr Pro Cys Leu Ile Asn Tyr Asp Phe Val Gly Lys Phe Glu Thr Leu Glu Glu Asp Ala Asn Tyr Phe Leu Gln Met Ile Gly Ala Pro Lys Glu Leu Lys Phe Pro Asn Phe Lys Asp Arg His Ser Ser Asp Glu Arg Thr Asn Ala Gln Val Val Arg Gln Tyr Leu Lys Asp Leu Thr Arg Thr Glu Arg Gln Leu Ile Tyr Asp Phe Tyr Tyr Leu Asp Tyr Leu Met Phe Asn Tyr Thr Thr Pro Phe Leu <210> 4 <211> 396 <212> PRT
<213> Homo Sapiens <220>
<221> misC_feature <223> Incyte ID No: 7473323CD1 <400> 4 Met Ala Ile Asp Ala Leu Val Ser Leu Cys Leu Pro Glu Val Ile Arg Ile Lys Phe Asn Ile Arg Pro Arg Gln Pro His His Asp Leu Pro Pro Gly Gly Ser Gln Asp Gly Asp Leu Lys Glu Pro Thr Glu Arg Val Thr Arg Asp Leu Ser Ser Gly Ala Pro Arg Gly Arg Asn Leu Pro Ala Pro Asp Gln Pro Gln Pro Pro Leu Gln Arg Gly Thr Arg Leu Arg Leu Arg Gln Arg Arg Arg Arg Leu Leu Ile Lys Lys Met Pro Ala Ala Ala Thr Ile Pro Ala Asn Ser Ser Asp Ala Pro Phe Ile Arg Pro Gly Pro Gly Thr Leu Asp Gly Arg Trp Val Ser Leu His Arg Ser Gln Gln Glu Arg Lys Arg Val Met Gln Glu Ala Cys Ala Lys Tyr Arg Ala Ser Ser Ser Arg Arg Ala Val Thr Pro Arg His Val Ser Arg Ile Phe Val Glu Asp Arg His Arg Val Leu Tyr Cys Glu Val Pro Lys Ala Gly Cys Ser Asn Trp Lys Arg Val Leu Met Val Leu Ala Gly Leu Ala Ser Ser Thr Ala Asp Ile Gln His Asn Thr Val His Tyr Gly Ser Ala Leu Lys Arg Leu Asp Thr Phe Asp Arg Gln Gly Ile Leu His Arg Leu Ser Thr Tyr Thr Lys Met Leu Phe Val Arg Glu Pro Phe Glu Arg Leu Val Ser Ala Phe Arg Asp Lys Phe Glu His Pro Asn Ser Tyr Tyr His Pro Val Phe Gly Lys Ala Ile Leu Ala Arg Tyr Arg Ala Asn Ala Ser Arg Glu Ala Leu Arg Thr Gly Ser Gly Val Arg Phe Pro Glu Phe Val Gln Tyr Leu Leu Asp Val His Arg Pro Val Gly Met Asp Ile His Trp Asp His Val Ser Arg Leu Cys Ser Pro Cys Leu Ile Asp Tyr Asp Phe Val Gly Lys Phe Glu Ser Met Glu Asp Asp Ala Asn Phe Phe Leu Ser Leu Ile Arg Ala Pro Arg Asn Leu Thr Phe Pro Arg Phe Lys Asp Arg His Ser Gln Glu Ala Arg Thr Thr Ala Arg Ile Ala His Gln Tyr Phe Ala Gln Leu Ser Ala Leu Gln Arg Gln Arg Thr Tyr Asp Phe Tyr Tyr Met Asp Tyr Leu Met Phe Asn Tyr Ser Lys Pro Phe Ala Asp Leu Tyr <210> 5 <211> 395 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7472777CD1 <400> 5 Met Trp Leu Pro Arg Val Ser Ser Thr Ala Val Thr Ala Leu Leu Leu Ala Gln Thr Phe Leu Leu Leu Phe Leu Val Ser Arg Pro Gly Pro Ser Ser Pro Ala Gly Gly Glu Ala Arg Val His Val Leu Val Leu Ser Ser Trp Arg Ser Gly Ser Ser Phe Val Gly Gln Leu Phe Asn Gln His Pro Asp Val Phe Tyr Leu Met Glu Pro Ala Trp His Val Trp Thr Thr Leu Ser Gln Gly Ser Ala Ala Thr Leu His Met Ala Val Arg Asp Leu Val Arg Ser Val Phe Leu Cys Asp Met Asp Val Phe Asp Ala Tyr Leu Pro Trp Arg Arg Asn Leu Ser~Asp Leu Phe Gln Trp Ala Val Ser Arg Ala Leu Cys Ser Pro Pro Ala Cys Ser Ala Phe Pro Arg Gly Ala Ile Ser Ser Glu Ala Val Cys Lys Pro Leu Cys Ala Arg Gln Ser Phe Thr Leu Ala Arg Glu Ala Cys Arg Ser Tyr Ser His Val Val Leu Lys Glu Val Arg Phe Phe Asn Leu Gln Val Leu Tyr Pro Leu Leu Ser Asp Pro Ala Leu Asn Leu Arg Ile Val His Leu Val Arg Asp Pro Arg Ala Val Leu Arg Ser Arg Glu Gln Thr Ala Lys Ala Leu Ala Arg Asp Asn Gly Ile Val Leu Gly Thr Asn Gly Thr Trp Val Glu Ala Asp Pro Gly Leu Arg Val Val Arg Glu Val Cys Arg Ser His Val Arg Ile Ala Glu Ala Ala Thr Leu Lys Pro Pro Pro Phe Leu Arg Gly Arg Tyr Arg Leu Val Arg Phe Glu Asp Leu Ala Arg Glu Pro Leu Ala Glu Ile Arg Ala Leu Tyr Ala Phe Thr Gly Leu Ser Leu Thr Pro Gln Leu Glu Ala Trp Ile His Asn Ile Thr His Gly Ser Gly Pro Gly Ala Arg Arg Glu Ala Phe Lys Thr Ser Ser Arg Asn Ala Leu Asn Val Ser Gln Ala Trp Arg His Ala Leu Pro Phe Ala Lys Ile Arg Arg Val Gln Glu Leu Cys Ala Gly Ala Leu Gln Leu Leu Gly Tyr Arg Pro Val Tyr Ser Glu Asp Glu Gln Arg Asn Leu Ala Leu Asp Leu Val Leu Pro Arg Gly Leu Asn Gly Phe Thr Trp Ala Ser Ser Thr Ala Ser His Pro Arg Asn <210> 6 <211> 504 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 1272843CD1 <400> 6 Met Glu Ala Thr Gly Thr Trp Ala Leu Leu Leu Ala Leu Ala Leu Leu Leu Leu Leu Thr Leu Ala Leu Ser Gly Thr Arg Ala Arg Gly His Leu Pro Pro Gly Pro Thr Pro Leu Pro Leu Leu Gly Asn Leu Leu Gln Leu Arg Pro Gly Ala Leu Tyr Ser Gly Leu Met Arg Leu Ser Lys Lys Tyr Gly Pro Val Phe Thr Ile Tyr Leu Gly Pro Trp Arg Pro Val Val Val Leu Val Gly Gln Glu Ala Val Arg Glu Ala Leu Gly Gly Gln Ala Glu Glu Phe Ser Gly Arg Gly Thr Val Ala Met Leu Glu Gly Thr Phe Asp Gly His Gly Val Phe Phe Ser Asn Gly Glu Arg Trp Arg Gln Leu Arg Lys Phe Thr Met Leu Ala Leu Arg Asp Leu Gly Met Gly Lys Arg Glu Gly Glu Glu Leu Ile Gln Ala Glu Ala Arg Cys Leu Val Glu Thr Phe Gln Gly Thr Glu Gly Arg Pro Phe Asp Pro Ser Leu Leu Leu Ala Gln Ala Thr Ser Asn Val Val Cys Ser Leu Leu Phe Gly Leu Arg Phe Ser Tyr Glu Asp Lys Glu Phe Gln Ala Val Val Arg Ala Ala Gly Gly Thr Leu Leu Gly Val Ser Ser Gln Gly Gly Gln Thr Tyr Glu Met Phe Ser Trp Phe Leu Arg Pro Leu Pro Gly Pro His Lys Gln Leu Leu His His Val Ser Thr Leu Ala Ala Phe Thr Val Arg Gln Val Gln Gln His Gln Gly Asn Leu Asp Ala Ser Gly Pro Ala Arg Asp Leu Val Asp Ala Phe Leu Leu Lys Met Ala Gln Glu Glu Gln Asn Pro Gly Thr Glu Phe Thr Asn Lys Asn Met Leu Met Thr Val Ile Tyr Leu Leu Phe Ala Gly Thr Met Thr Val Ser Thr Thr Val Gly Tyr Thr Leu Leu Leu Leu Met Lys Tyr Pro His Val Gln Lys Trp Val Arg Glu Glu Leu Asn Arg Glu Leu Gly Ala Gly Gln Ala Pro Ser Leu Gly Asp Arg Thr Arg Leu Pro Tyr Thr Asp Ala Val Leu His Glu Ala Gln Arg Leu Leu Ala Leu Val Pro Met Gly Ile Pro Arg Thr Leu Met Arg Thr Thr Arg Phe Arg Gly Tyr Thr Leu Pro Gln Gly Thr Glu Val Phe Pro Leu Leu Gly Ser Ile Leu His Asp Pro Asn Ile Phe Lys His Pro Glu Glu Phe Asn Pro Asp Arg Phe Leu Asp Ala Asp Gly Arg Phe Arg Lys His Glu Ala Phe Leu Pro Phe Ser Leu Gly Lys Arg Val Cys Leu Gly Glu Gly Leu Ala Lys Ala Glu Leu Phe Leu Phe Phe Thr Thr Ile Leu Gln Ala Phe Ser Leu Glu Ser Pro Cys Pro Pro Asp Thr Leu Ser Leu Lys Pro Thr Val Ser Gly Leu Phe Asn Ile Pro Pro Ala Phe Gln Leu Gln Val Arg Pro Thr Asp Leu His Ser Thr Thr Gln Thr Arg <210> 7 <211> 229 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7472790CD1 <400> 7 Met Asn Ile Arg Asn Ala Gln Pro Asp Asp Leu Met Asn Met Gln His Cys Asn Leu Leu Cys Leu Pro Glu Asn Tyr Gln Met Lys Tyr Tyr Leu Tyr His Gly Leu Ser Trp Pro Gln Leu Ser Tyr Ile Ala Glu Asp Glu Asp Gly Lys Ile Val Gly Tyr Val Leu Ala Lys Met Glu Glu Glu Pro Asp Asp Val Pro His Gly His Ile Thr Ser Leu Ala Val Lys Arg Ser His Arg Arg Leu Gly Leu Ala Gln Lys Leu Met Asp Gln Ala Ser Arg Ala Met Ile Glu Asn Phe Asn Ala Lys Tyr Val Ser Leu His Val Arg Lys Ser Asn Arg Pro Ala Leu His Leu Tyr Ser Asn Thr Leu Asn Phe Gln Ile Ser Glu Va1 Glu Pro Lys Tyr Tyr Ala Asp Gly Glu Asp Ala Tyr Ala Met Lys Arg Asp Leu Ser Gln Met Ala Asp Glu Leu Arg Arg Gln Met Asp Leu Lys Lys Gly Gly Tyr Val Val Leu Gly Ser Arg Glu Asn Gln Glu Thr Gln Gly Ser Thr Leu Ser Asp Ser Glu Glu Ala Cys Gln Gln Lys Asn Pro Ala Thr Glu Glu Ser Gly Ser Asp Ser Lys Glu Pro Lys Glu Ser Val Glu Ser Thr Asn Val Gln Asp Ser Ser Glu Ser Ser Asp Ser Thr Ser <210> 8 <211> 347 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7473944CD1 <400> 8 Met Lys Pro Ala Leu Leu Glu Val Met Arg Met Asn Arg Ile Cys Arg Met Val Leu Ala Thr Cys Leu Gly Ser Phe Ile Leu Val Ile Phe Tyr Phe Gln Ile Met Arg Arg Asn Pro Phe Gly Val Asp Ile Cys Cys Arg Lys Gly Ser Arg Ser Pro Leu Gln Glu Leu Tyr Asn Pro Ile Gln Leu Glu Leu Ser Asn Thr Ala Val Leu His Gln Met Arg Arg Asp Gln Val Thr Asp Thr Cys Arg Ala Asn Ser Ala Thr Ser Arg Lys Arg Arg Val Leu Thr Pro Asn Asp Leu Lys His Leu Val Val Asp Glu Asp His Glu Leu Ile Tyr Cys Tyr Val Pro Lys Val Ala Cys Thr Asn Trp Lys Arg Leu Met Met Val Leu Thr Gly Arg Gly Lys Tyr Ser Asp Pro Met Glu Ile Pro Ala Asn Glu Ala His Val Ser Ala Asn Leu Lys~Thr Leu Asn Gln Tyr Ser Ile Pro Glu Ile Asn His Arg Leu Lys Ser Tyr Met Lys Phe Leu Phe Val Arg Glu Pro Phe Glu Arg Leu Val Ser Ala Tyr Arg Asn Lys Phe Thr Gln Lys Tyr Asn Ile Ser Phe His Lys Arg Tyr Gly Thr Lys Ile Ile Lys Arg Gln Arg Lys Asn Ala Thr Gln Glu Ala Leu Arg Lys Gly Asp Asp Val Lys Phe Glu Glu Phe Val Ala Tyr Leu Ile Asp Pro His Thr Gln Arg Glu Glu Pro Phe Asn Glu His Trp Gln Thr Val Tyr Ser Leu Cys His Pro Cys His Ile His Tyr Asp Leu Val Gly Lys Tyr Glu Thr Leu Glu Glu Asp Ser Asn Tyr Val Leu Gln Leu Ala Gly Val Gly Ser Tyr Leu Lys Phe Pro Thr Tyr Ala Lys Ser Thr Arg Thr Thr Asp Glu Met Thr Thr Glu Phe Phe Gln Asn Ile Ser Ser Glu His Gln Thr Gln Leu Tyr Glu Val Tyr Lys Leu Asp Phe Leu Met Phe Asn Tyr Ser Val Pro Ser Tyr Leu Lys Leu Glu <210> 9 <211> 218 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 2244136CD1 <400> 9 Met Thr Pro Ala Pro Pro Pro Gly Ala Arg Pro Gly Ala Ala Ser Leu Ala Gly Phe Ala Gly Val Ala Ser Leu Gly Pro Gly Asp Pro Arg Arg Ala Ala Asp Pro Arg Pro Leu Pro Pro Ala Leu Cys Phe Ala Val Ser Arg Ser Leu Leu Leu Thr Cys Leu Val Pro Ala Ala Leu Leu Gly Leu Arg Tyr Tyr Tyr Ser Arg Lys Val Ile Arg Ala Tyr Leu Glu Cys Ala Leu His Thr Asp Met Ala Asp Ile Glu Gln Tyr Tyr Met Lys Pro Pro Gly Ser Cys Phe Trp Val Ala Val Leu Asp Gly Asn Val Val Gly Ile Val Ala Ala Arg Ala His Glu Glu Asp Asn Thr Val Glu Leu Leu Arg Met Ser Val Asp Ser Arg Phe Arg Gly Lys Gly Ile Ala Lys Ala Leu Gly Arg Lys Val Leu Glu Phe Ala Val Val His Asn Tyr Ser Ala Val Val Leu Gly Thr Thr Ala Val Lys Val Ala Ala His Lys Leu Tyr Glu Ser Leu Gly Phe Arg His Met Gly Ala Ser Asp His Tyr Val Leu Pro Gly Met Thr Leu Ser Leu Ala Glu Arg Leu Phe Phe Gln Val Arg Tyr His Arg Tyr Arg Leu Gln Leu Arg Glu Glu <210> 10 <211> 318 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474327CD1 <400> 10 Met Ala Ser His Ile Val Leu Asn Asn Gly Thr Lys Met Pro Ile Leu Gly Leu Gly Thr Trp Asn Ser Pro Pro Gly Gln Val Thr Glu Ala Val Lys Val Ala Ile Asn Val Gly Tyr Cys His Ile Asp Cys Ala His Val Tyr Gln Asn Glu Asn Asp Val Gly Val Ala Ile Arg Glu Lys Leu Arg Glu Gln Val Val Lys Cys Glu Glu Leu Phe Ile Thr Ser Lys Leu Trp Cys Ala Tyr His Glu Lys Gly Leu Val Lys Gly Ala Cys Gln Lys Met Leu Ile Asp Leu Lys Leu Asp Tyr Leu Asp Leu Tyr Leu Ile Arg Trp Pro Thr Ser Phe Lys Pro Gly Lys Glu Phe Phe Pro Leu Asp Glu Pro Gly Asn Gly Asn Val Val Pro Ser Asn Ser Asn Ile Leu Asp Thr Trp Ala Gly Met Glu Glu Leu Val Asp Glu Gly Leu Val Lys Ala Ile Gly Ile Ser Asn Phe Asn His Leu Gln Val Glu Arg Ile Leu Asn Lys Pro Asp Leu Lys Tyr Lys Pro Val Val Asn Gln Ile Glu Cys His Pro Tyr Leu Thr Gln Glu Lys Leu Ile Gln Tyr Cys Gln Ser Lys Gly Ile Met Val Thr Ala Tyr Ser Ser Phe Ser Ser Pro Asp Arg Pro Trp Ala Lys Pro Glu Asp Pro Ser Leu Leu Glu Asp Pro Arg Ile Lys Ala Ile Thr Ala Lys His Asn Lys Thr Thr Ala Gln Val Leu Ile Trp Phe Pro Met Gln Arg Asn Leu Val Val Ile Pro Lys Ser Val Thr Pro Glu Cys Ile Ala Glu Asn Phe Lys Val Phe Asn Phe Glu Leu Asn Ser Gln Asp Met Thr Thr Leu Phe Ser Tyr Asn Arg Asn Trp Arg Val Cys Ala Leu Val Ser Cys Ala Ser His Lys Asp Tyr Pro Phe His Glu Glu Phe <210> 11 <211> 1636 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 2434655CB1 <400> 11 gatcagtgtg tgagggaact gccatcatga ggtctgacaa gtcagctttg gtatttctgc 60 tcctgcagct cttctgtgtt ggctgtggat tctgtgggaa agtcctggtg tggccctgtg 120 acatgagcca ttggcttaat gtcaaggtca ttctagaaga gctcatagtg agaggccatg 180 aggtaacagt attgactcac tcaaagcctt cgttaattga ctacaggaag ccttctgcat 240 tgaaatttga ggtggtccat atgccacagg acagaacaga agaaaatgaa atatttgttg 300 acctagctct gaatgtcttg ccaggcttat caacctggca atcagttata aaattaaatg 360 atttttttgt tgaaataaga ggaactttaa aaatgatgtg tgagagcttt atctacaatc 420 agacgcttat gaagaagcta caggaaacca actacgatgt aatgcttata gaccctgtga 480 ttccctgtgg agacctgatg gctgagttgc ttgcagtccc ttttgtgctc acacttagaa 540 tttctgtagg aggcaatatg gagcgaagct gtgggaaact tccagctcca ctttcctatg 600 tacctgtgcc tatgacagga ctaacagaca gaatgacctt tctggaaaga gtaaaaaatt 660 caatgctttc agttttgttc cacttctgga ttcaggatta cgactatcat ttttgggaag 720 agttttatag taaggcatta ggaaggccca ctacattatg tgagactgtg ggaaaagctg 780 agatatggct aatacgaaca tattgggatt ttgaatttcc tcaaccatac caacctaact 840 ttgagtttgt tggaggattg cactgtaaac ctgccaaagc tttgcctaag gaaatggaaa 900 attttgtcca gagttcaggg gaagatggta ttgtggtgtt ttctctgggg tcactgtttc 960 aaaatgttac agaagaaaag gctaatatca ttgcttcagc ccttgcccag atcccacaga 1020 aggtgttatg gaggtacaaa ggaaaaaaac catccacatt aggagccaat actcggctgt 1080 atgattggat accccagaat gatcttcttg gtcatcccaa aaccaaagct tttatcactc 1140 atggtggaat gaatgggatc tatgaagcta tttaccatgg ggtccctatg gtgggagttc 1200 ccatatttgg tgatcagctt gataacatag ctcacatgaa ggccaaagga gcagctgtag 1260 aaataaactt caaaactatg acaagcgaag atttactgag ggctttgaga acagtcatta 1320 ccgattcctc ttataaagag aatgctatga gattatcaag aattcaccat gatcaacctg 1380 taaagcccct agatcgagca gtcttctgga tcgagtttgt catgcgccac aaaggagcca 1440 agcacctgcg atcagctgcc catgacctca cctggttcca gcactactct atagatgtga 1500 ttgggttcct gctgacctgt gtggcaactg ctatattctt gttcacaaaa tgttttttat 1560 tttcctgtca aaaatttaat aaaactagaa agatagaaaa gagggaatag atctttccaa 1620 attcaagaaa gacctg 1636 <210> 12 <211> 2086 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 2516747CB1 <400> 12 cctacctctt cctaggccca cagccagtgc ctttggagta ctgaggcgcg cacagagtcc 60 ttagcccggc gcagggcgcg cagcccaggc tgagatccgc tgcttctgtg gaagtgagca 120 tggttgggca gcgggtgctg cttctagtgg ccttccttct ttctggggtc ctgctctcag 180 aggctgccaa aatcctgaca atatctacac tgggtggaag ccattaccta ctgttggacc 240 gggtgtctca gattcttcaa gagcatggtc ataatgtgac tatgcttcat cagagtggaa 300 agtttttgat cccagatatt aaagaggagg aaaaatcata ccaagttatc aggtggtttt 360 cacctgaaga tcatcaaaaa agaattaaga agcattttga tagctacata gaaacagcat 420 tggatggcag aaaagaatct gaagcccttg taaagctaat ggaaatattt gggactcaat 480 gtagttattt gctaagcaga aaggatataa tggattcctt aaagaatgag aactatgatc 540 tggtatttgt tgaagcattt gatttctgtt ctttcctgat tgctgagaag cttgtgaaac 600 catttgtggc cattcttccc accacattcg gctctttgga ttttgggcta ccaagcccct 660 tgtcttatgt tccagtattc ccttccttgc tgactgatca catggacttc tggggccgag 720 tgaagaattt tctgatgttc tttagtttct ccaggagcca atgggacatg cagtctacat 780 ttgacaacac catcaaggag catttcccag aaggctctag gccagttttg tctcatcttc 840 tactgaaagc agagttgtgg tttgttaact ctgattttgc ctttgatttt gcccggcccc 900 tgcttcccaa cactgtttat attggaggct tgatggaaaa acctattaaa ccagtaccac 960 aagacttgga caacttcatt gccaactttg gggatgcagg gtttgtcctt gtggcctttg 1020 gctccatgtt gaacacccat cagtcccagg aagtcctcaa gaagatgcac aatgcctttg 1080 cccacctccc tcaaggagtg atatggacat gtcagagttc tcattggccc agagatgttc 1140 atttggccac aaatgtgaaa attgtggact ggcttcctcg gagtgacctc ctggctcacc 1200 ccagcatccg tctttttgtc actcatggtg ggcagaacag cgtaatggag gccatccgtc 1260 atggtgtgcc catggtggga ttaccagtca atggagacca gcatggaaac atggtccgag 1320 tagtagccaa aaattatggt gtctctatcc ggttgaatca ggtcacagcc gacacactga 1380 cacttacaat gaaacaagtc atagaagaca agaggtacaa gtcggcagtg gtggcagcca 1440 gtgtcatcct gcactctcag cccctgagcc ccgcacagcg gctggtgggc tggatcgacc 1500 acatcctcca gactggggga gcgacgcacc tcaagcccta tgccttccag cagccttggc 1560 atgagcagta cctcattgat gtctttgtgt ttctgctggg gctcactctg ggcactatgt 1620 ggctttgtgg gaagctgctg ggtgtggtgg ccaggtggct gcgtggggcc aggaaggtga 1680 agaagacatg aggctaggtg tagccttggg tgaggggagg gcatccctgg tcctttgaag 1740 gttctcccca ccccagcaca cgccacccct ctgttctctc ttcagctcca cctgccactg 1800 atcctgcaac ttgcttcttt ctattctctg cctctgttta gaaatcttca cacaccactg 1860 aggcttcttg acttgcccct tgtgacttga attcccagct cagatacaaa ttttcacctg 1920 ccagccctgc ctcctccttt ctcccttttc ctagacacag gactctgaca acttcatcct 1980 ccttgtttag atgacttccc agtttccagt ccccatttct ccttctatca cttttcataa 2040 aaaaactcag gaaatatttg acatatcttc catttcaaat tcttcc 2086 <210> 13 <211> 1814 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7472775CB1 <400> 13 cttggacgag ggggagagtg gagaagagaa gagaacaaaa agtaacttca ggatggggac 60 cagtgaagta cttgcggcct gtacccagaa tcaaacccca agtttcacat gcctgaggat 120 gtacgagaaa aaaaggaaaa tcttctactc aattctgaga gatctactag gctcttaaca 180 aagaccagtc attcacaagg aggggatcaa gctttaagta agtccacagg gtcaccaaca 240 gagaagttga ttgaaaaacg tcaaggagct aagactgttt ttaacaagtt cagcaacatg 300 aattggccag tggacattca ccctttaaac aaaagtttag tcaaagataa taaatggaag 360 aaaactgagg agacccaaga gaaacgaagg tctttccttc aggagttttg caagaaatac 420 ggtggggtga gtcatcatca gtcacatctt ttccatacag tatccagaat ctatgtagaa 480 gataaacaca aaatcttata ttgtgaggta cctaaggctg gctgttccaa ttggaaaaga 540 attctgatgg tactaaatgg attggcttcc tctgcataca acatctccca caatgctgtc 600 cactacpgga agcatttgaa gaagctagat agctttgacc taaaagggat atatacccgc 660 ttaaatactt acaccaaagc tgtgtttgtt cgtgatccca tggaaagatt agtatcagcc 720 tttagggaca aatttgaaca ccccaatagt tattaccatc cagtattcgg aaaggcaatt 780 atcaagaaat atcgaccaaa tgcctgtgaa gaagcattaa ttaatggatc tggagtcaag 840 ttcaaagagt ttatccacta cttgctggat tcccaccgtc cagtaggaat ggacattcac 900 tgggaaaagg tcagcaaact ctgctatccg tgtttgatca actatgattt tgtagggaaa 960 tttgagactt tggaagaaga tgccaattac tttttacaga tgatcggtgc tccaaaggag 1020 ctgaaatttc ccaactttaa ggataggcac tcttccgatg aaagaaccaa tgctcaagtc 1080 gtgagacagt atttaaagga tctgactaga actgagagac aattaatcta tgacttttat 1140 tacttggact atttaatgtt taattataca actccatttt tgtagtttgc attcattttc 1200 taaaaccctg tatatactta atgatgataa gttcaaatca gctgtaattt ttctataatt 1260 ctctgtatga cagaaattta accaagtgca gttgtcttga tttaatgtag atttttacca 1320 aatagtatga caccaattgg cacaaagtta taggaaaatc acctacagga gatgtaaaca 1380 acttgagttg ctctaaaatg tttggaaaag agctgctttt gcattatgaa ttatattgtt 1440 gaagcaataa cctagccagc tgttgcatta gctaaagcag cctcttgcaa tggtaggaaa 1500 aaaggatctc aaatagcatg agtgtatgtc tatatcctga aatttattgt ctaaaatgca 1560 tgaatatatt tttagcagtc tgtggcatat taatcaaact gttgaattgt tttcttacac 1620 cctggaaatc tttctatcaa ctataatgat aaatccattt tgaagtgata ttttggactt 1680 aggcatttta ctttagattg gaaggcatta tgtgatttac aatatgagaa tatagcagaa 1740 aaaccagatg aggctgtggc tttttatatt caacagccaa taaaaaatgc acaacatgct 1800 aagatcaaag caaa 1814 <210> 14 <211> 1650 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7473323CB1 <400> 14 atggccattg atgcactggt ctctctgtgt cttcctgagg tcatcagaat aaagttcaac 60 atcaggccaa ggcagcccca ccacgacctc ccaccaggcg gctcccagga tggtgacttg 120 aaggaaccca cagagagggt cactcgggac ttatccagtg gggccccgag gggccgcaac 180 ctgccagcgc ctgaccagcc tcaacccccg ctgcagaggg gaacccgtct gcggctccgc 240 cagcgccgtc gccgtctgct catcaagaaa atgccagctg cggcgaccat cccggccaac 300 agctcggacg cgcccttcat ccggccggga cccgggacgc tggatggccg ctgggtcagc 360 ctgcaccgga gccagcagga gcgcaagcgg gtgatgcagg aggcctgcgc caagtaccgg 420 gcgagcagca gccgccgggc cgtcacgccc cgccacgtgt cccgtatctt cgtggaggac 480 cgccaccgcg tgctctactg cgaggtgccc aaggccggct gctccaattg gaagcgggtg 540 ctcatggtgc tggccggcct ggcctcgtcc actgccgaca tccagcacaa caccgtccac 600 tatggcagcg ctctcaagcg cctggacacc ttcgaccgcc agggtatctt gcaccgtctc 660 agcacctaca ccaagatgct ctttgtccgc gagcccttcg agaggctggt gtccgccttc 720 cgcgacaagt ttgagcaccc caacagctac tatcacccgg tcttcggcaa ggccatcctg 780 gcccggtacc gcgccaatgc ctctcgggag gccctgcgga ccggctctgg ggtgcgtttt 840 cccgagttcg tccagtacct gctggacgtg caccggcccg tggggatgga cattcactgg 900 gaccatgtca gccggctctg cagcccctgc ctcatcgact acgatttcgt aggcaagttc 960 gagagcatgg aggacgatgc caacttcttc ctgagcctca tccgcgcgcc gcggaacctg 1020 accttccccc ggttcaagga ccggcactcg caggaggcgc ggaccacagc gaggatcgcc 1080 caccagtact tcgcccaact ctcggccctg caaaggcagc gcacctacga cttctactac 1140 atggattacc tgatgttcaa ctattccaag ccctttgcag atctgtactg aggggcgccg 1200 cagctggccg gggccgccct gccccggtca ctcacctgtg ctcccgggca tcctcctgtc 1260 cctggctcct catcctggga gcaacagggc tctgaggacg tgaggagcca tcgctgtggg 1320 aggcagcagg ccccgggtgg ggggcagagg cgcccagcct tggatgggga ccccagcccc 1380 tggcctgtac ctgtttcctc attccttggc tgagggagag gctgagaact gggcagacac 1440 ccctggagct cagccgacag ttttgatgag cagggaagtc tgaggcccag aggacggggg 1500 gcccagcggt aagggatgtc ccgcactccc ttagccattg ccttggacca aaccacgtgg 1560 tttgcagctt ttctacgagc caggggggag gttcccttgg attaaggttc caaataaagc 1620 acatggtttc cagaacaaaa aaaaacaaaa 1650 <210> 15 <211> 1647 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7472777CB1 <400> 15 atgtggctgc cgcgcgtctc cagcacagca gtgaccgcgc tcctcctggc gcagaccttc 60 ctcctcctct ttctggtttc ccggccaggg ccctcgtccc cagcaggcgg cgaggcgcgc 120 gtgcatgtgc tggtgctgtc ctcgtggcgc tcgggctcgt ccttcgtggg ccaactcttc 180 aaccagcacc ccgacgtctt ctacctaatg gagcccgcgt ggcacgtgtg gaccaccctg 240 tcgcagggca gcgccgcaac gctgcacatg gctgtgcgcg acctggtgcg ctccgtcttc 300 ctgtgcgaca tggacgtgtt tgatgcctat ctgccttggc gccgcaacct gtccgacctc 360 ttccagtggg ccgtgagccg tgcactgtgc tcgccacccg cctgcagtgc ctttccccga 420 ggcgccatca gcagcgaggc cgtgtgcaag ccactgtgcg cgcggcagtc cttcaccctg 480 gcccgggagg cctgccgctc ctacagccac gtggtgctca aggaggtgcg cttcttcaac 540 ctgcaggtgc tctacccgct gctcagcgac cccgcgctca acctacgcat cgtgcacctg 600 gtgcgcgacc cgcgggccgt gctgcgctcc cgggagcaga cagccaaggc tctggcgcgt 660 gacaacggca tcgtgctggg caccaacggc acgtgggtgg aggccgaccc cggcctgcgc 720 gtggtgcgcg aggtgtgccg tagccacgta cgcatcgccg aggccgccac actcaagccg 780 ccaccctttc tgcgcggccg ctaccgcctg gtgcgcttcg aggacctggc gcgggagccg 840 ctggcagaaa tccgtgcgct ctacgccttc actgggctca gtctcacgcc acagctcgag 900 gcctggatcc ataacatcac ccacggatct ggacctggtg cgcgccgcga agccttcaag 960 acttcgtcca ggaatgcgct caacgtctcc caggcctggc gccatgcgct gccctttgcc 1020 aagatccgcc gcgtgcagga actgtgcgct ggtgcgctgc agctgctggg ctaccggcct 1080-gtgtactctg aggacgagca gcgcaacctc gcccttgatc tggtgctgcc acgaggcctg 1140 aacggcttca cttgggcatc atccaccgcc tcgcaccccc gaaattagtg gaggccacag 1200 ttgtagcagg cgctaggccc gggaggagag tgcatggtgc agagggggct ggggcgcacg 1260 gagaagcagg tccctatatt gaccaaggag tttgtgagaa cctgcgtgct gctcctttgc 1320 ttcggacctc cgcctctgcc cgggagaaag cccaggccag cctgctggac aagcagagac 1380 catgagaagg agagttcagg ggtcccaaac caggccatcc tagaccagcc agctccagct 1440 gatccgcacg cagccacttc ggctaccttc tactggccaa agggagtccc agggctcacc 1500 cagattcaga ggtggggaaa ctgagtccac cacttgagaa gagtagctat aaagacatat 1560 gagcgaggcc agctgagccc agcactgcgg ccaagtcgaa gctttaggag caataaaagt 1620 gcttattgtg tttcagtcaa aaaaaaa 1647 <210> 16 <211> 2620 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 1272843CB1 <400> 16 cgcggagacc tgggagagga gaaggagccg acctgccgag atggaggcga ccggcacctg 60 ggcgctgctg ctggcgctgg cgctgctcct gctgctgacg ctggcgctgt ccgggaccag 120 ggcccgaggc cacctgcccc ccgggcccac gccgctacca ctgctgggaa acctcctgca 180 gctacggccc ggggcgctgt attcagggct catgcggctg agtaagaagt acggaccggt 240 gttcaccatc tacctgggac cctggcggcc tgtggtggtc ctggttgggc aggaggctgt 300 gcgggaggcc ctgggaggtc aggctgagga gttcagcggc cggggaaccg tagcgatgct 360 ggaagggact tttgatggcc atggggtttt cttctccaac ggggagcggt ggaggcagct 420 gaggaagttt accatgcttg ctctgcggga cctgggcatg gggaagcgag aaggcgagga 480 gctgatccag gcggaggccc ggtgtctggt ggagacattc caggggacag aaggacgccc 540 attcgatccc tccctgctgc tggcccaggc cacctccaac gtagtctgct ccctcctctt 600 tggcctccgc ttctcctatg aggataagga gttccaggcc gtggtccggg cagctggtgg 660 taccctgctg ggagtcagct cccagggggg tcagacctac gagatgttct cctggttcct 720 gcggcccctg ccaggccccc acaagcagct cctccaccac gtcagcacct tggctgcctt 780 cacagtccgg caggtgcagc agcaccaggg gaacctggat gcttcgggcc ccgcacgtga 840 ccttgtcgat gccttcctgc tgaagatggc acaggaggaa caaaacccag gcacagaatt 900 caccaacaag aacatgctga tgacagtcat ttatttgctg tttgctggga cgatgacggt 960 cagcaccacg gtcggctata ccctcctgct cctgatgaaa taccctcatg tccaaaagtg 1020 ggtacgtgag gagctgaatc gggagctggg ggctggccag gcaccaagcc taggggaccg 1080 tacccgcctc ccttacaccg acgcggttct gcatgaggcg cagcggctgc tggcgctggt 1140 gcccatggga ataccccgca ccctcatgcg gaccacccgc ttccgagggt acaccctgcc 1200 ccagggcacg gaggtcttcc ccctccttgg ctccatcctg catgacccca acatcttcaa 1260 gcacccagaa gagttcaacc cagaccgttt cctggatgca gatggacggt tcaggaagca 1320 tgaggcgttc ctgcccttct ccttagggaa gcgtgtctgc cttggagagg gcctggcaaa 1380 agcggagctc ttcctcttct tcaccaccat cctacaagcc ttctccctgg agagcccgtg 1440 cccgccggac accctgagcc tcaagcccac cgtcagtggc cttttcaaca ttcccccagc 1500 cttccagctg caagtccgtc ccactgacct tcactccacc acgcagacca gatgaaggaa 1560 ggcaacttgg aagtggtggg tgcccaggac ggtgcctcca gcctcaacag tgggcatgga 1620 cagggttaat gtctccagag tgtacactgc aggcagccac atttacacgc ctgcagttgt 1680 tttccggagt ctgtcccacg gcccacacgc tcacttgact catgctgcta agatgcacaa 1740 ccgcacaccc atacacaact acaagggcca caaagcaact gctgggttag ctttccacag 1800 acataaatat agtccatctg caatcacaag cacatagcca ggtaacccac caactcccct 1860 ggatctgcag cccacacgtg ggagtctggc tgtcaccttc acaagccaca gaaacggcca 1920 cacatgttca cagctcacac gccctctcca ttcatcgaac ttctcagtgt ccctgtccct 1980 ggtgcctggc acagggaaca gcatgccccc tccggggtca tgccacccag agactgtcgc 2040 tgtctatggc cccaactcat gctccctctc ttggctacac cactctccca gcctgtgacc 2100 accgatgtcc acacaccccc aaccacttgt ccacacagct acccacgtac gacatcgtcc 2160 tggctcccca gagtatcttc ccactgagac acgccgcccc cacagaggca cagtccccag 2220 ccacctctgc aactgcagcc ctcagtcacc cctttttaag caccctgatt ctaccaaatg 2280 caaacacatc tgggtctgcg attatgcaca gagactttgg acatacgagg accctcagac 2340 cggaggaaca cctgcccaac cccaacacgt gcttatgtaa ccacgtggaa agcggcccct 2400 gctgcccctc cacacacaca tacacactca ctgatctaca gcccctgttc ggcgtcagag 2460 tccccactag acccagtgga aggggttaga gaccaagtag gggccagttt ccaattcacc 2520 ctgtcaggga gtgagccgga tctgacgttc cttgtgactt aagggtccgg cttgggaatt 2580 aaagtttgtt tctggccttt agcctaaaaa aaaaaaaaaa 2620 <210> 17 <211> 690 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7472790CB1 <400> 17 atgaacatcc gcaacgctca gccagacgac ctgatgaata tgcaacactg caacctcctt 60 tgccttcctg agaactacca gatgaaatac tatttatatc atggcctttc ctggccccag 120 ctttcttaca tcgctgagga tgaggacggg aagattgtgg gctatgttct ggccaaaatg 180 gaggaggaac cagatgatgt cccgcatggc catatcacct cactggccgt gaagcgttca 240 caccggcgcc tcggcctggc ccagaagctg atggaccagg cctccagggc catgatagag 300 aactttaacg ccaaatacgt gtctctgcac gtcaggaaga gtaaccggcc agccttgcac 360 ctttattcta acaccctcaa ctttcagatt agtgaggtgg aacctaaata ctatgcagat 420 ggggaagatg cttatgctat gaagcgggat ctctcgcaga tggcagatga gctgagacga 480 caaatggacc tgaagaaggg cgggtatgtg gtcctgggct ccagggagaa ccaggagacc 540 cagggcagca cactttctga ttctgaagag gcctgtcagc aaaagaaccc ggctaccgaa 600 gaaagtggca gtgacagcaa agaacctaag gagtctgtgg agagcaccaa cgtccaggac 660 agctcagaaa gctcggattc cacctcctag 690 <210> 18 <211> 1510 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7473944CB1 <400> 18 gcggccgcga agcgactccg atcctccctc tgagccttgc tcagctctgc cccgcgcctc 60 ccgggctccg gtccgcgcgg cggggtccct gctcctgcgc cccgggcgcg cttcccggac 120 atcccggtcc ccgcagccag gacaaagcca tgaagccagc gctgctggaa gtgatgagga 180 tgaacagaat ctgccggatg gtgctggcca cttgcttggg atcctttatc ctggtcatct 240 tctatttcca aatcatgcgg aggaatccct ttggtgtgga catctgctgc cggaaggggt 300 cccgaagccc cctgcaggaa ctctacaacc caatccagct ggagctctca aacactgctg 360 tcctgcacca gatgcggcgg gaccaggtga cagacacgtg ccgagccaac agcgccacaa 420 gccgtaagcg gagggtgctg acccccaacg acctgaagca cttggtggtg gatgaggacc 480 acgagctcat ctactgctac gtgcccaagg tggcctgcac caactggaag cggctcatga 540 tggtcctgac cgggcggggg aagtacagcg accccatgga gatcccggcc aacgaggcac 600 acgtctccgc caacctgaag accctgaacc agtacagcat cccagaaatc aaccaccgct 660 tgaaaagcta catgaagttc ctgtttgtcc gggagccctt cgagaggcta gtgtccgcct 720 accgcaacaa gttcacccag aagtacaaca tctccttcca caagcggtac ggcaccaaga 780 tcatcaaacg ccagcggaag aacgccaccc aggaggccct gcgcaaaggg gacgatgtca 840 aattcgagga gtttgtggcc tatctcatcg acccacacac ccagcgggag gagcctttca 900 acgaacactg gcaaaccgtc tactcactct gccatccctg ccacatccac tatgacctcg 960 tgggcaagta cgagacactg gaagaggatt ctaattacgt cctgcagctg gcaggagtgg 1020 gcagctacct gaagttcccc acctatgcaa agtctacgag aactactgat gaaatgacca 1080 cagaattctt ccagaacatc agctcagagc accaaacgca gctgtacgaa gtctacaaac 1140 tcgatttttt aatgttcaat tactcagtgc caagctacct gaaattggaa taaagggggt 1200 ggggagaggg agagaatcat gctttttaat ttaagatttt tatttgtcaa aagaattata 1260, tggatattgg gttattttgt aaattaatat ttctttgggg atgatgctgc gagcagcata 1320 gtgagaatta tttaaaatcc ttcgtaggga aggacagctg tctttgcagg ggaaatagga 1380 tgggtcgtcc ttgtctgtag aagtgaatac tgcaacactg tctcaaaggt ttcttgtgtt 1440 ctggtgaatt ccatgaattg tgcattccat aaattctaat taatattatt tatagttatt 1500 taaaaaaaaa 1510 <210> 19 <211> 3701 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 2244136CB1 <400> 19 gagctcggct cactatgtac gtgcgcagtg tgctggcaag gggagaagta gaaagcaccc 60 tgagatgacc ccggctcctc caccaggagc gcggccgggc gcggcgtccc tagcgggctt 120 cgccggggtg gcgtctctgg ggcctgggga cccccgccgc gccgctgacc cgcgccctct 180 gcccccagcg ctgtgcttcg ccgtgagccg ctcgctgctg ctgacgtgcc tggtgccggc 240 cgcgctgctg ggcctgcgct actactacag ccgcaaggtg atccgcgcct acctggagtg 300 cgcgctgcac acggacatgg cggacatcga gcagtactac atgaagccgc ccggctcctg 360 cttctgggtg gccgtgctgg atggcaacgt ggtgggcatt gtggctgcac gggcccacga 420 ggaggacaac acggtggagc tgctgcggat gtctgtggac tcacgtttcc gaggcaaggg 480 catcgccaag gcgctgggcc ggaaggtgct ggagttcgcc gtggtgcaca actactccgc 540 ggtggtgctg ggcacgacgg ccgtcaaggt ggccgcccac aagctctacg agtcgctggg 600 cttcagacac atgggcgcca gtgaccacta cgtgctgccg ggcatgaccc tctcgctggc 660 tgagcgcctc ttcttccagg tccgctacca ccgctaccgc ctgcagctgc gcgaggagtg 720 accgccgccg ctcgcccgcc cgcccccccg gccgccctgt ccgcctttgc ccgcctgccc 780 gccgcccggc gcggcctgct ttcagacgct cacttggcgt ttgtgttggg tttccccttt 840 tcaacatcct gcggttgtct ggctggttcc ggggggtgcg gggctgttgt tcttcggcga 900 cactttggtg ggggtgggtt gtttgtcgcc atagcccctc gcccttcccc acctgcctgg 960 gcggcttgcc acctgaagag tggcatcttg gaccaccgcg gctgtccatg acgctgccct 1020 gcccgccgcc actggggaag gcccagcctt gctcaccaag cacagaacct ctgcagcaga 1080 tcccggggcc aggctccggc cccgcctgcg gccccagcgc cactgcctgt ggaggcccga 1140 gctggccacg gcgctgcttt gctccgcgca tgccgagggt gtggcccggc tgagcatgcc 1200 gcatgcacac agccccgccc tgccgccctg cccagactgg acccggagac ccgggctggt 1260 gagcgcccct gtccccagcc cccagctggc tgtgggaggg cctgcccctg cccccacctc 1320 ctggagggcc tggtctgccc cgcgccgccc ggctctgtcc acacctgctt tgctctgacg 1380 ccctccattt ctctggctcc ggcccctccc ctgcctgggc tgtgctgact ggtgtcatca 1440 cccaggtgac tcccatggcg tccgtggcac agccagggtg ggggtccatg ggacccctct 1500 ccccagtgcc cactggatcg tgctggcctc tcccagatgt ccccggggac ctcctgcctc 1560 tggctgacgg tccaccctgt gaatcttatc agcccaggct gctgccaaca gcgcccagcc 1620 cacagcttct cccagcctga aaccaacaca ttttctaata agttatttag acagaatagc 1680 actctgcatg actttaattc ttgggacaaa acggtagttt gtaccctaag acacagtttc 1740 tggcccagtg tgatgggggt gggtggccgg gtgggtggag cgttttgctg ttggaaacct 1800 ggagggaaac cctgattgga tgtcatttcc tgccatggag cacgcctccc agccctggcc 1860 tgcagggtgg gcagggtggg gggcaaggga gtccgcagcc tccgggagga ggggcagggc 1920 gctgccttgg gctgggtggg aagaggggtg gccgcctcgg cttccgctgg ccatgctcct 1980 ggtctctcct tcctgaggtc acaggcaggg gctgccctgg acggggggcg gggggggtgg 2040 cctggaaggg gagacagagg tggagggtgg cacaggctgc acattcagct tagaagtgga 2100 cctggctttg gtggcaggag aagaataaac acttgcccag acccctttgt gtgggggaat 2160 tggggagggg tcgtggcagg cagggtgggc cacggaactg ggtcccaggc atcaaggcca 2220 cgtgcagggc catggaggga tgcttctcac gaggcgcttc agaagcgagc gaagggacag 2280 agaagccctg cgtccaaggg ccttttgtcc tgttagcaat tgaggtgtgc agagcactgt 2340 acagacccca ctcccctgta cattcctccc tggaggtgcc cggtccccgc.ttggggatgg 2400 gagttttgta gactgtacag aaatcggcac cctattttct tgcagctcag attttgttaa 2460 tctggaatat acagacagac gtaaagtgtt ttagcaaaat ggaaacaaac agttgtgcct 2520 ttttcctctt ttggtttggt ttgggtttgg cctggggctg gtcccagttg gtgcggggca 2580 tgctgggggc aggaggggca gggcgggcca ggtggagtca ggtcttgggg gtgtcatgtc 2640 ggggtgctgc cagcgtccct tggtcctgtg cctttggagc ctcgggctcc tggggtgcag 2700 ggtgcttggg ggtggctgtt ggagcccacc gacgccaggg cagggcctgg aggcccaggg 2760 actgccagtg tctccttgat attgatccta gcagatcccc ctcctggggg ttctgagagt 2820:
cctgggcagt gtggccttct ctcattctgg tggcatctgc gcccgtgagt gacctcttcc 2880' ttggctgcac tgccctgtgg gtggtgagac gcttggcctt ttttgttgct gccaggactt 2940 ggtagagatg gcaggaaggg tgtgcggggt ggttgtgtgc agaaccctgc cgcccctgag 3000 gtgagcagag gcactggtgt gcctgccagg ctggggcgga gctgcccgga acccttgcca 3060 ggccaatgtg tagcttggtg gcgcccttga aggccactgg ggggtaggtg tgtcctcccc 3120.
cggggctgga ggccgggtgc ctggtgggtg ggcctgacct ggcccacctc atccctccag 3180 cctgggatct cactgctctg cacctgtgca ctgacgtgaa ttttatacgt ttgtagaaac 3240 tctgatgtaa cttcttctac ctctgaagcg ccctcctggg ccctgctgtc acgtggctgg 3300' tgcggcttcc ccgagtgctg gccccctgcc cgctccccat gggcacccac cactcaaact 3360 ctgcgtggtg aggcccgggg aaagccaggc cgggccctag cactgctcag gggcctgggg 3420 ctcctgggat ttctgtgtgt ttggaagcct ctgtttttgg agtggggggc gtggaaggcg 3480 ggaggggctg acagtgcctg gggccagagc tgggcgaagg aggacatcct cactggacga 3540 gcactgcagg cctgacgaga ggctcccggc agctgagggc ttaagcgcct cgtgatgtcc 3600 ccaatggccc aagcccccgt tctgctttgc tggggtgggt ttgcccccgc gattgcactg 3660 tcccctggtg ttcttcgacc agctcctccg gggagggcct c 3701 <210> 20 <211> 960 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474327CB1 <400> 20 gcagccatgg ccagccacat tgtgctcaac aatggcacca agatgcccat cctggggcta 60 ggcacctgga attcccctcc aggccaggta actgaggctg tgaaggtggc cattaatgtt 120 gggtactgcc acatcgactg tgcccacgtg taccagaatg agaatgacgt gggggtggcc 180 attcgggaga agctcaggga gcaggtggtg aagtgtgagg agctcttcat caccagcaag 240 ctgtggtgcg cgtaccatga gaagggcctg gtgaaaggag cctgccagaa gatgctcatt 300 gacctgaagc tggactacct ggacctctac cttattcgct ggccaaccag cttcaagcct 360 gggaaggaat ttttcccatt ggatgagcca ggtaatggta atgtggttcc cagtaacagt 420 aacattctgg acacatgggc gggcatggaa gagctggtgg atgaagggct ggtgaaagct 480 attggcatct ccaacttcaa ccatctccag gttgagagga tcttaaacaa acctgactta 540 aagtataagc cggtggttaa tcagattgag tgccacccgt acctcactca ggagaagtta 600 atccagtact gccagtccaa aggcatcatg gtgactgcct acagctcctt cagctccccc 660 gacaggccct gggccaagcc tgaggaccct tccctcctgg aagatcccag gatcaaggcg 720 atcacagcca aacacaataa aactacagcc caggttctga tctggttccc catgcagagg 780 aacttggtgg tgatccccaa gtctgtgaca ccagaatgca ttgctgagaa ctttaaggtc 840 ttcaactttg aactgaacag ccaggatatg accaccttat tcagttacaa cagaaactgg 900 agggtctgtg ccttggtgag ctgtgcctcc cacaaggatt accccttcca tgaagagttt 960
(See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci.
USA 83:7353-7357.) Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding DME
on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.
In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps.
Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to l 1q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.
In another embodiment of the invention, DME, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between DME and the agent being tested may be measured.
Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT
application W084/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with DME, or fragments thereof, and washed. Bound DME is then detected by methods well known in the art.
Purified DME can also be coated directly onto plates for use in the aforementioned drug screening techniques.
Alternatively,.non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.
In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding DME specifically compete with a test compound for binding DME. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with DME.
In additional embodiments, the nucleotide sequences which encode DME may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
The disclosures of all patents, applications and publications, mentioned above and below, including U.S. Ser. No. 60/197,590, U.S. Ser. No. 601198,403, U.S. Ser. No.
60/200,185, U.S. Ser.
No. 60/202,234, and U.S. Ser. No. 60/203,509, are expressly incorporated by reference herein.
EXAMPLES
I. ~ Construction of cDNA Libraries Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD
database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCI cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.
Phenol extraction and~precipitation of RNA were repeated as necessary to increase RNA
purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX
latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN).
Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).
In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA
libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP
vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA
was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA
was size-selected (300-1000 bp) using SEPHACRYL S 1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto CA), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BIueMRF, or SOLR from Stratagene or DHSa, DH10B, or ElectroMAX
DH10B from Life Technologies.
II. Isolation of cDNA Clones Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis.
Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega);
an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.
Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II
fluorescence scanner (Labsystems Oy, Helsinki, Finland).
III. Sequencing and Analysis Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows.
Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI
sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI
protocols and base calling software; or other sequence analysis systems known iri the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, s-unra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.
The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) Curr.
Opin. Struct. Biol.
6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences.
Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS
PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).
Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN
multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.
Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).
The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ
B7 NO:11-20. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.
IV. Identification and Editing of Coding Sequences from Genomic DNA
Putative drug metabolizing enzymes were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA
sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin ( 1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon..
The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode drug metabolizing enzymes, the encoded polypeptides were analyzed by querying against PFAM models for drug metabolizing enzymes.
Potential drug metabolizing enzymes were also identified by homology to Incyte cDNA sequences that had been annotated as drug metabolizing enzymes. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST
hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST
analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA
coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.
V. Assembly of Genomic Sequence Data with cDNA Sequence Data "Stitched" Sequences Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example 1V. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent.
This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases.
Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.
"Stretched" Sequences Partial DNA sequences were extended to full length with an algorithm based on BLAST
analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST
analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog.
Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.
VI. Chromosomal Mapping of DME Encoding Polynucleotides The sequences which were used to assemble SEQ ID NO:11-20 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:11-20 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Genethon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.
Map locations are represented by ranges, or intervals, of human chromosomes.
The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM
distances are based on genetic markers mapped by Genethon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap~, can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.
VII. Analysis of Polynucleotide Expression Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.) Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:
BLAST Score x Percent Identity 5 x minimum { length(Seq. 1 ), length(Seq. 2) }
The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP
(separated by gaps). If there is more than one HSP, then the pair with the highest BLAST
score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A
product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88%
identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.
Alternatively, polynucleotide sequences encoding DME are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA
sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female;
genitalia, male; germ cells; heroic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed;
or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding DME. cDNA sequences and cDNA
library/tissue information are found in the LIFESEQ GOLD database (Incyte Genorriics, Palo Alto CA).
VIII. Extension of DME Encoding Polynucleotides Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.
Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.
High fidelity amplification was obtained by PCR using methods well known in the art. PCR
was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg2+, (NH4)ZS04, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE
enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2:
94°C, 15 sec; Step 3: 60°C, 1 min;
Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+
were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4:
68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.
The concentration of DNA in each well was determined by dispensing 100 p1 PICOGREEN
quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE
and 0.5 p1 of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II
(Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 ,u1 to 10 ~l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.
The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to relegation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE
(Promega). Extended clones were relegated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerise (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37 °C in 384-well plates in LB/2x carb liquid media.
The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerise (Amersham Pharmacia Biotech) and Pfu DNA polymerise (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3:
60°C, 1 min; Step 4: 72°C, 2 min;
Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA
recoveries were reamplified using the same conditions as described above.
Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI
PRISM
BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).
In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.
IX. Labeling and Use of Individual Hybridization Probes Hybridization probes derived from SEQ ID NO:11-20 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 ,uCi of [y-32P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25' superfine size exclusion dextran bead column (Amersham Pharmacia Biotech).
An aliquot containing 10' counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases:
Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).
The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5%
sodium dodecyl sulfate.
Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.
X. Microarrays The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink jet printing, See, e.g., Baldeschweiler, supra.), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), su ra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers.
Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645;
Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.) Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization.
The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.
Tissue or Cell Sample Preparation Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)+ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)+
RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/pl oligo-(dT) primer (2lmer), 1X
first strand buffer, 0.03 units/pl RNase inhibitor, 500 E.~M dATP, 500 pM
dGTP, 500 NM dTTP, 40 E.~M dCTP, 40 l.~M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech).
The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)+ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)+ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37 ° C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of O.SM sodium hydroxide and incubated for 20 minutes at 85°C to the stop the reaction and degrade the RNA.
Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC
(Savant Instruments Inc., Holbrook NY) and resuspended in 14 p1 SX SSC/0.2% SDS.
Microarrav Preparation Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts.
PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert.
Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 pg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).
Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1 % SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4%
hydrofluoric acid (VWR
Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.
Array elements are applied to the coated glass substrate using a procedure described in US
Patent No. 5,807,522, incorporated herein by reference. 1 p1 of the array element DNA, at an average concentration of 100 ng/pl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 n1 of array element sample per slide.
Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene).
Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water.
Non-specific binding sites are blocked by incubation of microarrays in 0.2%
casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C
followed by washes in 0.2% SDS and distilled water as before.
Hybridization Hybridization reactions contain 9 p1 of sample mixture consisting of 0.2 pg each of Cy3 and Cy5 labeled cDNA synthesis products in SX SSC, 0.2% SDS hybridization buffer.
The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an I .8 cmz coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 p1 of SX SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X
SSC), and dried.
Detection Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of CyS. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.
In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially.
Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT 81477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores.
Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for CyS.
Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.
The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A
specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are _ differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.
The output of the photomultiplier tube is digitized using a 12-bit RTI-835H
analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC
computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.
A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).
XI. Complementary Polynucleotides Sequences complementary to the DME-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring DME. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of DME. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the DME-encoding transcript.
XII. Expression of DME
Expression and purification of DME is achieved using bacterial or virus-based expression systems. For expression of DME in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA
transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the TS or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3).
Antibiotic resistant bacteria express DME upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of DME in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Auto~raphica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding DME by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect ~odoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases.
Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K.
et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al.
(1996) Hum. Gene Ther.
7:1937-1945.) In most expression systems, DME is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma Laponicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from DME at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG
antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified DME obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, and XVIII, where applicable.
XIII. Functional Assays DME function is assessed by expressing the sequences encoding DME at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA
expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 ~g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 ~cg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP;
Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP
or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM
detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA
with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface.
Methods in flow cytometry are discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.
The influence of DME on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding DME and either CD64 or CD64-GFP.
CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art.
Expression of mRNA encoding DME and other genes of interest can be analyzed by northern analysis or microarray techniques.
XIV. Production of DME Specific Antibodies DME substantially purified using polyacrylamide gel electrophoresis (PAGE;
see, e.g., Harnngton, M.G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.
Alternatively, the DME amino acid sequence is analyzed using LASERGENE
software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.) Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A
peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KL,H complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-DME activity by, for example, binding the peptide or DME
to a substrate, blocking with 1°lo BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.
XV. Purification of Naturally Occurring DME Using Specific Antibodies Naturally occurring or recombinant DME is substantially purified by immunoaffinity chromatography using antibodies specific for DME. An immunoaffinity column is constructed by covalently coupling anti-DME antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.
Media containing DME are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of DME (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/DME binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and DME is collected.
XVI. Identification of Molecules Which Interact with DME
DME, or biologically active fragments thereof, are labeled with'ZSI Bolton-Hunter reagent.
(See, e.g., Bolton A.E. and W.M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled DME, washed, and any wells with labeled DME complex are assayed. Data obtained using different concentrations of DME are used to calculate values for the number, affinity, and association of DME with the candidate molecules.
Alternatively, molecules interacting with DME are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).
DME may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al.
(2000) U.S. Patent No. 6,057,101).
XVII. Demonstration of DME Activity Cytochrome P450 activity of DME is measured using the 4-hydroxylation of aniline. Aniline is converted to 4-aminophenol by the enzyme, and has an absorption maximum at 630 nm (Gibson and Skett, supra). This assay is a convenient measure, but underestimates the total hydroxylation, which also occurs at the 2- and 3- positions. Assays are performed at 37°C and contain an aliquot of the enzyme and a suitable amount of aniline (approximately 2 mM) in reaction buffer. For this reaction, the buffer must contain NADPH or an NADPH-generating cofactor system. One formulation for this reaction buffer includes 85 mM Tris pH 7.4, 15 mM MgClz, 50 mM
nicotinamide, 40 mg trisodium isocitrate, and 2 units isocitrate dehydrogenase, with 8 mg NADP+
added to a 10 mL reaction buffer stock just prior to assay. Reactions are carried out in an optical cuvette, and the absorbance at 630 nm is measured. The rate of increase in absorbance is proportional to the enzyme activity in the assay. A standard curve can be constructed using known concentrations of 4-aminophenol.
1a,25-dihydroxyvitamin D 24-hydroxylase activity of DME is determined by monitoring the conversion of 3H-labeled 1a,25-dihydroxyvitamin D (1a,25(OH)ZD) to 24,25-dihydroxyvitamin D
(24,25(OH)zD) in transgenic rats expressing DME. 1 pg of 1a,25(OH)ZD dissolved in ethanol (or ethanol alone as a control) is administered intravenously to approximately 6-week-old male transgenic rats expressing DME or otherwise identical control rats expressing either a defective variant of DME or not expressing DME. The rats are killed by decapitation after 8 hrs, and the kidneys are rapidly removed, rinsed, and homogenized in 9 volumes of ice-cold buffer (15 mM Tris-acetate (pH 7.4), 0.19 M sucrose, 2 mM magnesium acetate, and 5 mM sodium succinate). A portion (e.g., 3 ml) of each homogenate is then incubated with 0.25 nM 1a,25(OH)2[1 3H]D, with a specific activity of approximately 3.5 GBq/mmol, for 15 min at 37 °C under oxygen with constant shaking.
Total lipids are extracted as described (Bligh, E.G. and W.J. Dyer (1959) Can.
J. Biochem. Physiol.
37: 911-917) and the chloroform phase is analyzed by HPLC using a FINEPAK SIL
column (JASCO, Tokyo, Japan) with a n-hexane/chloroform/methanol (10:2.5:1.5) solvent system at a flow rate of 1 ml/min. In the alternative, the chloroform phase is analyzed by reverse phase HPLC using a J SPHERE ODS-AM column (YMC Co. Ltd., Kyoto, Japan) with an acetonitrile buffer system (40 to 100%, in water, in 30 min) at a flow rate of 1 ml/min. The eluates are collected in fractions of 30 seconds (or less) and the amount of 3H present in each fraction is measured using a scintillation counter. By comparing the chromatograms of control samples (i.e., samples comprising 1a,25-dihydroxyvitamin D or 24,25-dihydroxyvitamin D (24,25(OH)zD), with the chromatograms of the reaction products, the relative mobilities of.the substrate (1a,25(OH)z[1-;H]D) and product (24,25(0H)2[1 3H]D) are determined and correlated with the fractions collected. The amount of 24,25(0H)2[1 3H]D produced in control rats is subtracted from that of transgenic rats expressing DME. The difference in the production of 24,25(0H)2[1 3H]D in the transgenic and control animals is proportional to the amount of 25-hydrolase activity of DME present in the sample. Confirmation of the identity of the substrate and products) is confirmed by means of mass spectroscopy (Miyamoto, Y. et al. (1997) J. Biol. Chem. 272:14115-14119).
Flavin-containing monooxygenase activity of DME is measured by chromatographic analysis of metabolic products. For example, Ring, B.J. et al. (1999; Drug Metab. Dis.
27:1099-1103) incubated FMO in 0.1 M sodium phosphate buffer (pH 7.4 or 8.3) and 1 mM NADPH
at 37°C, stopped the reaction with an organic solvent, and determined product formation by HPLC.
Alternatively, activity is measured by monitoring oxygen uptake using a Clark-type electrode. For example, Ziegler, D.M. and Poulsen, L.L. (1978; Methods Enzymol. 52:142-151) incubated the enzyme at 37°C in an NADPH-generating cofactor system (similar to the one described above) containing the substrate methimazole. The rate of oxygen uptake is proportional to enzyme activity.
UDP glucuronyltransferase activity of DME is measured using a colorimetric determination of free amine groups (Gibson and Skett, suera). An amine-containing substrate, such as 2-aminophenol, is incubated at 37°C with an aliquot of the enzyme in a reaction buffer containing the necessary cofactors (40 mM Tris pH 8.0, 7.5 mM MgCIZ, 0.025% Triton X-100, 1 mM ascorbic acid, 0.75 mM UDP-glucuronic acid). After sufficient time, the reaction is stopped by addition of ice-cold 20% trichloroacetic acid in 0.1 M phosphate buffer pH 2.7, incubated on ice, and centrifuged to clarify the supernatant. Any unreacted 2-aminophenol is destroyed in this step. Sufficient freshly-prepared sodium nitrite is then added; this step allows formation of the diazonium salt of the glucuronidated product. Excess nitrite is removed by addition of sufficient ammonium sulfamate, and the diazonium salt is reacted with an aromatic amine (for example, N-naphthylethylene diamine) to produce a colored azo compound which can be assayed spectrophotometrically (at 540 nm for the example). A standard curve can be constructed using known concentrations of aniline, which will form a chromophore with similar properties to 2-aminophenol glucuronide.
Glutathione S-transferase activity of DME is measured using a model substrate, such as 2,4-dinitro-1-chlorobenzene, which reacts with glutathione to form a product, 2,4-dinitrophenyl-glutathione, that has an absorbance maximum at 340 nm. It is important to note that GSTs have differing substrate specificities, and the model substrate should be selected based on the substrate preferences of the GST of interest. Assays are performed at ambient temperature and contain an aliquot of the enzyme in a suitable reaction buffer (for example, 1 mM
glutathione, 1 mM
dinitrochlorobenzene, 90 mM potassium phosphate buffer pH 6.5). Reactions are carried out in an optical cuvette, and the absorbance at 340 nm is measured. The rate of increase in absorbance is proportional to the enzyme activity in the assay.
N-acyltransferase activity of DME is measured using radiolabeled amino acid substrates and measuring radiolabel incorporation into conjugated products. Enzyme is incubated in a reaction buffer containing an unlabeled acyl-CoA compound and radiolabeled amino acid, and the radiolabeled acyl-conjugates are separated from the unreacted amino acid by extraction into n-butanol or other appropriate organic solvent. For example, Johnson, M.R. et al. (1990; J. Biol. Chem.
266:10227-10233) measured bile acid-CoA:amino acid N-acyltransferase activity by incubating the enzyme with cholyl-CoA and 3H-glycine or 3H-taurine, separating the tritiated cholate conjugate by extraction into n-butanol, and measuring the radioactivity in the extracted product by scintillation.
Alternatively, N-acyltransferase activity is measured using the spectrophotometric determination of reduced CoA (CoASH) described below.
N-acetyltransferase activity of DME is measured using the transfer of radiolabel from ['4C]acetyl-CoA to a substrate molecule (for example, see Deguchi, T. (1975) J. Neurochem.
24:1083-5). Alternatively, a spectrophotometric assay based on DTNB (5,5'-dithio-bis(2-nitrobenzoic acid; Ellman's reagent) reaction with CoASH may be used. Free thiol-containing CoASH is formed during N-acetyltransferase catalyzed transfer of an acetyl group to a substrate. CoASH is detected using the absorbance of DTNB conjugate at 412 nm (De Angelis, J. et al. (1997) J. Biol. Chem.
273:3045-3050). Enzyme activity is proportional to the rate of radioactivity incorporation into substrate, or the rate of absorbance increase in the spectrophotometric assay.
Protein arginine methyltransferase activity of DME is measured at 37 °C
for various periods of time. S-adenosyl-L-[methyl 3H]methionine ([3H]AdoMet; specific activity =
75 Ci/mmol; NEN
Life Science Products) is used as the methyl-donor substrate. Useful methyl-accepting substrates include glutathione S-transferase fibrillarin glycine-arginine domain fusion protein (GST-GAR), heterogeneous nuclear ribonucleoprotein (hnRNP), or hypomethylated proteins present in lysates from adenosine dialdehyde-treated cells. Methylation reactions are stopped by adding SDS-PAGE
sample buffer. The products of the reactions are resolved by SDS-PAGE and visualized by fluorography. The presence of 3H-labeled methyl-donor substrates is indicative of protein arginine methyltransferase activity of DME (Tang, J. et al. (2000) J. Biol. Chem.
275:7723-7730 and Tang, J.
et al. (2000) J. Biol. Chem.275:19866-19876).
Catechol-O-methyltransferase activity of DME is measured in a reaction mixture consisting of 50 mM Tris-HCl (pH 7.4), 1.2 mM MgCIZ, 200 pM SAM (S-adenosyl-L-methionine) iodide (containing 0.5 pCi of methyl-[H3]SAM), 1 mM dithiothreitol, and varying concentrations of catechol substrate (e.g., L-dopa, dopamine, or DBA) in a final volume of 1.0 ml. The reaction is initiated by the addition of 250-500 pg of purified DME or crude DME-containing sample and performed at 37 °C for 30 min. The reaction is arrested by rapidly cooling on ice and immediately extracting with 7 ml of ice-cold n-heptane. Following centrifugation at 1000 x g for 10 min, 3-ml aliquots of the organic extracts are analyzed for radioactivity content by liquid scintillation counting.
The level of catechol-associated radioactivity in the organic phase is proportional to the catechol-O-methyltransferase activity of DME (Zhu, B.T. and J.G. Liehr (1996) 271:1357-1363).
DHFR activity of DME is determined spectrophotometrically at 15 °C by following the disappearance of NADPH at 340 nm (e3ao = 11,800 M-'~crri'). The standard assay mixture contains 100 pM NADPH, 14 mM 2-mercaptoethanol, MTEN buffer (50 mM 2-morpholinoethanesulfonic acid, 25 mM tris(hydroxymethyl)aminomethane, 25 mM ethanolamine, and 100 mM
NaCI, pH 7.0), and DME in a final volume of 2.0 ml. The reaction is started by the addition of 50 pM dihydrofolate (as substrate). The oxidation of NADPH to NADP+ corresponds to the reduction of dihydrofolate in the reaction and is proportional to the amount of DHFR activity in the sample (Nakamura, T. and Iwakura, M. (1999) J. Biol. Chem. 274:19041-19047).
Aldo/keto reductase activity of DME is measured using the decrease in absorbance at 340 nm as NADPH is consumed. A standard reaction mixture is 135 mM sodium phosphate buffer (pH
6.2-7.2 depending on enzyme), 0.2 mM NADPH, 0.3 M lithium sulfate, 0.5-2.5 mg enzyme and an appropriate level of substrate. The reaction is incubated at 30°C and the reaction is monitored continuously with a spectrophotometer. Enzyme activity is calculated as mol NADPH consumed /
mg of enzyme.
Alcohol dehydrogenase activity of DME is measured using the increase in absorbance at 340 nm as NAD+ is reduced to NADH. A standard reaction mixture is 50 mM sodium phosphate, pH 7.5, and 0.25 mM EDTA. The reaction is incubated at 25°C and monitored using a spectrophotometer.
Enzyme activity is calculated as mol NADH produced / mg of enzyme.
Carboxylesterase activity of DME activity is determined using 4-methylumbelliferyl acetate as a substrate. The enzymatic reaction is initiated by adding approximately 10 p1 of DME-containing sample to 1 ml of reaction buffer (90 mM KHZP04, 40 mM KCI, pH 7.3) with 0.5 mM
4-methylumbelliferyl acetate at 37°C. The production of 4-methylumbelliferone is monitored with a spectrophotometer (s3so = 12.2 mM-' cm') for 1.5 min. Specific activity is expressed as micromoles of product formed per minute per milligram of protein and corresponds to the activity of DME in the sample (Evgenia, V. et al. (1997) J. Biol. Chem. 272:14769-14775).
In the alternative, the cocaine benzoyl ester hydrolase activity of DME is measured by incubating approximately 0.1 ml of enzyme and 3.3 mM cocaine in reaction buffer (50 mM
NaH2P04, pH 7.4) with 1 mM benzamidine, 1 mM EDTA, and 1 mM dithiothreitol at 37°C. The reaction is incubated for 1 h in a total volume of 0.4 ml then terminated with an equal volume of 5%
trichloroacetic acid. 0.1 ml of the internal standard 3,4-dimethylbenzoic acid (10 pg/ml) is added.
Precipitated protein is separated by centrifugation at 12,000 x g for 10 min.
The supernatant is transferred to a clean tube and extracted twice with 0.4 ml of methylene chloride. The two extracts are combined and dried under a stream of nitrogen. The residue is resuspended in 14% acetonitrile, 250 mM KHzP04, pH 4.0, with 8 p1 of diethylamine per 100 ml and injected onto a C18 reverse-phase HPLC column for separation. The column eluate is monitored at 235 nm.
DME activity is quantified by comparing peak area ratios of the analyte to the internal standard. A standard curve is generated with benzoic acid standards prepared in a trichloroacetic acid-treated protein matrix (Evgenia, V. et al. (1997) J. Biol. Chem. 272:14769-14775).
In another alternative, DME carboxyl esterase activity against the water-soluble substrate para-nitrophenyl butyric acid is determined by spectrophotometric methods well known to those skilled in the art. In this procedure, the DME-containing samples are diluted with 0.5 M Tris-HCl (pH 7.4 or 8.0) or sodium acetate (pH 5.0) in the presence of 6 mM
taurocholate. The assay is initiated by adding a freshly prepared para-nitrophenyl butyric acid solution (100 pg/ml in sodium acetate, pH 5.0). Carboxyl esterase activity is then monitored and compared with control autohydrolysis of the substrate using a spectrophotometer set at 405 nm (Wan, L. et al. (2000) J.
Biol. Chem. 275:10041-10046).
Sulfotransferase activity of DME is measured using the incorporation of 35S
from [35S]PAPS
into a model substrate such as phenol (Folds, A. and J.L. Meek (1973) Biochim.
Biophys. Acta 327:365-374). An aliquot of enzyme is incubated at 37°C with 1 mL of 10 mM phosphate buffer, pH
6.4, 50 mM phenol, and 0.4-4.0 mM [35S]PAPS. After sufficient time for 5-20%
of the radiolabel to be transferred to the substrate, 0.2 mL of 0.1 M barium acetate is added to precipitate protein and phosphate buffer. Then 0.2 mL of 0.1 M Ba(OH)Z-is added, followed by 0.2 mL
ZnS04. The supernatant is cleared by centrifugation, which removes proteins as well as unreacted [35S]PAPS.
Radioactivity in the supernatant is measured by scintillation. The enzyme activity is determined from the number of moles of radioactivity in the reaction product.
Heparan sulfate 6-sulfotransferase activity of DME is measured in vitro by incubating a sample containing DME along with 2.5 pmol imidazole HCl (pH 6.8), 3.75 ~tg of protamine chloride, nmol (as hexosamine) of completely desulfated and N-resulfated heparin, and 50 pmol (about 5 x 105 cpm) of ['SS] adenosine 3'-phosphate 5'-phosphosulfate (PAPS) in a final reaction volume of 50 p1 at 37°C for 20 min. The reaction is stopped by immersing the reaction tubes in a boiling water bath for 1 min. 0.1 pmol (as glucuronic acid) of chondroitin sulfate A is added to the reaction 20 mixture as a carrier. 35S-Labeled polysaccharides are precipitated with 3 volumes of cold ethanol containing 1.3% potassium acetate and separated completely from unincorporated [35S]PAPS and its degradation products by gel chromatography using desalting columns. One unit of enzyme activity is defined as the amount required to transfer 1 pmol of sulfate/min., determined by the amount of [35S]PADS incorporated into the precipitated polysaccharides (Habuchi, H. et al. (1995) J. Biol.
25 Chem.270:4172-4179).
In the alternative, heparan sulfate 6-sulfotransferase activity of DME is measured by extraction and renaturation of enzyme from gels following separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Following separation, the gel is washed with buffer (0.05 M Tris-HCI, pH 8.0), cut into 3-S mm segments and subjected to agitation at 4 °C with 100 ~1 of the same buffer containing 0.15 M NaCI for 48 h. The eluted enzyme is collected by centrifugation and assayed for the sulfotransferase activity as described above (Habuchi, H. et al.
(1995) J. Biol. Chem. 270:4172-4179).
In another alternative, DME sulfotransferase activity is determined by measuring the transfer of [35S]sulfate from [35S]PAPS to an immobilized peptide that represents the N-terminal 15 residues of the mature P-selectin glycoprotein ligand-1 polypeptide to which a C-terminal cysteine residue is added. The peptide spans three potential tyrosine sulfation sites. The peptide is linked via the cysteine residue to iodoacetamide-activated resin at a density of 1.5-3.0 pmol peptide/ml of resin.
The enzyme assay is performed by combining 10 p1 of peptide-derivitized beads with 2-20 p1 of DME-containing sample in 40 mM Pipes (pH 6.8), 0.3 M NaCI, 20 mM MnCl2, 50 mM
NaF, 1 %
Triton X-100, and I mM 5'-AMP in a final volume of 130 p1. The assay is initiated by addition of 0.5 pCi of [35S]PAPS (1.7 pM; 1 Ci = 37 GBq). After 30 min at 37°C, the reaction beads are washed with 6 M guanidine at 65°C and the.radioactivity incorporated into the beads is determined by liquid scintillation counting. Transfer of [35S]sulfate to the bead-associated peptide is measured to determine the DME activity in the sample. One unit of activity is defined as 1 pmol of product formed per min (Ouyang, Y.-B. et al. (1998) Biochemistry 95:2896-2901).
In another alternative, DME sulfotransferase assays are performed using [35S]PAPS as the sulfate donor in a final volume of 30 p1, containing 50 mM Hepes-NaOH (pH
7.0), 250 mM sucrose, 1 mM dithiothreitol, 14 pM[35S]PAPS (15 Ci/mmol), and dopamine (25 pM), p-nitrophenol (5 pM), or other candidate substrates. Assay reactions are started by the addition of a purified DME enzyme preparation or a sample containing DME activity, allowed to proceed for 15 min at 37°C, and terminated by heating at 100°C for 3 min. The precipitates formed are cleared by centrifugation.
The supernatants are then subjected to the analysis of 'SS-sulfated product by either thin-layer chromatography or a two-dimensional thin layer separation procedure.
Appropriate standards are run in parallel with the supernatants to allow the identification of the 35S-sulfated products and determine the enzyme specificity of the DME-containing samples based on relative rates of migration of reaction products (Sakakibara, Y. et al. (1998) J. Biol. Chem.
273:6242-6247).
Squalene epoxidase activity of DME is assayed in a mixture comprising purified DME (or a crude mixture comprising DME), 20 mM Tris-HCI (pH 7.5), 0.01 mM FAD, 0.2 unit of NADPH-cytochrome C (P-450) reductase, 0.01 mM ['4C]squalene (dispersed with the aid of 20 p1 of Tween 80), and 0.2% Triton X-100. 1 mM NADPH is added to initiate the reaction followed by incubation at 37 °C for 30 min. The nonsaponifiable lipids are analyzed by silica gel TLC developed with ethyl acetate/benzene (0.5:99.5, v/v). The reaction products are compared to those from a reaction mixture without DME. The presence of 2,3(S~-oxidosqualene is confirmed using appropriate lipid standards (Sakakibara, J. et al. (1995) 270:17-20).
Epoxide hydrolase activity of DME is determined by following substrate depletion using gas chromatographic (GC) analysis of ethereal extracts or by following substrate depletion and diol production by GC analysis of reaction mixtures quenched in acetone. A sample containing DME or an epoxide hydrolase control sample is incubated in 10 mM Tris-HCl (pH 8.0), 1 mM
ethylenediaminetetraacetate (EDTA), and 5 mM epoxide substrate (e.g., ethylene oxide, styrene oxide, propylene oxide, isoprene monoxide, epichlorohydrin, epibromohydrin, epifluorohydrin, glycidol, 1,2-epoxybutane, 1,2-epoxyhexane, or 1,2-epoxyoctane). A portion of the sample is withdrawn from the reaction mixture at various time points, and added to 1 ml of ice-cold acetone containing an internal standard for GC analysis (e.g., 1-nonanol). Protein and salts are removed by centrifugation (15 min, 4000 x g) and the extract is analyzed by GC using a 0.2 mm x 25-m CP-Wax57-CB column (CHROMPACK, Middelburg, The Netherlands) and a flame-ionization detector. The identification of GC products is performed using appropriate standards and controls well known to those skilled in the art. 1 Unit of DME activity is defined as the amount of enzyme that catalyzes the production of 1 pmol of diol/min (Rink, R. et al. (1997) J.
Biol. Chem.
272:14650-14657).
Aminotransferase activity of DME is assayed by incubating samples containing DME for 1 hour at 37°C in the presence of 1 mM L-kynurenine and 1 mM 2-oxoglutarate in a final volume of 200 p1 of 150 mM Tris acetate buffer (pH 8.0) containing 70 pM PLP. The formation of kynurenic acid is quantified by HPLC with spectrophotometric detection at 330 nm using the appropriate standards and controls well known to those skilled in the art. In the alternative, L-3-hydroxykynurenine is used as substrate and the production of xanthurenic acid is determined by HPLC analysis of the products with UV detection at 340 nm. The production of kynurenic acid and xanthurenic acid, respectively, is indicative of aminotransferase activity (Buchli, R. et al. (1995) J.
Biol. Chem. 270:29330-29335).
In another alternative, aminotransferase activity of DME is measured by determining the activity of purified DME or crude samples containing DME toward various amino and oxo acid substrates under single turnover conditions by monitoring the changes in the UV/VIS absorption spectrum of the enzyme-bound cofactor, pyridoxal 5'-phosphate (PLP). The reactions are performed at 25°C in SO mM 4-methylmorpholine (pH 7.5) containing 9 pM purified DME or DME containing samples and substrate to be tested (amino and oxo acid substrates). The half reaction from amino acid to oxo acid is followed by measuring the decrease in absorbance at 360 nm and the increase in absorbance at 330 nm due to the conversion of enzyme-bound PLP to pyridoxamine 5' phosphate (PMP). The specificity and relative activity of DME is determined by the activity of the enzyme preparation against specific substrates (Vacca, R.A. et al. (1997) J. Biol.
Chem. 272:21932-21937).
Superoxide dismutase activity of DME is assayed from cell pellets, culture supernatants, or purified protein preparations. Samples or lysates are resolved by electrophoresis on 15%
non-denaturing polyacrylamide gels. The gels are incubated for 30 min in 2.5 mM nitro blue tetrazolium, followed by incubation for 20 min in 30 mM potassium phosphate, 30 mM TEMED, and 30 pM riboflavin (pH 7.8). Superoxide dismutase activity is visualized as white bands against a blue background, following illumination of the gels on a lightbox.
Quantitation of superoxide dismutase activity is performed by densitometric scanning of the activity gels using the appropriate superoxide dismutase positive and negative controls (e.g., various amounts of commercially available E. coli superoxide dismutase (Harth, G. and Horwitz, M.A. (1999) J.
Biol. Chem.
274:4281-4292).
XVIII. Identification of DME Inhibitors Compounds to be tested are arrayed in the wells of a multi-well plate in varying concentrations along with an appropriate buffer and substrate, as described in the assays in Example XVII. DME activity is measured for each well and the ability of each compound to inhibit DME
activity can be determined, as well as the dose-response profiles. This assay could also be used to identify molecules which enhance DME activity.
Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.
A
H I
Q r-Ir-Ir1rir1~-IH ~-Ic-i.-i ~ 0~1P~lW P4POW GOPOW W
N U UU U UU U UU U
~
1J Lf1l~1nM l~M O Crl0[~
O Lf1d~(~N I~~ 01~M N
U
~ l0I~(~M l~ODl~01v-iM
d~l~N M NN N Md~d!
U
H M r1t~I~I~I~I~I~d~I~
y f1d~d~d~N d~~N d~
N Nl~L~L~r1I~I~N t r1 O
LL
N
.,1 ..
~O
O
,'~-, N
r-I-iNM d~~l0f~OO01O
(W
U r1r1r1r1~-1r1r1r1riN
H
?, W
r~i U~
O
Pa A
H
ri.--IH H r-1r-I.--I.--Ir-Ir-I
~--1N CaCaCaCaC1A CaCaCaq N'dU UU U UU U UU U
.I-1Lf1L~Lf1M I~M O d'l0f~
-.-i 1.1t17d~L~N L~V~O1~M N
U ~DL~L~M L~00l~01r1M
V~~ON M NN N Md~d~
H M lf~C~f~L~I~(~d'l~
d~r~ ~ ~N d~d'N d~
Ln r1 N NL~L~L~r1I~(~N L~
O
W
N
O
z ~, r1NM ~ Lf7l0I~0001 r-I
W
O
~
W
H Lf1(~1f1M l~M O ~l0L~
Q II1d~L~N L~d~01d~M N
J~
l0I~t~M L~00l~01r1M
d~~ON M NN N MV~~
M r1C~L~t~L~l L~d~I
H d~~d~d'd~N d~d~N d~
O
N NC~L~C~r1L~L~N L~
W
.u +~ ~ ui N N N ~ O
I ~, (n t~ to [-~ ~.1N O ~ -r1 ~
r N x U7 x N ~ x N f'.
~
I N ~ N ,~ r1 U U1 ~
ao ~O M i-1FC S-I H CZ ~I ~-i (~ c~S N
O
-1 m U z N Id ~ A u~ ~ -~I
N U
,~ ~ x ,-Ix m x ro c~v~
oo N ~
yo ~ x N x ~ -- r.>:o ~ cat~
..
U ~ cd C7 rt '~ O N ~ u1' m U7 M I
S-I M W al ~ ~ rl N O
O a~ N x O ~ ~a x m Oro .~ x ~ ~ ~
f~ cn o x -~I -~I - ~
c~ ~n ,-, ~ ~
1.1 td r O U UJ r1 r1 OI
U ~ V a '-' .-I
c0 ~1 u~ m m ~n ~ .~1 ~ ~ xuW
N .~1.o ~ I oo n ~ c~ ~ r-.N ~ a -~IU
cr ~r ?~ oo -o, ,7 w U ~-IU U7 U7 ~' N N u7 L~
O o1 a1 .~ r-I 00 cp U7 .riN -r1 O t0 .r1 S-1 J-1~ Nb~
~',01 01 ~ CA rtS ~ I d~
U ~ Cn W C71 N N I N O ~ ~ G
1~ N N N M O ~ Ln r1 N td N u1 N .r1N rl U S.1t~ U7O~
C7 I I .-I.r1 U
G' ~I N ~ N C.~4-t c0 CL U7 ~'.,r-I,~
~ ~ W l0 fY1 N N 01 -Id~
1 l0 M l d N H c0 UI J- U ~ N rU
N ~ O S-1O O ~ -rl U7 ''O00 .,~O~
FC r-I01 01 U7 r1 ~', N
C7 1~ d~ ..
N 't i."l~ ~"'-,1 (a ,p N -' C~
~ 01 01 ~ fx J~ t17 E-r U7 N O N O 1-1 S-I 4-1 11 L~ c~c0 ~ In O O
C7 O u1 w U7 ~ N rt O cd N u1U~n ~--Irl o .~ ~ ~ N
'.7 J~ ~ r1 ~ O O ~ r-Iu1 ~''., O -- N N ~O U ~' N N
M
~ U 1W ~ 1~ x 4-I O b~ N ca O NN
~ L~ O O WO C7 ~
C7 N N 1~ U1 1-1 '-'r-I ~', O S-IS-11~Ul-rl x N N V~ -r1 ~t ~ U
d~
U7 rl (~ I rd ~ U r1 .-.N O ~0~
~ rl fY1 G~.' N
I
~ c~ x o x N m ,~ o a~ W x ~Icd o, rt In -- ~ ,~
d~
S-I W7 - I -' U1 I C~ ~ U7 U7 ~ NUI
a ~' ~ L~ .-. In 01 U r-I
N J-1N d~ N lIjO ~ O flj.~, 4-1O
01 N 01 d~ 01 4-1 N N N i-II U1 ~'.,S.~ttfN U7O
r-I N ~ .~. o1 r-I ..-i U7 'LStl7N U1 N ~o ~C N 1-IN ~~
v U U a1 ~ '-'rl (Y1 d~
p -riId s~ ~ w ,-I PI7 4.-,1~ cdc0O
~ r-I O
o ~a ~ s~ -~1s~ cn a~ I ai ~n o ~I~Ix ~C a~ -- ~ . ..~
M
S-I td N .~.,N C",C', PI7 U1 ~",W N !~~
ri r-I .-I .~" U ri PI7 h +~ N w ~ w t0 -ri N c0 ~0 r1 4-I~1 10 - O O V -~1 ~d -1 N tn u1 U7 Sa ~ ~ ~I S.~~ u~>,N
O -rl .~1 r1 cn 1~ U >~ O ~ .1~ca O N 1~ U1 ~ -UU1 -rlW (.n N ~ 1~ r7 01 'r U7 U7 10 .L-Ic~ O U7 tn 4-I N I ctiNt6 N -, r-1 U 00 .~' O N ~I U ~-I 4-1O d~ U7 rl ~ ~IU1~
O u1 O 1~ CL ~ av U7 +~ ~ 1~ r-IU Pa ~ 'r O +~ctjU
LO h ~ ~7 -rlN t~ ri ~ O
O O O .H O ~ ~ ~ ai +~ G O I~
FC ~ N 0.l~ -rl ~ o --~I 1-1W (~ 4-W.N r-i N ~-1 N .r1W '-7.,''O
~ -rl ~1 O
d~ f~
U1 U r1 b) ~ I b1 ~ +~ U 1~ r1 ~ L~ CL I~ ".~ td ~ N
u1 U t~ ~ r1 ~ d~ r-1 O r-I (~ .r1~ NS-I
U7 o\ c0 ~ f7 r-1 r, S-I~- r-i I
r-Itn 5, U7 ?, ~I ~t I O N ,~O
~ o1 tn 01 I7 O U7 N
M ~
r-I ~ -i yJ ~-i U t~ ,L',1~ z ~I .riO
,~ r1 ~ d~ J~ ~,' .~"., 'O
N
~ b1 H N .-I FC N U N O '-Or11~U7 1~ ~ '-'O v O ~ U N r-I
u1 ,~
W C4 x to p4 rZ-Ica 1~ c0 f~ O x ~'ZS
~ U7 O o N 1~ fl, N ~
M O
~ ~ x z ~ I~ I ~, I x ~ z ~~
cn ~ ~ x r1 N a o ~ vv +~ x wca c~ ~o .~I z ~ U ~
-- z ~ ~n ~- a~ a -- w ~s N U
J, O 01 O [v 00 ~ d~ L~ 01MM
~ d~ M ~ ~ M N
r-I N I 1 1 -I r1 r1 I I I
N , -r-II 1 I I I
,~ W 0 o O o O W W W o O o oW
O O
c~ O ~ ~ ~ O o O d, H ~
U
O I~ I~ L~ O a0 ~I di N '-'I M N r-i M M l0 r1 LL
~H IW O '1 to ~ t0 ~ r-IIW O o0 x O O M O
O OJ r-1 c-I O ~O ~ O M
~ ~ ~
O ~ t~ t~ ~ t~ ~ ~ ~ ~ ~0 0o M d~
N l>7O O L~ N O l l ~ r r O d~ l0 lD ri O d N
Ca 00 N l0 N t0 ~ Q1 ~ N M M 01l0 H f1 i Lf1 l L~ N 10 U I- r N N ~ r is ~ ~ ~ Cs ~ Js ~ t5~b~ ~ b~
W -1 r-Ir1 r-I r-I r-I r-I r-I r1r-i G1 A A Ca Ca Ca Ca Ca ACa ~ U U U UU
N U V U V U
1W fl (~ II1 M l~ M O d~ l0t~
(~ Lf1 ~ I~ N (~ ~ O~ ~ MN
H ~O ~ ~ ~ 00 ~ 01 -IM
U I I M t l .
Ca' d~ l0 N M N N N M ~d~
H M r-iL~ I~ l~ l~ L~ I~ d~(~
H
O d~ t11d~ d~ d~ N d~ d~ Nd~
N N (~ C~ t~ r1 L~ I~ Nl~
O
.~
z "
r1 N M d~ In l0 I~ 00 01 a ,~
W
o ~' w yd ~ ~ O
N
U U
U7 fsa U2 O f~ U1 O
~ ~ ~ ~
('., I U1 Ul r1I I U1 C,' I r-iU1 I I
~' ,~", U1 '~", O ~c~f~ ~ W x ~IH H C~,tWd CLCx -~IPa H H
i0 O x O
~
~ WU W W ~ U u-Iu7 U7 I-aWU WW w ~ U U1 U7 ~ fa Ca ~ ~ ~
t ~ ~ W ~ ~ ~ U W f l~ W 1 -0 ~
o ~o r r-i ~ r1 r-I N r-I
ri r-I
u~ I Om cn t~ N m H O H I
O O
I I
M NO M
.. x O ON ~~ ~ U~ ~l~O MM I ~
~ '-i U7 N a ~ 00 ,~N N Q ~r1 r1 a ~ Q N ~
N 01 M ~-' M r a O cn~ ~ V ~ ~n o u~ oob~ ~ ~ ~ N ~ b~
u-I w z z w o U f~ I (0 U HIS d~I I a (0 I
-ri r1 I " ' '~ a ..
I ~ I N
I
~, MM ~-IU7 pa1-I ~ ?-1N01r~ LL ~A ~ ~
J-1 N N O ~ M N r1 N r1!~~ . Q W Q A
N OD ~ l0 l0 O V~ ~
~
NU " 4-IN I ~ N 4-I a1 4-1Na r1 N ~ ~ ~ ~
N ~ L~ ~ ' U1 O d ~ N M I I I
V
'~
N
d~
UI UI U1~ ~ N '~ U7 F4I ..N ~-If~ ~ M ,~
I ~ N H Z' '~N ~ L~ Ii "'' '~ N a ~ 00 ~ i j ~ a 0 1 ~
~r1Fi ~i-I ~ S-i s~ 1 ,~r ~[ a -1 ~a~'s~
z ~ ~sa~ ~ >~~a ~' G z .,Lf ~ a~ ~
~' ~ ~ ~a -~Is~ ~
M x 6 ~ N N '~ U N ~I ~0 ~I ~ ~N rt w U S~q c~
~j' c~W ~ OI I c0 ,-i ~ F~ 1.1f7 C~. Gi.L~ J-1 .~,M S-iA ~ JJ
N U1 I fn ~I ' O .-1~ r-I~ r1 r-1 Or--Ir-I~ r-I~ r-I
U7 N ~ O d~ N C37. ~ M
-I f~ -i N '~~7r~Pa... ~-~~ y ~~ ..tv''(~Sr~~-r-I. ~ N y ~ l N l0 N ~ . 1f1 M f~
M ~
J~ v N U7y..1 N U7 UI U7 Q~ NUl UI ~-I U7a ~
r1 ~ H O r U7O O M '~ O U1 ~ ., O O
~ . r1 O ~ . O p o d~ 00 ~ ~ 0o '~N S' ~ y ~ f'i . S~ -rl'>>~>~ ~ .1 ~ ~' ~ l ~ N U1 f, U7 -1 UI
M ~ U7 ~ M
M N
M
~ ~~a, o r Q o o o ~r ,o o r o ~ , o ~a ~ ~, a a~.. a~ ~acaa~ a~ 5, o o ~ z w ~ ~ a a~
x z ~
~
-r-I N ~.I~I~ ~IS~ N ~I N ~-I~.IS~ tn S~ ~I
~1 '~ N I oo u~-- m ~n cn O I a~o~N
M t~ M ~ o O
m ~
t' u7 N.-t~ O O O O O O N~ ~O O U~~~ O N U
U '~ UNU~o~d' rtfO c~ N U c0 ~0 U'~ S~I~
U Uo~M U I U U
S. ~~ U ~ S
~ I I
z x MrINd~ -I'y' 7 - - - MrIM X0(,7~
M N ' ~M
~ ~ ~, ~ ~ri N ~ O~ ~ ~ o I o .-Ir-1~ ri1n W N I : ~ ,--Ir-I~r1 N u1 ri r-I
~ d'C7., r1r1 o r-I 4-1.-,w ~ u-I
x 4-Io r-I +.1 4..1z r-i d' u-. r-I
rt~ m asas asu~aO b~m b~~N~Otnb~~nbarnb~ b~ ~tn I I I I I ~' '' I I I
' ~ I ~
W r-C U ~ ~ f~ 1 ~ ~~ W FC CL W
W C7 W P q W caC4 c~ U td W c0A CL ~d Crn t~ C4 -r-I-~If-I ~1~ ~1 A -r-I-~I~I~I ~-IG1 fa u ~Iw ~I -~ uu~~~ S-I
-- ~ ~
p u~~ H ~ , m 1 +,.
a O
M
-r1 M
(0 11 r1 r~
N
~, M
~t ~
' z o in W M N
'r .-I
zz z Q O d~
M
I~
M
N M
d~ C~
a1 N
V~ d~
~
01 Ll1 t!1 r1 N M
N ~O
N L
v-I o~
~o N
H u~
~o M
H ~
u~
y~
-ri ,--I V1 r~ Cl~ Ul .1.1 [~ d~
N tf1 M
d~
l0 O
M .-I
M l0 O N
M N
d~ N
d~ N
N M
N d' .-1 ~' N v~
~ u~ ,-I
~ M H
H r1 u~ H
~
N
H
O O O
~ ~
~ 01 r1 O
~ M
i ~
M r1 lW N
-1 Lf1 N d V d cn u~
H H
tn ~
E-~ ~
H cn H ~
O
'~
S=i f~ M
'~
-rl N N
U Ln u1 -~
~
N
O ri r-I
a Ca N U U
~
1 1 C~
~ u~ ~r a ~
, 1D L
() H
~H v0 H M ~-i ~
O
N N
wqz ,~ N
U O ~ ~ 0 ~
a 1 O O ~ U 0 ~ ~ W W A WO W I I I
'd .~
I I C.'I I Ir-II U7U1 Cl~ U1 U1 U7 ~"., ' U7 ~ H E-~ rxcoH H x-~ H u.,w H a~ r-. a, x rox ~ E-~
~
~ u~ cn w U~n un ww cnH~ z ~ z ~ w Uw ~ Q' FC U1FC ~, O ~ EnH H H H z U7 H
H
, a ~ wa a ~s~ a oax arx ax a 0o a~ x ~ncn oa w oo~m w oa w m x cn al p o -~ a ..
I I ~
.
. ..
M N M ' .' ~ l0 l0 N M M 00 N O r1 O ~
~
O L~ d~ .' 01 1p O W Nd~ d~ Lf1 t0 O
a ~ ~u w~ ~a~ aw a o " ~~ ..~o ~ ~ O
~I ~p ~O ~ ~~' O I ~ M ~
U I I I I I I
-rl I
~.," NV~ ~ fx~ , ILL ~ r-I ~', y~ 00N
l~ N N d~ O N ~ .' ~
O
l O .. .. t11MN ~ 1-riO Ma ~ ~ I 00 ~ N ~..
O e-1 M N ~
t!1 d .~-n N N ~ M UlCr ~ M~ O M' ~ Z '~ 01 ' ~ IN
O ' d~ C~ G4 C7-i U ' C~ '~' ~
Q
U7 N Fi,IO ~ M11 O d~H H , I r1S., ~ ~ [2, O N t51 '~
M -' ' fa (O I r1Ca '~ L4U7 O Ci.,~ a -rl -I~,-rl ~, y ~a ~w ~ z' ~..~ Ar~x ~
~' w~ l v w w I ..~ ..~..~ ..p .. p .. ~ "pa I ~ ~ ~ ' . U . ..
~ ' . ' ' . ..
' ~-I U7 N NUl O OO O O~ ~ ~ , O
U1 ' O ~ S-I ~ L~ 01 ~O 00 M , L~
M N M
O
S-, O t51~ L!7Lf7Ln lf11f1~ ~ ,~ O 01 a ~ ~ " ~ M . l0 ~
r1 ~O .-I M
Lfl d~
N 'CfNS-1d~ V~d~ d~d~O H M OD M ~ r~j(aN
' M 1J d~ V~ ~' M N
d~ d~
!O ~-1 SJ -r1,N W WG4 W QIO O ~ "1~~
~ w .. ~~~ v~ (O ~AC~aa ~aaa ~zU H
a ~ " " ,~4-I p ,.r, ,r, w, " b~
~ ~ ~ ~ ~ I I ' I
I I ~ I I
I I
CT o o OU7 N NN N Nd~ ~ ~ O
o 4-I w N N r-i~ ~ ~~ ~ ~(1, I , O p~r-I
-rl N ~ M N -.-i I~ r1 ~ I O o C~ ~ ~ N Ln O O O r1 '~ t r1 O N
01 V~ In u1 M
O d~
u7 r-1 r1 U(0 O OO O OI M M 1~ M ~ UN
I O u1 ~ d~ ..
~ d~ M
~
S-11-IS-I~-IS~I~1~ ~ ~ O
N U1 u~aaU ~ H
~~>au xa r1~I~ .~ ,~.~ro,~.~u~ ~, ~,~ ~,,~~
~ I
W A W 0O U UU U Ucti c~ M r~NU7 N ~ G . .. .. .. .. ..
.. .. ..
..
.-i -i ~ ~4-1O OO O Ori ~ o x~ x'~ -,~+~A~ca ~ ~U~UW~H owAwx ~ ,~,pwq z ~Z -~-~, ~1 ~, I I ~r -~,-.~~I
C~u1~ .,~ W W x U7v1E-~
v1 U C4 l W
x U Ur U U
O M
r1 N
O .ri z ~a ~
V -~I ~o o, c~ t~ 00 m J-1 00 l0 N
ri Ill N N
N N M N
Ci M
'' ~
M t z zz zz ~
o~
O N o O1 l0 U tf1 P
a d~ O M .-I
'r L!l zz O
~ zz zz >~
O r1 V~ M N
M l0 00 U7 V~ (~ 01 M N l0 L~
~f1 00 M d~ If1 r1 ~O M r1 M 01 ((S N M
~O ~-i N Ul -r-1 E-~ Ul C/~ 01 r-I M ~ E-~ E~
tn e--I Ul Ul [~
11 ~ 1D r1 01 N In N 00 H M t11 d~ r1 LI1 N M r1 N ~ M r1 00 M M N r1 Ld 10 N
E ~ E-~ U7 N u1 H
W ~ ~ [-a ~ -~
c I~ 01 N r1 n r1 O M
M
O Ill d~ OD M
~i OO d~ N d~
d~ 01 d~
lfl OO C~
~
01 r1 ~ r1 N H M M
~ M N
N d ~
N
~ 00 ~o I!1 d~
~
,~
-ri V1 01 01 O
M M M Lf1 N
O
A ~ A
U U U U U
~
y t~ N L~ d' ~
~1 , t~ M I~ 00 U
H
N M N N
H C~ C~ L~ L
H
O d~ d~ V~ N
r1 M d~ t!) 10 m G4 O C~.w O
~
~ O N ~ W O w c R: E-~E-~ CGH ttxP: W :4 E-~ H E ~I
W W W W -~ FC aC U~ ~C ~ H O H H FC ~C l~O
~a~A~ O a wo O a~~ ~ as ax O a os~
ax ax ax x mw w v vow ~nx x mm mw ovwm ~w N '- W
DN
O
r1f.L
r1 M
U H N U ~
r1 ~o I
W I N ~ ' ~ 1J ~ d'~r '~ N N
N ~ x y r ~ H
W
U
r1 ODU Ml -rlr1 -$-'., -r-1,~,'-ri N H " M l0M ~ ~ b1 O M ' ~
!x C7~ Id N -r-1 ~0 ~0 ~ ' a W W ~ WN ~
' ~~ N W
~
~
r ~ ~ ~ ~ O .MI ~ N~
O
L
f U rl ,~ d~ 01 O O 01 r1 a1 I
cn ~- H I-~ ~ o N N r1 N v N
~ W ~ '' N N N l o~
-I ~ OD a~
-I U1 ~' Ln l G
~ C
.. .. rtf~ ..N w r ~ ~U7 ~ , ~ r I
~ . 4 ~
N N !v ~ .. Q (IS~ N H ~ a I I .. ~ U~(a I a ~ I I I z M ~
I ~ I I I of H I
I I l~
M O
Q ..N y~ y~ ~ Q ~ ~~
M N N I u'1 a0 In u1 00 d~ N
N L V~ d~ a0 M
cts~ c<jN'QU7 NrtSU U U ~ U ~U
'1 N ~ ~ M l0 M 01 N 01 .-i 01 r1 c-I
N w1 N
J-1 ~-I~I 1-1a (d C51S-1~ ~ ~ ~ ~ ~ro -rl H ~ ~ s va~~~xN .o~x~~a "~ .~~
a ' ' ' ~a~l ~aa~~ o '' ~
W W W ~>~N ~W N N N U N OO
.. .. .. .. .. .. .. (1, .. .. .. ..
~ W ~~ ~ ~ ~ ~ ~ Q~, '~ ~ FC 00 U ~C PO oo ..
Ca W f~ U ~1 .
W
t~ >~ t~ N~Iu7 N>~ ~ y~u7 U1 (O N ~O r1 ~,' r-ifaO O O O 00 O 01 O O O
~ ~ ~ N ~ 00 OD 01 01 OO N Q
~-i~1 ~-IU flS US-1.!~J-1 ~ Q1 y, l0 ~, ~ Q1~
N ~ N ~ ~ 01 01 l0 l0 N 01 S-1 ~ ~ ~ ~ O1 01 l0 l0 O l ~ L~ L~ O O O
L~ O O
~
1~ J-1J-1 N ~-I J-1N L Q Q y~Q
' ' d~ ~ N N ~ L ooooo o r a t~ x oooooo o ,~ ,~ ,~ ,~~ " r-,r,,x ,,~ x ~ x o o I oooooo o000o o o ?, ?, c~u~0 cd? m ~ I N ~ x~
M a z p ~ aaaaaa xxxxx a z cd >, ~ ~ ~s~W ar,o o o o Q Qo ff w A w . moowcncnm wwwww w . a a . A .
o ~, ~, ~ ,~ ~,, ~ .~y , , ,o, o o o o U U U r-1~I~ r-1U r-Ir-I .-I r-ir-ir-Ir-I
-rl ~C ~C FC u~N u~ v~~Cr.CFC FC ~ FC FC~C
~
n s~
O
r-i -r-I
V
1-1 .-i r1 M d~
N N
>~ M
't ~
M ' zz ~, o n o o ~o z U io ., o uo rl ,-I r1 01 N z z M
zz ~
c 0 N V~ 01 Ln r1 d' O
O M N
O
M N d~
N l0 N
M
(a c-i ~--I N
4S U7 E-~ U1 e-I
E-~
~
1~ ~p C W
N /7 o ~o ~D
>~ ~r ov m n ~ o0 oo r-I
t~
oo N H O 01 r1 O H r1 N
-r1 01 N
M
O ~ E'' ~ E-~
~ E
u1 H~ ~ ~
~
W ~ ~ 00 d~
OO M O
O ~
d~
.-I
00 00 l0 t r1 u-I M
M
N
N
N
(' ~ O
ri N d~ r1 v-i U
-~
N N M N M
N
P.' N
A
A A Ca N U U U U
~
+~ o dm o ~
~ 01 d~ M N
'r L~ 01 r1 M
O
(~
U
H
N M d~ d~
H L~ C~ d~ L~
~, O ~ d~ N d~
L~ L~ N f~
o, G
.r1 O l001l0MO r-i 01 tn d~ I~~O M I~O
~ I
11 V~~ MN 00LfW-id~~M M 00 ~ c-iN01O MODM Lf1 '~ ~~ H ~ '~ '1 M O ~Od~O L~l0r1 O r1 00 f~00 N l0l0 .r1 ~~ ~ O O ~
(JI r1W -ir1N .-irir1 ~-i ~-I r1 '-Ir1 r1~-ir1 O
W
O
-r1 O C~~ II1d1O N M .-IO L~~ I~~ ~ t W -I
1J 111 d~00d~O 00 ~~ l N LI1~ W -i l Ld O H Nr L(1r1O r1 r1l01 r t!~ r1M N r O
.ri ~ O ~ N 10r1 tf1 M 00 U7 r1 ~-ic-Iv-i ~ ~ H
O
I
O
I
<i N
O
.-.~..~ .-.~O .~ .-. ..
U LI1N~-I M riI H r1 <-I
N
~' H
cr z Hm z o z z H O
H ~H PGI f3.' O ~H
U1P0U1 V7lY1l0 PI7 W O W
r1r1~-ic-i.-I~-I~ '-'N O '-' v v H ~ ~~ ~ ~ W O r1 O
',>l0lfl10O 00M u'7r100l0w-Id~ r1 ~1D y-I
O CLfxCs-iN d~OOM tnN Ct-ix01 x 00NC~01 00d~
r1LdMO r-il0O L~d~Lf1l0Lf1O r1l0OL(~tIWI701N 00 01l0Nr1O r1O N w1v-ilf~L~lO N r1d~M d~O0100r1 L~O ~f100O OO O OO M 01~7 N I~0001M M01N OD
d~o ~oo U UV FCUU a~o~o o~t~o~o~000~Int~
V'O 01O l~f~I~U1(~fWl1d~L~ 00O NlD10t0l0'-101 ~
- m~o~n>C5C>CU 5C~Coou,,~ ,-IN o.~u,do.oa ~I
L~M N'-IU1(!~U1U1UlU1N MC7 ~ ~ l0d~b7CrC51G410 rl v--I'~ 1D , d~
~ CO l0 -1 J~ V~ l0 r l0 O 00 M
O . to ,-I
U O\ N I d~
.-I r1 r1 I
N
N
I
I
r-i O~ 1 Lf~ ~O
~ I 01 ~i c-I
r1 ~ 01 l0 l0 M
M
I~
U1 I lO I~ I
~ O~ O
t!7 N
-I 01 r1 r1 c-i N
.-I
.-I
N
U
,~
1W O l0 ~ O
N M 00 v-i In LT
l0 0 00 ~D
W -i N r1 r1 a~
a m -I
a r~ w m on N U U U U
O
J-1 In L~ II1 M
O
'r Lf1 d~ I~ N
r1 q U tD t~ t M
U
H
VW O N M
H M r1 I~ l~
~ d~ Lf1 ~ d~
r1 N N L~ I~
O
W
N
l~
oz r1 H N M d~
(~
U ri r1 r1 ri H
Ga ~w r-, u~
w t~
-ri l~r100N OdlO 00 O M riO h r100Lf1NN
1 ~ O ~ N ~ ~ O
J-I d~O 00M N01l001' ~ l0~ r100r1~ N01~ O01Lf1Lf1Lf1~ l0 M l~M r10010InLf1Lf1M O~ r1ctt1.f1~ ~01~ lW-iI~MM ~
-rl O
U7 r1r1r1w-INN r1N N v-1 rlr1.-I rl MM N Nv-1 O
~, O
r1 O O Ml0 l0 Lf1<i 01 M01If1N
~ H ~ r l ~ ~
J-1 01 Inr101 M W -100 lf~ Nd~d~M
1 -I 0 O l I~l l -I-I Q1 10-i-I
f1 Lf1 r1. ~r1d~l~1 00N r Mr r O'~. .N M O~Dr1L~ ~ .
-ri O ~ N M
U7 ~-I r1N.-i r1 r1r1 r1 MN N r1 O
W
N N N
O O O
~ ~
d N I HN Ne-Ir1riI N ~M .-Ir1InN ~-1r-Id InN M I
-' -f .-IO 111 OO OO O OO O Lf1O O OO O OO O OO O d~
, H z ~ HH v~x x x,-1w oz w HH w U~ x r~x x o O O O ~p pO O OO W E-~faO HO ~ ~O Ca~H LaO
z z o HH Hz z zo w oH Az H ~z H Ha H p ~
N H C7o r.~E-~ xF E-~E-~o fxz~1 E-~E-~E-~N p U H o ~ o a~n az z zo ~ Hx ~ ~ ~n~n a o w I OW OH H HI H U1W W x~ W R:~ ~ a I
m cn~r UH Uu~cncn~,a xz ~nHr~H cncncncnw cnIn .rd, .rN .~pp~.
v v L~d W -i O 00 v l0r1111,'~r1l0,'W-ir1r1r1d~r1 N .-Ir1OO.-INr1r1l0r-iriI~
w x NM xH o xx x hN x ~-1x x xw x xx x wx h O
O r-1Ol0MM ~ I~l0M ~OO N f.2,'~-IN 01L~00Ol0r10000l0~H
r1tnL~00Nd~r1toN O NL~N N00ri00L~111v-1M I~00l0Lf1t~
01l0(77N InOOt~01Lf101Ind7(~l~M t11L~O N OD00N ~DL~01t51 M O1 01tDN ~Dl0O M O r1Od~riNr1N OM ~ 01L~00 0110 L~InL~LfIL~N N N,~0110O N ~1~ON (~C~1~01M 00 Lf100 O ON O L(10000OD M l0M M t!101M l01O l0l000 -1~ t7m n,-1~ ~~ w ot7c~01~or ~ou1~ ru1t~.-to~ot7 ~
U
b W o o ,-i ro .
~
.-i O
O
J Ln OD r1 In ~ ' L(1 N
~
~
N - O1 N O .1.f7 O1 U -W 0 l N
U f 01 l l M
N
d~
l ~ . . 1 r r"1 N N . l0I r ~ O l M
r-i N I
d~ 1 r-I
I
I
N L!1 I M d~ N
I N OD
M N
I
C~
N
41 e-i Ill 00v-I V~ N
~ N N L~ I
U7 I .-i O
I V~
C~
O
l~
f1 I
W O '-I 01N I
I , 1 r1 ri d~'r-1 M r1 00 r1 r1 r1 N
~O
r1 N
O
U
,~
~ ~ o 0 0 ,--I o 1y N d~ N ~ r1 O
t57 ~D vD X11 L~
~
C3' r1 N r1 M
U
a~
a ro w cn m w cn w ~ U U U U U U
O
J-1 L~ M O d~ l0 L~
N
?I L~ 'd~ 01d~ M N
r-i Ca U t~ ao I~a1 rl M
U I
H
N N N M V~
H L~ t~ I~l~ dl l~
~
V~ N d~d~ N
r1 f~ r1 l~I~ N l~
O
Oa O
'O
+~
O
oz A ~1 ~ ~ ~ ~ o U .-I r1 r1r1 .-I N
H
a ~
w w a~
r1d~r1.-Id~..-I01M
O ON O ~-IO O O
U HN z Nx H x O W
O H ; H[Z-iiH H
!] ~
, RU
.,~z ~z ~z ~ ~
'~ ~
~, v aw w mi cncn v x q H f~alPOW f~P~7COCO
N U UU U UU U U
J-1t17CWI7M L~M d~l0 ~t ~ ~(~N L~d~d~M
U
U ~o~~ M I~aoa~r1 N
C,''d~1DN M NN M
' H M r-I(~t~L~l~IW1' O
~1 d~u'7d~d~~HN d~N
f3~N NI~C~I~r1L~N
N
Oz N
ri .-iNM ~ Lf~l00001 f~
U r1r1~-ir1r1r1r1.-I
H
~r W
O
W
v rov a~
>~ ro r1~ ro v I
G
ro v ~ 1J ro ',~ OI 1 N
r1 b) C31 x '~ -r-I Lf7M OD
~-I r1 J~
m ~~ C S~ N N r1 +~ NN
x O G
ro w~I -~Iv ~ ~ . rov a am v r1 -.~
v U N~ U ~ N ro v 'L5 ro -r1ro U 1~ ro .t~
N r1 .-tN O O U ~ ~ro .-i ~-I~ ~ ro ,~
ro ~ U .-IO O~-I ~
a-I O N CL
t~ ro U N~ x ?, U '~ S-1 S-Ib1 O N~
'O ~-I N
R~
,~r-I N r-iN G 'O W~ Sa 1-~
ro 1~ro +~N ~ ~ N ro w ~U
O .H m O N
s~ ~.I~ ro a ~ ~~ ~,r-I
~ .~ ro ~
~,Q O O rl N N N'O 'O S-I
m ro ~ ro ~ O
dP ~
O ON U ~-I~ ~ U ~N N r1~
-rl ~ -r1~ Ln ro ~-I S-I1-I O w b~ U1 -rl O~ ~ r-IUI
~ rl ,~ v ro ~
ao 4-I wv r1~ ~,'U1 ~-I ~ro O roro N ~1 ~-I C~' -.-I
U ~-I'O rl -rlro NU ~ ~tT
b1 O O ''O O
'Lf 'Ty roN U ~ rl S-Ir1 N tJ~
'~ +~ S~-IO ~-I
O ~
v Nca -rl>~ O ~ r0 ~-I
d~ N ro U7 ~
~ ''ON ~ U NG ~I
~I N >~ ~
N
O Ow O p, ,~ O I ~.-i v O~
v r1 ro v O N
O ~IO ~ ro '-d U7+-I ~ ~-Iv 'd N -rl N
-r1 v vro w ,~ ,~ ~ ~ m~I N wI
N ~I ~I
~ ~
s~ ~IG 3 va +~ ~ ~Iv N x s~ -~I+~ ~ ~ s~
U
o roN o -~Ioo +~o a, ~
v v N.-i N v >~ 'd r1 rl y vO
O N a~ ~
N
N ~ r1 ~I v v s~o rd s~ -~ v .--, ,~
v ro N N-~I roro v ~ ~ o~ U ro v ~a s~ o 3 ~I
W U7U WI ~ 1J ro .-I +-I -r1 r1b1 1- -rlUI ~.~", x o v -a -~I~ ro ~ os~
ro w v ~ . ~
rd >~
1J 1~N N W ro U ro J~W ro U1-rl U ri J--I~ -rl ~ N
-r1 ~Ir-I~ O ~-I ~ N
b1 -rlO ~
ro s~tn G ~ N v ~Iv ~I
~ ro 3 -~I -~I
.,1r-1 r1~.," FCro N U1 f.~ N~r U FC'C3 ~ N ro 1J ,~
'y J-1 ro ro-rl .-i+~ ro O ~~ f~
rl as +.IS-a-r1 l~ ro N
u I N ~ O
I 'a O ro ~ 7 -.-v .I -r; a r, v t~ ,~ > .u r1~
ro ~ ~ v -~I ~
Z3 b1U 3 ~ U1 U b1ro ~ ~ -rl~ ''O
U N
U7 ~"~ ro +~ O ~v ~ >~
v ~-I~., ~
v U
NO ON -rlro N p, O+~ O -r1N
N ~ rl r-1 r1 +~ ro OSa Sari u1U .~ ~I ro Nro Sa m4-I
ri r1 v u1 U
4-t q4-I wro ~ ''~1~ O ~ 4-IRW,' 4-a +~ r1 .C,~, 1-I
'Z~l-I4-Iro N .(~', r--I J-tU ri ~
'O 'bN 'drl ~''., ~ '~~' ''O ''Oro O S-I r-I,S~ U7 N
~,v vw v o ~I ~ o v~ v v-~I
-~I o ~ -~Iw ~ ~, r1 a I w o >~ ~r1 a ro~N
o w ~
o ro roG U ?-IU1 O .-I roro ro-riUro ro ~ '~ O -.-I O -ri ,~
~~-I r1ro ~ ro '~ r-IU rl-rl r-Ix ~U
J--I J..I v ~-Iro J~ J~ Ul U UI
.,~O O-rl ~IN r1 O S.I O1~ O O 1-I~
U1 +~ ~ ~ ro U7 v r1 au1 NN ~ ~, o x ro N~I N s~~ro v ~ ro v o s~ -~I ~
~ ~
r1 r1ro U7I i-IJ~ U -rlro -rlroU7U
01 v U ~.'t~.,'LS .~. O
N -r1 U ~ 111N ro O CL >~
+~ r1 --I~ ~
FC ~C~ O In ~ P, -ri r.>;~ FC~ O'~
~ ro z3 '~ U ~ ro r1 ~ ' U7 ro U 1~ CL ~-Ib~ ro O Ur-i G ~-rl ro N ro N ~ ro l U r-I f-~
~ ' ' f U
? U N -r 7 >~ C C51 4-I
v aU -I U , v b roS
O v L ~ ~
~ ro I
~
l b1 3~u1 ro~ r1 O -rl b1~ ~ -I
N ~ ~ O r ~ >
3 s~r1 3 0 ro ~I o ~-~ a d 3ro m ~ -~Ix ro ~I
rd I -~Io ~I ~ ~ ~ ~I~I -~Iv v ro o ro ~ ro a~ r1 N ~
U7 U1I ~ w O N U U1~ U7wi~~
ch r1 U S~ ?-I ro U
v ~ ~Sa O x ~I O ~''d ~ 'OS.II
N N N ro ~
rox ro~~ ro ~ ro~ N ro~~
~ ~
~ 'Ltv S~v 3 ~. v 'dv rdo ~r1 ~ ~ O ~ N v v v v v~, a ~ ro ro ~d vr1 v .~~~
ro ro v ,~ >~ ro rn ~1 ~Io v ~I ~ ~ro ~ 3 -~ro w w v o ~ ~
~I -~I
U UO r-I~ S1 b1 r1 U~ U r-Ir1 ''~ O ''~ 1~
~
N ~~ N N ''OU ~ro ~ N ~
4-I ro ?, f~ U
N
I s~ b ~I ~ r-Is~ ~Ia ~Ir1fdo -~ ro v .a ro a a aro v ~ +~ ro -~I ~ro ~ rov~I
~ ~, ~ ~ m ~ -~I
m m~, ~ v ro ~ . N-~I N ~
o >~ ro ~ s~
v O >~w -~I~ U U >, s~cn G -rl>, O t~ ro -r1u1 r1 O ~I
o oo saN N ~ ~ oro o x s~~
~ r1 -~ ~ v ~ ~I
-~ o U UO G1U1 '~ O UU U U ~1,v 3 U 1~ +~ ~-I O
N -r1U7 N .u ~ ro ,~ ~-I v -.-I O
N
U7 U7~ ro~ 1J U7 ~ U7 U7ro U7r-I~O
1J ro ~ S-1U W U7 ~-1 W
ro roO ~O U N CS'-rl roU roW O~
cn ro ~ N U7 -rI
W
3 3~ o~ ~I -~Iro ,~ 3~ 3 Zsv ~ w O ro w ro N ~
~ o ~ -~I ~a ro ~I r1 w ro -~
~ ~ - ?' ~
-I S-ro U~I~-Ix N S~ ~O ~-O ~-IN
-I I~ f~ ~ ''O~ O I >~
4 ~-I -rl ?
ro ro>J O N N CA v roI roI ~
O ro ~ I ro 1~ N
~ ~r ~I s-I~ s~m ~ ~ r-I~I s~~ ~Is~
v -r-I ~-I -~I ro r-I ro r-I ~O +~-riU7 ~ N 1.1 ,~ro ,~ro U7 O N r1 r-1 CL
.-~I f.~
ro -rl~-I tn.>~O O ~ ro rlv -rlN ~r1 N .~ ~ N --i N ro ro v a aw roH f.~U ,-~C4 a~, a ~,H~
~ r1 U .u 3 ~ ~ w w x ~z z q z z ~' >?' U Q' R' U
GL GL
01 V~ M d~ r1 r1 O r1 O O N O
H H ~ C~ H
H
~z z A z z H H H R; U E-~
H ~ H
a r~ cn w a w ~n v m ~I
~ ~
~ ,~ 5 - u~ N ~ R~
ca~ r-I ~, .uoas~ ro ~U ~ 3 S l - U O ~ s~ N N ~ o N -i to O
U a r 7 o t o~ ~ a~ ~ , n ~ ~ ~ ~ ~ ~ ~ ~ m rd i 4-m..~~ U7 a O ~ 'L3of~N N rl- O ~ N ~ N
.t~ O 1~ U '~ ~d ~0 'y,'O 'rCa ~ -..1 I ~ Oa ~ ~",c~ 11 b1 u) ~-IU7 d~ N ,5 -r1 U
~ ~ ~ ~ ~ ~-~ v ~~ ~ ~ o v o v --~ . ~ t 3 a 3 ~d , v ~ ~ -o r-I U7r1~ .--IW I 1~ a -f,a a N S~-I-r1 U7 t0 rd S- ~ ro N NO ~ --I'~r-Ito U v ~ O ~, ctSG S-ab~ v '~
s~ ~ N
.rt -~~ G ~ I 'd.-~-I-r1S-I ~N -rlU N i-1 N
wi U N O a ~., 1.1S-ICi S1 '$..,' O C,"c~U O r-I'J O ~I a '~
u1 U~ fa U7 O ~I ~ t0 N U7 .("., 1J
~a -~IO v a ,~ s~ s~ rd~~.,v ~,~w a ~ a ' O ro O r~ rd M ~I ~
N ~ t~~ a ~ c~ w va ~ ~o o v v r~ ~ Zs 3 U z ~ ~d ~ ~ m ~I ~
ov N .~-rim .rl W ~ 4-1O 1.~ ~ '-d~ U v ,~ r1 1-~ U 'Lf v FC ~ N 1~ t~ r-I U7 r.>;?~ U ~d ~ W O O ~I ~ 'U
U w 'O v i~ f-I
o s~ ~I 3 s~ . z N s~m v v-~I-~I~ o -~ ~ ro .~I~ ~r ~ ~ Zs o O U u1 N N N fa a rtfO ~ U ~ N >~ r1 >~
~ a O N N E-~
O v ~ U O x ~0 ~
w H
tr ~ a a ~I E-~ cd -~U~rtf. 4U caN ~ U7 A
Sa ~I U ~0 -I1 ~ A
s~ coo u~ v ~ x 3 b ,~~a~ ~Ir1~ ~ m o -~I
~ o U v .~I
w w U ~I ~ ~-I v UO ~ ~c0 c0 U7 ~
-rl -~ .t~ 'U -r1O ~
v 1~ N U7N 11 -rl (d r-I1-I~U ~ N U7?-I.ri (0 UI
'(j N 1.-~N .~'., v '~ 11 r-I?, .r1 '-O U7O ~ N ~ -ri O N ~S~ N N ~ C7~1-~ ~ -rl ~-I ~ ' O ~ G c~ ~-I i-~
v O S W ~ G' U1 O ,5U~-ir1 r1S.aO 'J O f.' O
~ i a r1 ..~ O a-I to rt -rl Ei 1J ~IU -rltd '~ N a .r1 7i 1 (~v S-1N N >~' 1~
1J G' N o1 ~ a r-I
'~ 1.1 U ~ ~I~n .~ v ~I v .-I~a d mg o ~ ~n -~ ~
u~ as ~I ~ r1 ~n v a ca ~ ~ O O ~ ~
~
?-I O 4-Iv N a O .(",(,"OU (d U7 U7 N
.~ vo .ri 'O U a ~I N ,~
,~
3 s~~ o u~ v o u~ -~Iv Iu~ ~ ~v ~ ~s ..~ ~a ~
o ~ rd v ~I ~ v ~ >~
U7 ~ r-IccS~ N ~ N a S-IO -.~ ~'-C5I ~ ''d U +~
1~ .,~ ~ O N U UI td a v v s~ 3 v ~ Wo ~ o caro ~ o s~s~ rt o ~a it ~I u~ ~ ~ o . ~I t~
v 0 0 s~~Iv w ~I ~ u~ v.~Ix v>~o .~ ~ w on -~
~I r1 o o, o v .~I
r1 ~
.~,U v ~a~u ~ U ~, ro ~o v .~ s~r1 r1 v 5 ,x ,~ o o~ ~, ~~I ~ v as ~~I 3 a ~ ~ u~ 4-I v >,I,- ~, ~,,~ rd ~ ~ ~I
~ ~ ~ ,-I ~ ~ o~ 'U d .~Im m ~ ,~ ~ N m N u~ o H ~ ~-.,-i. N a ~ t r1 ''O U O L~.-1N Oa ~ t~ O ~ t~ N
c>3 ~ ~ O r-I''U ~ u N >~ ~~ ~ N 1~
'd s O b~ ~n ~ ~ o a l v ~ ~
I ~ ~
3 I ~ c r ~ . ~ ~s + cd I U o v -~ v , , , -r1 >~
' N O c6 ~ ~ 1~ ~-IU caU7 1~ r-IN U N -rl 1~
4-It5)U r1 N .1~
N ' ~, ,~f~' N ~7 ~ J..1N U7 1.1 a 1~-r-IN 1.1 a U7 a ~-I r-I N ("., I r-I
U N ~ Sa O N r1 U7 r1~'-,~ ~~ N ''Oc0 ~ 'O
u7 N ~I ~ to .r1 -rlc~ O ~
N t0 q c0 m O ~ ~I U t~ O Ou7 -rl N U >~ v 1~ N -r1 -rl ,~ 'LS 1-~w 1~ -.-1 ca v v l-I '~(~w W1 v .~'., O U ~-Ia r1---rlr1 i,'' U1 1~ 1 t~'7to U7 ~ U7 U7 a N ~', r-I
,~ N 3 ~0 U -.-i U wO b1 r-i '~r-I1~ c0 ~
?, ~C N >~ O S-IU -rl c0 r1 1J J~ U U7 P4 ~I r1 .r1C' (a~-IG'~ ~ U ~ r-I
''~ !~ b O -rl ~0 I
W ~fv a U v s~ m ~ ~~ .~I 3~ -~m o v -~I
n -~ v w ~ ~I ~ ~ h ~' ~
~d U ~Iv -~Io v ~a -~v m s~ ~n ~ ~ ~ v In v I v ~a x v -,~v U a ~ o -,~ 3 ~ ~s~ .~I r1o a1~
r1 ?~ ~ ~ ~ ~ ~ -~ ~
-,~~ ~ ~ x o ~ ~ o v ~Iov s~ v-~I o -~I w v ~ ~ ~ ~ 3 a ~ u o ~a S ~ ro o ~
m s~E-~v U w ~n ?~ ~ ~5 ai 3~ I ~ a .
~ .~I ~ z v ~ >~
~
m -~I rt u~ o -~ ~I a v-~ u~ o.~o o +~ ~ o ~s >, ,~ ro v c~ v ~
~ s~
U ~' ~ ~~ _ '~o~o ~o ~'~v i '~~ o ~~ i i ~~ ~ ~~ a~
~
c ~,+ N U u~ - ~,NS~ a Nr.C'~rd v a LT>~U U7 ~ t~ ~ f~ +~ ~ 'n U >~
~ U ' U7 ~ N U7 w S-I
..-iO N f~ -rlO >~ --i-ri~v O ,~ !-IO -.-1 1-~
'' -r1~ w -ri to N ~ ~ -rl ~ ' ~ ~
'~
O ~-i~ -ri~ -r1 v r1 i-1U1a 1~ 1 S-IO c0 w ~
~ o v 1 O b) r1 ~C ~ cn~ ~ s~o 1 N 1 O ~ x u7 o -~I ~ .~ o o >~
~ ~I +~ -~ ~ -~Isa .~
~ s~ ~
v ~I
Q] rl ~ b~c0 ~ U 1~ 'd '~w1N U ,~O w ~ ~I S-I 'z3 -~I ~ ca -.-i U2 t~ c0 S-I
~ ~
~ ~ S-Ix v W 0 U7 ~ 1~,~ 1-I ~ 1~ a U ,~ -rl a a 1~ O O ,~
O
tdt0N ,~ N W ~ 1~ ~ ~, c0 ~ ~ O .. i cd ~ N .~ ~ 1~ w O 'd 1~
c~ a ~ 1~ b FC~~ U O1-~C7~'Zf~-I ~ U
N N G UI S-r O ~ N O U U7 ~ ~O -rl ~I O N a z3 U H
~ ~ b~ .H O oo b~ ~I '~ m ~
O ~ N ~ 'Ci ~ ~
Wit' ~ ~
.
N ~ N ~.,a . O r1U ~ uO O U ,~ v - O . 4-Ir1 ~ ~n -..~ v ~I~I r1 0 7, ~ t~-~Iv -,~ w ,~~ -~ ~I w ~I ~ 3 ~ ca m r1 o v ~ ~
~~ z ~ ~-~o~ U rt~~ ~, v3 ~ ~ ~~ ~, ~ ~~o~ o~ ~~v~~o r ~ r-IN c ~-I.~~U O ''dv 0 +~ r-I N ''O
n a n 'd OO ~ c U
-rl O W b~ W
-rI
a N U rt N ~-I .H w 1.-I-rld ~.r1 N ~ N a G
N u1 ~ O ~ N r1 .H ~ ' N
~
U7-rlU .~ U r-I I N 4-I~ >~ N1~ ~ U ~ N ca O 3 'Ci 1~ O c0 Sa ~I w O
'd td~-I-r-IE-~-r-I N ri N v +-~..-i~ r, U7 ...i O N U7 N a ~ ,~ N N ~ ~ N r-I
'~ ~ r-I
N N .U11 ~'., N (d'-O,~,'O xrJ7O U ~ JJ ~
ri J-1 U ((j ~-I .J~r-1 U1 '~ x ~., N u7~''.,~-I~,'~"., .rl~ ~c~ S-a vO -ri~-1~ -rl u7 U .-i ~, N -r1 r1 (~ 1-I
ca O
-., -~Iv O a v -~, ~n v ro~ ~ a ~nO ~n rd .~I
r1 s~ ~ N r1 >~ a~ ~ ~ O ~
r-I 'LS'JU N N -n N w .G N S-1 ~'w N O ~ N
1~ ''d-rtr1 1~ N a U7 cd t7~
co o ~ ~ ~ d v ~ ~ ov v ,~ ,~ a ~a ~ ~ 3 N s~ tn ,~ o o -~I
~
~ ~ ~ v -~ a -~ ~ ,~~w ~ ~~I~ ~ ~ -~ v ~
v ~ I v v o, ~ ~~, as ~ s 5, ro co ~
s I ~
~ x s ~ I ~ s~ ~ N -I ~a I ,-~ v x m ~ ca-~I ~ U U7 -.~oo ,~ +~3 v o ~ s~
o ~I ~ , rt b~ ,~ ca ~
~ >~ ca ~I rt ~ ~ v ~ -~ eo .~I
s~ a ~ v v U ~ r-I r1 m ~as v r-I~ 3 -~ v v ~ -~ N w g ~ ~ a ~ .~ ~
~
~ ~ . ~
. ~
O
O
U1 ~ >~U N a U1 U O.r1~ ~-1v O .~ v t ~ --IG r->r O O ~ f1 ~ ~ ~ ~0 ~-I r -I
..-Ir-I(a.r1'd a N ~-1 -r1~ r1i-1~I N'~~ .i-~~I '~ ~
'-C~ rtf b1 '-~,' rl id ~-I'~ N ', !--~ U
,.t~~ .Gw ~ rl ~ ~ ~ O~ ~ ~O ~ ~ ~ O rl G
~ a ~ O ~-I fa O ~ O Sa ~ !~
-rI -i H , J~O ~ ~ +~ H U U'~ '-' 3Ci1~W +y' w N
-rl t0 U7 .~., U U +~ w ~ J-1 -r-I
, 01 U1 ~ z z ~ a a .-~ r-I
~Iz U
aso ,!~ H
H z H H
w cn i ' ~ ~>, '' ~ a O
o p D ~ ~
w o ~b ~, O~. W ~" M '~
6.1 N
O
~
, y , >
~ ~D t-.
2f O
C ~ ~s.~.
V c~a v~
~
O _ > ~ W ~ ~
~y -o ao ~ w ~~
O ~ o 'S a ~1 y a' O N
c ti cGG
O
~
. 0 ~ ~
~ t "
n ~ ~ W ~ ' d., ~ ~ > ~
m ar 'ts .c ai W
o ~~ ~
~
' c o~
y ~. ~ .~ ~ ~ .= ,.~
.... o O
~ sy ao >
'g ni W 'J coo ~
~ ~' r' ~ y ~ a ~i w ~ ~
~
~
.~
~
ea ~ ~, ~ ~ ~ ~, w ~ ~ ~ ~ a c W o W ~; W ~o > '~ t a ~ a w ~
o.
~
w ... , , U
~.
~~~ M
N
~j N
.~
d d d ~ ~ W
M
>
o pa v M o~ w .
U U U . _, N C ' o ~ .~
_' ~ o ~ .-7 o~o 0 ~o ' ' >' ~ '~ O '~ .~C Pa y G I~ W
N N
O
~ t'~n . ~ C M ~;
.. U U M ~ w G W ~' :
U ~ ~
' ~ ~ ~ ~ ~ ~ ~r ~
~
~
~
~
p~ C~j ~ C O p M w ~ ~ N o N ~
N
a C
o, M ~ ~, ~;
w w w . . . ~, ~
~a " ~
A ~ ' a\
' d y C
~ -d ~ ~
'~' a~
b b ~ ~ ~ ~ ~, _ a~ ~ ~ d ~ ~
, "., ~
~ v ~ v~
.~ d ~
w o W N ~ ~ ~ ~ ' >> c~ >, t~ U ~C"" ~ U
>, ~ O~ b ~ cG
~ ~ O C
j ~!
~ c~ 01 v c b fx CG M
u'' ~ .
~ ~ _ N
O_ O_ O ~ ~ p ~/j ~ ~ . 4w., v-j ' a W f~ f~ ~ ~ d ~ ~ ,~.; ~ Q
~ y' O o ~ o G. ~
., r.
,~ o ~ ~ ~
d ~
d b ~
x d da, d aNz r~z3 xd~NU x ~d N..~z . w O
W ~ ~
O O
d .
U vi U C c~ U U bp a v~
~
C
G N U C _ .O N U c0 Cn ~ ~
> tn CO G 'O G -p '~ tn E-, U
' N O C by O tn crs ~ ,."' ' ~
C
U
~n U C p~ C ~ N w C
U U O N y ~, O N
~ tn 'O c S ~ N C
O" ~ cC ca .
~
a . ~ b -d c b ~ ~ ~ '~ a~
~' U w b ~' a ~
'~
b b , ~ ~ P, ~ ~ v~
V ~ ~ y ~
~
~ d ~
~ _ ~ ~ ' ~ C ~ ' U ~ /~ cV ,'"
U U ~ '''..' ~ O
~ b 0 ~
( ~ U ~ N
~
C
d ,.,~'O .~ U ~ '~ O ~ a' " ' U ~ ~ " O G
U ; ''~' s tn U ~
~ C .. y~ ~ a '~ cG
~ , ~
w a ~. Q' 'n ~
C . _ ~ . Op ~ ~ j >, U GG w C N U
~ N G' U ~ ~ ~ C . C
t, ~ ~ C cn Y
~ ~ ~ ~ b U
b ~ C C/~ N ~
p~ ~
O c~G ~ ~ N 'C1 p ~ ~
V y cG .b G tn U '~ y c0 N _ > 'rJ
cG b A
>' N "n C ~ ~ G. O O
C ~ a- ~ ~
~ rn O
~
d O
" ~
.
~
G.' ~, ~ C ~ .~ ,, p . .~
_ C
c N
V ~ ~ w ~
~ b .a ~ O
~
O
w O .ac~ ~ C w c ctf oU ~ j N v n ~ w C .
C, ~ > .
U
r p~ ~ brp'~ C ..U..L' ~. bp ~ s'~' C O C C
C C
~
w t~.t~Lt.i O. C1C1 ~ fir ~1 a Q C O
C U p- ~ ~ ~O
p ~
y L d ~ d d d ~ ~ d d ~ ~1 d ~ w ~~ w 'w~ :~
~ o.
?:
~
A
w w Q
U ~
a w d ~ ~ d d rn ' ~ Q Q a w w a a U -~
i N
w v.N.
N '~
O
~ ~ ~.. v..
t' Y > ~ cd p y rr N cC
~ ~
U
i,' ~ [~ b~
~ cn E~ ~' .~"" O .y ..
, o ~
~ O
~ O
y 'C c~ N M
~' II II
U ' U f"" a.UJ ~ N
U
a ;z "~ ~ ~
' ~
"
GL v~ rn ~ N a.
N _ N ' O ~ U
, V
N , 00 7 O~
~ ~ w r., N G
~O O > f ~
~G ~ 'O ''~'~ O~ G ~ O .C ~ ~ .O
Ov ~ O
>, Q~~ ~ ~ Via, C ~ ~.-~ C C ~ p Cn W 'v~0 ~ .r0 G w ~ >
~ U
G ' ~ G -- p p a O ~ ~ a ~ ~
o ~ p; ~ " ~ ~ w ~ ~' p. G o ~ ~ U
~1 ~ '' C7 ~ ~ a ~ ~ o a ~~
. .~ 0~, ~ ~ c~; ~
o ~ ~:~ ~3 ~ o~ ~ ~''~ ~ ~, N ~ G f~ ~ f~ O U ~ ~ ~ C ~
~ '~ ~ ~ G :~
cC
y~ C7 a w z 0 o Q ~j C ~ ~ . . ~ ~ ~ a~ ~, N ~ Y ~ ~ c o.
. ...
-.~~ 3~:
w ~ U N Oyl ~ U ~ ~ ~ ~ y~ ~ O~
~ ~ p ~ '~
~
Cn _ _ cn ~~
M N
~ U
cCcC.~N ~G~r ~ON . ~ ~
~ ~ a C ~
O~ N N~O ~ ~..U.
1 N ~ ~ , a5 ctt ~ ~ ~ V
~ U ~. M w .
6 ~ ~ ~
. ~ ~ ~ U ~' ~ ",~ _ 3 ~ N cG y iC U
w ~ N w ~
G ~ ~ ~ N ~ ~ p N Q ~ ~ ~ N
> > i~ V1 N w ~ G ~ xi U ~ a C
~' G ~ V C4 G C7 ~ N ~
O O ~O ~ ~ [~ C/~ V7 ~ ~ ~ ~ C G 0 C c~ O ~ ~
~ N 3 U O\
x x v ~ ' O ~O G ' i ~--i 0 N ~ ~
rwn .~ ~ U Y .~ ~ ~ t~ G O ~ .~
.fl ~ . .~ Y y O y ~
~ ~ ~ ~ . m ~ cC 'D
iG
3 ~ ~ . N
x ~~ ~~ a3 ~~ ~ z wNa ~ 3~
z ~~
~ w ~ c U , U x, G
.b G N
G ~
vi UN H.cG ~~
~i ~ G ~ b c~
~
a b~ 3~~~ N W~. ~ ~- o ' ~ N ~
~ ' Q Y ~ ~ O :~ ~ a~ w y ~ U ' ca ~
U cG p N s"' cGcn C ~ p bD p ~ O ~ N U '-' G N
~ ~
0 p , ~ C G ~ C N .N
G w C ~
, .
~ ~ C1 U p U
~
~ > G 'n O O a, G ~ G N tU-~ U 'x ~ '~
~ m .., ~ b N y ~ ~ c~
~ .~ O
G c O ~ ~
~ 0 O , . ~ O f G
w cd cUn C~ b by O O G N b0 C
O U
, 3 ~ on vv G
_ .
U y L ~ C G N .v~ U .C N w U G G
.O
~o .Y a~~~~c '> T; 3~~ c ,y G
~s~.~
y .c ~ ~ .b o ~ e ~ o ~ ~ o N o . ~ ~
y0 ~U cOnO"O O _ _ Wny iCy ~ _ ~G
~i~..s.,O
O ~-" G c~ i .~ ~ O . ~ C G t -p y cd s:.
y ~ U~ ~ ~ ~~ ~ ~ ~U
~ i U
Y
G1 s:.G y ~ ~
O A- G
c C
n ~ ~p N C ,~ ~ ~ C. ~ G by ~ ~ " ~ cc5 U C U U
~
~
fn y~ m N N cC '~ O O U O
~ N
v c o '~ ~ c . o ~ ou 3 a. a a. v a ~
Q. c -b a' ~
fa a ~-v a ~ aU o ~' a a ~' a a-o ~ a~
b-o U
p 'C CL ~ V W
a ~ ~ H
f~. w .~ ., U ~
p <110> INCYTE GENOMICS, INC.
POLICKY, Jennifer L.
HAFALIA, April BURFORD, Neil RING, Huijun Z.
LAL, Preeti TRIBOULEY, Catherine M.
YAO, Monique G.
YUE, Henry TANG, Y. Tom PATTERSON, Chandra DAS, Debopriya SANJANWALA, Madhu S.
GANDHI, Ameena R.
REDDY, Roopa KHAN, Farrah A.
BAUGHN, Mariah R.
RAMKUMAR, Jaya GRIFFIN, Jennifer A.
AU-YOUNG, Janice <120> DRUG METABOLIZING ENZYMES
<130> PI-0070 PCT
<140> To Be Assigned <141> Herewith <150> 60/197,590; 60/198,403; 60/200,185; 60/202,234; 60/203,509 <151> 2000-04-13; 2000-04-19; 2000-04-28; 2000-05-05; 2000-05-11 <160> 20 <170> PERL Program <210> 1 <211> 527 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 2434655CD1 <400> 1 Met Arg Ser Asp Lys Ser Ala Leu Val Phe Leu Leu Leu Gln Leu Phe Cys Val Gly Cys Gly Phe Cys Gly Lys Val Leu Val Trp Pro Cys Asp Met Ser His Trp Leu Asn Val Lys Val Ile Leu Glu Glu Leu Ile Val Arg Gly His Glu Val Thr Val Leu Thr His Ser Lys Pro Ser Leu Ile Asp Tyr Arg Lys Pro Ser Ala Leu Lys Phe Glu Val Val His Met Pro Gln Asp Arg Thr Glu Glu Asn Glu Ile Phe Val Asp Leu Ala Leu Asn Val Leu Pro,Gly Leu Ser Thr Trp Gln Ser Val Ile Lys Leu Asn Asp Phe Phe Val Glu Ile Arg Gly Thr Leu Lys Met Met Cys Glu Ser Phe Ile Tyr Asn Gln Thr Leu Met Lys Lys Leu Gln Glu Thr Asn Tyr Asp Val Met Leu Ile Asp Pro Val Ile Pro Cys Gly Asp Leu Met Ala Glu Leu Leu Ala Val Pro Phe Val Leu Thr Leu Arg Ile Ser Val Gly Gly Asn Met Glu Arg Ser Cys Gly Lys Leu Pro Ala Pro Leu Ser Tyr Val Pro Val Pro Met Thr Gly Leu Thr Asp Arg Met Thr Phe Leu Glu Arg Val Lys Asn Ser Met Leu Ser Val Leu Phe His Phe Trp Ile Gln Asp Tyr Asp Tyr His Phe Trp Glu Glu Phe Tyr Ser Lys Ala Leu Gly Arg Pro Thr Thr Leu Cys Glu Thr Val Gly Lys Ala Glu Ile Trp Leu Ile Arg Thr Tyr Trp Asp Phe Glu Phe Pro Gln Pro Tyr Gln Pro Asn Phe Glu Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Ala Leu Pro Lys Glu Met Glu Asn Phe Val Gln Ser Ser Gly Glu Asp Gly Ile Val Val Phe Ser Leu Gly Ser Leu Phe Gln Asn Val Thr Glu Glu Lys Ala Asn Ile Ile Ala Ser Ala Leu Ala Gln Ile Pro Gln Lys Val Leu Trp Arg Tyr Lys Gly Lys Lys Pro Ser Thr Leu Gly Ala Asn Thr Arg Leu Tyr Asp Trp Ile Pro Gln Asn Asp Leu Leu Gly His Pro Lys Thr Lys Ala Phe Ile Thr His Gly Gly Met Asn Gly Ile Tyr Glu Ala Ile Tyr His Gly Val Pro Met Val Gly Val Pro Ile Phe Gly Asp Gln Leu Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Val Glu Ile Asn Phe Lys Thr Met Thr Ser Glu Asp Leu Leu Arg Ala Leu Arg Thr Val Ile Thr Asp Ser Ser Tyr Lys Glu Asn Ala Met Arg Leu Ser Arg Ile His His Asp Gln Pro.Val Lys Pro Leu Asp Arg Ala Val Phe Trp Ile Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Ser Ala Ala His Asp Leu Thr Trp Phe Gln His Tyr Ser Ile Asp Val Ile Gly Phe Leu Leu Thr Cys Val Ala Thr Ala Ile Phe Leu Phe Thr Lys Cys Phe Leu Phe Ser Cys Gln Lys Phe Asn Lys Thr Arg Lys Ile Glu Lys Arg Glu <210> 2 <211> 523 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 2516747CD1 <400> 2 Met Val Gly Gln Arg Val Leu Leu Leu Val Ala Phe Leu Leu Ser Gly Val Leu Leu Ser Glu Ala Ala Lys Ile Leu Thr Ile Ser Thr Leu Gly Gly Ser His Tyr Leu Leu Leu Asp Arg Val Ser Gln Ile Leu Gln Glu His Gly His Asn Val Thr Met Leu His Gln Ser Gly Lys Phe Leu Ile Pro Asp Ile Lys Glu Glu Glu Lys Ser Tyr Gln Val Ile Arg Trp Phe Ser Pro Glu Asp His Gln Lys Arg Ile Lys Lys His Phe Asp Ser Tyr Ile Glu Thr Ala Leu Asp Gly Arg Lys Glu Ser Glu Ala Leu Val Lys Leu Met Glu Ile Phe Gly Thr Gln Cys Ser Tyr Leu Leu Ser Arg Lys Asp Ile Met Asp Ser Leu Lys Asn Glu Asn Tyr Asp Leu Val Phe Val Glu Ala Phe Asp Phe Cys Ser Phe Leu Ile Ala Glu Lys Leu Val Lys Pro Phe Val Ala Ile Leu Pro Thr Thr Phe Gly Ser Leu Asp Phe Gly Leu Pro Ser Pro Leu Ser Tyr Val Pro Val Phe Pro Ser Leu Leu Thr Asp His Met Asp Phe Trp Gly Arg Val Lys Asn Phe Leu Met Phe Phe Ser Phe Ser Arg Ser Gln Trp Asp Met Gln Ser Thr Phe Asp Asn Thr Ile Lys Glu His Phe Pro Glu Gly Ser Arg Pro Val Leu Ser His Leu Leu Leu Lys Ala Glu Leu Trp Phe Val Asn Ser Asp Phe Ala Phe Asp Phe Ala Arg Pro Leu Leu Pro Asn Thr Val Tyr Ile Gly Gly Leu Met Glu Lys Pro Ile Lys Pro Val Pro Gln Asp Leu Asp Asn Phe Ile Ala Asn Phe Gly Asp Ala Gly Phe Val Leu Val Ala Phe Gly Ser Met Leu Asn Thr His Gln Ser Gln Glu Val Leu Lys Lys Met His Asn Ala Phe Ala His Leu Pro Gln Gly Val Ile Trp Thr Cys Gln Ser Ser His Trp Pro Arg Asp Val His Leu Ala Thr Asn Val Lys Ile Val Asp Trp Leu Pro Arg Ser Asp Leu Leu Ala His Pro Ser Ile Arg Leu Phe Val Thr His Gly Gly Gln Asn Ser Val Met Glu Ala Ile Arg His Gly Val Pro Met Val Gly Leu Pro Val Asn Gly Asp Gln His Gly Asn Met Val Arg Val Val Ala Lys Asn Tyr Gly Val Ser Ile Arg Leu Asn Gln Val Thr Ala Asp Thr Leu Thr Leu Thr Met Lys Gln Val Ile Glu Asp Lys Arg Tyr Lys Ser Ala Val Val Ala Ala Ser Val Ile Leu His Ser Gln Pro Leu Ser Pro Ala Gln Arg Leu Val Gly Trp Ile Asp His Ile Leu Gln Thr Gly Gly Ala Thr His Leu Lys Pro Tyr Ala Phe Gln Gln Pro Trp His Glu Gln Tyr Leu Ile Asp Val Phe Val Phe Leu Leu Gly Leu Thr Leu Gly Thr Met Trp Leu Cys Gly Lys Leu Leu Gly Val Val 500' 505 510 Ala Arg Trp Leu Arg Gly Ala Arg Lys Val Lys Lys Thr <210> 3 <211> 358 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7472775CD1 <400> 3 Met Pro Glu Asp Val Arg Glu Lys Lys Glu Asn Leu Leu Leu Asn Ser Glu Arg Ser Thr Arg Leu Leu Thr Lys Thr Ser His Ser Gln Gly Gly Asp Gln Ala Leu Ser Lys Ser Thr Gly Ser Pro Thr Glu Lys Leu Ile Glu Lys Arg Gln Gly Ala Lys Thr Val Phe Asn Lys Phe Ser Asn Met Asn Trp Pro Val Asp Ile His Pro Leu Asn Lys Ser Leu Val Lys Asp Asn Lys Trp Lys Lys Thr Glu Glu Thr Gln Glu Lys Arg Arg Ser Phe Leu Gln Glu Phe Cys Lys Lys Tyr Gly Gly Val Ser His His Gln Ser His Leu Phe His Thr Val Ser Arg Ile Tyr Val Glu Asp Lys His Lys Ile Leu Tyr Cys Glu Val Pro Lys Ala Gly Cys Ser Asn Trp Lys Arg Ile Leu Met Val Leu Asn Gly Leu Ala Ser Ser Ala Tyr Asn Ile Ser His Asn Ala Val His Tyr Gly Lys His Leu Lys Lys Leu Asp Ser Phe Asp Leu Lys Gly Ile Tyr Thr Arg Leu Asn Thr Tyr Thr Lys Ala Val Phe Val Arg Asp Pro Met Glu Arg Leu Val Ser Ala Phe Arg Asp Lys Phe Glu His Pro Asn Ser Tyr Tyr His Pro Val Phe Gly Lys Ala Ile Ile Lys Lys Tyr Arg Pro Asn Ala Cys Glu Glu Ala Leu Ile Asn Gly Ser Gly Val Lys Phe Lys Glu Phe Ile His Tyr Leu Leu Asp Ser His Arg Pro Val Gly Met Asp Ile His Trp Glu Lys Val Ser Lys Leu Cys Tyr Pro Cys Leu Ile Asn Tyr Asp Phe Val Gly Lys Phe Glu Thr Leu Glu Glu Asp Ala Asn Tyr Phe Leu Gln Met Ile Gly Ala Pro Lys Glu Leu Lys Phe Pro Asn Phe Lys Asp Arg His Ser Ser Asp Glu Arg Thr Asn Ala Gln Val Val Arg Gln Tyr Leu Lys Asp Leu Thr Arg Thr Glu Arg Gln Leu Ile Tyr Asp Phe Tyr Tyr Leu Asp Tyr Leu Met Phe Asn Tyr Thr Thr Pro Phe Leu <210> 4 <211> 396 <212> PRT
<213> Homo Sapiens <220>
<221> misC_feature <223> Incyte ID No: 7473323CD1 <400> 4 Met Ala Ile Asp Ala Leu Val Ser Leu Cys Leu Pro Glu Val Ile Arg Ile Lys Phe Asn Ile Arg Pro Arg Gln Pro His His Asp Leu Pro Pro Gly Gly Ser Gln Asp Gly Asp Leu Lys Glu Pro Thr Glu Arg Val Thr Arg Asp Leu Ser Ser Gly Ala Pro Arg Gly Arg Asn Leu Pro Ala Pro Asp Gln Pro Gln Pro Pro Leu Gln Arg Gly Thr Arg Leu Arg Leu Arg Gln Arg Arg Arg Arg Leu Leu Ile Lys Lys Met Pro Ala Ala Ala Thr Ile Pro Ala Asn Ser Ser Asp Ala Pro Phe Ile Arg Pro Gly Pro Gly Thr Leu Asp Gly Arg Trp Val Ser Leu His Arg Ser Gln Gln Glu Arg Lys Arg Val Met Gln Glu Ala Cys Ala Lys Tyr Arg Ala Ser Ser Ser Arg Arg Ala Val Thr Pro Arg His Val Ser Arg Ile Phe Val Glu Asp Arg His Arg Val Leu Tyr Cys Glu Val Pro Lys Ala Gly Cys Ser Asn Trp Lys Arg Val Leu Met Val Leu Ala Gly Leu Ala Ser Ser Thr Ala Asp Ile Gln His Asn Thr Val His Tyr Gly Ser Ala Leu Lys Arg Leu Asp Thr Phe Asp Arg Gln Gly Ile Leu His Arg Leu Ser Thr Tyr Thr Lys Met Leu Phe Val Arg Glu Pro Phe Glu Arg Leu Val Ser Ala Phe Arg Asp Lys Phe Glu His Pro Asn Ser Tyr Tyr His Pro Val Phe Gly Lys Ala Ile Leu Ala Arg Tyr Arg Ala Asn Ala Ser Arg Glu Ala Leu Arg Thr Gly Ser Gly Val Arg Phe Pro Glu Phe Val Gln Tyr Leu Leu Asp Val His Arg Pro Val Gly Met Asp Ile His Trp Asp His Val Ser Arg Leu Cys Ser Pro Cys Leu Ile Asp Tyr Asp Phe Val Gly Lys Phe Glu Ser Met Glu Asp Asp Ala Asn Phe Phe Leu Ser Leu Ile Arg Ala Pro Arg Asn Leu Thr Phe Pro Arg Phe Lys Asp Arg His Ser Gln Glu Ala Arg Thr Thr Ala Arg Ile Ala His Gln Tyr Phe Ala Gln Leu Ser Ala Leu Gln Arg Gln Arg Thr Tyr Asp Phe Tyr Tyr Met Asp Tyr Leu Met Phe Asn Tyr Ser Lys Pro Phe Ala Asp Leu Tyr <210> 5 <211> 395 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7472777CD1 <400> 5 Met Trp Leu Pro Arg Val Ser Ser Thr Ala Val Thr Ala Leu Leu Leu Ala Gln Thr Phe Leu Leu Leu Phe Leu Val Ser Arg Pro Gly Pro Ser Ser Pro Ala Gly Gly Glu Ala Arg Val His Val Leu Val Leu Ser Ser Trp Arg Ser Gly Ser Ser Phe Val Gly Gln Leu Phe Asn Gln His Pro Asp Val Phe Tyr Leu Met Glu Pro Ala Trp His Val Trp Thr Thr Leu Ser Gln Gly Ser Ala Ala Thr Leu His Met Ala Val Arg Asp Leu Val Arg Ser Val Phe Leu Cys Asp Met Asp Val Phe Asp Ala Tyr Leu Pro Trp Arg Arg Asn Leu Ser~Asp Leu Phe Gln Trp Ala Val Ser Arg Ala Leu Cys Ser Pro Pro Ala Cys Ser Ala Phe Pro Arg Gly Ala Ile Ser Ser Glu Ala Val Cys Lys Pro Leu Cys Ala Arg Gln Ser Phe Thr Leu Ala Arg Glu Ala Cys Arg Ser Tyr Ser His Val Val Leu Lys Glu Val Arg Phe Phe Asn Leu Gln Val Leu Tyr Pro Leu Leu Ser Asp Pro Ala Leu Asn Leu Arg Ile Val His Leu Val Arg Asp Pro Arg Ala Val Leu Arg Ser Arg Glu Gln Thr Ala Lys Ala Leu Ala Arg Asp Asn Gly Ile Val Leu Gly Thr Asn Gly Thr Trp Val Glu Ala Asp Pro Gly Leu Arg Val Val Arg Glu Val Cys Arg Ser His Val Arg Ile Ala Glu Ala Ala Thr Leu Lys Pro Pro Pro Phe Leu Arg Gly Arg Tyr Arg Leu Val Arg Phe Glu Asp Leu Ala Arg Glu Pro Leu Ala Glu Ile Arg Ala Leu Tyr Ala Phe Thr Gly Leu Ser Leu Thr Pro Gln Leu Glu Ala Trp Ile His Asn Ile Thr His Gly Ser Gly Pro Gly Ala Arg Arg Glu Ala Phe Lys Thr Ser Ser Arg Asn Ala Leu Asn Val Ser Gln Ala Trp Arg His Ala Leu Pro Phe Ala Lys Ile Arg Arg Val Gln Glu Leu Cys Ala Gly Ala Leu Gln Leu Leu Gly Tyr Arg Pro Val Tyr Ser Glu Asp Glu Gln Arg Asn Leu Ala Leu Asp Leu Val Leu Pro Arg Gly Leu Asn Gly Phe Thr Trp Ala Ser Ser Thr Ala Ser His Pro Arg Asn <210> 6 <211> 504 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 1272843CD1 <400> 6 Met Glu Ala Thr Gly Thr Trp Ala Leu Leu Leu Ala Leu Ala Leu Leu Leu Leu Leu Thr Leu Ala Leu Ser Gly Thr Arg Ala Arg Gly His Leu Pro Pro Gly Pro Thr Pro Leu Pro Leu Leu Gly Asn Leu Leu Gln Leu Arg Pro Gly Ala Leu Tyr Ser Gly Leu Met Arg Leu Ser Lys Lys Tyr Gly Pro Val Phe Thr Ile Tyr Leu Gly Pro Trp Arg Pro Val Val Val Leu Val Gly Gln Glu Ala Val Arg Glu Ala Leu Gly Gly Gln Ala Glu Glu Phe Ser Gly Arg Gly Thr Val Ala Met Leu Glu Gly Thr Phe Asp Gly His Gly Val Phe Phe Ser Asn Gly Glu Arg Trp Arg Gln Leu Arg Lys Phe Thr Met Leu Ala Leu Arg Asp Leu Gly Met Gly Lys Arg Glu Gly Glu Glu Leu Ile Gln Ala Glu Ala Arg Cys Leu Val Glu Thr Phe Gln Gly Thr Glu Gly Arg Pro Phe Asp Pro Ser Leu Leu Leu Ala Gln Ala Thr Ser Asn Val Val Cys Ser Leu Leu Phe Gly Leu Arg Phe Ser Tyr Glu Asp Lys Glu Phe Gln Ala Val Val Arg Ala Ala Gly Gly Thr Leu Leu Gly Val Ser Ser Gln Gly Gly Gln Thr Tyr Glu Met Phe Ser Trp Phe Leu Arg Pro Leu Pro Gly Pro His Lys Gln Leu Leu His His Val Ser Thr Leu Ala Ala Phe Thr Val Arg Gln Val Gln Gln His Gln Gly Asn Leu Asp Ala Ser Gly Pro Ala Arg Asp Leu Val Asp Ala Phe Leu Leu Lys Met Ala Gln Glu Glu Gln Asn Pro Gly Thr Glu Phe Thr Asn Lys Asn Met Leu Met Thr Val Ile Tyr Leu Leu Phe Ala Gly Thr Met Thr Val Ser Thr Thr Val Gly Tyr Thr Leu Leu Leu Leu Met Lys Tyr Pro His Val Gln Lys Trp Val Arg Glu Glu Leu Asn Arg Glu Leu Gly Ala Gly Gln Ala Pro Ser Leu Gly Asp Arg Thr Arg Leu Pro Tyr Thr Asp Ala Val Leu His Glu Ala Gln Arg Leu Leu Ala Leu Val Pro Met Gly Ile Pro Arg Thr Leu Met Arg Thr Thr Arg Phe Arg Gly Tyr Thr Leu Pro Gln Gly Thr Glu Val Phe Pro Leu Leu Gly Ser Ile Leu His Asp Pro Asn Ile Phe Lys His Pro Glu Glu Phe Asn Pro Asp Arg Phe Leu Asp Ala Asp Gly Arg Phe Arg Lys His Glu Ala Phe Leu Pro Phe Ser Leu Gly Lys Arg Val Cys Leu Gly Glu Gly Leu Ala Lys Ala Glu Leu Phe Leu Phe Phe Thr Thr Ile Leu Gln Ala Phe Ser Leu Glu Ser Pro Cys Pro Pro Asp Thr Leu Ser Leu Lys Pro Thr Val Ser Gly Leu Phe Asn Ile Pro Pro Ala Phe Gln Leu Gln Val Arg Pro Thr Asp Leu His Ser Thr Thr Gln Thr Arg <210> 7 <211> 229 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7472790CD1 <400> 7 Met Asn Ile Arg Asn Ala Gln Pro Asp Asp Leu Met Asn Met Gln His Cys Asn Leu Leu Cys Leu Pro Glu Asn Tyr Gln Met Lys Tyr Tyr Leu Tyr His Gly Leu Ser Trp Pro Gln Leu Ser Tyr Ile Ala Glu Asp Glu Asp Gly Lys Ile Val Gly Tyr Val Leu Ala Lys Met Glu Glu Glu Pro Asp Asp Val Pro His Gly His Ile Thr Ser Leu Ala Val Lys Arg Ser His Arg Arg Leu Gly Leu Ala Gln Lys Leu Met Asp Gln Ala Ser Arg Ala Met Ile Glu Asn Phe Asn Ala Lys Tyr Val Ser Leu His Val Arg Lys Ser Asn Arg Pro Ala Leu His Leu Tyr Ser Asn Thr Leu Asn Phe Gln Ile Ser Glu Va1 Glu Pro Lys Tyr Tyr Ala Asp Gly Glu Asp Ala Tyr Ala Met Lys Arg Asp Leu Ser Gln Met Ala Asp Glu Leu Arg Arg Gln Met Asp Leu Lys Lys Gly Gly Tyr Val Val Leu Gly Ser Arg Glu Asn Gln Glu Thr Gln Gly Ser Thr Leu Ser Asp Ser Glu Glu Ala Cys Gln Gln Lys Asn Pro Ala Thr Glu Glu Ser Gly Ser Asp Ser Lys Glu Pro Lys Glu Ser Val Glu Ser Thr Asn Val Gln Asp Ser Ser Glu Ser Ser Asp Ser Thr Ser <210> 8 <211> 347 <212> PRT
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7473944CD1 <400> 8 Met Lys Pro Ala Leu Leu Glu Val Met Arg Met Asn Arg Ile Cys Arg Met Val Leu Ala Thr Cys Leu Gly Ser Phe Ile Leu Val Ile Phe Tyr Phe Gln Ile Met Arg Arg Asn Pro Phe Gly Val Asp Ile Cys Cys Arg Lys Gly Ser Arg Ser Pro Leu Gln Glu Leu Tyr Asn Pro Ile Gln Leu Glu Leu Ser Asn Thr Ala Val Leu His Gln Met Arg Arg Asp Gln Val Thr Asp Thr Cys Arg Ala Asn Ser Ala Thr Ser Arg Lys Arg Arg Val Leu Thr Pro Asn Asp Leu Lys His Leu Val Val Asp Glu Asp His Glu Leu Ile Tyr Cys Tyr Val Pro Lys Val Ala Cys Thr Asn Trp Lys Arg Leu Met Met Val Leu Thr Gly Arg Gly Lys Tyr Ser Asp Pro Met Glu Ile Pro Ala Asn Glu Ala His Val Ser Ala Asn Leu Lys~Thr Leu Asn Gln Tyr Ser Ile Pro Glu Ile Asn His Arg Leu Lys Ser Tyr Met Lys Phe Leu Phe Val Arg Glu Pro Phe Glu Arg Leu Val Ser Ala Tyr Arg Asn Lys Phe Thr Gln Lys Tyr Asn Ile Ser Phe His Lys Arg Tyr Gly Thr Lys Ile Ile Lys Arg Gln Arg Lys Asn Ala Thr Gln Glu Ala Leu Arg Lys Gly Asp Asp Val Lys Phe Glu Glu Phe Val Ala Tyr Leu Ile Asp Pro His Thr Gln Arg Glu Glu Pro Phe Asn Glu His Trp Gln Thr Val Tyr Ser Leu Cys His Pro Cys His Ile His Tyr Asp Leu Val Gly Lys Tyr Glu Thr Leu Glu Glu Asp Ser Asn Tyr Val Leu Gln Leu Ala Gly Val Gly Ser Tyr Leu Lys Phe Pro Thr Tyr Ala Lys Ser Thr Arg Thr Thr Asp Glu Met Thr Thr Glu Phe Phe Gln Asn Ile Ser Ser Glu His Gln Thr Gln Leu Tyr Glu Val Tyr Lys Leu Asp Phe Leu Met Phe Asn Tyr Ser Val Pro Ser Tyr Leu Lys Leu Glu <210> 9 <211> 218 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 2244136CD1 <400> 9 Met Thr Pro Ala Pro Pro Pro Gly Ala Arg Pro Gly Ala Ala Ser Leu Ala Gly Phe Ala Gly Val Ala Ser Leu Gly Pro Gly Asp Pro Arg Arg Ala Ala Asp Pro Arg Pro Leu Pro Pro Ala Leu Cys Phe Ala Val Ser Arg Ser Leu Leu Leu Thr Cys Leu Val Pro Ala Ala Leu Leu Gly Leu Arg Tyr Tyr Tyr Ser Arg Lys Val Ile Arg Ala Tyr Leu Glu Cys Ala Leu His Thr Asp Met Ala Asp Ile Glu Gln Tyr Tyr Met Lys Pro Pro Gly Ser Cys Phe Trp Val Ala Val Leu Asp Gly Asn Val Val Gly Ile Val Ala Ala Arg Ala His Glu Glu Asp Asn Thr Val Glu Leu Leu Arg Met Ser Val Asp Ser Arg Phe Arg Gly Lys Gly Ile Ala Lys Ala Leu Gly Arg Lys Val Leu Glu Phe Ala Val Val His Asn Tyr Ser Ala Val Val Leu Gly Thr Thr Ala Val Lys Val Ala Ala His Lys Leu Tyr Glu Ser Leu Gly Phe Arg His Met Gly Ala Ser Asp His Tyr Val Leu Pro Gly Met Thr Leu Ser Leu Ala Glu Arg Leu Phe Phe Gln Val Arg Tyr His Arg Tyr Arg Leu Gln Leu Arg Glu Glu <210> 10 <211> 318 <212> PRT
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474327CD1 <400> 10 Met Ala Ser His Ile Val Leu Asn Asn Gly Thr Lys Met Pro Ile Leu Gly Leu Gly Thr Trp Asn Ser Pro Pro Gly Gln Val Thr Glu Ala Val Lys Val Ala Ile Asn Val Gly Tyr Cys His Ile Asp Cys Ala His Val Tyr Gln Asn Glu Asn Asp Val Gly Val Ala Ile Arg Glu Lys Leu Arg Glu Gln Val Val Lys Cys Glu Glu Leu Phe Ile Thr Ser Lys Leu Trp Cys Ala Tyr His Glu Lys Gly Leu Val Lys Gly Ala Cys Gln Lys Met Leu Ile Asp Leu Lys Leu Asp Tyr Leu Asp Leu Tyr Leu Ile Arg Trp Pro Thr Ser Phe Lys Pro Gly Lys Glu Phe Phe Pro Leu Asp Glu Pro Gly Asn Gly Asn Val Val Pro Ser Asn Ser Asn Ile Leu Asp Thr Trp Ala Gly Met Glu Glu Leu Val Asp Glu Gly Leu Val Lys Ala Ile Gly Ile Ser Asn Phe Asn His Leu Gln Val Glu Arg Ile Leu Asn Lys Pro Asp Leu Lys Tyr Lys Pro Val Val Asn Gln Ile Glu Cys His Pro Tyr Leu Thr Gln Glu Lys Leu Ile Gln Tyr Cys Gln Ser Lys Gly Ile Met Val Thr Ala Tyr Ser Ser Phe Ser Ser Pro Asp Arg Pro Trp Ala Lys Pro Glu Asp Pro Ser Leu Leu Glu Asp Pro Arg Ile Lys Ala Ile Thr Ala Lys His Asn Lys Thr Thr Ala Gln Val Leu Ile Trp Phe Pro Met Gln Arg Asn Leu Val Val Ile Pro Lys Ser Val Thr Pro Glu Cys Ile Ala Glu Asn Phe Lys Val Phe Asn Phe Glu Leu Asn Ser Gln Asp Met Thr Thr Leu Phe Ser Tyr Asn Arg Asn Trp Arg Val Cys Ala Leu Val Ser Cys Ala Ser His Lys Asp Tyr Pro Phe His Glu Glu Phe <210> 11 <211> 1636 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 2434655CB1 <400> 11 gatcagtgtg tgagggaact gccatcatga ggtctgacaa gtcagctttg gtatttctgc 60 tcctgcagct cttctgtgtt ggctgtggat tctgtgggaa agtcctggtg tggccctgtg 120 acatgagcca ttggcttaat gtcaaggtca ttctagaaga gctcatagtg agaggccatg 180 aggtaacagt attgactcac tcaaagcctt cgttaattga ctacaggaag ccttctgcat 240 tgaaatttga ggtggtccat atgccacagg acagaacaga agaaaatgaa atatttgttg 300 acctagctct gaatgtcttg ccaggcttat caacctggca atcagttata aaattaaatg 360 atttttttgt tgaaataaga ggaactttaa aaatgatgtg tgagagcttt atctacaatc 420 agacgcttat gaagaagcta caggaaacca actacgatgt aatgcttata gaccctgtga 480 ttccctgtgg agacctgatg gctgagttgc ttgcagtccc ttttgtgctc acacttagaa 540 tttctgtagg aggcaatatg gagcgaagct gtgggaaact tccagctcca ctttcctatg 600 tacctgtgcc tatgacagga ctaacagaca gaatgacctt tctggaaaga gtaaaaaatt 660 caatgctttc agttttgttc cacttctgga ttcaggatta cgactatcat ttttgggaag 720 agttttatag taaggcatta ggaaggccca ctacattatg tgagactgtg ggaaaagctg 780 agatatggct aatacgaaca tattgggatt ttgaatttcc tcaaccatac caacctaact 840 ttgagtttgt tggaggattg cactgtaaac ctgccaaagc tttgcctaag gaaatggaaa 900 attttgtcca gagttcaggg gaagatggta ttgtggtgtt ttctctgggg tcactgtttc 960 aaaatgttac agaagaaaag gctaatatca ttgcttcagc ccttgcccag atcccacaga 1020 aggtgttatg gaggtacaaa ggaaaaaaac catccacatt aggagccaat actcggctgt 1080 atgattggat accccagaat gatcttcttg gtcatcccaa aaccaaagct tttatcactc 1140 atggtggaat gaatgggatc tatgaagcta tttaccatgg ggtccctatg gtgggagttc 1200 ccatatttgg tgatcagctt gataacatag ctcacatgaa ggccaaagga gcagctgtag 1260 aaataaactt caaaactatg acaagcgaag atttactgag ggctttgaga acagtcatta 1320 ccgattcctc ttataaagag aatgctatga gattatcaag aattcaccat gatcaacctg 1380 taaagcccct agatcgagca gtcttctgga tcgagtttgt catgcgccac aaaggagcca 1440 agcacctgcg atcagctgcc catgacctca cctggttcca gcactactct atagatgtga 1500 ttgggttcct gctgacctgt gtggcaactg ctatattctt gttcacaaaa tgttttttat 1560 tttcctgtca aaaatttaat aaaactagaa agatagaaaa gagggaatag atctttccaa 1620 attcaagaaa gacctg 1636 <210> 12 <211> 2086 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 2516747CB1 <400> 12 cctacctctt cctaggccca cagccagtgc ctttggagta ctgaggcgcg cacagagtcc 60 ttagcccggc gcagggcgcg cagcccaggc tgagatccgc tgcttctgtg gaagtgagca 120 tggttgggca gcgggtgctg cttctagtgg ccttccttct ttctggggtc ctgctctcag 180 aggctgccaa aatcctgaca atatctacac tgggtggaag ccattaccta ctgttggacc 240 gggtgtctca gattcttcaa gagcatggtc ataatgtgac tatgcttcat cagagtggaa 300 agtttttgat cccagatatt aaagaggagg aaaaatcata ccaagttatc aggtggtttt 360 cacctgaaga tcatcaaaaa agaattaaga agcattttga tagctacata gaaacagcat 420 tggatggcag aaaagaatct gaagcccttg taaagctaat ggaaatattt gggactcaat 480 gtagttattt gctaagcaga aaggatataa tggattcctt aaagaatgag aactatgatc 540 tggtatttgt tgaagcattt gatttctgtt ctttcctgat tgctgagaag cttgtgaaac 600 catttgtggc cattcttccc accacattcg gctctttgga ttttgggcta ccaagcccct 660 tgtcttatgt tccagtattc ccttccttgc tgactgatca catggacttc tggggccgag 720 tgaagaattt tctgatgttc tttagtttct ccaggagcca atgggacatg cagtctacat 780 ttgacaacac catcaaggag catttcccag aaggctctag gccagttttg tctcatcttc 840 tactgaaagc agagttgtgg tttgttaact ctgattttgc ctttgatttt gcccggcccc 900 tgcttcccaa cactgtttat attggaggct tgatggaaaa acctattaaa ccagtaccac 960 aagacttgga caacttcatt gccaactttg gggatgcagg gtttgtcctt gtggcctttg 1020 gctccatgtt gaacacccat cagtcccagg aagtcctcaa gaagatgcac aatgcctttg 1080 cccacctccc tcaaggagtg atatggacat gtcagagttc tcattggccc agagatgttc 1140 atttggccac aaatgtgaaa attgtggact ggcttcctcg gagtgacctc ctggctcacc 1200 ccagcatccg tctttttgtc actcatggtg ggcagaacag cgtaatggag gccatccgtc 1260 atggtgtgcc catggtggga ttaccagtca atggagacca gcatggaaac atggtccgag 1320 tagtagccaa aaattatggt gtctctatcc ggttgaatca ggtcacagcc gacacactga 1380 cacttacaat gaaacaagtc atagaagaca agaggtacaa gtcggcagtg gtggcagcca 1440 gtgtcatcct gcactctcag cccctgagcc ccgcacagcg gctggtgggc tggatcgacc 1500 acatcctcca gactggggga gcgacgcacc tcaagcccta tgccttccag cagccttggc 1560 atgagcagta cctcattgat gtctttgtgt ttctgctggg gctcactctg ggcactatgt 1620 ggctttgtgg gaagctgctg ggtgtggtgg ccaggtggct gcgtggggcc aggaaggtga 1680 agaagacatg aggctaggtg tagccttggg tgaggggagg gcatccctgg tcctttgaag 1740 gttctcccca ccccagcaca cgccacccct ctgttctctc ttcagctcca cctgccactg 1800 atcctgcaac ttgcttcttt ctattctctg cctctgttta gaaatcttca cacaccactg 1860 aggcttcttg acttgcccct tgtgacttga attcccagct cagatacaaa ttttcacctg 1920 ccagccctgc ctcctccttt ctcccttttc ctagacacag gactctgaca acttcatcct 1980 ccttgtttag atgacttccc agtttccagt ccccatttct ccttctatca cttttcataa 2040 aaaaactcag gaaatatttg acatatcttc catttcaaat tcttcc 2086 <210> 13 <211> 1814 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7472775CB1 <400> 13 cttggacgag ggggagagtg gagaagagaa gagaacaaaa agtaacttca ggatggggac 60 cagtgaagta cttgcggcct gtacccagaa tcaaacccca agtttcacat gcctgaggat 120 gtacgagaaa aaaaggaaaa tcttctactc aattctgaga gatctactag gctcttaaca 180 aagaccagtc attcacaagg aggggatcaa gctttaagta agtccacagg gtcaccaaca 240 gagaagttga ttgaaaaacg tcaaggagct aagactgttt ttaacaagtt cagcaacatg 300 aattggccag tggacattca ccctttaaac aaaagtttag tcaaagataa taaatggaag 360 aaaactgagg agacccaaga gaaacgaagg tctttccttc aggagttttg caagaaatac 420 ggtggggtga gtcatcatca gtcacatctt ttccatacag tatccagaat ctatgtagaa 480 gataaacaca aaatcttata ttgtgaggta cctaaggctg gctgttccaa ttggaaaaga 540 attctgatgg tactaaatgg attggcttcc tctgcataca acatctccca caatgctgtc 600 cactacpgga agcatttgaa gaagctagat agctttgacc taaaagggat atatacccgc 660 ttaaatactt acaccaaagc tgtgtttgtt cgtgatccca tggaaagatt agtatcagcc 720 tttagggaca aatttgaaca ccccaatagt tattaccatc cagtattcgg aaaggcaatt 780 atcaagaaat atcgaccaaa tgcctgtgaa gaagcattaa ttaatggatc tggagtcaag 840 ttcaaagagt ttatccacta cttgctggat tcccaccgtc cagtaggaat ggacattcac 900 tgggaaaagg tcagcaaact ctgctatccg tgtttgatca actatgattt tgtagggaaa 960 tttgagactt tggaagaaga tgccaattac tttttacaga tgatcggtgc tccaaaggag 1020 ctgaaatttc ccaactttaa ggataggcac tcttccgatg aaagaaccaa tgctcaagtc 1080 gtgagacagt atttaaagga tctgactaga actgagagac aattaatcta tgacttttat 1140 tacttggact atttaatgtt taattataca actccatttt tgtagtttgc attcattttc 1200 taaaaccctg tatatactta atgatgataa gttcaaatca gctgtaattt ttctataatt 1260 ctctgtatga cagaaattta accaagtgca gttgtcttga tttaatgtag atttttacca 1320 aatagtatga caccaattgg cacaaagtta taggaaaatc acctacagga gatgtaaaca 1380 acttgagttg ctctaaaatg tttggaaaag agctgctttt gcattatgaa ttatattgtt 1440 gaagcaataa cctagccagc tgttgcatta gctaaagcag cctcttgcaa tggtaggaaa 1500 aaaggatctc aaatagcatg agtgtatgtc tatatcctga aatttattgt ctaaaatgca 1560 tgaatatatt tttagcagtc tgtggcatat taatcaaact gttgaattgt tttcttacac 1620 cctggaaatc tttctatcaa ctataatgat aaatccattt tgaagtgata ttttggactt 1680 aggcatttta ctttagattg gaaggcatta tgtgatttac aatatgagaa tatagcagaa 1740 aaaccagatg aggctgtggc tttttatatt caacagccaa taaaaaatgc acaacatgct 1800 aagatcaaag caaa 1814 <210> 14 <211> 1650 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7473323CB1 <400> 14 atggccattg atgcactggt ctctctgtgt cttcctgagg tcatcagaat aaagttcaac 60 atcaggccaa ggcagcccca ccacgacctc ccaccaggcg gctcccagga tggtgacttg 120 aaggaaccca cagagagggt cactcgggac ttatccagtg gggccccgag gggccgcaac 180 ctgccagcgc ctgaccagcc tcaacccccg ctgcagaggg gaacccgtct gcggctccgc 240 cagcgccgtc gccgtctgct catcaagaaa atgccagctg cggcgaccat cccggccaac 300 agctcggacg cgcccttcat ccggccggga cccgggacgc tggatggccg ctgggtcagc 360 ctgcaccgga gccagcagga gcgcaagcgg gtgatgcagg aggcctgcgc caagtaccgg 420 gcgagcagca gccgccgggc cgtcacgccc cgccacgtgt cccgtatctt cgtggaggac 480 cgccaccgcg tgctctactg cgaggtgccc aaggccggct gctccaattg gaagcgggtg 540 ctcatggtgc tggccggcct ggcctcgtcc actgccgaca tccagcacaa caccgtccac 600 tatggcagcg ctctcaagcg cctggacacc ttcgaccgcc agggtatctt gcaccgtctc 660 agcacctaca ccaagatgct ctttgtccgc gagcccttcg agaggctggt gtccgccttc 720 cgcgacaagt ttgagcaccc caacagctac tatcacccgg tcttcggcaa ggccatcctg 780 gcccggtacc gcgccaatgc ctctcgggag gccctgcgga ccggctctgg ggtgcgtttt 840 cccgagttcg tccagtacct gctggacgtg caccggcccg tggggatgga cattcactgg 900 gaccatgtca gccggctctg cagcccctgc ctcatcgact acgatttcgt aggcaagttc 960 gagagcatgg aggacgatgc caacttcttc ctgagcctca tccgcgcgcc gcggaacctg 1020 accttccccc ggttcaagga ccggcactcg caggaggcgc ggaccacagc gaggatcgcc 1080 caccagtact tcgcccaact ctcggccctg caaaggcagc gcacctacga cttctactac 1140 atggattacc tgatgttcaa ctattccaag ccctttgcag atctgtactg aggggcgccg 1200 cagctggccg gggccgccct gccccggtca ctcacctgtg ctcccgggca tcctcctgtc 1260 cctggctcct catcctggga gcaacagggc tctgaggacg tgaggagcca tcgctgtggg 1320 aggcagcagg ccccgggtgg ggggcagagg cgcccagcct tggatgggga ccccagcccc 1380 tggcctgtac ctgtttcctc attccttggc tgagggagag gctgagaact gggcagacac 1440 ccctggagct cagccgacag ttttgatgag cagggaagtc tgaggcccag aggacggggg 1500 gcccagcggt aagggatgtc ccgcactccc ttagccattg ccttggacca aaccacgtgg 1560 tttgcagctt ttctacgagc caggggggag gttcccttgg attaaggttc caaataaagc 1620 acatggtttc cagaacaaaa aaaaacaaaa 1650 <210> 15 <211> 1647 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7472777CB1 <400> 15 atgtggctgc cgcgcgtctc cagcacagca gtgaccgcgc tcctcctggc gcagaccttc 60 ctcctcctct ttctggtttc ccggccaggg ccctcgtccc cagcaggcgg cgaggcgcgc 120 gtgcatgtgc tggtgctgtc ctcgtggcgc tcgggctcgt ccttcgtggg ccaactcttc 180 aaccagcacc ccgacgtctt ctacctaatg gagcccgcgt ggcacgtgtg gaccaccctg 240 tcgcagggca gcgccgcaac gctgcacatg gctgtgcgcg acctggtgcg ctccgtcttc 300 ctgtgcgaca tggacgtgtt tgatgcctat ctgccttggc gccgcaacct gtccgacctc 360 ttccagtggg ccgtgagccg tgcactgtgc tcgccacccg cctgcagtgc ctttccccga 420 ggcgccatca gcagcgaggc cgtgtgcaag ccactgtgcg cgcggcagtc cttcaccctg 480 gcccgggagg cctgccgctc ctacagccac gtggtgctca aggaggtgcg cttcttcaac 540 ctgcaggtgc tctacccgct gctcagcgac cccgcgctca acctacgcat cgtgcacctg 600 gtgcgcgacc cgcgggccgt gctgcgctcc cgggagcaga cagccaaggc tctggcgcgt 660 gacaacggca tcgtgctggg caccaacggc acgtgggtgg aggccgaccc cggcctgcgc 720 gtggtgcgcg aggtgtgccg tagccacgta cgcatcgccg aggccgccac actcaagccg 780 ccaccctttc tgcgcggccg ctaccgcctg gtgcgcttcg aggacctggc gcgggagccg 840 ctggcagaaa tccgtgcgct ctacgccttc actgggctca gtctcacgcc acagctcgag 900 gcctggatcc ataacatcac ccacggatct ggacctggtg cgcgccgcga agccttcaag 960 acttcgtcca ggaatgcgct caacgtctcc caggcctggc gccatgcgct gccctttgcc 1020 aagatccgcc gcgtgcagga actgtgcgct ggtgcgctgc agctgctggg ctaccggcct 1080-gtgtactctg aggacgagca gcgcaacctc gcccttgatc tggtgctgcc acgaggcctg 1140 aacggcttca cttgggcatc atccaccgcc tcgcaccccc gaaattagtg gaggccacag 1200 ttgtagcagg cgctaggccc gggaggagag tgcatggtgc agagggggct ggggcgcacg 1260 gagaagcagg tccctatatt gaccaaggag tttgtgagaa cctgcgtgct gctcctttgc 1320 ttcggacctc cgcctctgcc cgggagaaag cccaggccag cctgctggac aagcagagac 1380 catgagaagg agagttcagg ggtcccaaac caggccatcc tagaccagcc agctccagct 1440 gatccgcacg cagccacttc ggctaccttc tactggccaa agggagtccc agggctcacc 1500 cagattcaga ggtggggaaa ctgagtccac cacttgagaa gagtagctat aaagacatat 1560 gagcgaggcc agctgagccc agcactgcgg ccaagtcgaa gctttaggag caataaaagt 1620 gcttattgtg tttcagtcaa aaaaaaa 1647 <210> 16 <211> 2620 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 1272843CB1 <400> 16 cgcggagacc tgggagagga gaaggagccg acctgccgag atggaggcga ccggcacctg 60 ggcgctgctg ctggcgctgg cgctgctcct gctgctgacg ctggcgctgt ccgggaccag 120 ggcccgaggc cacctgcccc ccgggcccac gccgctacca ctgctgggaa acctcctgca 180 gctacggccc ggggcgctgt attcagggct catgcggctg agtaagaagt acggaccggt 240 gttcaccatc tacctgggac cctggcggcc tgtggtggtc ctggttgggc aggaggctgt 300 gcgggaggcc ctgggaggtc aggctgagga gttcagcggc cggggaaccg tagcgatgct 360 ggaagggact tttgatggcc atggggtttt cttctccaac ggggagcggt ggaggcagct 420 gaggaagttt accatgcttg ctctgcggga cctgggcatg gggaagcgag aaggcgagga 480 gctgatccag gcggaggccc ggtgtctggt ggagacattc caggggacag aaggacgccc 540 attcgatccc tccctgctgc tggcccaggc cacctccaac gtagtctgct ccctcctctt 600 tggcctccgc ttctcctatg aggataagga gttccaggcc gtggtccggg cagctggtgg 660 taccctgctg ggagtcagct cccagggggg tcagacctac gagatgttct cctggttcct 720 gcggcccctg ccaggccccc acaagcagct cctccaccac gtcagcacct tggctgcctt 780 cacagtccgg caggtgcagc agcaccaggg gaacctggat gcttcgggcc ccgcacgtga 840 ccttgtcgat gccttcctgc tgaagatggc acaggaggaa caaaacccag gcacagaatt 900 caccaacaag aacatgctga tgacagtcat ttatttgctg tttgctggga cgatgacggt 960 cagcaccacg gtcggctata ccctcctgct cctgatgaaa taccctcatg tccaaaagtg 1020 ggtacgtgag gagctgaatc gggagctggg ggctggccag gcaccaagcc taggggaccg 1080 tacccgcctc ccttacaccg acgcggttct gcatgaggcg cagcggctgc tggcgctggt 1140 gcccatggga ataccccgca ccctcatgcg gaccacccgc ttccgagggt acaccctgcc 1200 ccagggcacg gaggtcttcc ccctccttgg ctccatcctg catgacccca acatcttcaa 1260 gcacccagaa gagttcaacc cagaccgttt cctggatgca gatggacggt tcaggaagca 1320 tgaggcgttc ctgcccttct ccttagggaa gcgtgtctgc cttggagagg gcctggcaaa 1380 agcggagctc ttcctcttct tcaccaccat cctacaagcc ttctccctgg agagcccgtg 1440 cccgccggac accctgagcc tcaagcccac cgtcagtggc cttttcaaca ttcccccagc 1500 cttccagctg caagtccgtc ccactgacct tcactccacc acgcagacca gatgaaggaa 1560 ggcaacttgg aagtggtggg tgcccaggac ggtgcctcca gcctcaacag tgggcatgga 1620 cagggttaat gtctccagag tgtacactgc aggcagccac atttacacgc ctgcagttgt 1680 tttccggagt ctgtcccacg gcccacacgc tcacttgact catgctgcta agatgcacaa 1740 ccgcacaccc atacacaact acaagggcca caaagcaact gctgggttag ctttccacag 1800 acataaatat agtccatctg caatcacaag cacatagcca ggtaacccac caactcccct 1860 ggatctgcag cccacacgtg ggagtctggc tgtcaccttc acaagccaca gaaacggcca 1920 cacatgttca cagctcacac gccctctcca ttcatcgaac ttctcagtgt ccctgtccct 1980 ggtgcctggc acagggaaca gcatgccccc tccggggtca tgccacccag agactgtcgc 2040 tgtctatggc cccaactcat gctccctctc ttggctacac cactctccca gcctgtgacc 2100 accgatgtcc acacaccccc aaccacttgt ccacacagct acccacgtac gacatcgtcc 2160 tggctcccca gagtatcttc ccactgagac acgccgcccc cacagaggca cagtccccag 2220 ccacctctgc aactgcagcc ctcagtcacc cctttttaag caccctgatt ctaccaaatg 2280 caaacacatc tgggtctgcg attatgcaca gagactttgg acatacgagg accctcagac 2340 cggaggaaca cctgcccaac cccaacacgt gcttatgtaa ccacgtggaa agcggcccct 2400 gctgcccctc cacacacaca tacacactca ctgatctaca gcccctgttc ggcgtcagag 2460 tccccactag acccagtgga aggggttaga gaccaagtag gggccagttt ccaattcacc 2520 ctgtcaggga gtgagccgga tctgacgttc cttgtgactt aagggtccgg cttgggaatt 2580 aaagtttgtt tctggccttt agcctaaaaa aaaaaaaaaa 2620 <210> 17 <211> 690 <212> DNA
<213> Homo Sapiens <220>
<221> misc_feature <223> Incyte ID No: 7472790CB1 <400> 17 atgaacatcc gcaacgctca gccagacgac ctgatgaata tgcaacactg caacctcctt 60 tgccttcctg agaactacca gatgaaatac tatttatatc atggcctttc ctggccccag 120 ctttcttaca tcgctgagga tgaggacggg aagattgtgg gctatgttct ggccaaaatg 180 gaggaggaac cagatgatgt cccgcatggc catatcacct cactggccgt gaagcgttca 240 caccggcgcc tcggcctggc ccagaagctg atggaccagg cctccagggc catgatagag 300 aactttaacg ccaaatacgt gtctctgcac gtcaggaaga gtaaccggcc agccttgcac 360 ctttattcta acaccctcaa ctttcagatt agtgaggtgg aacctaaata ctatgcagat 420 ggggaagatg cttatgctat gaagcgggat ctctcgcaga tggcagatga gctgagacga 480 caaatggacc tgaagaaggg cgggtatgtg gtcctgggct ccagggagaa ccaggagacc 540 cagggcagca cactttctga ttctgaagag gcctgtcagc aaaagaaccc ggctaccgaa 600 gaaagtggca gtgacagcaa agaacctaag gagtctgtgg agagcaccaa cgtccaggac 660 agctcagaaa gctcggattc cacctcctag 690 <210> 18 <211> 1510 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7473944CB1 <400> 18 gcggccgcga agcgactccg atcctccctc tgagccttgc tcagctctgc cccgcgcctc 60 ccgggctccg gtccgcgcgg cggggtccct gctcctgcgc cccgggcgcg cttcccggac 120 atcccggtcc ccgcagccag gacaaagcca tgaagccagc gctgctggaa gtgatgagga 180 tgaacagaat ctgccggatg gtgctggcca cttgcttggg atcctttatc ctggtcatct 240 tctatttcca aatcatgcgg aggaatccct ttggtgtgga catctgctgc cggaaggggt 300 cccgaagccc cctgcaggaa ctctacaacc caatccagct ggagctctca aacactgctg 360 tcctgcacca gatgcggcgg gaccaggtga cagacacgtg ccgagccaac agcgccacaa 420 gccgtaagcg gagggtgctg acccccaacg acctgaagca cttggtggtg gatgaggacc 480 acgagctcat ctactgctac gtgcccaagg tggcctgcac caactggaag cggctcatga 540 tggtcctgac cgggcggggg aagtacagcg accccatgga gatcccggcc aacgaggcac 600 acgtctccgc caacctgaag accctgaacc agtacagcat cccagaaatc aaccaccgct 660 tgaaaagcta catgaagttc ctgtttgtcc gggagccctt cgagaggcta gtgtccgcct 720 accgcaacaa gttcacccag aagtacaaca tctccttcca caagcggtac ggcaccaaga 780 tcatcaaacg ccagcggaag aacgccaccc aggaggccct gcgcaaaggg gacgatgtca 840 aattcgagga gtttgtggcc tatctcatcg acccacacac ccagcgggag gagcctttca 900 acgaacactg gcaaaccgtc tactcactct gccatccctg ccacatccac tatgacctcg 960 tgggcaagta cgagacactg gaagaggatt ctaattacgt cctgcagctg gcaggagtgg 1020 gcagctacct gaagttcccc acctatgcaa agtctacgag aactactgat gaaatgacca 1080 cagaattctt ccagaacatc agctcagagc accaaacgca gctgtacgaa gtctacaaac 1140 tcgatttttt aatgttcaat tactcagtgc caagctacct gaaattggaa taaagggggt 1200 ggggagaggg agagaatcat gctttttaat ttaagatttt tatttgtcaa aagaattata 1260, tggatattgg gttattttgt aaattaatat ttctttgggg atgatgctgc gagcagcata 1320 gtgagaatta tttaaaatcc ttcgtaggga aggacagctg tctttgcagg ggaaatagga 1380 tgggtcgtcc ttgtctgtag aagtgaatac tgcaacactg tctcaaaggt ttcttgtgtt 1440 ctggtgaatt ccatgaattg tgcattccat aaattctaat taatattatt tatagttatt 1500 taaaaaaaaa 1510 <210> 19 <211> 3701 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 2244136CB1 <400> 19 gagctcggct cactatgtac gtgcgcagtg tgctggcaag gggagaagta gaaagcaccc 60 tgagatgacc ccggctcctc caccaggagc gcggccgggc gcggcgtccc tagcgggctt 120 cgccggggtg gcgtctctgg ggcctgggga cccccgccgc gccgctgacc cgcgccctct 180 gcccccagcg ctgtgcttcg ccgtgagccg ctcgctgctg ctgacgtgcc tggtgccggc 240 cgcgctgctg ggcctgcgct actactacag ccgcaaggtg atccgcgcct acctggagtg 300 cgcgctgcac acggacatgg cggacatcga gcagtactac atgaagccgc ccggctcctg 360 cttctgggtg gccgtgctgg atggcaacgt ggtgggcatt gtggctgcac gggcccacga 420 ggaggacaac acggtggagc tgctgcggat gtctgtggac tcacgtttcc gaggcaaggg 480 catcgccaag gcgctgggcc ggaaggtgct ggagttcgcc gtggtgcaca actactccgc 540 ggtggtgctg ggcacgacgg ccgtcaaggt ggccgcccac aagctctacg agtcgctggg 600 cttcagacac atgggcgcca gtgaccacta cgtgctgccg ggcatgaccc tctcgctggc 660 tgagcgcctc ttcttccagg tccgctacca ccgctaccgc ctgcagctgc gcgaggagtg 720 accgccgccg ctcgcccgcc cgcccccccg gccgccctgt ccgcctttgc ccgcctgccc 780 gccgcccggc gcggcctgct ttcagacgct cacttggcgt ttgtgttggg tttccccttt 840 tcaacatcct gcggttgtct ggctggttcc ggggggtgcg gggctgttgt tcttcggcga 900 cactttggtg ggggtgggtt gtttgtcgcc atagcccctc gcccttcccc acctgcctgg 960 gcggcttgcc acctgaagag tggcatcttg gaccaccgcg gctgtccatg acgctgccct 1020 gcccgccgcc actggggaag gcccagcctt gctcaccaag cacagaacct ctgcagcaga 1080 tcccggggcc aggctccggc cccgcctgcg gccccagcgc cactgcctgt ggaggcccga 1140 gctggccacg gcgctgcttt gctccgcgca tgccgagggt gtggcccggc tgagcatgcc 1200 gcatgcacac agccccgccc tgccgccctg cccagactgg acccggagac ccgggctggt 1260 gagcgcccct gtccccagcc cccagctggc tgtgggaggg cctgcccctg cccccacctc 1320 ctggagggcc tggtctgccc cgcgccgccc ggctctgtcc acacctgctt tgctctgacg 1380 ccctccattt ctctggctcc ggcccctccc ctgcctgggc tgtgctgact ggtgtcatca 1440 cccaggtgac tcccatggcg tccgtggcac agccagggtg ggggtccatg ggacccctct 1500 ccccagtgcc cactggatcg tgctggcctc tcccagatgt ccccggggac ctcctgcctc 1560 tggctgacgg tccaccctgt gaatcttatc agcccaggct gctgccaaca gcgcccagcc 1620 cacagcttct cccagcctga aaccaacaca ttttctaata agttatttag acagaatagc 1680 actctgcatg actttaattc ttgggacaaa acggtagttt gtaccctaag acacagtttc 1740 tggcccagtg tgatgggggt gggtggccgg gtgggtggag cgttttgctg ttggaaacct 1800 ggagggaaac cctgattgga tgtcatttcc tgccatggag cacgcctccc agccctggcc 1860 tgcagggtgg gcagggtggg gggcaaggga gtccgcagcc tccgggagga ggggcagggc 1920 gctgccttgg gctgggtggg aagaggggtg gccgcctcgg cttccgctgg ccatgctcct 1980 ggtctctcct tcctgaggtc acaggcaggg gctgccctgg acggggggcg gggggggtgg 2040 cctggaaggg gagacagagg tggagggtgg cacaggctgc acattcagct tagaagtgga 2100 cctggctttg gtggcaggag aagaataaac acttgcccag acccctttgt gtgggggaat 2160 tggggagggg tcgtggcagg cagggtgggc cacggaactg ggtcccaggc atcaaggcca 2220 cgtgcagggc catggaggga tgcttctcac gaggcgcttc agaagcgagc gaagggacag 2280 agaagccctg cgtccaaggg ccttttgtcc tgttagcaat tgaggtgtgc agagcactgt 2340 acagacccca ctcccctgta cattcctccc tggaggtgcc cggtccccgc.ttggggatgg 2400 gagttttgta gactgtacag aaatcggcac cctattttct tgcagctcag attttgttaa 2460 tctggaatat acagacagac gtaaagtgtt ttagcaaaat ggaaacaaac agttgtgcct 2520 ttttcctctt ttggtttggt ttgggtttgg cctggggctg gtcccagttg gtgcggggca 2580 tgctgggggc aggaggggca gggcgggcca ggtggagtca ggtcttgggg gtgtcatgtc 2640 ggggtgctgc cagcgtccct tggtcctgtg cctttggagc ctcgggctcc tggggtgcag 2700 ggtgcttggg ggtggctgtt ggagcccacc gacgccaggg cagggcctgg aggcccaggg 2760 actgccagtg tctccttgat attgatccta gcagatcccc ctcctggggg ttctgagagt 2820:
cctgggcagt gtggccttct ctcattctgg tggcatctgc gcccgtgagt gacctcttcc 2880' ttggctgcac tgccctgtgg gtggtgagac gcttggcctt ttttgttgct gccaggactt 2940 ggtagagatg gcaggaaggg tgtgcggggt ggttgtgtgc agaaccctgc cgcccctgag 3000 gtgagcagag gcactggtgt gcctgccagg ctggggcgga gctgcccgga acccttgcca 3060 ggccaatgtg tagcttggtg gcgcccttga aggccactgg ggggtaggtg tgtcctcccc 3120.
cggggctgga ggccgggtgc ctggtgggtg ggcctgacct ggcccacctc atccctccag 3180 cctgggatct cactgctctg cacctgtgca ctgacgtgaa ttttatacgt ttgtagaaac 3240 tctgatgtaa cttcttctac ctctgaagcg ccctcctggg ccctgctgtc acgtggctgg 3300' tgcggcttcc ccgagtgctg gccccctgcc cgctccccat gggcacccac cactcaaact 3360 ctgcgtggtg aggcccgggg aaagccaggc cgggccctag cactgctcag gggcctgggg 3420 ctcctgggat ttctgtgtgt ttggaagcct ctgtttttgg agtggggggc gtggaaggcg 3480 ggaggggctg acagtgcctg gggccagagc tgggcgaagg aggacatcct cactggacga 3540 gcactgcagg cctgacgaga ggctcccggc agctgagggc ttaagcgcct cgtgatgtcc 3600 ccaatggccc aagcccccgt tctgctttgc tggggtgggt ttgcccccgc gattgcactg 3660 tcccctggtg ttcttcgacc agctcctccg gggagggcct c 3701 <210> 20 <211> 960 <212> DNA
<213> Homo sapiens <220>
<221> misc_feature <223> Incyte ID No: 7474327CB1 <400> 20 gcagccatgg ccagccacat tgtgctcaac aatggcacca agatgcccat cctggggcta 60 ggcacctgga attcccctcc aggccaggta actgaggctg tgaaggtggc cattaatgtt 120 gggtactgcc acatcgactg tgcccacgtg taccagaatg agaatgacgt gggggtggcc 180 attcgggaga agctcaggga gcaggtggtg aagtgtgagg agctcttcat caccagcaag 240 ctgtggtgcg cgtaccatga gaagggcctg gtgaaaggag cctgccagaa gatgctcatt 300 gacctgaagc tggactacct ggacctctac cttattcgct ggccaaccag cttcaagcct 360 gggaaggaat ttttcccatt ggatgagcca ggtaatggta atgtggttcc cagtaacagt 420 aacattctgg acacatgggc gggcatggaa gagctggtgg atgaagggct ggtgaaagct 480 attggcatct ccaacttcaa ccatctccag gttgagagga tcttaaacaa acctgactta 540 aagtataagc cggtggttaa tcagattgag tgccacccgt acctcactca ggagaagtta 600 atccagtact gccagtccaa aggcatcatg gtgactgcct acagctcctt cagctccccc 660 gacaggccct gggccaagcc tgaggaccct tccctcctgg aagatcccag gatcaaggcg 720 atcacagcca aacacaataa aactacagcc caggttctga tctggttccc catgcagagg 780 aacttggtgg tgatccccaa gtctgtgaca ccagaatgca ttgctgagaa ctttaaggtc 840 ttcaactttg aactgaacag ccaggatatg accaccttat tcagttacaa cagaaactgg 900 agggtctgtg ccttggtgag ctgtgcctcc cacaaggatt accccttcca tgaagagttt 960
Claims (64)
1. An isolated polypeptide selected from the group consisting of:
a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90%
identical to an amino acid sequence selected from the group consisting of SEQ
ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10.
a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90%
identical to an amino acid sequence selected from the group consisting of SEQ
ID NO:1-10, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10.
2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-10.
3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide encoding a polypeptide of claim 2.
5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID
NO:11-20.
NO:11-20.
6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
7. A cell transformed with a recombinant polynucleotide of claim 6.
8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
9. A method for producing a polypeptide of claim 1, the method comprising:
a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and b) recovering the polypeptide so expressed.
a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and b) recovering the polypeptide so expressed.
10. An isolated antibody which specifically binds to a polypeptide of claim 1.
11. An isolated polynucleotide selected from the group consisting of:
a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:11-20, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90%
identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:11-20, c) a polynucleotide complementary to a polynucleotide of a), d) a polynucleotide complementary to a polynucleotide of b), and e) an RNA equivalent of a)-d).
a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:11-20, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90%
identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:11-20, c) a polynucleotide complementary to a polynucleotide of a), d) a polynucleotide complementary to a polynucleotide of b), and e) an RNA equivalent of a)-d).
12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.
13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.
15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
16. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.
17. A composition of claim 16, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-10.
18. A method for treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment the composition of claim 16.
19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting agonist activity in the sample.
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting agonist activity in the sample.
20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.
21. A method for treating a disease or condition associated with decreased expression of functional DME, comprising administering to a patient in need of such treatment a composition of claim 20.
22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting antagonist activity in the sample.
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting antagonist activity in the sample.
23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.
24. A method for treating a disease or condition associated with over expression of functional DME, comprising administering to a patient in need of such treatment a composition of claim 23.
25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:
a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.
a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.
26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:
a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1, b) assessing the activity of the polypeptide of claim l, in the presence of the test compound, and c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.
a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1, b) assessing the activity of the polypeptide of claim l, in the presence of the test compound, and c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.
27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:
a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
28. A method for assessing toxicity of a test compound, said method comprising:
a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
29. A diagnostic test for a condition or disease associated with the expression of DME in a biological sample comprising the steps of:
a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
30. The antibody of claim 10, wherein the antibody is:
a) a chimeric antibody, b) a single chain antibody, c) a Fab fragment, d) a F(ab')2 fragment, or e) a humanized antibody.
a) a chimeric antibody, b) a single chain antibody, c) a Fab fragment, d) a F(ab')2 fragment, or e) a humanized antibody.
31. A composition comprising an antibody of claim 10 and an acceptable excipient.
32. A method of diagnosing a condition or disease associated with the expression of DME
in a subject, comprising administering to said subject an effective amount of the composition of claim 31.
in a subject, comprising administering to said subject an effective amount of the composition of claim 31.
33. A composition of claim 31, wherein the antibody is labeled.
34. A method of diagnosing a condition or disease associated with the expression of DME
in a subject, comprising administering to said subject an effective amount of the composition of claim 33.
in a subject, comprising administering to said subject an effective amount of the composition of claim 33.
35. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 10 comprising:
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
b) isolating antibodies from said animal; and c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10.
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
b) isolating antibodies from said animal; and c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10.
36. An antibody produced by a method of claim 35.
37. A composition comprising the antibody of claim 36 and a suitable carrier.
38. A method of making a monoclonal antibody with the specificity of the antibody of claim comprising:
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
b) isolating antibody producing cells from the animal;
c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
d) culturing the hybridoma cells; and e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID
NO:1-10.
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
b) isolating antibody producing cells from the animal;
c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
d) culturing the hybridoma cells; and e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID
NO:1-10.
39. A monoclonal antibody produced by a method of claim 38.
40. A composition comprising the antibody of claim 39 and a suitable carrier.
41. The antibody of claim 10, wherein the antibody is produced by screening a Fab expression library.
42. The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.
43. A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10 in a sample, comprising the steps of:
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10 in the sample.
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10 in the sample.
44. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10 from a sample, the method comprising:
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10.
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-10.
45. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:1.
NO:1.
46. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:2.
NO:2.
47. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:3.
NO:3.
48. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:4.
NO:4.
49. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:5.
NO:5.
50. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:6.
NO:6.
51. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:7.
NO:7.
52. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:8.
NO:8.
53. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:9.
NO:9.
54. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID
NO:10.
NO:10.
55. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:11.
NO:11.
56. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:12.
NO:12.
57. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:13.
NO:13.
58. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:14.
NO:14.
59. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:15.
NO:15.
60. A polynucleotide of claim 1l, comprising the polynucleotide sequence of SEQ ID
NO:16.
NO:16.
61. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:17.
NO:17.
62. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:18.
NO:18.
63. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:19.
NO:19.
64. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID
NO:20.
NO:20.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19759000P | 2000-04-13 | 2000-04-13 | |
US60/197,590 | 2000-04-13 | ||
US19840300P | 2000-04-19 | 2000-04-19 | |
US60/198,403 | 2000-04-19 | ||
US20018500P | 2000-04-28 | 2000-04-28 | |
US60/200,185 | 2000-04-28 | ||
US20223400P | 2000-05-05 | 2000-05-05 | |
US60/202,234 | 2000-05-05 | ||
US20350900P | 2000-05-11 | 2000-05-11 | |
US60/203,509 | 2000-05-11 | ||
PCT/US2001/011869 WO2001079468A2 (en) | 2000-04-13 | 2001-04-12 | Drug metabolizing enzymes |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2403644A1 true CA2403644A1 (en) | 2001-10-25 |
Family
ID=27539372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002403644A Abandoned CA2403644A1 (en) | 2000-04-13 | 2001-04-12 | Drug metabolizing enzymes |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1272638A2 (en) |
JP (1) | JP2004512818A (en) |
AU (1) | AU2001255324A1 (en) |
CA (1) | CA2403644A1 (en) |
WO (1) | WO2001079468A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6852518B1 (en) | 1999-07-20 | 2005-02-08 | The Regents Of The University Of California | Glycosyl sulfotransferases GST-4α, GST-4β, and GST-6 |
WO2002026834A2 (en) * | 2000-09-25 | 2002-04-04 | Millennium Pharmaceuticals Inc. | 32624 a novel human udp-glucuronosyl and glycosyl transferase family member and uses thereof |
US20020123475A1 (en) * | 2000-06-30 | 2002-09-05 | Leiby Kevin R. | 32626, a novel human UDP-glycosyltransferase and uses thereof |
US6987014B2 (en) * | 2000-08-30 | 2006-01-17 | Applera Corporation | Isolated nucleic acid molecules encoding human drug metabolizing proteins |
WO2002042325A2 (en) | 2000-10-31 | 2002-05-30 | Zycos Inc. | Cyp1b1 nucleic acids and methods of use |
GB0307914D0 (en) * | 2003-04-07 | 2003-05-14 | Univ Dundee | Cytochrome p450 |
WO2023081000A1 (en) * | 2021-11-03 | 2023-05-11 | Simbiosys, Inc. | Metabolic modeling for disease prognosis and treatment |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2103756T3 (en) * | 1990-06-22 | 1997-10-01 | Hoffmann La Roche | DETECTION OF INEFFECTIVE PHARMACEUTICAL METABOLIZERS. |
AU2687897A (en) * | 1996-05-17 | 1997-12-09 | Endorecherche Inc. | Characterization and use of an isolated uridine diphospho-glucurono syltransferase |
JP4246264B2 (en) * | 1996-12-12 | 2009-04-02 | 協和発酵キリン株式会社 | Novel β1 → 4N-acetylglucosaminyltransferase and gene encoding it |
-
2001
- 2001-04-12 CA CA002403644A patent/CA2403644A1/en not_active Abandoned
- 2001-04-12 JP JP2001577452A patent/JP2004512818A/en active Pending
- 2001-04-12 EP EP01928472A patent/EP1272638A2/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/011869 patent/WO2001079468A2/en not_active Application Discontinuation
- 2001-04-12 AU AU2001255324A patent/AU2001255324A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2001255324A1 (en) | 2001-10-30 |
WO2001079468A2 (en) | 2001-10-25 |
JP2004512818A (en) | 2004-04-30 |
WO2001079468A3 (en) | 2002-07-18 |
EP1272638A2 (en) | 2003-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1254235A2 (en) | Drug metabolizing enzymes | |
US20040029132A1 (en) | Drug metabolizing enzymes | |
US20030143589A1 (en) | Drug metabolizing enzymes | |
US20040110259A1 (en) | Drug metabolizing enzymes | |
CA2403644A1 (en) | Drug metabolizing enzymes | |
WO2001059127A2 (en) | Drug metabolizing enzymes | |
US20050181415A1 (en) | Drug metabolizing enzymes | |
EP1370662A2 (en) | Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor | |
CA2417769A1 (en) | Drug metabolizing enzymes | |
US20040029125A1 (en) | Drug metabolizing enzymes | |
EP1399564A2 (en) | Drug metabolizing enzymes | |
US20040082061A1 (en) | Drug metabolizing enzymes | |
US20040086887A1 (en) | Drug metabolizing enzymes | |
CA2453075A1 (en) | Drug metabolizing enzymes | |
WO2002026988A2 (en) | Human drug metabolizing enzymes | |
US20030138895A1 (en) | Drug metabolizing enzymes | |
WO2002090521A2 (en) | Drug metabolizing enzymes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |